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Abstract 
Antithrombotic drugs are increasingly used for the prevention of atherothrombotic events in 
cardiovascular diseases and represent a paradigm for the study of personalised medicine 
because of the need to balance potential benefits with the substantial risks of bleeding harms. 
To be effective, personalised medicine needs validated prognostic risk models, rich 
phenotypes, and patient monitoring over time. 
The opportunity to use linked electronic health records has potential advantages; we have rich 
longitudinal data spanning patients’ entire journey through the healthcare system including 
primary care visits, clinical biomarkers, hospital admissions, hospital procedures and 
prescribed medication. Challenges include structuring the data into research-ready format and 
accurately defining clinical endpoints and handling missing data. 
The data used in this thesis was from the CALIBER platform: linked routinely-collected 
electronic health records from general practices, hospitals admissions, myocardial infarction 
registry and death registry for 2 million patients in England from 1997 to 2010. 
In this thesis I (1) developed comprehensive bleeding phenotypes in linked electronic health 
records, (2) assessed the incidence and prognosis of bleeding in atrial fibrillation and coronary 
disease patients in England, (3) developed and validated prognostic models for 
atherothrombotic and bleeding events in stable myocardial infarction survivors pertaining to 
the benefits and harms of prolonged dual antiplatelet therapy,  (4) assessed the predictors and 
outcomes associated with time in therapeutic range for patients treated with oral 
anticoagulants (5) assessed the predictive value of novel measures of international normalised 
ratio control in patients treated with oral anticoagulants for atherothrombotic and bleeding 
outcomes.  
Taken together these findings offer researchers scalable methodological approaches, that may 
be applied to other diseases and treatments with crucial benefits and harms considerations, 
and demonstrates how records used in clinical practice maybe harnessed  to improve 
treatment decisions, monitoring and overall care of a cardiovascular disease population 
treated with a class of drugs. 
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1 Introduction 
1.1 Background 
1.1.1 Antithrombotic therapies and their uses 
Antithrombotic therapies are a class of drugs which act to reduce blood clot (thrombus) 
formation. Blood clots limit the flow of blood through arteries and veins which can lead to 
conditions such as stroke. Blood clots are formed through the combination of two 
components: platelets (a type of blood cell) and proteins called coagulation factors. There are 
two types of antithrombotic therapy, each with a different mechanism of action:  
 Antiplatelets which act to inhibit the production of a chemical called thromboxane 
which is used to call for platelets to gather at the site of an injury. Common 
antiplatelets include aspirin and clopidogrel. 
 Anticoagulants which act to prevent the production of coagulation factors, for 
example through inhibiting Vitamin K, which is required to produce coagulation 
factors. Common anticoagulants include warfarin and heparin.  
There are a wide range of indications for antithrombotic therapies as many conditions involve 
risks of blood clotting. The most common indication is for the prevention of primary and 
secondary cardiovascular disease. In 2014 in the UK the prevalence of atrial fibrillation (AF) 
was around 2%, and coronary artery disease (CAD) is prevalent in around 5.5% of men and 
2.5% of women.1 Cardiovascular disease is among the top causes of death in the United 
Kingdom (UK), accounting for around 30% of deaths.1 Antiplatelets are among the most 
commonly prescribed treatments for preventing cardiovascular disease, behind lipid regulating 
drugs (statins) and antihypertensive drugs, whilst prescribing of anticoagulants is also 
increasing.1 
Within the classes of antithrombotic therapies there are a large and increasing number of 
different agents approved for medical use. Furthermore, there are a variety of antithrombotic 
therapy treatment strategies. Some conditions are indicated for short term treatment (e.g. 
venous thromboembolism (VTE)) while others are indicated for lifelong treatment (e.g. AF, 
acute coronary syndromes (ACS)). Combinations of antithrombotic agents, such as dual 
antiplatelet therapy and triple therapy, are also indicated in some instances, for patients at 
greatest atherothrombotic risk. 
1.1.2 Antithrombotic therapies: side effects and monitoring considerations 
Antithrombotic therapy is associated with an increased risk of bleeding.2 Antithrombotic 
therapy related bleeding is a heterogeneous side effect and can range in severity, from 
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manageable nosebleeds to life-changing or fatal intracranial bleeding. There are a number of 
bleeding classification schemes used in clinical trials which describe minor and major bleeding, 
and in some cases a third middle category, such as moderate bleeding. However there are 
variations between classifications in how bleeding severity is defined and efforts have been 
made to standardise bleeding definitions.3 It is important that in studies of antithrombotic 
therapies, the risks of different bleeding severities are accounted for and a consensus in 
bleeding definition would allow for easier interpretation and comparability of results between 
studies. 
Vitamin K antagonists (VKAs) are a group of oral anticoagulants commonly prescribed to 
patients with atrial fibrillation for stroke prevention. VKAs are sensitive to interactions with 
concomitant treatments (e.g. aspirin) and dietary habits (e.g. vitamin K rich food) and 
therefore require frequent monitoring and dosage adjustments to ensure the treatment is 
maintained within the limits of a narrow therapeutic range. If patients fall out of the 
therapeutic range the treatment may be ineffective to prevent thrombotic risks or may 
increase the risk of bleeding. The international normalised ratio (INR) is the test used to assess 
the therapeutic level of patients treated with VKAs, by measuring the time taken for blood to 
clot. The time in therapeutic range (TTR), calculated using longitudinal INR records, is a 
commonly used measure for assessing the overall level of patients’ VKA treatment control.  
1.1.3 Antithrombotic therapies: balancing benefits and harms 
Antithrombotic therapies are an important class of drugs; they can prevent potential fatal or 
life-changing atherothrombotic events in high risk populations but can equally pose serious 
bleeding harms. There is potential for an iatrogenic epidemic of bleeding if treatment decisions 
considering potential benefits and harms are not carefully considered. Therefore it is 
important that clinicians and patients are able to weigh up potential benefits versus potential 
harms when deciding on treatment strategy.  
Current efforts to consider benefits and harms as part of treatment decisions exist for the 
atrial fibrillation population. Clinical guidelines4,5 recommend using the CHA2DS2-VASc score6 to 
assess stroke risk and the HAS-BLED score7 to assess bleeding risk in the atrial fibrillation 
patients to determine whether anticoagulation therapy is suitable and whether patients may 
require extra monitoring for bleeding.  
1.1.4 CALIBER linked electronic health records 
In this thesis the data used to address the aims and objectives is from the CALIBER8 (Clinical 
research using Linked Bespoke studies and Electronic health Records), linked electronic health 
records platform. CALIBER contains linkages between primary care general practices (Clinical 
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Practice Research Datalink (CPRD)), hospital admissions (Hospital Episode Statistics (HES)), 
myocardial infarction disease registry (Myocardial Ischaemic National Audit Project (MINAP)) 
and cause of death (Office for National Statistics (ONS)) data sources. Primary care data from 
CPRD contains patient demographic data, diagnoses and procedures coded using Read terms, 
clinical biomarkers and prescribed drugs. Hospital admissions data from HES includes 
diagnoses coded using ICD-10 terms and procedures coded using OPCS-4 terms. MINAP is 
national registry for hospitalised acute coronary syndrome (ACS) events covering 230 hospitals 
in England and Wales. ONS mortality data includes underlying cause of death and up to 15 
secondary causes of death coded using ICD-9 and ICD-10 term. 
Using CALIBER the platform, reproducible high-resolution phenotypes which utilise records 
across the linked data sources have been developed and validated for numerous diseases and 
conditions, including MI and AF. However bleeding phenotypes relevant to antithrombotic use 
have yet to be developed. 
The CALIBER data used in this thesis contains a sample of 2 million patients in England, 
representative of the general population, registered at CPRD general practices which 
consented to linkage between 1997 and 2010. 
1.2 Thesis objectives 
In this section I described the main analytical objectives of the thesis. A mind map of the 
themes and topics explored in this thesis are shown in Figure 1.1. 
Figure 1.1: Themes and topics explored in this thesis 
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Chapter 4: Indications for ATT prescriptions in electronic health records 
Within primary care electronic health records there is rich prescribing data, however 
indications for prescriptions are not captured. 
The aims of this chapter were (1) to investigate the prevalence of antithrombotic therapy 
prescribing in CALIBER; (2) to determine how many of patients first antithrombotic 
prescription had an indication recorded within a reasonable timeframe. 
Chapter 5: Developing bleeding phenotypes using linked electronic health records 
Bleeding is the main side effect associated with antithrombotic therapies. Bleeding varies in its 
manifestation for instance, with respect to anatomical site and severity. As identified in clinical 
trials and prospective observational studies it is important to have standardised definitions 
and classifications for bleeding events. 
Studies of bleeding relating to antithrombotic use in using EHRs have produced a number of 
differing bleeding phenotypes. The phenotypes are not comprehensive, for example they use a 
single healthcare setting (e.g. hospitalisations only) or only use bleeding terms relating to 
particular anatomical sites (e.g. gastrointestinal) or do not distinguish between bleeding events 
of different severities. As for studies in clinical settings, it is important to have comprehensive, 
reproducible and standardised definitions for bleeding for use in EHR to allow for scientific 
replication and ease comparability between different EHR studies. 
Therefore the objectives in this chapter were (1) to determine the extent  that population-
based EHRs can replicate the definitions of bleeding used in trials; (2) to determine if bleeding 
severity can be defined within EHRs using information on bleeding diagnosis, anatomical site, 
fatality, length of stay, haemoglobin, transfusion, endoscopy, surgical interventions across 
primary and secondary care.  
Chapter 6: Population-based estimates of bleeding incidence and prognosis 
There are increasing numbers of patients with common heart diseases treated with one or a 
combination of antithrombotic therapies. The population of burden of bleeding is unknown 
and there are no studies which compare bleeding across common cardiovascular disorders. 
Furthermore, bleeding definitions differ across studies.  
The objectives of this chapter were (1) to estimate the incidence of major bleeding and any 
bleeding across patients with atrial fibrillation, acute myocardial infarction, unstable and stable 
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angina who are on different antiplatelet and anticoagulation regimens;  (2) to assess time 
trends in bleeding incidence along with the changes in antithrombotic management (3) to 
evaluate the association between major and minor bleeding and long term prognosis in terms 
of all-cause mortality, a composite of cardiovascular mortality, MI and stroke and recurrent 
bleeding. 
Chapter 7: Developing and validating prognostic models for benefits and harms of prolonged 
dual antiplatelet therapy in myocardial infarction survivors 
Among patients who survived a year since their last acute myocardial infarction (MI), the risks 
of subsequent major cardiovascular events, all-cause mortality and major bleeding are high. 
Recent evidence from clinical trials has shown the duration of dual antiplatelet therapy 
following an MI may be prolonged beyond a year, as currently suggested by guidelines, for 
effective reduction of atherothrombotic risks. However the decision to prolong dual 
antiplatelet therapy should be based on balancing patient’s risks of further atherothrombotic 
events and bleeding. How to assess these risks is unknown as there are currently no prognostic 
models to assess patient risks one year following MI. Therefore I sought to (1) develop and 
validate prognostic models for atherothrombotic and bleeding risks using a cohort of patients 
who were atherothrombotic event-free one year following a MI and (2) demonstrate how 
these models may be used to aid treatment decisions. 
Chapter 8: Time in therapeutic range: predictors and outcomes 
INR control measured using TTR in atrial fibrillation patients has been well documented, and is 
a key part of treatment management in atrial fibrillation guidelines. However it is not known 
how well INR control compares between atrial fibrillation and other disease populations 
indicated for warfarin use. 
The objectives of this chapter were (1) to describe INR and TTR data within CALIBER within 4 
distinct populations indicated for VKA therapy (AF, VTE, heart valve replacement or other 
indication); (2) to assess patient baseline characteristics associated with time in therapeutic 
range in the study population and whether they agree with the conclusions made in previous 
literature; (3) to assess the strength of the SAME-TT2R2 score for predicting TTR in the study 
population; (4) to assess all-cause mortality, atherothrombotic and bleeding outcomes 
following  INR spells with TTR below recommended levels (<60, 65, 70) 
Chapter 9: Predictive value of measures of INR control 
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Extending on the previous chapter I evaluate a range of novel, alternative measures of INR 
control beyond TTR, including INR variability, time above therapeutic range, time below 
therapeutic range and INR trajectory. It is not known whether TTR or alternative measures of 
INR may be useful predictors in models for estimating atherothrombotic or bleeding risks. The 
objectives in this chapter were (1) To illustrate overall distribution of INR control within the 
study cohort; (2) To estimate predictors of INR variability and (3) To estimate the predictive 
value of a range of measures of INR control for atherothrombotic and bleeding events; Is TTR 
the best measure and do measures of INR control work well for predicting both bleeding and 
atherothrombotic endpoints and add value to standard risk factors? 
Thesis structure 
In this thesis firstly I will explore the literature relevant to the objectives, secondly I will 
describe the CALIBER data resource and the approaches and principles I used in preparing the 
data for analysis, thirdly I present the studies to address the thesis objectives and finally in the 
conclusion I will summarise key findings and implications arising from the studies, and make 
recommendations for further research. 
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2 Literature 
In this chapter I described the literature that helped to shape the areas of research in my 
thesis. I used a non-systematic approach to identify the papers discussed, which provided a 
broad summary of the topics explored. As this thesis is not focussed around a single research 
question this scoping approach was more appropriate than carrying out multiple exhaustive 
systematic reviews, in which finding further older or smaller studies would be likely of little 
scientific benefit.  The purpose of my literature reviews was to clarify and specify my research 
questions and understand what each individual study that I carried out added to existing 
knowledge. 
I carried out literature reviews in the following areas: 
 Indications for antithrombotic therapies and guidelines 
 Electronic records and studies of antithrombotic therapies 
o Data quality 
o Phenotyping 
o CALIBER 
 Antithrombotic therapies and bleeding 
o Bleeding definitions in trials 
o Bleeding definitions in electronic health records 
o Population-based risks of bleeding 
 Prognostic modelling 
o Methods  
o Applications to cardiovascular diseases and bleeding 
 International normalised ratio 
o  Time in therapeutic range, risk factors and prognosis 
o Further measures of INR control 
Methods 
For each area I begun with broad search terms (e.g. for the topic of bleeding in electronic 
health records [“bleeding” OR  “haemorrhage”] AND “electronic health records”) to identify 
initial studies of interest. Studies were limited to those published in English. Following the 
ascertainment of initial studies I carried out a process of forward and backward citation 
tracking i.e. looking at studies cited within and studies that have cited the works of interest.  
2.1 Antithrombotic therapies 
Antithrombotic therapies (ATT) are a class of drugs used to prevent the formation of, or 
dissolve thrombi, or clots, in the circulatory system. Blockages in arteries and veins can lead to 
diseases such as myocardial infarction (MI), stroke and pulmonary embolism, causing 
significant disability and increasing mortality to the sufferers.9 
ATT consist of anticoagulant and antiplatelet drugs which both act to prevent clotting but with 
distinct mechanisms.  
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Anticoagulants can be divided into two groups according to administration method, parenteral 
and oral. The parenteral anticoagulants consist of unfractionated heparin and low molecular 
weight heparin (LMWH) and the oral anticoagulants consist of vitamin K antagonists (VKA’s) 
and novel oral anticoagulants.  
Novel oral anticoagulants - the newest class of antithrombotic therapy - include rivaroxaban, 
dabigatran and apixaban. They are advantageous over traditional anticoagulants since they do 
not require regular monitoring as warfarin does nor do they interact with food or drugs, which 
is a common drawback of warfarin treatment. However not all drugs in this class have an 
antidote (in 2016, idarucizumab was approved for the use of reversing the effects of 
dabigatran), therefore it is difficult to prevent bleeds in over-coagulated patients.10  
Antiplatelet drugs can be grouped as cyclooxygenase inhibitors, such as aspirin, adenosine 
diphosphate (ADP) receptor inhibitors (or P2Y12 inhibitors), such as clopidogrel, prasugrel and 
ticagrelor, glycoprotein IIB/IIIA inhibitors, such as abciximab, adenosine reuptake inhibitors, 
such as dipyridamole, thromboxane inhibitors and phosphodiesterase inhibitors all of which 
act to reduce platelet aggregation. 
The primary adverse event related to antithrombotic use is bleeding which can range from 
minor bleeds to potentially fatal haemorrhages in the gut or brain.2 Patients prescribed 
warfarin, a VKA, must undergo regular blood tests to ensure their international normalised 
ratio (INR) is kept within a safe range. Thus the patients are neither over-anticoagulated (i.e. at 
increased risk of haemorrhage), nor under-anticoagulated (i.e. at increased risk of stroke). 
2.1.1 Indications for antithrombotic therapy 
While antithrombotic therapies are prescribed and recommended as both preventative and 
therapeutic treatment for a wide range of indications (Table 2.1), they are primarily used in 
cardiovascular diseases. Numerous large scale randomised control trials have provided 
evidence towards their wide use. Recent trials involving antithrombotic therapy have been 
held to investigate the use of novel oral anticoagulants in patients with atrial fibrillation and 
acute coronary syndromes.11-16   
Additionally there are large trials to investigate the use of antiplatelets in previously 
unexplored cardiovascular disease populations. An example of this is the Pegasus-TIMI trial 17 
which tested dual antiplatelet therapy in the survivors of myocardial infarction, whilst 
international treatment guidelines currently suggest patients should only be treated with 
aspirin monotherapy in the long term.18 Pegasus-TIMI trial results suggested dual antiplatelet 
therapy reduces atherothrombotic events whilst increasing bleeding risk, clinicians and 
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patients will have to balance bleeding risks and survival benefits should this treatment strategy 
be approved by regulatory bodies. The use of prognostic risk scores is apt to optimise the 
balance of risk and benefit in new evidence-based treatment strategies that may improve 
current cardiovascular care practice. 
2.1.2 Cardiovascular indications: evidence and guidelines 
2.1.2.1 Atrial Fibrillation 
What is atrial fibrillation? 
Atrial fibrillation (AF) is the most common form of cardiac arrhythmia. AF affects 1-2% of the 
population and is increasing.19 AF can be ‘silent’ – patients with AF may never present to 
hospitals therefore actual prevalence of AF may be higher. AF has increasing prevalence with 
age and in men. AF is associated with increased rate of death, stroke and other 
thromboembolic (blood clot) events, heart failure, hospitalisations, lowered quality of life, 
reduced exercise capacity and left ventricular dysfunction.  
Oral anticoagulants are used to prevent ischemic events in individuals with AF. Prognostic 
scores such as CHADS220 and CHA2DS2-VASc 6 are used to determine individuals risk of stroke 
and the HAS-BLED7 score is used to estimate risk of bleeding. European Society of Cardiology 
(ESC) guidelines21 suggest, based on evidence from clinical trials and using CHA2DS2-VASc 
scoring, oral anticoagulants (OAC) are recommended for a score of 2 or higher, either OAC 
(preferred) or 75-325mg aspirin for a score of 1 and either 75-325mg  aspirin or no ATT 
(preferred) for a score of 0. Patients should be monitored for bleeding if they have a HAS-BLED 
score of 3 or higher. 
Patients with AF and stable coronary artery disease are usually treated with a VKA (e.g. 
warfarin) plus an antiplatelet (e.g. aspirin or clopidogrel). Patients with AF and post-acute 
coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) patients 
should be treated with triple therapy (e.g. aspirin, clopidogrel and warfarin) in the short term 
followed by a VKA and single antiplatelet combination for the long term. The length of time a 
patient is recommended to have each regimen depends on their risk of bleeding (the HAS-
BLED risk score is recommend to evaluate bleeding risk), whether they are elective or 
emergency  and the type of stent used in the PCI procedure. Dual antiplatelet therapy is 
recommended for patients with AF and non-ST elevated myocardial infarction (NSTEMI). 
Patients with an increased risk of stroke should also be given an oral anticoagulant (i.e. triple 
therapy). Acute ST-elevated myocardial infarction (STEMI) patients should initially be given 
triple therapy followed by VKA plus clopidogrel for long term management. 
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Anticoagulation is not recommended for patients with acute stroke as it may result in 
intracranial haemorrhage. In AF patients presenting with acute stroke or transient ischemic 
attack (TIA) haemorrhage should be excluded and uncontrolled hypertension should be 
managed prior to anticoagulation. 
The guidelines were updated in 201222 in light of the results of the ROCKET-AF13 (rivaroxaban 
vs VKA), ARISTOTLE14 (apixaban) and AVERROES16 (apixaban vs. aspirin) trials. Novel oral 
anticoagulants (NOAC’s) are recommended over warfarin, whilst taking into consideration 
both clinician and patient preference, for anticoagulation. NOAC’s do not have food and drug 
interactions or require regular blood monitoring however not all of the drugs in this class 
currently have an antidote in the case of a bleeding adverse event. Guidelines have shifted 
focus to identifying truly ‘low-risk’ patients who do not need, benefit from or may even be 
harmed by any ATT. This requires stronger risk scores than the previously advocated simple 
CHADS2. The HAS-BLED score is preferred over the complicated HEMORR2HAGES and less 
practical ATRIA scores for assessing bleeding risk. The 2014 NICE guideline recommends the 
use of CHA2DS2-VASc and HAS-BLED scores to assess stroke and bleeding risk respectively in AF 
patients.4 Anticoagulation is recommended for patients with a CHA2DS2-VASc score of 2 or 
higher with bleeding risk also to be simultaneously considered. Anticoagulation may be with 
apixaban, dabigatran, rivaroxaban or a VKA depending on an individual’s clinical features and 
preference. Antiplatelet monotherapy is not recommended as an intervention to prevent 
stroke in AF patients. 
2.1.2.2 Acute coronary syndromes 
What are acute coronary syndromes? 
Acute coronary syndromes are a range of acute diseases resulting from complete blockage or 
reduced flow of blood through the coronary arteries and thus decreased heart function. ACS 
usually presents as chest pain and can be classified as one of three conditions depending on 
electrocardiogram (ECG) results and cardiac biomarkers (e.g. troponin): 
 ST-elevation myocardial infarction (STEMI): If the ECG results show ST-segment 
elevation and severe rise in cardiac biomarkers this indicates STEMI, which is the 
complete blockage of a major coronary artery. 
 No ST-elevation myocardial infarction (NSTEMI): If the ECG results show ST-segment 
depression and slight rise in cardiac biomarkers this indicates NSTEMI, which is the 
complete blockage of a minor coronary artery and is less severe compared with STEMI. 
 Unstable angina: Unstable angina initially presents similarly to NSTEMI – the ECG 
shows ST-segment depression and is distinguished from NSTEMI by through the lack of 
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troponin elevation. An unstable angina diagnosis indicates lack of injury to the heart 
which would otherwise occur with an MI. 
Patients with ACS are at heightened risk of stroke and further ACS events and are usually 
prescribed differing antiplatelet therapy depending on their type of ACS and their risk level.  
Acute myocardial infarction with ST-elevation  
The ESC 201223 and NICE 201324 guidelines advise prasugrel, ticagrelor or clopidogrel in 
addition to aspirin is recommended for patients undergoing primary PCI. In addition patients 
are recommended anti-thrombin treatment with heparin or LMWH if they have been treated 
with prasugrel or ticagrelor, or bivalirudin in combination with clopidogrel. Recent trials of 
novel oral anticoagulants on post ACS patients (ATLAS ACS 2-TIMI 51 [rivaroxaban] and 
APPRAISE-2 [apixaban] and phase ii trials with dabigatran) are acknowledged but no 
recommendations for using this class of drugs as a whole in this population are made due to 
mixed results. Low dose rivaroxaban may be considered for patients with a low bleeding risk 
and currently use dual antiplatelet therapy. 
Dual antiplatelet therapy (clopidogrel/ticagrelor and aspirin) is recommended for up to 12 
months following a STEMI with a minimum of 1 month DAPT if the patient received and bare 
metal stent during PCI or 6 months if the patient received a drug eluting stent during PCI. 
Indefinite treatment with low dose aspirin (or clopidogrel for aspirin intolerant) is 
recommended following a STEMI. Triple therapy is recommended for patients with 
comorbidity such as AF (i.e. also indicated for oral anticoagulation) with minimum duration of 
dual antiplatelet use in order to minimise bleeding risk. 
Acute coronary syndromes without ST-elevation  
ESC 201125 and NICE 201026 guidelines suggest assessing ischaemic and bleeding risk in ACS 
patients without ST-elevation using the CRUSADE 27and GRACE28 scores, respectively. For the 
prevention of further ischaemic events, dual antiplatelet therapy (aspirin and a P2Y12 inhibitor) 
is recommended for 12 months except for those at high risk of bleeding. The choice of P2Y12 
inhibitor depends on the characteristics of the patient. Ticagrelor is recommended for all 
patients, prasugrel is only recommended for patients who have had a PCI and not previously 
used clopidogrel and clopidogrel should be chosen if ticagrelor or prasugrel are 
contraindicated. Aspirin monotherapy should be continued indefinitely (or clopidogrel if 
aspirin intolerant). 
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2.1.2.3 Stable coronary artery disease  
What is stable coronary artery disease? 
Stable coronary artery disease (SCAD) is a chronic condition and includes patients who have 
stable angina or those who have had a past ACS and have remained stable symptom-wise. 
Stable angina presents as chest tightness or pain and is caused by the narrowing of coronary 
arteries and thus insufficient blood supply to the heart muscle. SCAD patients are at high risk 
of further coronary events and often have long-term antiplatelet treatment to reduce their 
risk. 
ESC 201318 and  NICE 201129 guidelines suggest aspirin (or clopidogrel in aspirin intolerant 
patients) is recommended for the prevention of ischaemic events in those with SCAD, but it is 
advised to consider bleeding risk and comorbidities. No cardiovascular or bleeding prognostic 
risk tools are recommended for this population. Dual antiplatelet therapy is not recommended 
for stable patients but post-hoc analyses in the CHARISMA study 30 demonstrated a potential 
benefit in SCAD patients with a history of MI. It is suggested that dual antiplatelet therapy may 
be beneficial in stable patients who remain at high risk of ischaemic events and low risk of 
bleeding but no recommendations are made due to lack of evidence at the time of publication. 
2.1.2.4 Peripheral arterial disease  
What is peripheral arterial disease? 
Peripheral arterial disease is a build-up of plaque in arteries carrying blood to limbs and organs 
which restricts blood-flow. PAD usually refers to restricted blood flow to the legs. Patients with 
PAD are at increased risk of thrombosis, embolism and stroke. 
ESC 201131 guidelines state antiplatelet therapy with clopidogrel is recommended for the 
prevention of ischaemic events in patients with symptoms of PAD. Dual antiplatelet therapy is 
not recommended due to it not showing large enough increase in benefit relative to the 
increased bleeding risk when compared with antiplatelet monotherapy. Patients undergoing 
revascularisation with carotid artery stenting should be given dual antiplatelet therapy with 
clopidogrel and aspirin. Patients with SCAD and PAD should consider clopidogrel over aspirin 
for long-term antiplatelet therapy. 
2.1.2.5 Cardiovascular disease prevention  
There is an increasing prevalence in cardiovascular disease (CVD) and it is a leading cause of 
early death. Known risk factors for developing CVD include medical risk factors such as 
diabetes, renal disease and hypertension and lifestyle factors such as weight, smoking and 
alcohol consumption. 
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Antithrombotic therapies can be prescribed as preventative treatment in patients with 
presenting with known CVD risk factors. ESC 201232 guidelines suggest aspirin may be 
considered for hypertensive patients with no history of CVD and poor renal function but also 
considering their bleeding risk. Due to inconsistent study results there are no longer firm 
recommendations for aspirin in diabetic patients with no prior CVD. Antiplatelet therapy with 
clopidogrel in patients without overt CVD has not shown any significant benefit but increases 
bleeding risk and therefore is not recommended. 
2.1.2.6 Venous thromboembolism  
What is venous thromboembolism? 
A venous thromboembolism (VTE) is a blood clot that has broken free and travels in the 
bloodstream. An example of this is where a deep vein thrombosis (DVT), a blood clot in the 
deep veins of the leg moves to the lungs, a pulmonary embolism (PE). Both PE and DVT can be 
fatal or lead to chronic conditions. Anticoagulation is recommended to treat VTE and prevent 
further VTE events. 
NICE 201233 and ESC 201434 guidelines recommend patients with acute VTE should initially be 
administered with a parental anticoagulant. Low molecular weight heparins or fondaparinux 
are preferred to unfractionated heparins due lower bleeding risk. Oral anticoagulation should 
immediately follow parental anticoagulation. If VKA’s are used for oral anticoagulation, 
patients should continue using parental anticoagulants until they reach a stable INR 2-3 for 
two consecutive days. Additionally, the novel oral anticoagulants, rivaroxaban, dabigatran and 
apixaban are approved for treating VTE. Oral anticoagulation should continue for at least 3 
months following a VTE related event. Anticoagulation can be indefinite for individuals at high 
risk of further VTE events such as cancer patients as long as they are not at high risk of 
bleeding. 
2.2 Electronic health records and antithrombotic research 
Electronic health records are computerised collections of data. Such data may be collected for 
clinical care, administrative or auditing and quality assurance purposes. Information captured 
in electronic health records can include patient demographics, disease diagnoses and medical 
history, issued prescriptions, procedures and interventions and centre level information (e.g. 
general practices or hospitals).   
Linkage between different electronic health records, for example between primary care and 
hospital data, can be performed using unique patient identifiers or through probabilistic 
methods. Data linkage enhances the use of electronic health records for research as generally 
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different data sets complement each other in terms of data collected or can improve case 
ascertainment for variables in common.  
2.2.1 Assessment of data quality and validity in electronic health records 
Before performing research using electronic health records it is important to understand the 
quality and validity of the data, particularly in routinely collected or administrative patient data 
not specifically intended for research purposes. Research performed in poor quality data could 
potentially misinform if the limitations of the data are not addressed and interpreted correctly. 
The gold standard method for validating electronic health records is to compare them with the 
original patient medical charts. Herrett et al performed a systematic review of validation 
studies for diagnoses recorded in the General Practice Research Database (GPRD).35 The 
authors identified 212 studies in which 183 disease diagnoses were validated using a variety of 
methods. Internal validation methods included 1) diagnostic algorithms where diagnoses are 
made based on the presence of certain codes including supporting data such as symptoms, 
prescriptions and test results, 2) manual review of computerised free text, 3) sensitivity 
analysis in which disease definitions with broad criteria were compared with definitions with 
more restricted criteria. External validation methods included 1) sending questionnaires to 
general practitioners, 2) requesting paper medical records from general practitioners, 3) 
comparison of rates disease prevalence, incidence with known estimated from other sources. 
The most common validation methods were requesting additional information from general 
practitioners (160/357 validations) and comparison of rates (143/357 validations). The most 
common quantitative measure for assessing validity of disease diagnoses was the positive 
predictive value (PPV); the proportion of cases identified in GPRD that were found to be true 
cases. Disease diagnoses in GPRD were generally good, a median of positive predictive value of 
89% (range: 24-100%); however certain diseases had the tendency to be over or under 
reported in GPRD.  
Herrett et al36 sought to validate myocardial infarction diagnosis records captured in CALIBER 
(linked data from CPRD (primary care), HES (hospital admissions) and MINAP (national 
myocardial infarction disease registry)). The authors demonstrated that no single data source 
provided complete coverage of myocardial infarction events - only a third of events were 
captured in primary care, hospital admissions and disease registry data. Therefore the 
incidence of myocardial infarction events is underestimated when only a single data source 
was used.  
Rodriguez et al37 reviewed the use of GPRD for pharmacoepidemiology studies. The authors 
cited the fact that GPRD is a large population based and representative sample of the UK to be 
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a major advantage. Aspects of GPRD identified for improvement at the time of the study 
included improved capture of socioeconomic data and over-the-counter medication use, 
linkage to further healthcare data resources and wider use of GPRD data in research groups. 
The authors identified five key areas for which the GPRD may be applied to 
pharmacoepidemiology: 1) Studies of drug utilisation within disease groups, 2) drug safety 
surveillance, 3)  drug efficacy estimation,  4) improving the balance of benefits and harms of 
drugs and 5) to perform economic evaluation of treatments. 
2.2.2 Phenotype development using electronic health records 
Studies have demonstrated methodology for developing disease phenotypes in electronic 
health records. Morley et al38 developed atrial fibrillation phenotypes, in linked primary care 
and hospital admissions data. Further atrial fibrillation cases were inferred in patients without 
atrial fibrillation diagnosis records in primary or secondary care, through records of prescribed 
anticoagulation or antiarrhythmic treatments whilst excluding for other indications for 
treatment. No single data source had complete coverage of atrial fibrillation diagnosis and 40% 
of atrial fibrillation cases were captured in both primary and secondary care data. The 
characteristics of patients in terms of age, gender and comorbidities varied across atrial 
fibrillation patients depending on the source of their diagnosis record, primary care only, 
secondary care only or both primary and secondary care. 
2.2.3 CALIBER 
The CALIBER8 (Clinical research using Linked Bespoke studies and Electronic health Records) 
platform is a series of linkages between UK electronic healthcare databases: Clinical Practice 
Research Datalink (CPRD)  a longitudinal primary care database, Hospital Episode Statistics 
(HES) a database of hospital admissions and procedures, Myocardial Ischaemia National Audit 
Project (MINAP) a national acute coronary disease registry and the Office of National Statistics 
(ONS) for cause-specific mortality and social deprivation data.  
2.2.4 Exemplar CALIBER studies 
The scope of research performed using CALIBER is wide ranging. A core set of studies have 
assessed the associations between risk factors, including socio-economic deprivation,39 blood 
pressure,40 gender,41 smoking status,41 type 2 diabetes,42 rheumatoid arthritis,43 alcohol 
consumption,44 and neutrophil count,45 and the incidence of twelve cardiovascular diseases 
(stable angina, unstable angina, myocardial infarction, unheralded coronary death, cardiac 
arrest, heart failure, transient ischaemic attack, ischaemic stroke, subarachnoid haemorrhage, 
intracerebral haemorrhage, peripheral arterial disease and abdominal aortic aneurysm). These 
studies have emphasised the validity of the phenotyping of risk factors and cardiovascular 
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diseases within in the CALIBER platform, whilst also providing useful results that can aid and 
inform policies, approaches to clinical screening and risk factors for prognostic models. 
2.3 Bleeding and antithrombotic therapies 
2.3.1 Background 
Bleeding is the most common adverse effect of antithrombotic therapy.2,46 Antithrombotic 
therapies increase risk of bleeding through reduced platelet activity in the case of antiplatelet 
drugs and reduced clotting ability with oral anticoagulants. There is a wide range of severity of 
bleeding events associated with antithrombotic therapy use - for example, from minor 
nosebleeds to fatal intracranial haemorrhage. Given the heterogeneity of bleeding events it is 
important to have clear definitions for bleeding in research. It is also important to understand 
the incidence of bleeding in populations of patients prescribed antithrombotic therapies, and 
whether these events may be prevented through personalised treatment decisions that 
balance patients’ bleeding risks with their atherothrombotic risks. 
2.3.2 Bleeding classification in randomised trials and prospective cohort studies 
Due to the heterogeneity in the manifestation of bleeding events, there have been a number 
of bleeding definitions used in trials. The components used in bleeding classifications used to 
define severity are shown in Table 2.2. In trials and prospective studies bleeding severity is 
generally adjudicated by a number of study personnel at the time of the event.  
The Thrombolysis in Myocardial Infarction (TIMI) bleeding classification was developed in 
conjunction with trials conducted by the TIMI study group, which primarily investigated 
interventions for patients with ACS. The original TIMI bleeding definition47 classified bleeding 
events as major if they were intracranial or resulted in a haemoglobin drop >5g/dL. Bleeding 
events were classified as minor if it was spontaneous and observed as gross haematuria or 
hematemesis or had a haemoglobin drop >3g/dL. The current iteration of TIMI bleeding48 has 
three levels of severity, major, minor and minimal. Major TIMI bleeding events are fatal, 
intracranial, or bleeding with a haemoglobin drop ≥5g/dL. Minor TIMI bleeding events are 
bleeding with a haemoglobin drop 3 to 5g/dL, requires intervention to stop bleeding, leads to 
hospitalisation or prompts medical evaluation. Minimal TIMI bleeding events are any that do 
not meet the criteria of major or minor. In the TRITON-TIMI 38 trial49 which compared the use 
of prasugrel versus clopidogrel in ACS patients the risk of TIMI major bleeding was 2.4% for 
patients randomised to prasugrel and 1.8% for patients randomised to clopidogrel. In the 
PEGASUS-TIMI 54 trial17 which assessed the use of prolonged dual antiplatelet therapy (aspirin 
and ticagrelor) in myocardial infarction survivors the risk of TIMI major bleeding was 2.3% for 
patients randomised to ticagrelor 60mg and 1.06% for patients randomised to placebo. TIMI 
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minor bleeding was reported in 1.18% patients randomised to ticagrelor 60mg and 0.36% for 
patients randomised to placebo. 
The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded 
Coronary Arteries (GUSTO) bleeding definition50 classifies bleeding as severe or life-
threatening, moderate or mild. Severe or life-threatening events include intracerebral 
haemorrhage or bleeding resulting in haemodynamic compromise and moderate bleeding 
events are those that require transfusion with no haemodynamic compromise. All other 
bleeding events are classified as mild. GUSTO is the only bleeding classification assessed here 
that does not account for haemoglobin drop (Table 2.2). In the GUSTO trial randomised 
patients with acute MI to streptokinase and subcutaneous heparin, streptokinase and 
intravenous heparin, t-PA and intravenous heparin or streptokinase, t-PA and intravenous 
heparin. 30 day GUSTO severe or life-threatening bleeding occurred in 0.3%, 0.5%, 0.4% and 
0.6% of patients in the streptokinase and subcutaneous heparin, streptokinase and 
intravenous heparin, t-PA and intravenous heparin and streptokinase, t-PA and intravenous 
heparin groups respectively. 30 day GUSTO moderate bleeding occurred in 5.6%, 5.8%, 5.1% 
and 5.6% of patients in the streptokinase and subcutaneous heparin, streptokinase and 
intravenous heparin, t-PA and intravenous heparin and streptokinase, t-PA and intravenous 
heparin groups respectively. 
The ACUITY-HORIZONS bleeding classification51,52 defines major bleeding as intracranial or 
intraocular haemorrhage, bleeding that requires intervention, ≥5cm haematoma, 
retroperitoneal, ≥4g/dL haemoglobin drop without an overt source of bleeding, ≥3g/dL 
haemoglobin drop with an overt source of bleeding, any transfusion or reoperation for 
bleeding. The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial53 
randomised ACS patients to unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa 
inhibitor, bivalirudin plus a glycoprotein IIb/IIIa inhibitor, or bivalirudin alone. Major and minor 
bleeding according to the ACUITY-HORIZONS and the TIMI bleeding classification were 
reported. In the unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor 
group the risk of 30 day ACUITY-HORIZONS major and minor bleeding was 5.7% and 21.6% 
respectively and TIMI major and minor bleeding was 1.9% and 6.4% respectively. In the 
bivalirudin plus a glycoprotein IIb/IIIa inhibitor group the risk of 30 day ACUITY-HORIZONS 
major and minor bleeding was 5.3% and 21.7% respectively and TIMI major and minor 
bleeding was 1.7% and 6.1% respectively. In the bivalirudin alone group the risk of 30 day 
ACUITY-HORIZONS major and minor bleeding was 3.0% and 12.8% respectively and TIMI major 
and minor bleeding was 0.9% and 3.7% respectively. The Harmonising Outcomes with 
Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI)52 trial 
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randomised STEMI patients undergoing PCI to heparin plus a glycoprotein IIb/IIIa inhibitor or 
to bivalirudin alone. ACUITY-HORIZONS major, TIMI major, TIMI minor, and GUSTO life-
threatening or severe and GUSTO moderate bleeding events after 30 days follow-up were 
reported. In the heparin plus a glycoprotein IIb/IIIa inhibitor group 30 day ACUITY-HORIZONS 
major bleeding risk was 8.3%, TIMI major bleeding 5.0%, TIMI minor bleeding 4.6%, GUSTO life 
threatening or severe bleeding 0.6% and GUSTO moderate bleeding 5.0%. In bivalirudin group 
30 day ACUITY-HORIZONS major bleeding risk was 4.9%, TIMI major bleeding 3.1%, TIMI minor 
bleeding 2.8%, GUSTO life threatening or severe bleeding 0.4% and GUSTO moderate bleeding 
3.1%. 
The Clopidogrel in Unstable Angina to prevent Recurrent Events (CURE) bleeding 
classification54 has two levels of severity, major and minor. CURE major bleeding includes fatal 
bleeding, intracranial haemorrhage, bleeding that requires surgical intervention, bleeding 
resulting in hypotension, haemoglobin drop ≥5g/dL, bleeding requiring transfusion of 2-3units 
and intraocular bleeding. Minor bleeding events are those that led to discontinuation of 
treatment. The CURE trial54 randomised NSTE-ACS patients to clopidogrel or placebo in 
addition to aspirin for 3 to 12 months. In the clopidogrel group risk CURE major and minor 
bleeding was 3.7% and 5.1% respectively. In the placebo group risk of CURE major and minor 
bleeding was 2.7% and 2.4% respectively. In a study of ACS patients from CURE, OASIS, OASIS-2 
studies combined the risk of major bleeding at 6 months was 2%.55 
CURRENT-OASIS 7 bleeding classification56 defines severe, major and minor bleeding. Severe 
bleeding is defined as fatal, requiring transfusion ≥4units, haemoglobin drop ≥5g/dL, leading to 
hypotension, requiring surgery or intracranial. Major bleeding is defined as requiring 
transfusion 2-3 units, disabling, intraocular. Minor bleeding refers to events requiring 
modification of drug regimens. The trial compared double dose versus standard dose 
clopidogrel and high dose versus low dose aspirin in ACS patients undergoing PCI and reported 
CURRENT-OASIS 7 major, severe and minor bleeding as well as TIMI major bleeding events.57 
The risk of 30 day CURRENT-OASIS 7  major bleeding, CURRENT-OASIS 7  severe bleeding, TIMI 
major bleeding and minor bleeding in patients randomised to double dose clopidogrel was 
1.6%, 1.1%, 1.0% and 5.1% respectively. The risk of 30 day CURRENT-OASIS 7  major bleeding, 
CURRENT-OASIS 7  severe bleeding, TIMI major bleeding and minor bleeding in patients 
randomised to standard dose clopidogrel was 1.1%, 0.8%, 0.7% and 4.3% respectively. The risk 
of 30 day CURRENT-OASIS 7  major bleeding, CURRENT-OASIS 7  severe bleeding, TIMI major 
bleeding and minor bleeding in patients randomised to high dose aspirin was 1.5%, 1.1%, 0.9% 
and 5.0% respectively. The risk of 30 day CURRENT-OASIS 7  major bleeding, CURRENT-OASIS 7  
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severe bleeding, TIMI major bleeding and minor bleeding in patients randomised to low dose 
aspirin was 1.3%, 0.9%, 0.7% and 4.3% respectively. 
The Safety and Efficacy of Enoxaparin in PCI Patients, an International Randomized Evaluation 
(STEEPLE) bleeding classification58 defines major as fatal bleeding, retroperitoneal, intracranial 
or intraocular bleeding, bleeding that causes haemodynamic compromise, bleeding that 
requires surgical intervention, bleeding requiring transfusion ≥1 unit or bleeding with 
haemoglobin drop ≥3g/dL. STEEPLE minor bleeding is gross haematuria, prolonged epistaxis, 
gastrointestinal haemorrhage, haemoptysis, subconjunctival haemorrhage, haematoma ≥5cm, 
haemoglobin drop 2-3g/dL or uncontrolled bleeding requiring protamine sulphate. The 
STEEPLE trial58 randomised patients undergoing elective PCI to enoxaparin or unfractionated 
heparin. As well as STEEPLE bleeding, TIMI major, TIMI minor and GUSTO moderate or severe 
bleeding events were reported. In the heparin group STEEPLE major bleeding risk was 2.8%, 
STEEPLE minor bleeding 5.9%, TIMI major bleeding 0.3%, TIMI minor bleeding 1.9% and GUSTO 
moderate or severe bleeding 1.5%. In the enoxaparin 0.5mg per kilogram group STEEPLE major 
bleeding risk was 1.2%, STEEPLE minor bleeding 4.8%, TIMI major bleeding 0.3%, TIMI minor 
bleeding 1.8% and GUSTO moderate or severe bleeding 0.6%. 
The PLATelet inhibition and patient Outcomes (PLATO) bleeding classification59 has three 
defined levels of severity, major, minor and minimal bleeding. PLATO major bleeding includes 
fatal, intracranial, intrapericardial with cardiac tamponade, bleeding resulting in severe 
hypotension, haemoglobin drop≥5g/dL, transfusion of ≥4 units or significantly disabling events. 
PLATO minor bleeding events are those that require medical intervention to treat or stop 
bleeding, 3-5g/dL haemoglobin drop or transfusion of 2-3 units. Minimal bleeding events are 
those that do not meet the major or minor criteria. The PLATO trial60 randomised ACS patients 
to treatment with ticagrelor or clopidogrel. In the ticagrelor group the risk of PLATO and TIMI 
major bleeding was 4.5% and 2.8% respectively. In the clopidogrel group the risk of PLATO and 
TIMI major bleeding was 3.8% and 2.2% respectively. 
The Global Registry of Acute Coronary Events (GRACE) bleeding classification61 defines major 
bleeding as events that are fatal or result in stroke, intracerebral haemorrhage, require a 
transfusion of ≥2 units, or a decrease in haematocrit of≥10%. GRACE is multinational registry of 
ACS patients.62 Of the 24045 patients in GRACE hospitalised for ACS, 3.9% developed major 
bleeding.61 A later study of patients in the GRACE registry identified 2.8% of acute MI patients 
with major bleeding while hospitalised.63 
The International Society of Thrombosis and Haemostasis (ISTH) bleeding classification64 
defines major bleeding in non-surgical patients as fatal bleeding, symptomatic bleeding in a 
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critical area or organ or bleeding causing a fall in haemoglobin ≥2g/dL or transfusion of 2 or 
more units. The ISTH bleeding endpoint has been used in a number of clinical trials involving 
novel oral anticoagulants in atrial fibrillation and venous thromboembolism populations. In the 
ARISTOTLE trial population atrial fibrillation patients were randomised to apixaban or warfarin 
and the primary safety endpoint was ISTH major bleeding whilst GUSTO severe and TIMI major 
bleeding events were also reported.14 The risk of ISTH major bleeding was 2.13% in the 
apixaban group and 2.09% in the warfarin group. The risk of GUSTO severe bleeding was 0.52% 
in the apixaban group and 1.13% in the warfarin group. The risk of TIMI major bleeding was 
0.96% in the apixaban group and 1.69% in the warfarin group. Therefore in this setting ISTH 
major bleeding was shown to be a less conservative measure of major bleeding than the 
GUSTO and TIMI criteria. 
The Bleeding Academic Research Consortium (BARC) bleeding classification3 was developed in 
an effort to standardise the definition of bleeding in research. The BARC bleeding classification 
has 5 levels of severity: Type 1 – bleeding that does not result in hospitalisation or consultation 
of healthcare professionals; Type 2 – overt haemorrhage with either nonsurgical intervention, 
hospitalisation or prompts evaluation; Type 3a – Overt bleeding with haemoglobin drop 3 to 
5g/dL or transfusion; Type 3b – overt bleeding with haemoglobin drop ≥5g/dL, cardiac 
tamponade,  or requires surgical or pharmacological intervention; Type 3c – Intracranial 
haemorrhage or intraocular haemorrhage; Type 4 – CABG related bleeding; Type 5 – fatal 
bleeding. In a study of coronary artery disease patients undergoing PCI pooled from 6 clinical 
trials, the overall risk of BARC type ≥ 2, BARC type≥ 3 and TIMI major bleeding 5.4%, 4.0% and 
0.9% respectively.65 In a prospective cohort study of 4149 stable coronary artery disease 
patients, after two years follow up the risk of BARC type≥3 was 1.2%.66  
2.3.2.1 Comparisons of bleeding classifications 
There have been studies in prospective cohorts which sought to compare the incidence of 
bleeding events according to the various classification schemes and analysed the risks of 
subsequent mortality in a form of validation.  
Kikkert et al67 followed-up a prospective cohort of 2002 STEMI patients and used the TIMI, 
ISTH, GUSTO and BARC classification schemes to define bleeding events. Overall, 19% patients 
had ISTH major bleeding, 6.3% had GUSTO moderate bleeding, 2.7% had GUSTO severe 
bleeding, 7.9% had TIMI minor bleeding, 5.0% had TIMI major bleeding, 4.4% had BARC type 2 
bleeding, 8.5% had BARC Type 3a bleeding, 5.5% had BARC type 3b/3c bleeding, 1.3% had 
BARC Type 4 bleeding and 0.3% had BARC type 5 bleeding. In adjusted analysis the risk of one 
year mortality did not differ significantly between the levels of ISTH or GUSTO bleeding 
42 
 
severity. Patients with TIMI major bleeding had 2 (95% CI: 1.32, 3.01) times the risk of 
mortality compared with patients that had TIMI minimal or no bleeding. Patients with BARC 
type 3b/3c bleeding had 1.84 (95% CI: 1.23, 2.77) times the risk of mortality compared with 
patients who had BARC type 0 or 1 bleeding. The risk of mortality in patients who had BARC 
type 4 bleeding was not significantly different to those with BARC type 0 or 1. In an analysis of 
the individual components of the bleeding classification scheme it was found that a 
haemoglobin drop of ≥5 g/dL was associated with increased risk of mortality.  
Vranckx et al68 validated the BARC bleeding classification in the TRACER trial population of 
NSTE-ACS patients. In follow up 15.3% of the patients had BARC type≥2 bleeding, 3.7% had 
TIMI major or minor bleeding and 4.0% had GUSTO severe or moderate bleeding. The rate of 
mortality following bleeding was highest in those who has GUSTO severe bleeding (30.0% at 2 
years post-bleeding), followed by BARC type 3 bleeding (% at 2 years post-bleeding) and TIMI 
major bleeding (22.4% at 2 years post-bleeding). For the BARC classification, patients with 
Type ≥ 2 bleeding had increased mortality risk up to one year post-bleeding compared with 
patients that did not have a bleeding event. Patients with major TIMI bleeding had increased 1 
year mortality risk compared with patients that had no TIMI bleeding. Patients with moderate 
or severe GUSTO bleeding had increased 1 year mortality compared with patients that had no 
GUSTO bleeding. 
Kaatz et al69 highlighted the important of clinically relevant non-major bleeding, e.g. costs and 
management of such events, and sought to standardise the definition of non-major bleeding 
for patients treated with anticoagulants. Through reviewing trials of novel oral anticoagulants 
in atrial fibrillation and venous thromboembolism patients they found 47 distinct components 
used to define non-major bleeding. With this information they defined clinically relevant non-
major bleeding as a sign or symptom of bleeding that does not meet the ISTH criteria for major 
bleeding64 but requires medical intervention, leads to hospitalisation or prompts face to face 
evaluation. 
2.3.3 Bleeding phenotyping in electronic health records 
Bleeding phenotypes have been developed for use in electronic health care record systems, 
and there a large degree of heterogeneity was found between them, as summarised in Table 
2.3.  
Of the 8 phenotypes identified 5 were restricted to upper gastrointestinal bleeding events.70-74  
The three remaining phenotypes75-77 each explored at least 4 anatomical sites including 
intracranial, genitourinary, respiratory and gastrointestinal bleeding sites.  
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All bleeding phenotype studies used bleeding records captured hospital admissions data, 
except de Abajo et al71 who used bleeding diagnosis records from primary care general 
practices only. Only two studies assessed bleeding records captured in death registries.73,77 
Both primary care and hospital admissions data were used by Crooks et al73 (linked data) and 
Valkhoff et al74 (non-linked data). 
Most bleeding phenotypes comprised of ICD-9 or ICD-10 codes, with the exception of the 
studies in UK primary care data which used Read codes and IPCI primary care data which used 
in IPCI codes. The numbers of codes used in the bleeding definitions was variable amongst the 
studies. This was particularly noticeable when comparing the studies of upper GI bleeding in 
hospital admissions data. To define upper GI bleeding, Raiford et al70 used 30 ICD-9 codes, 
Wahl et al72 initially used 75 codes and refined to 33 codes in a secondary analysis, Crooks et 
al73 used 22 ICD-10 codes and Valkhoff et al74 used 26 ICD-9 codes and 16 ICD-10 codes.  
Three studies sought to differentiate between the severities of bleeding events. Arnason et al75 
and Cunningham et al76 ‘manually’ assigned severity using information recorded on patient 
charts. Friberg et al77 classified severity using information in the electronic health records. 
Initially, fatal bleeding included bleeding records captured in the national death registry or 
hospital admissions with a discharge code indicating death; non-fatal major bleeding 
comprised of hospitalisations with bleeding as the primary diagnosis or secondary diagnosis 
with a coinciding record for transfusion or intracranial bleeding; hospitalised bleeding included 
any extracranial bleeding event with no coinciding transfusion record and minor bleeding was 
defined as any extracranial bleeding without hospitalisation or transfusion. However major 
bleeding was later redefined to combine the non-fatal major and hospitalised bleeding 
categories, due to a high number of missing transfusion records leading to missed major 
bleeding events. 
The gold standard for assessing the accuracy of electronic health records is to perform a 
manual review of patient charts. Most studies of bleeding phenotypes developed in the 
electronic health records had the facility to do this, for at least a sample of the bleeding 
events. The most commonly reported measure of accuracy was the positive predictive value 
which is the percentage of electronic bleeding records that are found to be true according to 
the manual chart review. The positive predictive value for bleeding events in electronic health 
records was generally high, >70%. A low positive predictive value (21%) was found for upper GI 
bleeding events defined using IPCI codes which is a much less granular coding system than ICD-
10.  
44 
 
Friberg et al77 was the only study to develop a phenotype in a wide range of anatomical sites, 
use supporting electronic health record data to define levels of severity and perform the gold 
standard chart review. However they did not use primary care bleeding records where 
clinically important events may also be captured. 
A major limitation of using electronic health records to define bleeding events is that a number 
of the components to classify bleeding severity in trials and prospective studies are unavailable 
or difficult to apply using retrospective cohorts from electronic health records. For example, 
change in haemoglobin and units of blood transfused are generally not captured in electronic 
health records, but has been shown to be a prognostically important component in defining 
severity of events.67  
2.3.4 Antithrombotic therapy and population-based risks of bleeding 
A number of studies have estimated the incidence and risks of bleeding in a variety of 
population-based cohorts of patients indicated for antithrombotic use, summarised in Table 
2.4. Understanding previous population-based estimates of bleeding incidence can help to 
inform the validity of phenotypes developed in electronic health records. 
For patients prescribed oral anticoagulants from population-based electronic health records in 
a Danish region78 and the United Kingdom79 the estimated fatal or hospitalised bleeding 
incidence was 3.5 and 6 per 100 patient years, respectively. A multicentre study of patients in 
Japan treated with antithrombotic therapies for stroke and cardiovascular disease (n=4,009) 
found higher incidence of bleeding events of all severities to be associated with the intensity of 
prescribed antithrombotic therapy.80 A large population-based patient registry in Denmark 
linked to prescribing and cause of death registries found increasing levels of antithrombotic 
therapies prescribing for atrial fibrillation patients (n=118,606) within 90 days of hospital 
discharge, from 21.4% in 1997 to 44.8% in 2006.81 The authors also identified 180 day bleeding 
incidence almost doubling from 4.7% to 9.0% in the same time period.81 In the same linked 
data a study of 11,480 patients with atrial fibrillation admitted to hospital for acute myocardial 
infarction, those treated with triple therapy (warfarin and dual antiplatelet therapy) had the 
highest bleeding incidence(14.2 per 100 person years) compared with other treatment 
groups.82 
A study of 16,513 atrial fibrillation patients using linked primary care, hospital admission and 
cause of mortality registry data found the incidence of any bleeding to be highest in patients 
currently exposed to vitamin K antagonists (3.9 per 100 patient years) compared to those with 
past vitamin K antagonist exposure or no vitamin K exposure (2.7 and 2.9 per 100 patient years 
respectively).83  
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The standardised incidence of intracerebral haemorrhage was estimated in patients with 
previous vascular disease using the Oxford stroke and vascular disease registers, OCSP and 
OXVASC.84 In both OCSP and OXVASC, the risk of intracerebral haemorrhage was markedly 
lower in patients aged under 75 (0.10 and 0.06 per 1000 patient years, respectively) compared 
with patients aged 75 years or above (1.55 and 1.44 per 1000 patient years, respectively).84 
In an Icelandic hospital database, the crude incidence of upper gastrointestinal bleeding was 
estimated to be 0.87 per 1000 patient years, and that the use of warfarin, non-steroidal anti-
inflammatory drugs and aspirin were associated with increased bleeding risk.85 A matched case 
control study of patients with serious upper gastrointestinal bleeding in Danish linked 
electronic health records also found increased bleeding odds associated with increased 
intensity of antithrombotic therapy regimen. Patients treated with aspirin and patients treated 
with triple therapy had 1.8 and 5.3 times the odds of upper gastrointestinal bleeding, 
respectively, compared with patients not treated with antithrombotic therapy.86  
2.3.5 Conclusion and implications for this thesis 
Bleeding is as serious side effect associated with the use of antithrombotic therapies and is 
heterogeneous in its manifestation, particularly in terms of site and severity. Numerous 
bleeding classification applied to different disease populations inhibits the ability to compare 
bleeding events across studies. While there have been efforts to standardise bleeding 
definitions in prospective studies and randomised clinical trials, such definitions are not always 
applicable in electronic health records. Therefore there is a need for a comprehensive 
standardised bleeding phenotype to be developed in linked electronic health records.  
The use of data beyond code lists to define severity of bleeding in electronic health records 
should be investigated because bleeding severity is prognostically important. A well-defined 
bleeding phenotype applied to population-based cohorts will help us to accurately estimate 
bleeding incidence, across severity levels, in different disease populations that are indicated 
for antithrombotic therapies. Following understanding bleeding incidence we can estimate the 
prognosis for all-cause mortality, atherothrombotic events and further bleeding in patients 
that experience bleeding of different severities.  
2.4 Prognostic modelling 
2.4.1 Background 
Prognostic models are used to assess patient risks of clinical events given their current health 
status and characteristics.87 Through assessing patient risks of diseases or clinical events, 
clinicians are able to make recommendations that may improve patient prognosis, for example 
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changing modifiable risk factors (smoking, weight etc.) or prescribing appropriate treatments. 
Therefore prognostic models play a vital role in the field of personalised medicine.  
Prognostic models can take various forms ranging from simple point-based calculations to 
more complex statistical models. Point-based scores are usually derived from statistical models 
which are then simplified to consist of few risk factors where patients are assigned a weighted 
score (e.g.  1 or 2 points) for each risk factor and their total score corresponds to a level of risk. 
Point-based scores have the advantage of ease of use and due to their simplicity they may be 
more likely to be adopted in clinical practice; whereas their main disadvantage is that they 
may lack the granularity to effectively discriminate between levels of risk. 
Prognostic models in the form of multivariable regression models, whilst more complex, have 
the advantage of assessing a wide range of risk factors and more flexible modelling of 
associations between risk factors and the events of interest.88  Regression models may be 
considered to be more difficult to adopt in clinical practice; however, with the increasing use 
of electronic health record systems in primary and secondary care, more complex prognostic 
models can be integrated within the EHR, or accessed using apps or web calculators with 
minimal computational effort from users. The output of these models depends on the type of 
statistical models used (e.g. logistic regression for binary outcomes, Cox regression for time to 
event outcomes, linear regression for continuous outcomes) and is usually a quantifiable 
estimate of risk, for example a percentage chance of events within a given timeframe. 
Prognostic models integrated within electronic health records may be advantageous as they 
provide the opportunity to monitor and dynamically update patient risks according to changing 
risk factors captured in primary and hospital care. For example, if a patient’s risk of clinical 
events crosses a predetermined threshold they could be flagged for further assessment and a 
change in treatment strategy. 
2.4.2 Model development methods 
Study population 
Study populations used for developing prognostic models can come from randomised 
controlled trials or observational cohorts. Randomised control trial populations and 
observational disease registry cohorts will generally have rich data with respect to treatments, 
interventions and patient characteristics or clinical biomarkers relevant and specific to the 
disease population. Unselected populations from routinely collected linked electronic health 
records, for example primary care and hospital admissions records, could provide cohorts that 
are more representative of patients in real-world settings. 
47 
 
Prognostic risk factors and multivariable modelling 
Risk factors commonly used in prognostic models include age, sex, ethnicity, behaviours, 
socioeconomic factors, medical history, clinical biomarkers and medications previously and 
currently used. Genetic markers have also been incorporated in prognostic models.  
In selecting risk factors to include in prognostic models, researchers should consider those risk 
factors known to be associated with the outcome of interest from the literature and also novel 
risk factors with previously unassessed utility that may be clinically relevant. It is important to 
consider the functional form of risk factors, for example, log transformations and 
categorisation. Furthermore, clinically plausible interactions between prognostic factors 
should be investigated. 
Linear regression, logistic regression and proportional hazard models are examples of types of 
models for continuous, binary and time to event (survival) outcomes respectively. For time to 
event outcomes models, fully parametric models are ideal for prognostic models, particularly if 
the goal is to be able to produce predictions for individuals as well as estimate the relative 
risks (hazard ratios) for the risk factors, because the baseline hazard function is estimated. 
Care must be taken when choosing the functional form for underlying baseline hazards. 
Common choices of baseline hazard function include exponential, Weibull and gamma. Flexible 
parametric baseline hazards can incorporate different baseline hazard shapes (e.g. using 
restricted cubic splines) but are more computationally intensive. 
 In the case of semi-parametric models, i.e. Cox proportional hazards models, because no 
assumptions are made about the underlying hazard function and it is not estimated, it is not 
possible to produce individual predictions, only hazard ratios, for the risk factors in the model. 
Proportional hazards assumptions can be checked using log(-log) plots and residual plots. 
To ensure the most parsimonious model is arrived at, model selection procedures may be 
used. This includes backwards selection, where a model with all potential prognostic factors 
are included and iteratively checked for the significance of prognostic risk factors. These 
checks or selection rules are generally pre-determined p-values or Akaike information criterion 
(AIC) values.  
2.4.3 Model validation methods 
In order to be considered useful, prognostic models are required to undergo validation. Model 
validation can be performed internally, i.e. using the same cohort in which the model was 
developed using methods such as bootstrapping and k-fold cross-validation. Model validation 
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can also be performed externally by applying the prognostic model in a new cohort not 
involved in the model development process. 
The main measures used to assess model validation are discrimination and calibration. 
Model discrimination is how well models distinguish between patients with different risk 
levels. Harrell’s C-index (also known as the area under receiver operator characteristic curve) is 
the most commonly used measure of discrimination. The c-index can take values from 0 to 1 
and is interpreted as the probability that a patient that has an event is assigned a higher risk 
score than a patient that does not have an event. Therefore a c-index of 0.5 suggests the 
model as no discriminative ability i.e. no better than a coin flip. 
Model calibration is the accuracy of model predictions when compared with observed events. 
An example of model calibration is to graphically compare observed events with prognostic 
model predictions and 95% confidence intervals, overall and across risk strata. The Hosmer-
Lemeshow goodness of fit test is an example of a statistical measure of calibration that can be 
applied to logistic regression models. For the external validation of Cox proportional hazards 
prognostic models, Royston and Altman89 summarise step-by-step approaches with research 
examples. 
2.4.4 Prognostic models and electronic health records 
Using electronic health records of 20 million patients from more than 1000 primary care 
general practices linked with hospital admissions data from HES and cause-specific mortality 
data from ONS, the QRESEARCH group have developed prognostic models for use in the 
general population such as QRISK90-92 for predicting cardiovascular risk, QBLEED93 for predicting 
intracranial and gastrointestinal bleeding risk and scores for numerous other clinical outcomes 
such as type 2 diabetes,94 stroke95 and chronic kidney disease.96 The models developed and 
validated by the QRESEARCH group have been implemented and integrated in clinical 
computer systems used by general practitioners (EMIS) and can flag up patients at high risk of 
events. 
Certain regression modelling methods are ideal for electronic health records. Dynamic 
prognostic models take account for the effects of changes in risk factors over time and update 
predicted risks for patients accordingly. Such models would fully harness the longitudinal data 
available within electronic health records, as opposed to using baseline risk factors alone. 
2.4.5 Prognostic models for cardiovascular diseases 
Prognostic models have been used to estimate long term cardiovascular disease risk in 
otherwise healthy patients. Multivariable risk models for cardiovascular events commonly use 
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prognostic factors such as patient characteristics (e.g. age, sex, and ethnicity), socioeconomic 
status, patient behaviours (smoking, alcohol consumption, physical activity and diet), 
comorbidities (e.g. diabetes), family history of cardiovascular disease, clinical biomarkers (e.g. 
body mass index, cholesterol, blood pressure) and prior and currently prescribed medications. 
These models are useful to identify patients at high risk of cardiovascular events, allowing for 
clinicians to advise lifestyle changes for modifiable risk factors (e.g. smoking and diet) or 
prescribe treatments that may lower cardiovascular risk. The QRISK90-92 models are examples 
of cardiovascular prognostic models used in clinical practice. 
Prognostic models for estimating risk of secondary events in patients with existing 
cardiovascular disease have also been developed and are used in clinical practice. For example 
atrial fibrillation patients are at increased risk of ischaemic stroke and may be prescribed with 
aspirin or warfarin in order to reduce their risk. CHADS220 which was later expanded to 
CHA2DS2-VASc6 are examples of risk scores developed to estimate the risk of stroke in atrial 
fibrillation patients and help inform the appropriate intensity of treatment to reduce stroke 
risk. They are simple point based scores; each prognostic factor is worth 1 or 2 points and the 
sum of the points is the measure of the patients risk.  
2.4.6 Prognostic models for bleeding events 
Prognostic models that have been developed for estimating risk of bleeding events are 
summarised in Table 2.5. 
The models were developed using disease registries (HAS-BLED,7 REACH97), clinical trial 
participants (CRUSADE,27 ACUITY/HORIZONS-AMI28), population-based cohorts (QBLEED93) or 
derived from previous models (HAEMORR2HAGES98) to estimate bleeding risk at the point of 
cardiovascular event diagnosis to aid antithrombotic therapy treatment decisions for acute 
myocardial infarction and atrial fibrillation patients. Since there is no universal major bleeding 
definition the bleeding outcomes were defined differently in each of the models, limiting their 
comparability. Prognostic factors used across the models include age, cardiovascular 
comorbidities, creatinine and antiplatelet or oral anticoagulant use. All of the bleeding 
prognostic models were externally validated and had good discrimination (c-index ranging 
from 0.62 to 0.86) and were calibrated well. 
2.4.7 Using prognostic models to balance the benefits and harms of antithrombotic 
therapies 
With the availability of developed and validated prognostic models for outcomes relating to 
the benefits and harms of antithrombotic therapies, atherothrombotic event prevention and 
bleeding respectively, it is possible to use such models in tandem to fully assess the suitability 
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of treatment for patients. Using the methodology described by Pocock et al99 we can consider 
predicted treatment efficacy and predicted harms along with patient and clinician values 
regarding the benefits and harms in question. An example of this methodology is illustrated in 
Figure 2.1. In the figure, ‘X’ represents an individual who may benefit from treatment A as 
their predicted treatment benefit is greater than their predicted treatment harms. ‘O’ 
represents an individual who may not benefit from treatment A as their predicted harms will 
outweigh the benefits.  This is under the rule of equal trade off, where treatment benefits and 
harms are valued and weighted equally. Other scenarios may apply, for example if clinicians or 
patients believe the treatment harms are considered to carry more weight than benefits and 
vice versa. 
2.4.8 Prognostic models recommended in clinical guidelines 
The use of prognostic models is recommended in a number of clinical guidelines. The CHA2DS2-
VASc score for stroke risk and the HAS-BLED score for bleeding risk have frequently been 
implemented in clinical guidelines for atrial fibrillation, with the advice that they be used to aid 
determining the appropriate antithrombotic therapy for patients (i.e. warfarin vs. aspirin) 
based on their stroke and bleeding risks.4 NICE recommends the use of QRISK2 to assess 
patient’s cardiovascular risk before prescribing lipid intervention.100  
Internationally, cardiovascular risk is assessed by primary care practitioners in New Zealand for 
general population who are 40 years and older, depending on the risk score, recommendation 
for interventions are suggested. [PREDICT programme: 
https://www.fmhs.auckland.ac.nz/en/soph/about/our-departments/epidemiology-and-
biostatistics/research/view-study/research.html] 
2.4.9 Initiatives to improve the quality of prognostic research 
The PROGRESS group [www.progress-partnership.org] introduced a framework with a view to 
improving the study of prognosis.101 The framework has four key themes: (1) Understanding 
health conditions and their nature and quality of care; (2) Identifying risk factors associated 
with prognosis; (3) Developing and validating prognostic models; (4) Using prognostic models 
to aid treatment/intervention decisions 
The TRIPOD (Transparent Reporting of multivariable prediction model for Individual Prognosis 
Or Diagnosis) statement102 is a set of recommendations developed to help improve the quality 
of reporting on development and validation of prognostic models and to standardise 
prognostic research methods. It is developed through convening of healthcare professionals, 
clinicians, researchers and questionnaires. Details of the 22 items comprising the TRIPOD 
checklist are listed in Table 2.6. 
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2.4.10 Conclusion and implications for this thesis 
Prognostic modelling is an established and still growing field of research and has demonstrated 
clinical utility, as evidenced by the recommendation for their use in treatment guidelines. 
Prognostic models have been developed for the outcomes relating to benefits and harms of 
antithrombotic therapy, for use prior to patients first prescription. There is a need to assess 
patient’s benefits and harms for novel uses of antithrombotic therapies, for example, 
prolonged dual antiplatelet therapy in myocardial infarction survivors.17 Patients who have 
been treated with dual antiplatelet therapy for a year may have different risk profiles from 
patients at the time of their acute myocardial infarction, therefore existing prognostic models 
for acute patients may not calibrate well in stable coronary disease populations. 
2.5 International normalised ratio control 
2.5.1 Background 
Oral anticoagulants are a widely used class of drugs primarily for stroke prevention in atrial 
fibrillation, treating venous thromboembolism and prevent atherothrombotic events in 
patients who underwent heart valve replacement. Vitamin K antagonists (VKA) are currently 
the class of oral anticoagulants most commonly used for long-term treatment. The therapeutic 
range for VKA treatment is particularly narrow and there are severe implications for patients 
who consistently fall outside of it. If over treated with VKAs i.e. dosage too high, patients are at 
increased risk of major bleeding or if undertreated patients (VKA dosage too low) may be at 
increased risk of atherothrombotic events. VKAs are particularly sensitive drugs and their 
effectiveness may be altered by comorbidities, concomitant medications, diet and alcohol 
consumption103. Therefore there is a wide personal variation for optimal VKA dosage which 
distinguishes it from other drugs commonly used to treat and prevent cardiovascular diseases 
which have a known optimal dose.  
The international normalised ratio (INR) is widely used biomarker for patients being treated 
with VKAs in order to measure treatment control and requires patients to undergo regular 
blood tests at specialised anticoagulation clinics.  INR is a standardised calculation of 
prothrombin time which is the time taken for blood to clot. In healthy people not treated with 
oral anticoagulants a normal INR is between 0.8 and 1.2. For patients being treated with oral 
anticoagulants the therapeutic range for most diseases is between 2 and 3. Therefore patients 
with INR values greater than 3 may be at increased of bleeding and patients with INR values 
below 2 may be receiving no benefit from their VKA therapy and even at increased risk of 
atherothrombotic events. 
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Given the concern of bleeding for patients above the therapeutic range and atherothrombotic 
events for patients below the therapeutic range, patients are monitored regularly for the 
duration of their treatment with oral anticoagulants. The frequency of INR tests is dependent 
on the stage of anticoagulation, presence of bleeding risk factors, concomitant prescriptions 
with drugs known to interact with oral anticoagulants, and poor INR.104 Depending on the 
indication for oral anticoagulation patients may be treated for 3 months (e.g. venous 
thromboembolism) to lifelong (e.g. for atrial fibrillation with high stroke risk). 
2.5.2 Time in therapeutic range 
There are many ways repeated INR tests may be summarised for analysis, the most common 
being percent time in therapeutic range (TTR). In calculating TTR a commonly used assumption 
is linear trajectory between consecutive INR measures, known as Roosendaal’s method.105  
The guidelines for VKA therapy control in atrial fibrillation, venous thromboembolism and 
heart valve replacement patients are summarised in Table 2.7. The NICE 2014 guidelines for 
atrial fibrillation management4 state anticoagulation should be reassessed if a patient’s INR 
value exceeds 5 on more than one occasion, if their INR drops below on more than one 
occasion or if their TTR is below 65%. The ESC 2016 guidelines for atrial fibrillation 
management5 recommend TTR is maintained above 70%. 
Guidelines for treatment of patients with venous thromboembolism33,34,106 suggests an initial 3 
months of VKA therapy with the potential to extend the duration for long term secondary 
prevention of atherothrombotic events in high risk patients. Patients with mechanical heart 
valve replacements are recommended to undergo lifelong VKA therapy.107,108 The intensity of 
treatment defined by the therapeutic range is dependent on the presence of additional risk 
factors for atherothrombotic events. Patients with bio-prosthetic heart valve replacements are 
recommended to undergo 3months of VKA therapy.107,108 No target time in therapeutic range 
is recommended in guidelines for treating venous thromboembolism or heart valve 
prostheses. 
2.5.3 Risk factors associated with time in therapeutic range 
A number of studies have assessed risks factors associated with INR control measured using 
time in therapeutic range. An overview of the studied risk factors is shown in Figure 2.2, and 
described in more detail in the following tables, sorted by study setting:  
 The studies of electronic health records are summarised in Table 2.8,  
 The studies of non-EHR observational cohorts are summarised in Table 2.9  
 The studies of randomised control trial populations are summarised in Table 2.10  
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2.5.3.1 Patient demographics 
Across the studies most found increasing age to be associated with higher TTR.109-118 For 
example in UK population based linked electronic health records from primary care and 
hospital admissions,  Macedo et al estimated that atrial fibrillation patients aged above 80 
years 50% lower odds of having a TTR<70% compared with patients aged between 18 and 44 
years and a similar estimate for venous thromboembolism patients.109 Three studies, with 
smaller sample sizes, found the increased age to be associated with lower TTR119-121 and 
several studies found no significant association between age and TTR.122-132 In most studies 
women were found to have lower TTR compared with men.109,110,112,114-120,122,123,126,128,133 One 
study found women to have higher TTR compared with men.129  
Four studies assessed the effects of ethnicity on TTR and all found patients with non-white 
ethnicity to have lower TTR compared with white patients.110,116-118 Two studies investigated 
the association between deprivation and TTR, and both found higher levels of deprivation to 
be associated with lower TTR.110,114  
Singer et al116 studied AF patients recruited in an international randomised control trial and 
found patients in Latin America, South Africa, Eastern Europe, East Asia and India had lower 
TTR compared with patients in North America. Kooistra et al132 studied VTE patients recruited 
in an international randomised control trial and found of the patients randomised to warfarin, 
those in Eastern Europe, Asia or South America had lower TTR compared with patients from 
Western Europe, Israel or South Africa whilst patients from Australia or New Zealand had 
higher TTR. In a smaller scale international cohort study Ansell et al found patients in Spain and 
Italy had higher mean TTR compared with patients in USA and France.134 
2.5.3.2 Patient behaviours 
Smoking status has been shown to have a negative impact on INR control and time in 
therapeutic range.109,117,135 However in two smaller observational cohorts positive associations 
between smoking and TTR were observed.125,129 Alcohol abuse and substance abuse has also 
been shown to be associated with lower TTR.110,116 However in smaller cohorts significant 
associations were not observed.125,128,129 
2.5.3.3 INR indication and target therapeutic range 
Three studies compared TTR in populations with more than one indication or target 
therapeutic range. Witt et al found patients with a target INR>3 had less stable TTR compared 
with patients with an INR target of 2.5.111 The authors also found no significant difference in 
TTR stability between patients with atrial fibrillation, venous thromboembolism, heart valve 
replacement or other indications.111 In a study of veteran healthcare data, Rose et al found 
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patients with venous thromboembolism compared with AF patients had higher TTR in the first 
6 months of anticoagulation, but worse TTR after 6 months.110 Witt et al found patients with 
lower target INR (2 vs. 2.5) had higher odds of very stable INR (100% TTR) than patients with 
higher target INR (3 vs. 2.5), but there were no significant differences INR stability between 
patients with different indications for anticoagulation (venous thromboembolism, heart valve 
replacement and other indications versus atrial fibrillation).112 
Four studies investigated the frequency of INR monitoring and all found an association 
between higher frequency of monitoring and worse TTR.114,119,120,131 Dlott et al found a 
negative quadratic association between INR monitoring frequency and TTR i.e. patients with 
the least frequent and most frequent monitoring had lower TTR.114 
2.5.3.4 Medical history: Cardiovascular diseases 
Patients with history of stroke were found to have lower TTR in three studies. Melamed et al 
found 7.4% of patients with excellent anticoagulation control (TTR>75%) had prior stroke 
compared with 20.3% of patients with poor anticoagulation control (TTR<60%).120 Nelson et al 
found that patients with prior stroke had 1.15 (95% CI: 1.04, 1.27) times the odds of having a 
TTR<55% compared to patients with no history of stroke.123 Sanchez et al found patients with 
prior stroke had 31% lower odds of achieving TTR≥65%.129 However, in a small single centre 
study patients with a prior history of stroke were found to have TTR 26.23% higher than 
patients without.130 A number of studies included stroke in their analyses but found no 
significant association with TTR. 
Three studies assessed the association between myocardial infarction and TTR. Two studies 
found a negative association: In a population based analysis of atrial fibrillation patients in 
Stockholm, Szummer et al included myocardial infarction as part of a composite vascular 
disease risk factor and found those patients to have lower TTR124 and Apostolakis et al found 
patients with a history of myocardial infarction had mean TTR of 61% compared to 65% for 
patients without.117 Barrios et al found no significant association.128 
Of the seven studies assessing coronary artery disease as a risk factor for TTR, two studies 
found a positive association: Singer et al found patients with coronary artery disease had 2.4% 
higher TTR than patients without116 and Wypasek et al found patients with a history of 
coronary artery disease had 11.8% higher TTR than those without. Two studies found a 
negative association: Rose et al found patients with a history of coronary artery disease had 
lower TTR in the long term, after 6 months of oral anticoagulation110 and Gotsman et al found 
patients with prior coronary artery disease had 9.2% lower TTR than patients without.135 Three 
studies found no association between coronary artery disease and TTR.127,129,131 
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Three studies in electronic health records have found that patients with hypertension had 
higher TTR110,115,123 whilst a small single centre cohort study found a negative association 
between hypertension and TTR,127 otherwise studies of hypertension as a risk factor found no 
significant association.  
Heart failure has consistently been found to be negatively associated with TTR and INR 
stability.109-112,115-118,120,122-124,126,128 For example, in a study of a large healthcare database for 
veterans Rose et al found patients with heart failure had 1.0% (95% CI: 0.7, 1.3) lower TTR in 
the long term.110 Szummer et al estimated that those with heart failure had 17.1% (95% CI: 7.7, 
26.4) lower TTR than those without.124 Macedo et al found heart failure to be associated with 
lower TTR for patients with atrial fibrillation but not those with venous thromboembolism.109 
Studies have shown history of peripheral arterial disease to be associated with lower 
TTR.110,118,124,128 For example, in a study of a large healthcare database for veterans Rose et al 
found patients with peripheral arterial disease had 0.5% (95% CI: 0.1, 0.8) lower TTR in the 
long term.110 Szummer et al estimated that patients with the composite risk factor of vascular 
disease which included peripheral arterial disease had 10.5% (95% CI: 2.5, 18.5) lower TTR than 
those without.124  
In a randomised controlled population trial comparing acenocoumarol with warfarin for 
patients with venous thromboembolism, those with prior venous thromboembolism events 
had higher TTR than those who were experiencing their first event.132 
2.5.3.5 Medical history: Non-cardiovascular diseases 
Diabetic patients have been shown to have lower TTR than non-diabetics in a number of 
studies.109-111,115-118,120,122,123,133 For example, Maecdo et al found diabetic patients indicated for 
oral anticoagulation with atrial fibrillation or venous thromboembolism had 2.01 (95% CI: 0.44, 
3.58) and 2.83 (95% CI: 0.31, 5.35) lower TTR, respectively, compared to patients without 
diabetes.109  
Nine studies assessed the association between history of bleeding and TTR. Two studies found 
a significant negative association between bleeding history and INR control. In a cohort of 
atrial fibrillation patients recruited from primary care centres in Spain, Barrios et al found 
11.3% of patients with poor INR control had a history of bleeding, anaemia or a pre-disposition 
to bleeding compared to 7.1% of patients with good INR control.128 In a prospective atrial 
fibrillation registry based in the US, Pokorney et al showed that 10% of patients in the lowest 
quartile of INR control (TTR 0-53%) had a prior gastrointestinal bleeding event compared with 
7% of patients in the highest INR control group (TTR >80%).118 In univariable analysis, Singer et 
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al showed that patients with a prior gastrointestinal bleeding event had higher mean TTR 
compared with patients who did not, however in multivariable analysis this association was 
not significant.116 
Ten studies assessed the relationship between renal disease and INR control and five 
estimated negative associations,110,118,121,129,133 while the remaining five studies found no 
significant association.109,117,128,130,131 
Three studies identified a negative association between history of liver disease and TTR. Rose 
et al found liver disease was associated poor TTR during long term anticoagulation (more than 
6 months), but was not a risk factor during the first 6 months of anticoagulation.110 Macedo et 
al found liver disease was associated with lower TTR in venous thromboembolism patients but 
not atrial fibrillation patients.109 In univariable analysis, Singer et al estimated that patients 
with liver disease had a lower mean TTR compared to those without.116 Chronic lung diseases 
including chronic obstructive pulmonary disease and asthma have been shown to be 
associated with worse INR control.109,110,116-118 In veterans’ healthcare data, Rose et al observed 
that patients with hyperlipidaemia had better TTR than patients without.110 However, in other 
studies hyperlipidaemia has been found to have either a negative association128 or no 
significant association with TTR.109,127,129,131 Cancer has been shown to be associated with poor 
INR control.109,110 Macedo et al found that for patients undergoing oral anticoagulation for 
venous thromboembolism those with rheumatoid arthritis had lower TTR than those 
without.109 Epilepsy has been shown to be associated with poor INR control.109,110 Using 
veterans’ healthcare data, Rose et al found a range of mental health conditions, including 
depression, bipolar disorder and dementia to be associated with poorer INR control, in both 
the initial 6 months of anticoagulation and longer term treatment.110 Macedo et al also 
evaluated the associations of mental health conditions on TTR and found dementia to have a 
negative impact for venous thromboembolism patients, but not atrial fibrillation patients.109 
2.5.3.6 Clinical biomarkers 
The associations between TTR and clinical biomarkers are inconclusive, mostly owing to 
varying study designs. In large-scale linked electronic health records from primary care and 
hospital admissions, overweight (body mass index (BMI): 25-29.9kg/m2), obese (BMI: 20-
39.9kg/m2) and morbidly obese (BMI: ≥ 40kg/m2) patients with atrial fibrillation or venous 
thromboembolism were reported to be associated with higher TTR compared with normal 
weight patients (BMI: 18.5-24.9 kg/m2), whilst underweight patients (BMI: <18.5kg/m2) were 
associated with lower TTR.109 Smaller scale studies have found higher BMI to be associated 
with lower TTR.117,127 
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In patients with renal dysfunction diagnosed with atrial fibrillation, higher estimated 
glomerular filtration rate (eGFR) was associated with higher TTR.124 A similar association was 
found in a more general atrial fibrillation registry cohort. Patients had 8% increased odds of 
being in the lowest TTR quartile per 5mg/dL decrease in eGFR and eGFR <60mg/dL.118 
Conversely, among high risk AF patients enrolled in the ROCKET-AF clinical trial, in unadjusted 
analysis patients with eGFR ≥68mL/min had 0.3% (p=0.016) lower TTR than patients with 
eGFR<68mL/min. In multivariable analysis a quadratic shaped association between eGFR and 
TTR was observed.116 
2.5.3.7 Prescribed medication 
There appeared to be a null or negative association between prescribed medications such as 
aspirin and antiplatelets and TTR. This may be due to interactions with warfarin or reverse 
causality in observational studies. On the other hand, in a few studies patients prescribed lipid 
lowering drugs109,116 or beta blockers116,117 were found to have higher TTR. 
2.5.4 Time in therapeutic range as a risk factor for prognosis following oral anticoagulation 
Studies of outcomes following oral anticoagulation with INR monitoring are shown in Table 
2.11. These studies focus on atherothrombotic events, and bleeding – relating to the benefits 
and harms of oral anticoagulation and also all-cause mortality. 
2.5.4.1 All-cause mortality and atherothrombotic events 
In large observational cohorts and population-based EHR studies of patients treated with oral 
anticoagulants, researchers have found that higher INR control, measured by TTR is associated 
with lower risk of all-cause mortality and atherothrombotic events.  
Morgan et al136 assessed time to mortality amongst atrial fibrillation patients stratified by 
CHADS2 score, a measure of stroke risk commonly used with atrial fibrillation patients. 
Amongst high stroke risk patients (CHADS2 score ≥2), warfarin therapy benefits were observed 
only if TTR was maintained at a sufficiently stable level. Those treated with warfarin had lower 
risks of stroke if their TTR>70% and mortality if their TTR>40% compared with those not 
treated with warfarin. Similar results were found among patients with lower stroke risk 
(CHADS2 score of 1). 
In a study of 2504 patients with stable INR (defined as 100% TTR) compared with 3569 patients 
with <100% TTR the stable patients had lower risk of all-cause mortality (0.4% vs 1.6% at 180 
days follow up respectively), but the incidence of thrombosis events did not significantly differ 
between the groups.111 In a study with a longer follow up of 1 year, patients with stable INR 
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had fewer thrombosis events than comparator patients and the mortality benefits of stable 
INR remained.112 
Using linked EHRs in Finland, Lehto et al. studied outcomes in 54568 atrial fibrillation patients. 
Patients with TTR≤40% had increased risk of all-cause mortality and stroke compared to 
patients with TTR 60-70% (Hazard ratios: 2.4 and 1.8 respectively). Patients with TTR >80% had 
lower risks of all-cause mortality and stroke compared to patients with TTR 60-70% (Hazard 
ratios: 0.4 and 0.7 respectively).137 
In a large scale study from anticoagulation clinic EHR of 42415 patients treated with warfarin 
for various indications, a U-shaped association between INR and all-cause mortality was 
identified. That is patients with very low or very high INR were at increased risk of death.138 
2.5.4.2 Bleeding events 
In large observational cohorts and population-based EHR studies of patients treated with oral 
anticoagulants, researchers have found that higher INR control, measured by TTR, is associated 
with lower risk of bleeding events.  
In a study of 2504 patients with stable INR (100% TTR) compared with 3569 patients with 
TTR<100%, the stable patients had lower incidence of bleeding at 180 days follow up (0.8% vs. 
2.8% respectively).111 In a similar study with a longer follow up time of 1 year, the association 
between stable INR and lower bleeding risk remained.112 
Similarly, Lehto et al found patients with TTR≤40% had increased risk of bleeding compared to 
patients with TTR 60-70% (Hazard ratio: 1.6). Patients with TTR >80% had lower risk of 
bleeding compared to patients with TTR 60-70% (Hazard ratio: 0.6).137 
2.5.5 Novel markers of INR control 
A number of studies have investigated measures of INR control as an alternative to TTR, 
summarised in Table 2.12. Examples of these measures of INR control include mean INR,139 INR 
variability,139-144 time above therapeutic range,144,145  time below therapeutic range,145 
percentage of records within therapeutic range,139,144 percentage of records outside 
therapeutic range,139 percentage of records above therapeutic range,139 and percentage of 
records below therapeutic range,139 first INR measure,145 last INR measure,145  linear slope,145 
and area under the curve.144 
In these studies, INR variability appeared to be a potentially a better measure of INR control 
than TTR, according to its association with all-cause mortality, atherothrombotic and bleeding 
events.139-144  
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Proietti et al studied the predictive ability of TTR when it was included in established bleeding 
risk scores as an additional prognostic factor. The authors used statistical measures such as the 
net reclassification index and the integrated discrimination improvement, and found that the 
models had improved predictive performance when accounting for patients previous TTR.146 It 
is unknown whether the novel markers of INR control can confer any additional predictive 
ability to existing prognostic models. 
2.5.6 Conclusion and implications for this thesis 
Despite numerous studies demonstrating TTR as a marker of INR control and prognostically 
important for future cardiovascular, bleeding and all-cause mortality events, few guidelines 
have adopted recommendations relating to TTR and INR control, particularly in non-AF 
populations. 
Previous studies, in a range of settings, have identified numerous risk factors associated with 
TTR. However the majority of studies populations comprised of atrial fibrillation patients. It is 
not known whether the findings in atrial fibrillation patients are applicable to or comparable 
with other disease populations indicated for oral anticoagulation and INR monitoring. 
Despite the prognostic importance of TTR being demonstrated, it is rarely adopted in 
prognostic models for relevant populations e.g. for stroke and bleeding risk. It is not known if 
TTR or other measures of INR control such as INR variability will contribute to prognostic 
models in the presence of known and regularly used atherothrombotic and bleeding risk 
factors. 
Within the CALIBER platform, using longitudinal INR records there is the opportunity to assess 
predictors of TTR and all-cause mortality, atherothrombotic and bleeding outcomes in patients 
following oral anticoagulation and we can compare across different patients groups indicated 
for oral anticoagulation, such as atrial fibrillation, venous thromboembolism and heart valve 
replacement. 
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2.6 Tables and Figures 
Table 2.1: Antithrombotic therapies and their indications 
 
Antithrombotic 
therapy classes and 
agents 
Primary 
CVD 
prevention 
for high risk 
individuals 
AT event 
prevention 
(following 
CAD) 
AT event 
prevention 
(following 
PAD) 
AT event 
prevention 
(following 
AF) 
AT event 
prevention 
(following 
ischaemic 
stroke) 
Treatment 
and 
prevention 
of VTE 
Heart valve 
disease or 
prosthetic 
heart 
valves 
Surgery with 
high VTE risk 
(e.g. 
orthopaedic) 
Haemo
dialysis 
Other 
A
n
ti
p
la
te
le
ts
 
COX inhibitors           
Aspirin          a 
ADP receptor 
inhibitors 
          
Clopidogrel           
Ticagrelor           
Prasugrel           
Ticlopidine           
Thromboxane 
inhibitors 
          
Dipyridamole           
Glycoprotein IIb/ 
IIIa inhibitors 
          
Abciximab           
O
ra
l a
n
ti
co
ag
u
la
n
ts
 Vitamin K 
antagonists 
          
Warfarin          b 
Acenocoumarol          b 
Phenindione           
Direct oral 
anticoagulants 
          
Dabigatran           
Rivaroxaban           
Apixaban           
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Antithrombotic 
therapy classes and 
agents 
Primary 
CVD 
prevention 
for high risk 
individuals 
AT event 
prevention 
(following 
CAD) 
AT event 
prevention 
(following 
PAD) 
AT event 
prevention 
(following 
AF) 
AT event 
prevention 
(following 
ischaemic 
stroke) 
Treatment 
and 
prevention 
of VTE 
Heart valve 
disease or 
prosthetic 
heart 
valves 
Surgery with 
high VTE risk 
(e.g. 
orthopaedic) 
Haemo
dialysis 
Other 
P
ar
en
te
ra
l 
an
ti
co
ag
u
la
n
ts
 
Heparin          c 
Low molecular 
weight heparins 
          
Bemiparin           
Certoparin           
Dalteparin           
Enoxaparin           
Fondaparinux           
Reviparin           
Tinzaparin           
CVD= cardiovascular disease; AT= atherothrombotic; CAD= coronary artery disease [myocardial infarction, acute coronary syndromes, unstable and stable angina]; PAD= 
peripheral arterial disease; AF= atrial fibrillation; VTE= venous thromboembolism 
a other indications for aspirin include pain relief, fever, inflammatory diseases (e.g. rheumatoid arthritics, systemic lupus erythematosus), antiphospholipid syndrome, and 
pregnancy with high pre-eclampsia risk;  
 b other indications for warfarin and acenocoumarol include treatment of cardiomyopathy;  
c other indications for heparin include AT event prevention during pregnancy  
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Table 2.2: Components of bleeding classifications used in randomised clinical trials and prospective observational studies 
Component TIMI48 GUSTO50 ACUITY51, 
HORIZONS52 
CURE54 CURRENT-
OASIS 756 
STEEPLE58 PLATO59 GRACE61 ISTH64 BARC3 
Fatality ● ● ● ● ● ● ● ● ● ● 
Anatomic 
bleeding site 
● 
Intracranial 
● 
Intracerebral 
● 
Intracranial 
Intraocular 
Retro-
peritoneal 
● 
Intracranial 
Intraocular 
● 
Intracranial  
Intraocular 
● 
Retro-
peritoneal 
Intracranial 
Intraocular 
Epistaxis 
Gastro-
intestinal 
● 
Intracranial 
Intra-
pericardial 
Epistaxis 
● 
Intracerebral 
● 
Intracranial 
Intraspinal 
Intraocular 
Retro-
peritoneal 
Intraarticular 
Pericardial 
Intramuscular  
● 
Intracranial 
Intraocular 
Haemoglobin 
drop 
● 
3 - <5g/dL 
≥5g/dL 
○ ● 
≥3g/dL w. 
overt bleeding 
≥4g/dL w/o 
overt bleeding 
● 
≥5g/dL 
● 
≥5g/dL 
● 
≥3g/dL 
2-3g/dL 
● 
>5g/dL 
3-5g/dL 
● 
Haematocrit 
≥10% 
● 
≥2 g/dL 
● 
3 - <5g/dL 
≥5g/dL 
Blood 
transfusion 
● ● ● ● ● ● ● ● ● ● 
Number of units 
transfused 
○ ○ ○ ● ● ● ● ● ● ● 
Haematoma size ○ ○ ● 
≥5cm 
○ ○ ● 
>5cm 
○ ○ ○ ○ 
Hospitalisation ○ ○ ○ ○ ○ ○ ○ ○ ● ● 
Medical/surgical 
consultation 
● ○ ○ ○ ○ ○ ○ ○ ● ● 
Medical/ 
surgical 
intervention 
● ○ ● ● ● ● ● ○ ● ● 
Haemodynamic 
compromise 
○ ● ○ ○ ○ ● ○ ○ ● ○ 
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Component TIMI48 GUSTO50 ACUITY51, 
HORIZONS52 
CURE54 CURRENT-
OASIS 756 
STEEPLE58 PLATO59 GRACE61 ISTH64 BARC3 
Severe 
hypotension 
○ ○ ○ ● ● ○ ● ○ ○ ○ 
Significantly 
disabling 
○ ○ ○ ○ ○ ○ ● ○ ○ ○ 
Change in 
antithrombotic 
therapy 
● ○ ○ ● ● ○ ○ ○ ● ○ 
Note: BARC=Bleeding Academic Research Consortium; ISTH= International Society on Thrombosis and Haemostasis; TIMI=Thrombosis In Myocardial Infarction  
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Table 2.3: Bleeding phenotypes developed using electronic health records 
Author Year Bleeding 
endpoint(s) 
evaluated 
No. of  
Bleeding 
anatomical 
sites 
Data 
source(s) 
Setting Study Population Coding 
system  
(n codes) 
Supporting 
EHR data used 
in case 
definition 
Algorithm 
figure 
reported 
Assessment of 
phenotype 
accuracy 
Raiford et 
al70 
 
1996 Upper 
gastrointestinal 
bleeding or 
perforation 
1 Saskatchewan 
Hospital 
Services Plan 
Hospital 
admissions 
Patients 
hospitalised for 
upper GI bleeding 
ICD-9 (30) No No Site specific codes 
PPV: 91% 
Nonspecific codes 
PPV: 68% 
De Abajo et 
al71 
1999 Upper 
gastrointestinal 
bleeding 
1 GPRD 
 
(UK) 
Primary 
care 
Patients with a 
record for acute 
upper GI bleeding 
Read 
(codes not 
stated)  
No No PPV: 95/96 
Arnason et 
al75 
2006 Any bleeding  
Major bleeding  
8 A university 
hospital, 
Ottawa 
Hospital 
admissions 
Patients with a 
record for 
thromboembolism 
or bleeding 
ICD-9 (81) No  
(information 
from patient 
charts were 
used to classify 
severity) 
No Definite bleeding 
PPV: 91%; NPV: 
91% 
Major bleeding 
PPV: 87%; NPV: 
92% 
Wahl et al72  2010 Severe upper 
gastrointestinal 
bleeding 
1 HealthCore 
Integrated 
Research 
Database 
(USA) 
Hospital 
admissions 
Patients with a 
record for upper 
GI bleeding 
ICD-9 
(original:75; 
refined:33)  
Procedure 
codes 
No PPV:  
original: 56.5% 
refined: 87.8%  
Cunningham 
et al76 
2011 Serious bleeding 
related to oral 
anticoagulation 
>4 Tennessee 
Medicaid 
program 
Hospital 
admissions 
Medicaid enrolees 
>30 years old 
ICD-9 (39) No  
(information 
from patient 
charts were 
used to classify 
severity) 
No PPV assessed for 
individual codes 
ranged from 71.4% 
to 100% (>5 charts) 
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Author Year Bleeding 
endpoint(s) 
evaluated 
No. of  
Bleeding 
anatomical 
sites 
Data 
source(s) 
Setting Study Population Coding 
system  
(n codes) 
Supporting 
EHR data used 
in case 
definition 
Algorithm 
figure 
reported 
Assessment of 
phenotype 
accuracy 
Crooks et 
al73  
2012 Upper 
gastrointestinal 
bleeding 
1 CPRD 
HES 
ONS 
 
(UK) 
Primary 
care 
Hospital 
admissions 
Death 
registry 
Patients with a 
record for acute 
upper GI bleeding 
Read (46) 
ICD-10 (22) 
Causes, 
symptoms, 
endoscopy, 
death, 
transfusion, 
procedures, 
alcohol, 
anaemia, 
coagulation, 
collapse, other 
Yes None 
Valkhoff et 
al74  
2014 Upper 
gastrointestinal 
bleeding 
1 IPCI 
(Netherlands) 
HSD (Italy) 
ARS (Italy) 
Aarhus 
(Denmark) 
Primary 
care 
Hospital 
admissions 
Patients with a 
record for upper 
GI bleeding 
IPCI (4) 
ICD-9 (26) 
ICD-10 (16) 
No No IPCI - PPV: 21% 
HSD - PPV: 78% 
ARS - PPV: 72% 
Aarhus - PPV: 77% 
Friberg et 
al77 
 
2016 Fatal 
Non-fatal major 
Hospitalised 
Minor 
4 Swedish 
Patient 
register 
Hospital 
admissions 
Hospital 
outpatients 
Death 
registry 
Atrial fibrillation 
patients 
ICD-10 (38) Anatomical site 
(intracranial) 
Transfusion 
Hospitalisation 
Diagnosis 
position 
No Fatal 
PPV: 88.1%;  
NPV: 99.7% 
Non-fatal major 
PPV: 90.6%;  
NPV: 91.5% 
Hospitalised 
PPV: 65.1%;  
NPV: 97.5% 
Minor 
PPV: 84.2%;  
NPV: 98.9% 
PPV: positive predictive value; NPV: negative predictive value;  
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Table 2.4: Population-based estimates of bleeding incidence 
Study Year 
 
Setting Population Bleeding 
endpoint(s) 
n Bleeding incidence and risk factors 
Steffensen 
et al78 
1997 North Jutland County 
pharmaco-
epidemiologic 
database linked to 
regional hospital 
discharge registry 
Patients treated 
with oral 
anticoagulants 
Major bleeding (fatal 
or requiring 
hospitalisation) 
682 Major bleeding rate: 6 per 100 treatment years 
Gastrointestinal bleeding rate: 2.7 per 100 treatment years 
Intracranial bleeding rate: 1.3 per 100 treatment years 
 
Major bleeding incidence increases with age 
Hollowell 
et al79 
2003 General Practice 
Research Database 
Patients 
prescribed 
warfarin 
Fatal bleeding 
(death within 7 
days) 
Hospitalised 
bleeding 
Minor bleeding 
3958 Gastrointestinal (20%), genitourinary (25%) and epistaxis (20%) most 
common bleeding events. All intracranial events were fatal/ 
hospitalised. 
Bleeding incidence per 100 patient years: 
Any: 15.2 (13.5, 17.0); Fatal/hospitalised: 3.5 (2.7, 4.6); Minor: 9.1 
(7.8, 10.6) 
Patients with valve disorders had the highest risk of bleeding.  
Hallas et 
al86 
2006 Funen County patient 
admin system linked 
to pharmaco-
epidemiological 
database and Danish 
central person 
register 
Cases with 
serious upper GI 
bleeding and 
age/sex matched 
controls  
Serious upper 
gastrointestinal 
bleeding 
1443 
cases 
 
57720 
controls 
Gastrointestinal bleeding adjusted odds ratios with ATT use: 
Aspirin: 1.8 (1.5, 2.1) 
Clopidogrel: 1.1 (0.6, 2.1) 
VKA: 1.8 (2.3, 2.4) 
Aspirin +clopidogrel: 7.4 (3.5, 15) 
Aspirin + VKA: 5.3 (2.9, 9.5) 
Lovelock et 
al84 
2007 Oxford community 
stroke project & 
Oxford vascular study 
Patients with 
previous vascular 
events  
Intracerebral 
haemorrhage 
52 
cases in 
OXVASC 
55 
cases in 
OCSP 
Standardised incidence (per 1000 per year) of intracerebral 
haemorrhage 
OXVASC <75yrs: 0.06  (0.03, 0.08) 
OXVASC ≥75yrs: 1.44 (0.95, 1.92) 
 
OCSP <75yrs: 0.10 (0.07, 0.14) 
OCSP ≥75yrs: 1.55 (0.96, 2.13) 
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Study Year 
 
Setting Population Bleeding 
endpoint(s) 
n Bleeding incidence and risk factors 
Toyoda et 
al80 
2008 19 stroke and CVD 
centres in Japan 
Patients taking 
ATT for stroke 
and CVD 
Life threatening or 
major bleeding 
Any bleeding 
Minor bleeding 
(MATCH trial 
criteria) 
4009 Incidence of bleeding events was higher in patients treated with more 
intense ATT combinations 
Life threatening or major bleeding incidence (% per year): 
Single antiplatelet: 1.21 
Dual antiplatelet: 2.00 
Warfarin: 2.06 
Warfarin + antiplatelet: 3.56 
 
Similar trends for any and minor bleeding 
Hansen et 
al81 
2010 Danish National 
Patient Registry, 
Danish Register of 
Medicinal Product 
Statistics, National 
Causes of Death 
Register 
Patients 
hospitalised with 
atrial fibrillation 
Nonfatal; Fatal  
Intracranial; Airway  
Gastrointestinal; 
Urinary tract  
118606 Prescribing of ATT drugs within 90 days of discharge increased from 
21.4% in 1997 to 44.8% in 2006 
Bleeding within 180 days of discharge increased from 4.7% to 9.0% 
Increasing bleeding risk with increasing intensity of ATT combination 
Lamberts 
et al82 
2012 Danish National 
Patient Registry, 
Danish Register of 
Medicinal Product 
Statistics, National 
Causes of Death 
Register 
Atrial fibrillation 
patients admitted 
with MI/PCI 
Fatal or nonfatal 
bleeding 
 
1 year follow up 
 
11480 Overall, 6.3% had fatal or nonfatal bleeding 
Triple therapy patients had highest bleeding incidence (14.2 events 
per 100 person years) 
Bleeding incidence increased with increasing intensity of ATT  
70/75 fatal bleeding events were intracranial or gastrointestinal 
Hreinsson 
et al85 
2013 National University 
Hospital Iceland 
All patients who 
underwent upper 
gastrointestinal 
endoscopy 
Upper 
gastrointestinal 
bleeding 
1731 Crude upper GI bleeding incidence: 0.87 per 1000 patients per year 
Incidence increases with age groups 
Duodenal (20.5%) and gastric ulcer (14.7%) most common bleeding 
diagnoses 
Warfarin, NSAIDS, aspirin associated with higher odds of bleeding 
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Study Year 
 
Setting Population Bleeding 
endpoint(s) 
n Bleeding incidence and risk factors 
Gallagher 
et al83 
2014 CPRD, HES, ONS 
linked data 
Atrial fibrillation 
patients 
Any bleeding 
Fatal 
Intracranial 
Extracranial  
Gastrointestinal  
16513 Incidence of bleeding events (per 100 person years): 
Bleeding 
event 
Current VKA 
exposure 
Past VKA 
exposure 
No VKA use 
Any 3.9 2.7 2.9 
Fatal 0.3 0.2 0.2 
Intracranial 0.4 0.2 0.4 
Extracranial 3.4 2.5 2.5 
GI 0.9 1.0 1.1 
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Table 2.5: Comparison of bleeding risk prediction models 
 REACH97 CRUSADE27 ACUITY/ HORIZONS-
AMI28 
HAS-BLED7 HAEMORR2HAGES98 QBLEED93 
Year 2010 2009 2010 2010 2006 2014 
Population Stable patients at risk 
for atherothrombotic 
events 
Treated NSTEMI ACS Atrial fibrillation Atrial fibrillation Patients aged 21-99 not 
currently using 
anticoagulants 
n population 68236 71277 17421 3978 0 (model derivation 
driven by literature 
alone) 
4.4 million 
Bleeding outcome Serious bleed leading to 
both hospitalization and 
transfusion within 2 
years 
In-hospital major 
bleeding 
Non-CABG related major 
bleeding within 30 days 
of ACS presentation 
Major bleeding within 1 
year 
Hospitalisation for 
haemorrhage up to 1000 
days 
Upper gastrointestinal 
and intracranial  
Follow up t 2 years  30 days 1 year 1000 days  
n events  804 6701 520 53 - 21641 upper GI 
9040 intracranial 
Prognostic factors       
Demographics & 
behaviours 
2 (age, smoking) 2 (age, sex) 2 (age, sex) 2 (age, drug or alcohol 
abuse) 
2 (age, alcohol abuse) 6 (age, sex, ethnicity, 
deprivation, smoking, 
alcohol) 
Clinical diagnoses 5 (peripheral arterial 
disease, congestive 
heart failure, diabetes, 
hypercholesterolemia, 
hypertension) 
2 (prior vascular disease, 
diabetes) 
2 (anaemia, ACS 
presentation) 
4 (hypertension, 
abnormal renal/ liver 
function, history of 
stroke, bleeding history 
or anaemia) 
7 (Liver or renal disease, 
malignancy, prior bleed, 
uncontrolled 
hypertension, anaemia, 
excessive fall risk, prior 
stroke) 
9 (atrial fibrillation, 
heart failure, high blood 
pressure, cancer, liver 
disease, pancreatitis, 
oesophageal varices, 
bleeding, VTE) 
Biomarkers 0 4 (Haematocrit, 
creatinine clearance, 
heart rate, systolic blood 
pressure) 
2 (serum creatinine, 
white blood cell count) 
1 (INR in 2-3 range <60% 
of time) 
2 (reduced platelet 
count, genetic factors 
(CYP 2C9 single 
nucleotide 
polymorphisms)) 
2 (reduced platelet 
count, BMI) 
Pharmacological 
interventions 
2 (antiplatelets, oral 
anticoagulants) 
0 1 (ATT: heparin +GPI vs. 
bivalirudin 
monotherapy) 
1 (antiplatelet or NSAID) 0 5 ( antiplatelet drugs, 
NSAIDs, steroids, 
antidepressants, 
anticonvulsants) 
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 REACH97 CRUSADE27 ACUITY/ HORIZONS-
AMI28 
HAS-BLED7 HAEMORR2HAGES98 QBLEED93 
Included patients 
with missing data 
No Missing age, sex, 
ethnicity, haematocrit 
excluded. Single 
imputation used on 
remaining variables. 
No No - Yes. Multiple imputation 
used for missing BMI, 
SBP, smoking and 
alcohol status 
Externally validated Yes 
CHARISMA trial 
population N=15603 
Yes 
N=4500 ACS patients 
Yes 
N=4500 ACS patients 
Yes 
SPORTIF trial population 
N=7329 AF patients 
Yes 
SPORTIF trial population 
N=7329 AF patients 
Yes 
QResearch validation 
population  
N=1.4 million patients 
Discrimination 
measure used 
c-index c-index c-index c-index c-index c-index 
Discrimination 0.64 0.8 0.75 0.65 0.62 Upper gastrointestinal 
bleeding: 0.77 
Intracranial bleeding: 
0.86 
Calibration 
measure used 
Modified Hosmer 
Lemeshow 
Hosmer Lemeshow Hosmer Lemeshow Hosmer Lemeshow Hosmer Lemeshow Graphically compared 
mean predicted and 
observed risks in deciles 
Calibration P=0.31 P=0.5 P=0.3 P>0.05 P>0.05 N/A 
Used electronic 
health records 
No No No No No Yes 
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Figure 2.1: A graphical representation of weighing benefits and harms to aid treatment decisions  
 
Adapted from Pocock et al. American Heart Journal 2014 168, 607-610DOI: 10.1016/j.ahj.2014.08.003 
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Table 2.6: The TRIPOD checklist 
Section/Topic Item  Checklist Item Page 
Title and abstract 
Title 1 D;V 
Identify the study as developing and/or validating a multivariable prediction 
model, the target population, and the outcome to be predicted. 
 
Abstract 2 D;V 
Provide a summary of objectives, study design, setting, participants, sample size, 
predictors, outcome, statistical analysis, results, and conclusions. 
 
Introduction 
Background and 
objectives 
3a D;V 
Explain the medical context (including whether diagnostic or prognostic) 
and rationale for developing or validating the multivariable prediction 
model, including references to existing models. 
 
3b D;V 
Specify the objectives, including whether the study describes the 
development or validation of the model or both. 
 
Methods 
Source of data 
4a D;V 
Describe the study design or source of data (e.g., randomized trial, cohort, 
or registry data), separately for the development and validation data sets, 
if applicable. 
 
4b D;V 
Specify the key study dates, including start of accrual; end of accrual; and, 
if applicable, end of follow-up.  
 
Participants 
5a D;V 
Specify key elements of the study setting (e.g., primary care, secondary 
care, general population) including number and location of centres. 
 
5b D;V Describe eligibility criteria for participants.   
5c D;V Give details of treatments received, if relevant.   
Outcome 
6a D;V 
Clearly define the outcome that is predicted by the prediction model, 
including how and when assessed.  
 
6b D;V Report any actions to blind assessment of the outcome to be predicted.   
Predictors 
7a D;V 
Clearly define all predictors used in developing or validating the 
multivariable prediction model, including how and when they were 
measured. 
 
7b D;V 
Report any actions to blind assessment of predictors for the outcome and 
other predictors.  
 
Sample size 8 D;V Explain how the study size was arrived at.  
Missing data 9 D;V 
Describe how missing data were handled (e.g., complete-case analysis, 
single imputation, multiple imputation) with details of any imputation 
method.  
 
Statistical 
analysis 
methods 
10a D Describe how predictors were handled in the analyses.   
10b D 
Specify type of model, all model-building procedures (including any 
predictor selection), and method for internal validation. 
 
10c V For validation, describe how the predictions were calculated.   
10d D;V 
Specify all measures used to assess model performance and, if relevant, 
to compare multiple models.  
 
10e V 
Describe any model updating (e.g., recalibration) arising from the 
validation, if done. 
 
Risk groups 11 D;V Provide details on how risk groups were created, if done.   
Development vs. 
validation 
12 V 
For validation, identify any differences from the development data in setting, 
eligibility criteria, outcome, and predictors.  
 
Results 
Participants 
13a D;V 
Describe the flow of participants through the study, including the number 
of participants with and without the outcome and, if applicable, a summary 
of the follow-up time. A diagram may be helpful.  
 
13b D;V 
Describe the characteristics of the participants (basic demographics, 
clinical features, available predictors), including the number of participants 
with missing data for predictors and outcome.  
 
13c V 
For validation, show a comparison with the development data of the 
distribution of important variables (demographics, predictors and 
outcome).  
 
Model 
development  
14a D Specify the number of participants and outcome events in each analysis.   
14b D 
If done, report the unadjusted association between each candidate 
predictor and outcome. 
 
Model 
specification 
15a D 
Present the full prediction model to allow predictions for individuals (i.e., all 
regression coefficients, and model intercept or baseline survival at a given 
time point). 
 
15b D Explain how to the use the prediction model.  
Model 
performance 
16 D;V Report performance measures (with CIs) for the prediction model.  
Model-updating 17 V 
If done, report the results from any model updating (i.e., model specification, 
model performance). 
 
Discussion 
Limitations 18 D;V 
Discuss any limitations of the study (such as nonrepresentative sample, few 
events per predictor, missing data).  
 
Interpretation 19a V 
For validation, discuss the results with reference to performance in the 
development data, and any other validation data.  
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19b D;V 
Give an overall interpretation of the results, considering objectives, 
limitations, results from similar studies, and other relevant evidence.  
 
Implications 20 D;V 
Discuss the potential clinical use of the model and implications for future 
research.  
 
Other information 
Supplementary 
information 
21 D;V 
Provide information about the availability of supplementary resources, such as 
study protocol, Web calculator, and data sets.  
 
Funding 22 D;V Give the source of funding and the role of the funders for the present study.   
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Table 2.7: International normalised ratio (INR) and time in therapeutic range (TTR) in European and US guidelines for atrial fibrillation, venous thromboembolism and heart valve replacement 
patients 
Indication Guidance INR therapeutic range VKA therapy 
duration 
INR test frequency Recommended 
TTR threshold % 
Other recommended INR or 
TTR checks 
Atrial fibrillation NICE 20144 2-3 Lifelong NR 65 INR>5 
INR< 1.5 
ESC 20165 2-3 Lifelong NR 70 SAME-TT2R2 score 
AHA/ACC/HRS 
2014147 
2-3 Lifelong Initiation: weekly 
Stable: monthly 
NR  
Venous 
thromboembolism 
NICE 201233 NR 3 months+ NR NR NR 
ESC 201434 2-3 3 months+ NR NR Pharmacogenetic testing 
(CYP2C9) may improve TTR 
CHEST 2016106 2-3 3 months+ NR NR NR 
Heart valve 
replacement 
ESC 2012108 Mechanical valve w/o 
risk factors or bio 
prosthetic valve: 2-3 
 
Mechanical valve w. risk 
factors: 2.5-3.5 
Mechanical valve: 
Lifelong 
 
Bio prosthetic 
valve: 3months+ 
NR NR NR 
AHA/ACC 2014107 w/o risk factors: 2-3 
 
w. risk factors: 2.5-3.5 
Mechanical valve: 
Lifelong 
 
Bio prosthetic 
valve: 3months+ 
NR NR NR 
NR= No recommendation given  
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Figure 2.2: A summary of risk factors for INR time in therapeutic range 
 
Note: Green boxes indicate risk factors presence was associated with higher TTR, red boxes indicate risk factors presence was associated with worse TTR, grey 
boxes indicate no association found between risk factors presence and TTR and white boxes indicate the risk factor was not studied.  
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Table 2.8: Risk factors for INR time in therapeutic range: assessed in electronic health records 
Author  Year 
Electronic health 
records 
Study Population n Endpoint 
Overall 
Mean (SD) TTR 
Main findings;  
(+)= associated with higher TTR, (-) = associated with lower TTR 
Currie et 
al119 
2005 
Hospital inpatient  
Haematology lab  
ONS mortality 
 
linked data 
UK 
NVAF patients 1513 TTR 
Stable group 
74.9 
 
Unstable group 
44.7 
Morbidity (-), monitoring frequency (-), female+age (-) 
Boulanger 
et al122 
2006 
General Electric 
Electronic Medical 
Records Logician 
database 
USA 
NVAF patients 
 
1998-2003 
6454 
PT/%INR in 
range 
48 (47, 49) 
Men (+), congestive heart failure (-), diabetes (-), Northeast vs. 
Western/Midwest (-) 
Witt et 
al111 
2009 
Kaiser Permanente 
Colorado, 
Clinical Pharmacy 
Anticoagulation 
Service 
USA 
Patients with >90 
days warfarin 
therapy 
 
2000-2005 
6073 TTR=100% 
Comparator 
group: mean 
proportion of 
INR values in 
therapeutic 
range 49.9% 
(22) 
2504 stable patients, 3569 comparator patients 
Age>70 (+), INR target >3 vs. 2.5 (-), diabetes (-), heart failure (-), oestrogen 
therapy (-), chronic disease score (-) 
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Author  Year 
Electronic health 
records 
Study Population n Endpoint 
Overall 
Mean (SD) TTR 
Main findings;  
(+)= associated with higher TTR, (-) = associated with lower TTR 
Rose et 
al110  
2010 
Veterans Health 
Administration 
(VARIA) 
 
USA 
Patients receiving 
oral anticoagulation 
therapy 
(valvular heart 
disease, VTE, AF, 
other) 
 
2006-2008 
124619 
TTR during 
inception and 
experienced 
phases 
First 6 months: 
48 
 
6 months+: 
61 
TTR (first 6 months): Age(+), non-white(-), deprivation (-), distance to 
nearest VA facility (-), VTE vs. AF (+), other indications vs. AF (-), cancer (-), 
CKD (-), diabetes (-), hyperlipidaemia (+), alcohol (-), bipolar (-), dementia (-), 
substance abuse (-), no. of concomitant medications (-), no. of 
hospitalisations (-) 
 
TTR (6 months+): female (-), age (+), black ethnicity (-), deprivation (-), VTE 
and other indications vs. AF (-), cancer (-), CKD (-), liver disease (-), lung 
disease (-), CAD (-), diabetes (-), epilepsy (-), HF (-), hyperlipidaemia (+), 
hypertension (+), PAD (-), alcohol (-), bipolar (-), dementia (-), depression (-), 
substance abuse (-), no. of concomitant medications (-), no. of 
hospitalisations (-) 
 
Developed a prediction model for TTR 
 
Witt et 
al112 
2010 
Kaiser Permanente 
Colorado, 
Clinical Pharmacy 
Anticoagulation 
Service 
USA 
Patients with >90 
days warfarin 
therapy 
 
2000-2005 
3088 TTR=100% 
Comparator 
group: 
42.1 (5.7) 
533 patients with 100% TTR, 2555 comparator patients 
Age (+), male (+), INR target 2 vs 2.5 (+), INR target>3 vs. 2.5 (-),heart failure 
(-), chronic disease score (-) 
Melamed 
et al120 
2011 
Clalit Health Services 
database  
 
(Israel) 
AF patients within a 
large managed care 
organisation 
 
2006-2007 
906 
TTR<60% 
TTR 60-75% 
TTR>75% 
48.6 (23.1) 
TTR<60% (n=611, 67.4%) 
TTR 60-75 (n= 187, 20.6%) 
TTR>75% (n=108, 11.9%) 
 
Age(-), female (-), >16 INR records (-), diabetes (-), heart failure (-), prior 
stroke (-), non-board certified physician (-) 
Walker et 
al148 
2011 
Veterans Health 
Administration 
 
AF/atrial flutter 
patients 
 
2002-2003 
296 TTR 
MHC 
56.8 (16.9) 
No MHC 65.9 
(18.2) 
Mental health conditions (MHC)  (-) 
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Author  Year 
Electronic health 
records 
Study Population n Endpoint 
Overall 
Mean (SD) TTR 
Main findings;  
(+)= associated with higher TTR, (-) = associated with lower TTR 
Wieloch et 
al113 
2011 
AuriculA 
 
Sweden 
Atrial fibrillation  
 
2008 
18391 TTR 76.2 Age (+) 
Nelson et 
al123 
2013 
CoagClinic 
 
USA (49 states) 
 
NVAF 
2006-2010 
23425 TTR<55 67.3 (14.4) 
Men (+),US region: West vs Northeast  (-), US region: South vs Northeast (-), 
heart failure (-), Diabetes (-), previous stroke (-), hypertension (+) 
Rodriguez 
et al149 
2013 
Massachusetts Gen. 
Hosp. 
Anticoagulation 
Management 
Service, 
Research Patient 
Data Repository 
 
Linked data, USA 
Indicated for oral 
anticoagulation  
(2-3) 
 
2009-2010 
3770 TTR 73.8 Limited English proficiency (-) 
Dlott et 
al114 
2014 
Quest Diagnostics 
Informatics Data 
 
USA 
AF patients  
2007-2008 
138319 TTR 53.7 (23.3) 
INR test frequency (-quadratic), study length<6months (-), age (+), women (-
), median income (+), US region 
Razouki et 
al150 
2014 
Veterans Health 
Administration 
(VARIA) 
 
USA 
Patients receiving 
warfarin, target 
INR:2-3 
 
2006-2008 
103897 
TAR (time 
above range) 
 
TBR (Time 
below range) 
Not stated 
(Note: Associations with TAR and TBR not TTR.) 
TAR: Women (+), age (-), non-white (+), deprivation (+), AF vs. VTE (+), 
cancer (+), CKD (+), lung disease (+), diabetes (+), HF (+), alcohol (+), bipolar 
(+), dementia (+), depression (+), substance abuse (+), no. of concomitant 
meds (+), no. of hospitalisations (+) 
 
TBR: Women (+), age (-), deprivation (+), distance to nearest VA (-), AF vs. 
VTE (-), cancer (+), CKD (+), liver disease (+), lung disease (+), diabetes (-), 
epilepsy (+), HF (+), alcohol (+), depression (+), alcohol (-), no. of concomitant 
meds (+), no. of hospitalisations (+) 
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Author  Year 
Electronic health 
records 
Study Population n Endpoint 
Overall 
Mean (SD) TTR 
Main findings;  
(+)= associated with higher TTR, (-) = associated with lower TTR 
Macedo et 
al 109 
2015 
CPRD, HES  
 
Linked data 
 
(UK) 
AF + VTE patients 
with warfarin rx in 
first 12 months of 
anticoagulation 
 
2000-2013 
AF: 
29717 
 
VTE: 
19113 
TTR 
TTR<70% 
TBR>30% 
TAR>30% 
44% AF and 
36% VTE had 
TTR>70% 
AF: age (+), BMI, current smoking (-), acute respiratory infection (-), chronic 
lung disease (-), pain medication (-), diabetes (-), epilepsy (-), lipid lowering 
drugs (+), 5-10 hospitalisations per year (-) 
 
VTE: female (-), age (+), BMI (+), current smoking (-), substance abuse (-), 
cancer (-), chronic lung disease (-), pain medication (-), dementia (-), diabetes 
(-), epilepsy (-), rheumatoid arthritis (-) 
 
Nelson et 
al115 
2015 
CoagClinic 
 
USA (49 states) 
 
NVAF 
2006-2010 
9433 
Quartile with 
highest % INR 
out of range 
66.8 Age (+), male (+), heart failure (-), diabetes (-), hypertension (+)  
Yong et 
al151 
2016 TREAT-AF 
 
Veterans Health 
Administration 
Newly diagnosed AF 
2003-1012 
184161 TTR Ranged from 
59(18) to 
52(20) 
amongst 
ethnicity 
groups 
Black ethnicity (-) 
 
Gryzmala-
Lubanski 
et al152 
2017 
AURICULA, Swedish 
National Patient 
Registry, 
SWEDEHEART, Cause 
of Death Registry 
 
Linked data 
Mechanical heart 
valve patients 
 
2006-2011 
3831 TTR  Mitral valve vs. aortic valve (-) 
Hellyer et 
al153 
2017 
Veterans Health 
Administration 
 
USA 
AF patients 
 
2003-2012 
167190 TTR Not stated 
Similar rates of INR monitoring across risk groups 
 
CHA2DS2-VASc score (-) 
 
HAS-BLED score (-) 
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Author  Year 
Electronic health 
records 
Study Population n Endpoint 
Overall 
Mean (SD) TTR 
Main findings;  
(+)= associated with higher TTR, (-) = associated with lower TTR 
Szummer 
et al124 
2017 
Stockholm 
CREAtinine 
Measurements 
(SCREAM), 
Swedish Renal 
Register 
 
Linked data 
Newly diagnosed AF 
patients initiating 
warfarin 
 
2006-2011 
7738 TTR 
Median (IQR) 
83 (71, 92) 
Poor renal function (low eGFR) (-), diabetes (-), vascular disease (-), heart 
failure (-), aspirin (+) 
 
 
Williams et 
al154 
 
(ACC 
abstract 
only) 
2017 
Electronic medical 
records  
 
(exact resource not 
specified) 
Newly diagnosed 
NVAF patients 
 
8867 TTR 
Median (IQR) 
55 (34, 68) 
19 factors included in final prediction model (85 evaluated in total) 
 
Strongest predictors of low TTR: antiarrhythmic drug use, anaemia, lung 
disease, aspirin, low red blood cell count 
 
Better predictive performance than SAMEe-TT2R2 score in validation cohort  
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Table 2.9: Risk factors for INR time in therapeutic range: assessed in observational cohorts and disease registries 
Author  Year Setting Study Population n Endpoint 
Overall 
Mean (SD) 
TTR 
Main findings;  
(+)= associated with higher TTR, (-) = associated with lower TTR 
Penning-van 
Beest et al125 
2002 
Red Cross 
anticoagulation clinic 
 
Netherlands 
All patients treated 
with oral 
anticoagulants 
1997-1999 
602 INR>6 
Median INR 
Cases: 6.8 
 
Controls: 3.2 
(2-4) 
 
BMI<20 (-), weight loss (-), below average physical activity (-), decrease in 
drinking (-), smoking (+) 
Veeger et 
al155 
2005 
Anticoagulation 
clinic 
 
Netherlands 
Patients with VTE 
 
1995-1998 
2304 TTR (2-3.5) 63% 30 day TTR(+) 
Burton et 
al156 
2006 
27 general practices 
 
Scotland 
Atrial fibrillation 
patients  
 
1998 
601 TTR 68%  
Ansell et al134 2007 
Multicentre 
 
USA, Canada, France, 
Italy, Spain 
NVAF patients 
taking OAC for at 
least 60 days 
1511 TTR 
USA 
57 (24.1) 
Canada 
61 (25.2) 
France 
58.1 (25.1) 
Italy 
68.9 (17.0) 
Spain 
64.4 (19.4) 
USA vs. Italy (-), France vs. Italy (-), France vs. Spain (-), USA vs. Spain (-) 
Cavallari et 
al157 
2009 
Antithrombosis Clinic  
University of Illinois 
Medical Centre 
African American 
patients (and 
Caucasian controls) 
at the ATC 
118 
Unstable (% 
INR out of 
range > 
median) 
Median 
proportion 
out of range 
INR 44% (14-
82%) 
African American: No. of clinic visits (-), warfarin adherence (+), ≥3 
episodes of vomiting or diarrhoea (-), ≥1 anti-infective rx (-) 
 
Caucasian: No. of clinic visits (-), warfarin adherence (+) 
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Author  Year Setting Study Population n Endpoint 
Overall 
Mean (SD) 
TTR 
Main findings;  
(+)= associated with higher TTR, (-) = associated with lower TTR 
Okumura et 
al158 
2011 
Multicentre study 6 
institutions, 1 clinic 
in 5 prefectures in 
Japan 
NVAF undergoing 
warfarin ≥2 years 
 
2008-2010 
501 TTR 64 (25) Age (+), Warfarin dose (-) 
Costa et al159 2012 
Single 
anticoagulation clinic 
 
Brazil 
Patients taking OAC 
for at least 90 days 
from enrolment 
2006-2008 
134 TTR 64.7 (17.1) 
Variability of daily vitamin K intake (-), male (+), warfarin treatment 
duration >2months (+), presence of family support (+), good medication 
management capacity (cognitive ability to take meds as prescribed) (+) 
Han et al160 2013 
Multicentre  
10 cardiology 
practices and 30 
primary care 
practices 
USA 
NVAF patients 392 TTR 56.7 
Cardiology vs. primary care practices(+) 
(Mean TTR: 60.8 vs. 55.3) 
Tomita et 
al126 
2013 
Outpatients from 4 
institutes  
Japan 
NVAF patients 163 TTR 69.7 (25.1) Women (-), congestive heart failure (-) 
Ciurus et al127 2015 
Department of 
Cardiology of the 
Medical 
University of Lodz 
 
Poland 
NVAF or VTE 
patients indicated 
for OAC 
149 
TTR>80 
(stable) 
 
TTR<80 
(unstable) 
76 (21) Arterial hypertension (-), amiodarone (-), BMI (-) 
Barrios et 
al128  
2015 
Multicentre 
 
Spain 
NVAF patients 
receiving VKA >1 
year 
1524 TTR 69.0 (17.7) 
Women (-), dyslipidaemia (-), heart failure (-), PAD (-), dietary habits (-), 
bleeding/anaemia (-), history of TTR<60 (-), no. of concomitant meds (-)  
Sanchez et 
al129 
2015 
120 cardiology clinics  
(CALIFA) 
 
Spain 
NVAF patients 1056 TTR<65 63.8 (25.9) 
Kidney disease (-), no ARB treatment (-), antiplatelets (-), regular NSAID use 
(-) 
male (-), unemployed vs. employed (-), homemaker vs. employed (-), 
institutional resident vs. lives with partner (-), previous stroke (-), MRA (-), 
diuretics (-) 
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Author  Year Setting Study Population n Endpoint 
Overall 
Mean (SD) 
TTR 
Main findings;  
(+)= associated with higher TTR, (-) = associated with lower TTR 
Porkorney et 
al118 
2015 
ORBIT-AF registry 
 
USA 
AF patients treated 
with warfarin 
5210 
TTR in the 
lowest 
quartile 
(TTR<53) 
65 (20) 
Age (+), Diabetes(-), eGFR (+), INR at clinic (+), weight (+), haematocrit (+), 
COPD (-), prior valve surgery (-), NYHA class (HF) (-), AF diagnosis >1 year 
prior to enrolment (+), frailty (-) 
Bishop et 
al161 
2016 
John Hopkins 
Hospital 
 
USA 
Adult patients 
whose warfarin 
managed by face-to-
face visits at clinic 
249 TTR 50.1 Primary AC provider vs. no primary AC provider (+) 
Wypasek et 
al130  
2016 Poland 
Patients with aortic 
valve replacement 
(mechanical or 
bioprosthesis) with 
genetic guided 
warfarin dosing 
200 TTR<60 
Median 
59.6 (38.7, 
82.7) 
CAD (+), previous stroke (+), CYP2C9*2 (-) 
Alyousif et 
al162 
2016 
KAMC  
Saudi Arabia 
AF patients treated 
with warfarin 
>3months 
 
2012-2013 
110 TTR 59 (24.2) CHADS2 (-) 
Atas et al121 2017 
Tertiary care, 
university hospital 
 
Turkey 
AF patients treated 
with warfarin 
2014-2016 
170 TTR<55 54.2 (21.4) Elderly [age>75] (-), renal dysfunction [eGFR<60] (-) 
Mohammed 
et al131 
2017 
Heart Hospital 
outpatient clinic 
 
Qatar 
NVAF patients with 
>6 months warfarin  
 
241 TTR<65 
Median 
(range) 
70 (19, 100) 
Polypharmacy (-), no. of clinic visits (-) 
 
  
84 
 
 
Table 2.10: Risk factors for INR time in therapeutic range: assessed in randomised controlled trial populations 
Author  Year Trial(s) Study Population n Endpoint 
Overall 
Mean (SD) 
TTR 
Main findings;  
(+)= associated with higher TTR, (-) = associated with lower TTR 
Rombouts et 
al163 
2007 
Leiden 
anticoagulation clinic 
 
Netherlands 
Patients with an 
indication for long-
term OAC 
randomised to 
Vitamin K or placebo 
182 TTR 
Vitamin K: 
89.5 (86.4, 
92.5) 
 
Placebo: 
85.5 (82.3, 
88.6) 
Vitamin K supplementation (+) 
Sconce et 
al164 
2007 
Anticoagulation 
clinics 
Freeman Hospital 
and Royal Victoria 
Infirmary 
 
UK 
Atrial fibrillation 
patients treated 
with warfarin (2-3) 
for at least 9 months 
with unstable 
control 
randomised to 
Vitamin K or placebo 
68 TTR 
Baseline 
Vitamin K: 
59 (20) 
 
Control: 
63 (18) 
Vitamin K supplementation (+) 
Singer et al116 2013 ROCKET-AF trial 
 
(45 countries, 7 
regions) 
AF patients 
randomised to 
warfarin 
6983 TTR 55.2 (21.3) Age (+), VKA/warfarin naïve (-), Latin America vs. USA/Canada (-), South 
Africa vs. USA/Canada (-), Eastern Europe vs. USA/Canada (-), East Asia vs. 
USA/Canada (-), India vs. USA/Canada (-), Congestive heart failure (-), 
women (-), COPD (-), eGFR (-quadratic), haemoglobin (- quadratic), SBP (-), 
BMI (+quadratic), diabetes (-), heavy alcohol consumption (-), amiodarone 
(-), statin (+), aspirin (-), non-white ethnicity(-) 
Apostolakis 
et al117 
2013 Model derivation: 
AFFIRM 
 
Model validation: 
prospective cohort 
from Sandwell + 
West Birmingham 
Hospitals 
AF patients treated 
with OAC 
 
 
1061 
 
 
286  
TTR Derivation 
64 (18) 
Validation 
66 (16) 
Women (-), minority (-), age (+), BMI>30 (-), MI (-), heart failure (-), PAD (-), 
diabetes (-), pulmonary disease (-), smoking (-), rhythm control (-), beta 
blockers (+), verapamil (+), amiodarone (-), >2 comorbidities (-), >1 
comorbidity (-) 
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Author  Year Trial(s) Study Population n Endpoint 
Overall 
Mean (SD) 
TTR 
Main findings;  
(+)= associated with higher TTR, (-) = associated with lower TTR 
Smith et al165 2013 TREAT (intensive 
educational 
intervention vs. 
usual care) 
 
UK 
AF patients newly 
referred for warfarin 
therapy 
97 TTR Intervention 
group 
76.2 (64.1, 
97.3) 
Control group 
71.3 (51.2, 
84.7) 
 
Intensive educational therapy vs. usual care (+) 
Kooistra et 
al132 
2015 EINSTEIN-DVT 
EINSTEIN-PE  
VTE patients 
randomised to VKA 
therapy 
Warfarin or 
acenocoumarol 
3825 TTR<64.7 
(also TTR 
variability) 
Median  
64.7 
Warfarin:  
Eastern Europe vs. Western Europe/Israel/South Africa (-), Australia/NZ vs. 
Western Europe/Israel/South Africa (+), Asia/South America vs. Western 
Europe/Israel/South Africa (-), weight <50kg (-), active cancer (-), 
secondary VTE (-), previous VTE (+) 
 
Acenocoumarol:  
Eastern Europe vs. Western Europe/Israel/South Africa (+), secondary VTE 
(-), age (+) 
Proietti et 
al133 
2016 SPORTIF III and V Atrial fibrillation 
patients randomised 
to warfarin with 
data on renal 
function 
3646 TTR 
TTR>70 
Median  
68.6 (56.5, 
80.6) 
All Patients: Chronic kidney disease (-), chronic AF (+), Men (+), diabetes (-
), aspirin (-) 
 
CKD subgroup: weight (+), chronic AF (+), congestive heart failure (+) 
Gotsman et 
al135 
2017 standard care vs. 
one time 
intervention 
assessing potential 
risk factors for labile 
INR and giving advice 
Patients with heart 
failure on warfarin 
therapy  
145 TTR 
 
Median 
61 (42, 85) 
Intervention: 
80 (62, 93) 
Control: 
44 (29, 61) 
 
Pre intervention TTR: Education>10years (+), ischaemic heart disease (-), 
smoker (-), amiodarone (-) 
 
Post intervention TTR: Patient tailored AC advice (+), amiodarone(-) 
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Table 2.11: Studies of prognosis following monitoring for oral anticoagulation 
Author  Year Setting Population n Exposure(s) Endpoint(s) Main Findings 
Hylek et al166 2000 
Anticoagulation 
clinic; prospective 
cohort 
 
USA 
Patients treated with 
warfarin with 
therapeutic range 2-
3 
114+ 
268 
INR>6 vs. INR 
within target 
range (1.7 – 3.3) 
Major haemorrhage 
(fatal, intracranial or 
requiring hospitalisation 
and transfusion of at 
least 2U of blood) within 
2 weeks 
 
INR decay to <4 in the 
INR>6 group 
4.4% of patients with INR>6  had major haemorrhage (vs 0 
in target range group) in the 2 week follow up 
Patients with INR>6 had an observed INR of <4 at a median 
time of 4 days 
Oden at al138 2002 
EHR: 
Anticoagulation 
clinic 
 
Sweden 
 
Patients treated with 
warfarin (various 
indication) 
42451 
INR (continuous 
values) 
All-cause mortality 
 
Death caused by 
intracranial haemorrhage 
Lowest risk of death seen at INR 2.2 to 2.3 for all 
indications for warfarin and therapeutic ranges 
 
U-shaped hazard for all-cause mortality 
 
Increasing risk of bleeding deaths with increasing INR 
Freixa et 
al167 
2003 
Prospective 
observational study 
of outpatients 
Patients treated with 
acenocoumarol 
(various indications) 
104 
High INR (INR >5) 
Controlled INR 
(patients with all 
INR within target 
range for 3 
months prior to 
inclusion) 
Haemorrhage (major if 
required transfusion 
otherwise classed as 
minor) 
2% of all INR tests were >5 and corresponded to 55 
patients 
Factors associated with the high INR group: weight, 
female, number of drugs, concomitant medication, 
prosthesis, compliance, intercurrent disease 
High INR had more minor (20% vs 4.8%) and major (1.8% 
vs 0%) bleeding episodes than the control group. 
Wittkowsky 
et al168 
2004 
Retrospective 
medical record 
review 
 
Anticoagulation 
clinic 
Warfarin treated 
patients (various 
indications) 
1020 
Over-
anticoagulation 
(INR >4) 
Under-
anticoagulation 
(INR<2) 
INR within range 
Thromboembolic events 
Major bleed 
 
Causes for out of range 
INR also examined 
Major bleed rate 4%/patient-yr – most likely to occur in 
over-anticoagulated patients 
Thromboembolic event rate 2%/patient-yr – most likely to 
occur in under-anticoagulated patients 
 
INR<2 (n=2881), INR>4 (n=603) 
Causes: initiation, treatment intentionally held prior to 
procedure, response to dosage change, non-compliance, 
dose error, food/drug interactions. 
Majority unexplained. 
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Author  Year Setting Population n Exposure(s) Endpoint(s) Main Findings 
Clark et al169 2008 
Retrospective 
matched cohort; 
centralised 
anticoagulation 
service  
Patients treated with 
warfarin 
2597 
Stable INR (2 INR 
values within or 
above INR 
therapeutic 
range. 3rd INR 
within 
therapeutic 
range) 
 
Low INR (As 
above but 3rd 
INR value ≥0.5 
units below 
therapeutic 
range) 
Anticoagulation related 
thromboembolic events 
within 90 days of index 
INR 
Characteristics: Patients in the Low INR group had higher 
target ranges, poorer compliance, and less likely to have 
had previous thrombosis compared with the therapeutic 
INR group. 
 
Outcomes: No significant difference in thrombosis events 
between the groups at 90 days (0.4% vs. 0.1%) 
No significant difference found for other AC related 
complications (bleeding and death). 
Patients in the Low INR group were more likely to receive 
a dose boost (65% vs. 0.3%) 
Morgan et 
al136 
2009 
Retrospective 
cohort analysis of 
linked inpatient, 
haematology and 
mortality data 
 
 
Patients with AF and 
>5 INR tests 
2235 
TTR 
 
CHADS2 score≥2 
Time to stroke 
 
Time to mortality 
Patients with a CHADS2 risk score≥2 were less likely to 
have INR TTR >70%, more likely to have further 
comorbidities, were younger and more likely to be female 
than those with a lower risk score. 
 
CHADS2 score≥2: Compared with patients not on warfarin 
therapy, treated patients only have a significantly lower 
risk of stroke when their TTR% >70 [HR: 0.2 [0.05-0.82]] 
but have a lower risk of mortality when their TTR% >40. 
 
CHADS2 score=1: Compared with patients not on warfarin 
therapy, treated patients have a significantly lower risk of 
stroke when their TTR% >60 but have a lower risk of 
mortality when their TTR% >40. 
 
Overall patients with TTR<40% had reduced time to stroke 
and patients with TTR<30% had reduced time to death 
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Author  Year Setting Population n Exposure(s) Endpoint(s) Main Findings 
Witt et al111 2009 
Kaiser Permanente 
Colorado, 
Clinical Pharmacy 
Anticoagulation 
Service 
USA 
Patients with >90 
days warfarin 
therapy 
 
2000-2005 
2504 stable  
 
3569 
comparators 
Stable INR (100% 
TTR) vs 
comparators 
All-cause mortality 
Thrombosis 
Bleeding 
 
180 day follow up 
Stable patients were older, less likely to have 
comorbidities such as diabetes and heart failure, less likely 
to have a target INR ≥3  
 
The stable group had fewer incidences of receiving heparin 
(0.3% vs 3.2%), mortality (0.4% vs 1.6%) and bleeding 
(0.8% vs 2.8%). There was no difference in thrombosis 
events between the groups (0.4% vs 0.7%) 
 
 
Wallentin et 
al170 
2010 
RE-LY randomised 
control trial 
 
906 international 
centres 
AF patients 
randomised to  
warfarin or 
dabigatran 
18024 
Centre mean INR 
control (cTTR)  
 
Stroke and systemic 
embolism (SE) 
 
Major bleeding 
 
Intracranial bleeding 
 
Death 
 
Composite of stroke, SE, 
MI, PE, death and major 
bleeding 
 
Composite of non-
haemorrhagic stroke, SE, 
MI, PE, and death 
Centres with higher cTTR had older mean ages, lower 
mean CHADS2 scores, fewer cases of previous stroke 
 
The benefit of dabigatran to reduce bleeding adverse 
events compared with warfarin was consistent across 
centres irrespective of cTTR quartile 
 
For vascular events, non-haemorrhagic events and 
mortality the benefits of dabigatran more pronounced at 
centres with poorer INR control. 
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Author  Year Setting Population n Exposure(s) Endpoint(s) Main Findings 
Witt et al112  2010 
EHR: 
Kaiser Permanente 
Colorado, 
Clinical Pharmacy 
Anticoagulation 
Service 
USA 
Patients with >90 
days warfarin 
therapy 
 
2000-2005 
533 stable 
 
2555 
comparator 
Stable INR (100% 
TTR) 
All-cause mortality 
Thrombosis 
Bleeding 
 
365 day follow up 
Characteristics: The stable group was older, more likely to 
be male, more likely to have AF, less likely to have heart 
valve replacement, less likely to have previous venous 
thrombosis, had a higher (not sig) median duration of 
warfarin therapy and had a lower chronic disease score. 
 
Outcomes: During the 365 follow up period, stable group 
were less likely to receive heparin, die, have an AC-related 
thrombosis event or  have an AC-related bleeding event 
Gallagher et 
al171 
2011 GPRD AF patients 37907 
No warfarin use 
vs. warfarin use 
stratified by TTR 
groups 
Stroke and transient 
ischaemic attack 
Patients with INR<40% had increased stroke risk compared 
with patients not on warfarin. 
Adjusted RR, TTR<30 vs. non users: 1.44 (1.28-1.59) 
Patients with TTR>40%had lower stroke risk 
Adjusted RR,  TTR ≥70 vs. non users: 0.33 (0.30, 0.36) 
 
These associations remained consistent in subgroup 
analysis by CHA2DS2-VASc score 
Lehto et al137 2017 
Linkages between: 
FinWAF; 
Finnish Care 
Register; Finnish 
Cancer Registry; 
National 
prescription 
Registry; National 
Cause of Death 
Register; 6 regional 
laboratory 
databases; 
Population Register  
 
AF patients 54568 TTR 
Bleeding, stroke, 
cardiovascular death, all-
cause mortality 
Adjusted hazard ratios: 
TTR≤40% vs. TTR 60-70 
Bleeding: 1.6 (1.5, 1.8) 
Stroke: 1.8 (1.7, 2.0) 
CV death: 2.0 (1.8, 2.2) 
All-cause mortality: 2.4 (2.2, 2.5) 
TTR>80% vs. TTR 60-70 
Bleeding: 0.6 (0.5, 0.7) 
Stroke: 0.7 (0.6, 0.8) 
CV death: 0.5 (0.4, 0.5) 
All-cause mortality: 0.4 (0.4, 0.5) 
 
  
90 
 
 
Table 2.12: Studies of novel measures of INR control: risk factors, prognosis and predictive ability 
Name Year Study population n Objectives Exposures Endpoints Main findings 
Jones et 
al139 
2005 
Record linkage 
study in 
secondary care 
setting, 
patients with 
NVAF, no heart 
valve replacement 
and ≥5 INR 
readings 
2223 
To assess the association 
between measures of INR 
control with outcomes 
Mean INR 
INR standard deviation 
% in target 
% INR<2 
% INR>3 
% out target 
Mortality, ischaemic 
stroke, thromboembolic 
events, bleeding, 
hospitalisation, INR 
patterns monitoring 
 
(ICD-10 codes used are 
given in appendix) 
All-cause mortality was 
associated with all measures 
of INR 
Increased bleed odds 
associated with SD INR 
Thromboembolic events 
associated with %INR<2,% in 
target range and mean INR 
Ischaemic stroke similarly 
associated with %INR<2 
Increased hospitalisation 
when out of INR range 
van 
Leeuwen 
et al140 
2008 
LAVA cohort 
Patients with 
mechanical heart 
valve prosthesis 
(1985-1993) 
630 
To assess 3 INR variability 
measures and their 
association with thrombotic 
and bleeding events 
3 measures of INR variance 
growth rate 
(Fihn and Cannegieter) 
A: captures deviation from 
target range 
B1 and B2: captures deviation 
from previous record (measure 
to measure) 
Thrombotic events 
Haemorrhagic events 
 
Combination of all adverse 
events 
Method A was best associated 
with events. B1 and B2 had 
equally good performance 
when combined with TTR. 
Lind et 
al141 
2012 
AF patients 
Anticoagulation 
registries linked 
with, hospital 
admissions and 
death registry 
19180 
To determine if INR standard 
deviation is more 
prognostically important than 
TTR 
TTR 
INR standard deviation 
All-cause mortality 
Stroke 
Bleeding 
 
Low correlation between TTR 
and INR SD. 
INR SD had better predictive 
ability (measured by hazard 
ratios). 
With both in the model TTR 
was no longer sig. 
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van Den 
Ham et 
al145 
2013 
AF patients aged 
>40 excl. heart 
valve 
disease/replacem
ent patients 
Linked CPRD-HES 
records (1987-
2010) 
27381 
To evaluate if TTR can be 
improved by considering 
patterns of INR over time 
%TTR 
Combination of simple 
measures split into 6 clusters: 
%Time below range, %Time 
above range, mean INR above 
normal, number of INR 
measures within 6 month 
period, first measure, last 
measure, linear slope  
All-cause mortality 
(CPRD record) 
Ischaemic or haemorrhagic 
stroke and TIA (CPRD-HES) 
Major bleed (CPRD) 
Minor bleed (CPRD) 
(ISTH criteria) 
Hospitalised bleed (HES) 
Clusters of INR patterns and 
measures resulted in 
improved prediction of events 
Ibrahim et 
al142 
2013 
AF, DVT/PE, heart 
valve and other 
patients from the 
European Action 
on 
Anticoagulation 
study 
819 
To assess 3 INR variability 
measures and their 
association with thrombotic 
and bleeding events and 
compare with TTR 
3 measures of INR variance 
growth rate 
(Fihn and Cannegieter) 
A: captures deviation from 
target range 
B1 and B2: captures deviation 
from previous record (measure 
to measure) 
All-cause mortality 
Thromboembolism 
Bleeding 
 
Method A was the strongest 
predictor at 3 months prior to 
events 
 
INR variability was a better 
predictor than TTR 
Razouki et 
al143 
2014 
AF patients 
Veterans Health 
Administration 
40404 
To determine whether  %TTR 
and INR variability associated 
with risks of events  
%TTR and INR variability 
Ischaemic stroke  
Major bleeding 
Fatal bleeding 
High INR variability was 
associated with higher risks of 
events. 
High TTR alone may not be 
enough to reduce risks of 
events - variability should be 
considered too. 
Rose et 
al144 
2015 
Admin database 
anticoagulation 
clinic data 
676 
To determine which INR 
summary measures are best 
correlated with bleeding 
Proportion of INR in range 
INR variability 
% TTR 
TTR and INR variability 
% time above range 
% time with INR >4 
Area under curve above range 
Area under curve above range 
squared 
Clinically relevant bleeding 
INR variability had strongest 
association with bleeding, 
followed by TTR 
Simple measures were also 
shown to have some value 
(proportion) 
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Proietti et 
al146 
2016 
Atrial fibrillation 
SPORTIF trial 
population 
 
3551 
Investigating if predictions of 
bleeding  events improve 
with TTR  included in ATRIA, 
HEMORR2HAGES and ORBIT 
scores 
labile INR  
(TTR <65%) 
Major bleeding  
1) all reported 
2) adjudicated  
Net reclassification index and 
Integrated discrimination 
improvement estimates 
showed improved predictive 
performance in modified 
models that included labile 
TTR as a prognostic factor 
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3 Approaches to curating and phenotyping national linked electronic 
health records for research in CALIBER 
 
Chapter Summary 
Linked electronic health records contain a wealth of information that may be useful for 
researchers. However some data manipulation is required to transform the raw health records 
into a research ready datasets. 
In this chapter I provide an introduction to electronic health records, and to the CALIBER linked 
electronic health record platform. I describe the data available within CALIBER and the 
approaches taken to transform raw data into research ready datasets. 
I then describe the datasets used within each of the studies in this thesis, including the study 
populations, the risk factors and endpoints and how these components were formulated and 
generated. 
Finally, I identified the limitations of the CALIBER platform and make recommendations for 
future improvements. 
 
3.1 Electronic health records 
3.1.1 General background to EHRs 
Electronic health records (EHRs) are computerised collections of health data, from health 
services. Health data can include patient demographics, prescriptions, medical history and 
diagnoses, treatment and interventions, patient monitoring, drug safety monitoring, public 
health surveillance, costings and hospital level information. These data may be collected for 
clinical care, administration or auditing and quality assurance purposes.  
EHR data can be input at the point of care (e.g. at general practices), or input retrospectively 
using medical notes by specialist coders. 
3.1.2 Potential strengths of EHRs for clinical research 
The increasing use and availability of EHRs has provided opportunities for clinical research. 
EHRs have the potential to contain large amounts of longitudinal data, which may be costly to 
procure in prospective studies and therefore allows studies of epidemiological trends over 
time, and studies with long follow up. Administrative records are useful for investigating 
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quality of care within patient groups. Population-based EHR cohorts allow for large scale 
studies on cohorts that are representative of the real world which is ideal for epidemiological, 
public health, drug uptake and safety studies. 
In this chapter I describe the CALIBER linked electronic health records platform used in this 
thesis and the principles and approaches (Figure 3.1) I used to prepare the data for statistical 
analysis. 
3.2 CALIBER: a linked electronic health records platform 
3.2.1 Introduction 
The CALIBER8 (Clinical research using Linked Bespoke studies and Electronic health Records) 
platform is a series of linkages between UK electronic healthcare databases: Clinical Practice 
Research Datalink (CPRD)  a longitudinal primary care database, Hospital Episode Statistics 
(HES) a database of hospital admissions and procedures, Myocardial Ischaemia National Audit 
Project (MINAP) a national acute coronary disease registry and the Office of National Statistics 
(ONS) for cause-specific mortality and social deprivation data. The CALIBER dataset used in this 
PhD holds data comprising of approximately 2 million patients from 225 general practices in 
England that have consented to linkage between 1997 and 2010.  
3.2.2 Data linkage 
CALIBER provides linkages between the anonymised datasets using encrypted CPRD patient 
identifiers allowing a more complete insight into patient’s medical journeys than if any data 
resource was used individually (Figure 3.2). Individual data sources alone may not accurately 
capture incidence of events, and different data sources collect different data. 
Data linkage of patient level data from CPRD to other anonymised data sources are performed 
by a Trusted Third Party using NHS numbers, gender and date of birth. 58% of UK CPRD general 
practices currently consent to data linkage and it has previously been demonstrated that 
CPRD-HES linked data are representative of the general UK population.172-174 
3.2.3 High resolution phenotypes 
While in traditional cohorts diseases and events are confirmed at the time of occurrence or 
retrospectively by checking hospital notes, within CALIBER high quality disease phenotypes are 
developed using the linked data through collaborations between clinicians, epidemiologists 
and statisticians. The phenotype development process is outlined in Figure 3.3.  
 In a test cohort descriptive and explorative analyses are performed on the potential 
phenotype components to determine which are suitable for use in the algorithm 
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 A preliminary phenotype algorithm is formed which is then tested and revised 
iteratively 
 The revised phenotype algorithm is implemented and tested and revised accordingly 
to reach the final version of the algorithm 
 The final phenotype is added to the CALIBER portal, including the codelists, metadata, 
code and programming scripts required to implement the algorithm given raw data 
 The phenotype is made available for the EHR community who provide feedback to 
help further enhance the algorithm 
Phenotypes for diseases and medical conditions have been developed for primary care records 
using Read codes in CPRD and secondary care records using ICD-10 codes in HES. The high 
resolution disease phenotypes usually include categories which are determined by wording 
and clinical usage of Read and ICD terms. Phenotype categories can denote: 
 Subtype (e.g. MI: STEMI, NSTEMI, unspecified;  Cancer: metastases, anatomical sites) 
 Severity (e.g. Renal disease: mild, moderate, severe) 
 Status (e.g. History of; monitoring; possible diagnosis; confirmed diagnosis) 
For many diseases, CALIBER researchers have developed composite phenotypes which fully 
harness the data across the linked data sources. The composite phenotypes often comprise of 
disease diagnoses in both primary and secondary care, procedures, test results and prescribed 
medications relevant to the disease. Such composite phenotypes ensure maximal case 
ascertainment of a disease within the linked electronic health records. 
Examples of phenotype development and validation In CALIBER have been published for 
myocardial infarction36 and atrial fibrillation.38 These studies demonstrate which codes are 
used from the various sources or how diagnoses may be inferred (e.g. from relevant 
biomarkers, prescriptions or procedures) and compare patient characteristics, risk factors or 
outcomes with those from traditional cohorts to confirm the validity of the phenotype.  
3.2.4 CALIBER study approval 
Studies of anonymised UK primary care data and linked data, such as CALIBER, are subject to 
approval from the Independent Scientific Advisory Committee (ISAC). ISAC approval is gained 
through submitting a protocol which outlines the study background and objectives, the data 
required including rationale and definitions (e.g. Read and ICD-10 codelists) for the study 
population, exposures and endpoints and a statistical analysis plan. The ISAC committee 
members (a multidisciplinary group of clinicians, statisticians, epidemiologists, health 
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informaticians, data scientists and lay members) provide detailed feedback and advise 
whether the study protocol is approved or requires revisions and resubmission.  
Lay summaries of studies approved by ISAC are available online. Published research articles 
which use UK primary care and linked data are required to report their approved ISAC protocol 
number. Any minor or major changes to an ISAC approved study protocol are subject to re-
review by the ISAC committee. 
3.2.5 CALIBER user tools 
The CALIBER data portal [https://www.caliberresearch.org/portal] contains a comprehensive 
collection of all phenotypes and their code lists developed in the CALIBER, spanning across 
numerous cardiovascular and non-cardiovascular disease areas. (Figure 3.4) 
A series of R packages to support the use of CALIBER data have been developed by Dr Anoop 
Shah, CALIBERlookups, CALIBERcodelists, CALIBERdatamanage. These packages include 
dictionaries for ICD-10, Read and ONS codes, functions to look up and generate codelists, map 
codelists between dictionaries  and to generally aid management of large datasets. 
3.2.6 CALIBER data management 
The CALIBER data platform is managed by the Data Lab: a team of data scientists who manage 
and maintain the catalogue of disease phenotypes in the CALIBER portal, perform data 
extraction and assist cohort formation. 
3.2.7 Strengths of the CALIBER platform and approach to phenotyping 
The CALIBER platform has a number of advantages for researchers. There is a wide range of 
linked data available, a representative sample of the English general population (2 million 
people registered at GP practices 1997-2010). The linkages between primary care, hospital 
admissions, disease registry and cause of death provide a comprehensive overview of these 
patients journey through the healthcare system.  
For researchers using EHRs there is potential for disease definitions to vary from study to 
study. This can be problematic for interpreting and comparing results and study replicability. 
Under the CALIBER programme, there is a standardised approach for developing disease 
phenotypes. The portal contains a large and growing number of validated and reproducible 
disease phenotypes available to researchers, therefore encouraging scientific replicability. 
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3.3 CALIBER data sources 
In the following subsections I describe each of the data sources that are linked within the 
CALIBER platform and their key data fields. A full CALIBER data dictionary is available in 
supplementary appendix 11.1.1. 
3.3.1 Clinical Practice Research Datalink  
The General Practice Research Database (GPRD) was founded in 1987 as a resource used to 
collect longitudinal primary care data on a large and representative sample covering 7% of the 
UK population.174 In 2012 the GPRD was relaunched as the Clinical Practice Research Datalink 
(CPRD) signalling an emphasis towards data linkage with other anonymised data sources.  
General practitioners can enter data on patients including demographics, blood test results 
and clinical biomarkers, disease diagnoses, prescribed medications and date of patient death.  
Diagnoses, clinical test results, and procedures are coded using Read terms, a hierarchical 
coding system developed by Dr James Read and eventually acquired by the NHS. Read terms 
are very granular and there are usually multiple terms for single conditions. CPRD developed a 
more refined coding system, medcodes, which are mapped to Read terms for easy transition 
between the coding systems. 
Prescriptions are recorded according to chapters of the British National Formulary (BNF), using 
BNF codes. Each chapter of the BNF refers to different disease areas, for example chapter 2 
contains all drugs used to treat cardiovascular diseases. The subsections within chapters refer 
to broad drug classes for example chapter 2.9 Antiplatelet drugs, and all drugs within this 
chapter have the BNF code 2090000. All prescriptions also have a prodcode which is a more 
granular coding system than BNF codes as they vary by drug substance, dosage and 
manufacturer. 
CPRD patient and general practice data fields: 
patid: Encrypted CPRD patient identifier 
pracid: Unique CPRD general practice identifier number 
prac_region: the UK region in which the general practice is situated; The NHS 
administrative regions in England are North East, North West, Yorkshire and 
Humberside, West Midlands, East Midlands, East of England, London, South East, 
South Central and South East. 
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prac_uts: date at which the general practice data was considered to be of up-to-
standard research quality. The date is determined using an algorithm which examines 
gaps in the data and the consistency of death recording in the general practice. 
gender: Patients gender 
dob: Patients date of birth. CPRD data includes year and month of birth only. 
tod: date of transfer out of CPRD general practice 
toreason: Reason for patients transfer out of CPRD practice. Reasons include patient 
death, the patient moving away from CPRD practice, or the last data collection date for 
the general practice. 
deathdate: patient date of death as recorded by their general practitioner  
date_entry: The date the patient enters the CPRD cohort, the latest date of patient 
registration at the CPRD practice and the date the practice reaches up-to-standard 
quality status 
date_exit: The date at which the patient exits the CPRD cohort. The earliest date of 
patient date of death, transfer out of general practice date, and general practice last 
data collection date 
CPRD diagnosis data fields: 
patid: Encrypted CPRD patient identifier 
eventdate: date of diagnosis record 
medcode: unique CPRD diagnosis code 
CALIBER phenotype category: The diagnosis category of the medcode as determined 
by CALIBER researchers  
CPRD prescription data fields: 
patid: Encrypted CPRD patient identifier 
eventdate: date of prescription record 
prodcode: unique CPRD product code 
bnfcode: code referring to the BNF chapter and section 
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qty: The quantity of the product prescribed 
ndd: The numeric daily dose prescribed 
numdays: Length of prescription/ therapy (days) 
numpacks: The number of product packs prescribed 
packtype: The size or type of pack 
issueseq: The sequence number for repeat prescriptions 
CPRD clinical biomarkers data fields:  
patid: Encrypted CPRD patient identifier 
eventdate: date of record 
data1: Depending on data type - usually biomarker measurement 
data2: Depending on data type - usually biomarker measurement units 
3.3.2 Hospital Episode Statistics 
 Hospital Episode Statistics (HES) captures data for all admissions to NHS hospitals in England. 
The primary diagnosis for the admission, admission and discharge dates and procedures 
performed while hospitalised can all be recorded. Diagnoses are coded using International 
Classification of Diseases (ICD-10) codes and procedures are recorded using Office of 
Population, Censuses and Surveys Classification of Surgical Operations and Procedures (OPCS) 
codes.  
ICD-10 codes are grouped into 22 chapters which each refer to distinct disease types or 
diseases of particular anatomical sites. ICD-10 codes are less granular than Read terms (16,000 
ICD-10 codes vs >200,000 Read codes). 
HES admission data fields: 
patid: Encrypted CPRD patient identifier 
date_admission: date of hospital admission 
date_discharged: date of hospital discharge  
icd: ICD-10 code for the hospital admission 
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hosp_primary: Indicates if the ICD-10 code is the primary diagnosis in the 
hospitalisation  
CALIBER phenotype category: The diagnosis category of the ICD-10 code as 
determined by CALIBER researchers  
HES procedure data fields: 
patid: Encrypted CPRD patient identifier 
date_admission: date of hospital admission 
date_procedure: date of procedure 
date_discharged: date of hospital discharge 
opcs: OPCS-4 code for the procedure 
CALIBER phenotype category: The diagnosis category of the OPCS-4 code as 
determined by CALIBER researchers  
3.3.3 Myocardial Ischaemia National Audit Project 
The Myocardial Ischaemia National Audit Project (MINAP)175 is a national registry for acute 
coronary events resulting in hospitalisation covering 230 hospitals in England and Wales from 
2000 onwards. Data is collected on patient demographics, the MI subtype (ST-elevation MI 
(STEMI) or non ST-elevation MI (NSTEMI)), electrocardiogram test results, cardiac biomarkers, 
complications, comorbidities, procedures and treatment prior to, during and following 
hospitalisation. 
3.3.4 Office for National Statistics 
The Office for National Statistics (ONS) independently collects and produces statistics 
regarding the population and economy of the UK. CALIBER has linkages to the social 
deprivation and mortality data collected by the ONS. The social deprivation data includes the 
Index of Multiple Deprivation (IMD) score, which is determined by the deprivation statistics in 
the local geographical area of general practices and is used as a proxy for patients’ socio-
economic status. The mortality data consists of the date of death as recorded on death 
certificates and the underlying cause and up to 15 secondary causes of death which is coded 
using ICD-9 codes (1997-2000) and ICD-10 codes (2000 onwards).  
ONS mortality data fields: 
patid: Encrypted CPRD patient identifier  
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dod: Patient date of death as recorded on their death certificate 
cod: ICD-10 code recorded as the underlying cause of death 
cod1-cod15: ICD-10 codes for up to 15 secondary causes of death 
3.4 Approach to data curation – principle and application 
In this section I describe the approaches I took for planning and preparing CALIBER data for 
analysis to answer my research questions, and provide examples of from the analysis chapters 
4-9, including excerpts of R programming scripts. Each of the steps described in this section are 
shown in Figure 3.1. 
I provide an estimated time required to complete each step and an example timeline based on 
these estimates is shown in Table 3.1. 
3.4.1 Develop a study protocol 
For a given research question it is important to develop a detailed study protocol that 
describes the background to the research question, how you intend to answer the question 
and the potential impact of the findings. 
A study protocol is required in the ISAC application and helps researchers to clarify their 
objectives and the methods and materials required to achieve the objectives. Having a study 
protocol also encourages scientific reproducibility. The contents of a study protocol will usually 
include a study background, a list of primary and secondary objectives, a statistical analysis 
plan and potential limitations. 
See my ISAC for the prognostic modelling work which includes a study protocol in 
supplementary appendix 11.1.2. 
Estimated duration: 4 weeks 
3.4.2 Exploratory/feasibility analysis 
Exploratory or feasibility analyses are required to determine if the available CALIBER data is 
sufficiently powered to answer the research question. These analyses are usually simple, for 
example, initial counts of the study population to estimate the sample size which in turn can 
inform power calculations. Such counts can be performed by the Data Lab before being 
granted access to the data which is subject to ISAC approval and the ISAC application requires 
an estimated sample size. 
For example, in the ISAC for the prognostic modelling study (Chapter 7) I provided the 
following sample size estimate: 
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Between 2000 and 2010 there were 35,858 patients with MI in CALIBER (linked electronic 
health records of CPRD, HES, MINAP and ONS), of which approximately 16,000 had continuous 
registration for >12 prior to and after their index MI, and survived with no recurrent MI for the 
12 month period following their index MI. These 16,000 post-MI 1-year survivors experienced 
approximately 2,400 CVD events and 1,300 non-CVD deaths over a mean follow-up of 3 (SD=2) 
years. The sample size and number of events will be considerably higher when data up to July 
2014 is used. 
Estimated duration: 1 week 
3.4.3 Define study population inclusion and exclusion criteria  
The study population required to answer the research question must be defined. This may be 
based on patient characteristics (e.g. all patients with a certain disease history), availability of 
data (e.g. patients with non-missing records for a certain biomarker), or date range etc. 
For the prognostic modelling study, I required all patients stable following a myocardial 
infarction. This was defined as patients who had an MI event and survived a year without a 
recurrent MI. I required all patients aged above 18 years and the study period was 2000-2010. 
I used MI events that were captured in CPRD, HES or MINAP. 
Estimated duration: 2 weeks 
3.4.4 Define the variables required to fulfil study objectives 
This usually includes required covariate data such as patient characteristics, medical history or 
biomarkers, exposures and study endpoints. 
First I checked whether the phenotypes I required were published on the CALIBER portal. A 
large number of analysis-ready and validated phenotypes are available on the CALIBER portal 
[https://www.caliberresearch.org/portal], and can simply be referred to in the ISAC application 
and data request stage. However, for required variables without an entry in the portal it is 
necessary to generate codelists as a starting point to developing a new phenotype. Codelists 
can be generated using the CALIBERcodelists and CALIBERlookups packages in R. Codelists can 
be formed using search terms and keywords with Boolean operators. 
For the bleeding phenotype development study I required a comprehensive list of bleeding 
events relevant to the harms of antithrombotic therapies. The code below is the initial search 
that I performed for bleeding codes in the Read dictionary in primary care. Initial search terms 
were informed by literature and included general bleeding related terms such as ‘bleed’ and 
‘haemorrhage’ whilst initial exclusion terms aimed to remove codes that may not be relevant 
such as historical events and trauma. This search produced a codelist containing 502 codes 
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which was eventually reduced to 215 bleeding codes relevant to the study, through further 
refinement of the searching algorithm, manual review and clinician input. An example of 
refinement included removing all codes with the prefixed with the letters ‘L’ or ‘Q’ as they 
pertain to childbirth related bleeding (pre-/peri-/post-natal bleeding). 
> setdictionary('read') 
 
CALIBERcodelists package, version 0.2.5 
Clearing categories in master dictionary. 
Using read dictionary. 
CPRD Pegasus Medical Dictionary, March 2010  
>  
> codes<-termhas("haemorrhage" 
+           %OR% "bleed" 
+           %OR% "blood in stool" 
+           %OR% "blood in faeces" 
+           %OR% "peptic ulcer" 
+           %OR% "gastric ulcer" 
+           %OR% "duodenal ulcer" 
+           %OR% "gastrojejunal ulcer" 
+           %OR% "haematuria" 
+           %OR% "haemoptysis" 
+           %OR% "haemoperitoneum" 
+           %OR% "melaena" 
+           %OR% "haematemesis" 
+           %OR% "haemorrhagic" 
+           %OR% "epistaxis" 
+           %OR% "haematoma" 
+           %AND% NOT("partum") 
+           %AND% NOT("fever") 
+           %AND% NOT("history") 
+           %AND% NOT("H/O") 
+           %AND% NOT("FH") 
+           %AND% NOT("F/H") 
+           %AND% NOT("disorder") 
+           %AND% NOT("screen") 
+           %AND% NOT("symptom") 
+           %AND% NOT("traumatic") 
+           %AND% NOT("operation") 
+           ) 
> bleed_cprd_initial <- data.frame(codelist(codes)) 
 
Once the bleeding Read codes were finalised, I ran an initial search of bleeding ICD-10 codes by 
converting the Read codes to ICD-10 using the mappings built into the CALIBERcodelists 
package. 
> # Convert bleeding Read codelist to ICD-10 
> # bleed_cprd is the final list of bleeding Read codes 
>  
> bleed_cprd <- codelist(bleed_cprd) 
>  
> bleed_icd10 <- data.frame(convert(bleed_cprd,  
+                                   toDictionary="icd10",  
+                                   fromDictionary="read")) 
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The result was not perfect and required further refinement, but provided a good starting point 
for developing the ICD-10 codelist. The refinement measures included removing ICD-10 codes 
picked up in the mapping that were not related to bleeding and searching the ICD-10 
dictionary for further bleeding codes that  may have been missed. 
To a produce a OPCS codelist for endoscopic examinations relevant to the development of 
bleeding phenotypes, I performed an initial search using the term ‘endoscop’ to allow for 
codes with the terms endoscopy or endoscopic and ‘exam’ or ‘diag’ to limit the search result to 
include examination or diagnostic procedures. I also included a range of NOT statements to 
exclude OPCS terms not relevant to the study. 
> setdictionary('opcs') 
 
CALIBERcodelists package, version 0.2.9 
Clearing categories in master dictionary. 
Using opcs dictionary. 
Office of Population Censuses and Surveys Codes 4.6, Jan 2011 V1.0, NH
S Classifications Service  
>  
> codes<-termhas("endoscop" 
+                %AND% ("exam"%OR% "diag") 
+                %AND% NOT("biopsy") 
+                %AND% NOT("lavage") 
+                %AND% NOT("organ") 
+                %AND% NOT("fetus") 
+                %AND% NOT("insert") 
+                %AND% NOT("brush") 
+                %AND% NOT("stain") 
+                %AND% NOT("sampling") 
+                %AND% NOT("joint")) 
>  
> endoscopy_opcs <- data.frame(codelist(codes)) 
 
To develop codelists for prescription data, we can perform searches of the CALIBER product 
dictionary. We may search for prescriptions by applying filters to columns containing BNF 
chapter names, BNF codes (derived from BNF chapter numbers) and drug substances. For 
example, I performed a search of the dictionary for all products in the BNF chapter 2.11:  
Antifibrinolytic drugs and Haemostatics using the BNF code ‘02110000’ as shown in the code 
excerpt below. 
> # load the CALIBER product dictionary 
> data(CALIBER_PRODDICT) 
>  
> # search for all products in BNF chapter 2.11  
> # Antifibrinolytic drugs and haemostatics 
>  
> antifib_drugs <- CALIBER_PRODDICT[which(grepl("02110000",bnfcode)),] 
 
Estimated duration: 2 weeks 
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3.4.5 Apply for ISAC approval 
Next an ISAC application must be submitted and approved. The application requires an overall 
study protocol including study background and objectives, defined study population, 
exposures, and endpoints which includes codelists or described phenotypes as appropriate 
and a detailed statistical analysis plan. The application is peer-reviewed by the ISAC committee 
and we received feedback approximately within 4 weeks of submission. Usually minor 
revisions and resubmission is required prior to acceptance. 
The complete ISAC application form for the prognostic modelling study is shown in 
supplementary material 11.1.2. 
Estimated duration: 4 weeks 
3.4.6 Request the data 
Once the study has received approval from ISAC, details of the study population and variables 
required can be compiled into a simple spreadsheet which is then provided to the Data Lab 
team member who will extract the data. The data request for the bleeding phenotype study is 
shown in Figure 3.5. 
Estimated duration: 3 days 
3.4.7 Receive the linked data 
We receive the data in the format of multiple ‘.csv’ files (Figure 3.6). Each file corresponds to 
longitudinal records for a single variable from a single data source. The format of the file name 
is ‘variable_datasource’ for example the file name af_hes contains all atrial fibrillation 
admission records in HES for patients in the cohort.  
We also receive a general cohort file with each patient’s CPRD general practice identifier, date 
of birth, gender, entry and exit dates to their CPRD general practice, ONS cause of death ICD-
10 codes and IMD score. 
Estimated duration: 4 weeks 
3.4.8 Construct cohort:  applying inclusion and exclusion criteria 
The data is usually extracted for a broader cohort and we apply the inclusion and exclusion 
criteria ourselves. 
For example, for the prognostic modelling study, I was provided with a table of all patients 
who had an MI record in CPRD, HES or MINAP, and the dates of all of their MI records. With 
this data, I had to determine which patients could be classed as stable post-MI, i.e. the 
patients that survived 1 year following an MI without a recurrent event.  
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Estimated duration: 1 week 
3.4.9 Develop new phenotypes 
For the data required that does not have a phenotype defined in the CALIBER portal, it is 
necessary to develop a new phenotype. Once the phenotype has been tested and finalised it 
can be uploaded to the CALIBER portal where other researchers can access it and provide 
feedback. 
In my thesis I demonstrated the process of developing a bleeding phenotype algorithm relating 
to the side effects of antithrombotic therapy use (Chapter 5). Within the phenotype I defined 3 
distinct levels of bleeding event severity.  
The development of the bleeding phenotype is fully described in Chapter 5. In brief, I 
developed bleeding Read and ICD-10 codelists and performed a descriptive analysis of 
bleeding events captured in CPRD, HES, MINAP and ONS. I assessed the prevalence of 
procedures, diseases diagnoses, biomarkers and prescriptions recorded within different time 
windows (e.g. same day, within 30 days) with respect to the bleeding records. I identified 
events and records that may be associated with bleeding severity, by using short term all-
cause mortality used as a proxy for severity. Therefore I was able to determine which factors 
were suitable for use in the phenotype and formulated an algorithm (Figure 5.18). The 
bleeding phenotype algorithm was validated through application to the acute coronary disease 
and atrial fibrillation population and assessing the incidence and outcomes associated with 
bleeding events of differing severity. 
Estimated duration: 2 weeks 
3.4.10 Generate study exposures  
We generally need to transform the longitudinal records into a single variable per patient to 
describe their characteristics and disease status at baseline. 
Below I show the R scripts I used to apply the alcohol phenotype to the bleeding phenotype 
cohort, to determine which patients have a history of excess alcohol consumption. This 
phenotype uses patient gender, alcohol drinking status, alcohol units consumed (continuous 
and categorical) primary care records to determine patients alcohol consumption status.  
The excess alcohol consumption phenotype algorithm is shown as a visualisation in Figure 3.7. 
> setwd("R:/Pop_Health/EPH_CEG_CALIBER/_KEEP/14_133_Bleeding") 
>  
> # read in cohort patient ID's 
> cohort <- fread("Processed cohort/cohort_patid.csv") 
>  
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> # read in alcohol drinker status  phenotype components 
> 
> # CPRD alcohol status (categorical) 
> alcohol_drinker <- fread("cal_14_133_cohort_alcohol_drinker_gprd.csv") 
> 
> # CPRD alcohol units (continuous) records 
> alcohol_units <- fread("cal_14_133_cohort_alcohol_units.csv") 
> 
> # CPRD alcohol units (categorical) records 
> alcohol_units_cat <- fread("cal_14_133_cohort_alcohol_units_cat_gprd.csv") 
>  
> # read in gender data 
> gender <- fread("Processed cohort/cohort_entry_events_demog_death.csv") 
> gender <- gender[,c("patid","gender"),with=F] 
>  
> # merge cohort and gender data 
> cohort1 <- merge(cohort, gender, by="patid", all.x=T) 
>  
> # apply category labels to gender column 
> cohort1$gender <- factor(cohort1$gender) 
> levels(cohort1$gender) <- c("Men", "Women") 
>  
> # CALIBER alcohol composite phenoptype algorithm 
>  
> # If Read code in alcohol drinker code list,  
> # THEN alcohol_drinker_comp = relevant category  
>  
> # IF sex = 0 AND (alcohol_units > 21 per week OR alcohol_units_cat = 4 or 5),  
> # THEN alcohol_drinker_comp = 4 (Excess drinker) 
> # IF sex = 1 AND (alcohol_units > 14 per week OR alcohol_units_cat = 3, 4 or 5),  
> # THEN alcohol_drinker_comp = 4 (Excess drinker) 
>  
> # IF sex = 0 AND (alcohol_units >= and <= 21 per week OR alcohol_units_cat = 2 or 3),  
> # THEN alcohol_drinker_comp = 3 (Current drinker) 
> # IF sex = 1 AND (alcohol_units >= 1 and <= 14 per week OR alcohol_units_cat = 2),  
> # THEN alcohol_drinker_comp = 3 (Current drinker) 
>  
> # IF sex = 0 AND (alcohol_units <1 on single day OR alcohol_units_cat = 1),  
> # THEN alcohol_drinker_comp = 2 (Occasional drinker) 
> # IF sex = 1 AND (alcohol_units < 1 on single day OR alcohol_units_cat = 1),  
> # THEN alcohol_drinker_comp = 2 (Occasional drinker) 
>  
>  
> # apply category labels to CPRD alcohol status 
> alcohol_drinker[ ,alcohol_drinker_gprd:=as.factor(alcohol_drinker_gprd)] 
> levels(alcohol_drinker$alcohol_drinker_gprd)<- c("Non-drinker", "Ex-drinker",  
+                                              "Occasional drinker", "Current drinker",  
+                                              "Excess drinker", "Excess drinker",  
+                                              "Drink status NOS") 
>   
> # merge cohort and alcohol status data 
> cohort_alc <- merge(cohort1, alcohol_drinker, by="patid", all.x=T) 
>  
> # calculate time between baseline date and alcohol record 
> cohort_alc[, alc_t:=as.numeric(difftime(eventdate.y, eventdate.x, units="days"))] 
>  
> # create binary exceess alcohol variable 
> # if alcohol category is excess drinker and  
> # the record preceeds cohort entry 
> cohort_alc[,alcohol_history:= as.numeric(alc_t<0 & alcohol_drinker_gprd=="Excess drink
er")]  
>  
> # remove duplicate records 
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> cohort_alc<-unique(cohort_alc[,c("patid","eventdate.x","gender","alcohol_history"),wit
h=F]) 
>  
> # merge with numeric units data 
> cohort_alc1 <- merge(cohort_alc, alcohol_units, by="patid", all.x=T) 
>  
> # calculate time between baseline date and alcohol units record 
> cohort_alc1[, alc_t:=as.numeric(difftime(eventdate, eventdate.x, units="days"))] 
>  
> # determine which patients have excess alcohol history 
> # according to gender and units consumption (continuous) prior to baseline date 
> cohort_alc1[which(alc_t<0 & alcohol_units>21 & gender=="Men"),alcohol_history:=1] 
> cohort_alc1[which(alc_t<0 & alcohol_units>14 & gender=="Women"),alcohol_history:= 1] 
>  
> # remove duplicate records 
> cohort_alc1<-unique(cohort_alc1[,c("patid","eventdate.x","gender","alcohol_history"),w
ith=F]) 
>  
> # merge with categorical units data 
> cohort_alc2 <- merge(cohort_alc1, alcohol_units_cat, by="patid", all.x=T) 
>  
> # calculate time between baseline date and alcohol units record 
> cohort_alc2[, alc_t:=as.numeric(difftime(eventdate, eventdate.x, units="days"))] 
>  
> # determine which patients have excess alcohol history 
> # according to gender and units consumption (categorical) prior to baseline date 
> cohort_alc2[which(alc_t<0 & alcohol_units_cat_gprd %in% 4:5 & gender=="Men"), alcohol_
history:= 1] 
> cohort_alc2[which(alc_t<0 & alcohol_units_cat_gprd %in% 3:5 & gender=="Women"), alcoho
l_history:= 1] 
>  
> # remove duplicate records 
> cohort_alc2 <- unique(na.omit(cohort_alc2[,c("patid","eventdate.x","gender","alcohol_h
istory"), with=F])) 
>  
> cohort_excess_alc_hist <- merge(cohort, cohort_alc2, all.x=T, by="patid") 
>  
> # if patients have no past alcohol records, assume no excess alcohol history 
> cohort_excess_alc_hist[which(is.na(alcohol_history)), alcohol_history:=0] 
 
 
For patients biomarker data we generally select the nearest record to their baseline date 
within an appropriate time window. For example, we could select the nearest biomarker 
measure to baseline within a year prior to baseline. For patients with no record in the specified 
time window, their data for that biomarker is recorded as missing. Other approaches may be 
taken to generate baseline biomarker data, for example averaging multiple records instead of 
selecting a single value.  
Below I show an example of how I selected baseline blood pressure records for the bleeding 
phenotype cohort. For this study I defined baseline blood pressure as the record nearest to 
patients baseline date, but not more than a year prior.  
> library(data.table) 
>  
> setwd("R:/Pop_Health/EPH_CEG_CALIBER/_KEEP/14_133_Bleeding") 
>  
> # read in cohort patient ID's 
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> cohort <- fread("Processed cohort/cohort_patid.csv") 
>  
> # set format of cohort baseline dates 
> cohort$eventdate <- as.Date(cohort$eventdate) 
>  
> # read in longitudinal blood pressure records 
> bp <- fread("cal_14_133_cohort_bp_gprd.csv") 
Read 11363905 rows and 9 (of 9) columns from 0.475 GB file in 00:00:22 
>  
> # set format of bp record dates 
> bp$eventdate <- as.Date(bp$eventdate) 
>  
> # merge cohort patient ids and bp records 
> # retains only patients with at leastone bp record 
> cohort_bp <- merge(cohort, bp, by="patid") 
>  
> # calculate time difference (days) between  
> # cohort entry and blood pressure records 
> cohort_bp[, t_diff:=eventdate.y-eventdate.x] 
>  
> # select only blood pressure records within a year prior to baseline 
> cohort_bp <- cohort_bp[which(t_diff<=0 & t_diff>-366),]  
>  
> cohort_bp <- cohort_bp[,c("patid","sys_bp","t_diff"),with=F] 
>  
> setkeyv(cohort_bp,c("patid","t_diff")) 
>  
> # choose the most recent record relative to baseline dates 
> cohort_bp1 <- cohort_bp[,.SD[.N], by="patid"] 
>  
> # merge bp data back with cohort patient ID's 
> # patients with no bp record will have 'NA' entry 
> cohort_bp_all <- merge(cohort, cohort_bp1, by="patid", all.x=T) 
 
Estimated duration: 1 week 
3.4.11 Generate endpoints 
Next, we need to generate endpoints for patients. I mostly used time-to-event analysis in this 
thesis, therefore the endpoint information required is patient follow up time (i.e. the time 
between cohort entry and the event of interest or loss to follow up) and an indicator variable 
for whether the patient had an event or was censored. 
For cause-specific death, researchers have the option use events where the cause of interest 
was recorded as the underlying cause of death and in any of the 15 secondary cause of death 
fields.  
Below is an example of generating all-cause mortality time to event variables for the bleeding 
phenotype cohort. 
> # create all-cause mortality 
> # time to event variables 
>  
> # Initially set death binary indicator as 0 for all patients 
> cohort[, dead:=0] 
>  
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> # format ONS date of death 
> cohort[ ,dod:=as.Date(dod)] 
>  
> # If patients have an ONs date of death 
> # set the death indicator to 1 
> cohort[which(!is.na(dod)), dead:=1] 
>  
> # create a new death date variable 
> # date of death for patients who died 
> # end of follow up for patients who were censored 
> cohort[ ,dead_date:=as.Date(NA)] 
> cohort[which(dead==1), dead_date:=dod] 
> cohort[which(dead==0), dead_date:=date_exit] 
>  
> # patient follow up time from cohort entry to death or censoring  
> cohort[,dead_t:=as.numeric(difftime(dead_date, eventdate,units="days
"))] 
 
Estimated duration: 3 days 
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3.5 CALIBER study populations and phenotypes used in this thesis 
Following the processes described in the previous section, here I describe and summarise the 
study populations and variables used in the analyses chapters of this thesis. 
3.5.1 Study populations 
In this section I describe the inclusion and exclusion criteria that were used to define the 4 
distinct study populations used in this thesis. The study populations described in this section 
are summarised in Table 3.3. 
3.5.1.1 Chapter 4: Indications for antithrombotic therapies in linked electronic health 
records 
All patients in CALIBER with at least one antithrombotic therapy prescription [BNF chapters 
2.8: Anticoagulants and protamine and 2.9: Antiplatelet drugs] between 1997 and 2010 were 
entered into the study population.  
Patients were excluded if their first antithrombotic therapy prescription was within six months 
of entry to the CPRD cohort (i.e. excluding those on continuing prescriptions). Patient’s index 
date was the date of their first ATT prescription. 
3.5.1.2 Chapter 5: Development and validation of prognostic models for atherothrombotic 
and bleeding events in stable myocardial infarction survivors 
For this study, patients who had an MI and survived 1 year without any recurrent MI’s were 
entered into the cohort between 2000 and 2010. Their cohort entry date was their 1 year post 
the date of their index MI. The algorithm to determine MI patients is as follows: 
Myocardial Infarction (https://www.caliberresearch.org/portal/show/phenotype_mi) 
Patients had a diagnosis for myocardial infarction if they had a STEMI, NSTEMI or unspecified 
acute MI record in CPRD, an unspecified acute MI record in HES, a STEMI or NSTEMI recorded 
in MINAP, or  a transluminal coronary thrombolysis procedure in OPCS 
Patients were split into model development and model validation cohorts depending on the 
region of their general practice using a North-South divide. Patients registered at general 
practices in East Midlands, East of England, Greater London, South East, South Central and 
South West were used for model development and patients registered at general practices in 
the West Midlands, Yorkshire and Humberside, North East and North West were used for 
model validation. 
112 
 
3.5.1.3 Chapter 6: Developing bleeding phenotypes in CALIBER; Chapter 7: Incidence of 
bleeding events in four common cardiovascular diseases 
The cohort used for this study was patients with a diagnosis of atrial fibrillation, myocardial 
infarction, stable angina or unstable angina, excluding those whose first events were fatal 
between 1997 and 2010. Patients were entered into the cohort at their first diagnosis of one of 
the four diseases. The complete codelists and phenotype descriptions can be found on the 
CALIBER portal: 
Atrial fibrillation (https://www.caliberresearch.org/portal/show/phenotype_af) 
Patients had a diagnosis for atrial fibrillation if they had an atrial fibrillation record in HES or 
CPRD, excluding those with solely historical or monitoring records. Further cases were inferred 
for patients with no atrial fibrillation record in either HES or CPRD but have a prescription for 
warfarin and no history of heart valve replacement or prior deep vein thrombosis or 
pulmonary embolism or if they have a prescription for digoxin and no history of heart failure. 
Myocardial Infarction (https://www.caliberresearch.org/portal/show/phenotype_mi) 
Patients had a diagnosis for myocardial infarction if they had a STEMI, NSTEMI or unspecified 
acute MI record in CPRD, an unspecified acute MI record in HES, a STEMI or NSTEMI recorded 
in MINAP, or  a transluminal coronary thrombolysis procedure in OPCS 
Unstable angina (https://www.caliberresearch.org/portal/show/phenotype_ua) 
Patients had a diagnosis of unstable angina if they had unstable angina diagnosed in primary 
care, secondary care (HES or MINAP), or a diagnosis of acute coronary syndrome in primary 
care or an admission for acute ischaemic heart disease in secondary care. 
Stable angina (https://www.caliberresearch.org/portal/show/phenotype_sa) 
Stable angina was diagnosed based on chest pain attributed to coronary causes recorded in 
CPRD, a stable angina record in CPRD, a stable angina admission in HES, prescribed anti-anginal 
medication, primary or secondary care records of PCI or CABG performed or abnormal test 
results for any of stress echocardiogram, invasive coronary angiogram, CT coronary angiogram, 
MR coronary angiogram, exercise ECG, resting ECG or myocardial perfusion scan. 
3.5.1.4 Chapter 8: Predictors and outcomes of INR time in therapeutic range; Chapter 9: 
The predictive value of measures of INR control for atherothrombotic and bleeding 
outcomes 
All patients with an oral anticoagulant prescription [BNF chapter 2.8.2] and at least 5 
consecutive INR records were included in the study population. INR records were considered 
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to be consecutive with they occurred within 90 days of each other. For patients with multiple 
valid spells of INR monitoring, I chose the earliest spell as the index INR spell used in analysis. 
3.5.2 Risk factor and covariate phenotypes 
Risk factors and exposures available to use within CALIBER include disease history, procedures, 
longitudinal records of clinical biomarkers and records of prescribed medications.  All of the 
risk factor and covariate phenotypes described in this section are summarised in Table 3.3  
3.5.2.1 Demographics 
The majority of demographics data used in this thesis are available from CPRD. Age is 
calculated using the date of birth recorded in CPRD (only birth month and year available) and 
the dates of cohort entry. Sex, ethnicity and the geographical area of CPRD practices are also 
available. The index of multiple deprivation (IMD) is available from ONS, which is used as a 
measure of patients socioeconomic status. 
3.5.2.2 Behaviours 
The two behaviours used in analysis were smoking status and alcohol consumption. Both of 
these variables have composite CALIBER phenotypes. The smoking phenotype uses smoking 
status records in CPRD and HES as well as prescription records for smoking cessation products 
to define patients smoking status. The alcohol phenotype uses records of drinker status and 
alcohol units consumed captured in CPRD to define patients drinking status. 
3.5.2.3 Cardiovascular disease history 
All of the cardiovascular disease history variables were defined using data from more than one 
source. For example, to define a history of myocardial infarction, diagnosis records from CPRD, 
HES and MINAP as well as thrombolysis procedures OPCS-4 codes are used. Other phenotypes, 
such as hypertension and atrial fibrillation use prescription records in their definitions, for 
blood pressure lowering medication and warfarin or digoxin respectively. The hypertension 
phenotype also uses also uses blood pressure records. 
3.5.2.4 Non-cardiovascular disease history 
All of the non-cardiovascular disease history variables were defined using data from more than 
one source. However at this stage, few of the non-cardiovascular disease variables have 
definitions that use data beyond diagnosis records in CPRD and HES. 
3.5.2.5 Procedures 
Procedures phenotypes, such as those for transfusion and revascularisation were defined using 
OPCS-4 and Read codes. 
114 
 
3.5.2.6 Clinical biomarkers 
Clinical biomarker records were obtained from CPRD only. The biomarkers had varying levels 
of completeness. For example heart rate had a high rate of missingness whereas blood 
pressure was relatively well recorded.  
3.5.2.7 Prescribed medication 
Prescription records were obtained from CPRD only. A range of issued prescriptions for 
cardiovascular and non-cardiovascular therapy were used as covariates in analysis. In general 
they were included in analysis using a binary indicator for prescriptions issued prior to 
baseline, or as an estimated duration of therapy prior to baseline. 
3.5.3 Endpoint phenotypes 
The study endpoints used in this thesis are described in this section are summarised in Table 
3.4.  
All-cause mortality 
All-cause mortality is defined using date of death recorded in ONS, and CPRD for those without 
a date of death recorded in ONS. Patients without a date of death in either source are 
considered not to have died. 
Cardiovascular death 
Cardiovascular death is defined using ONS data as one of the following ICD-10 codes: I00-I02, 
I05-I09, I10-I15, I20-I25, I26-I28, I30-I52, I60-I69, I70-I79, I80-I89 and I95-I99 or for deaths prior 
to 2001, ICD-9 codes: 390, 4010, 4011, 4019, 4200, 4211, 4220, 42490, 42491, 42499, 4258, 
4299, 449, 452, 7854, recorded as the underlying cause of death. 
Cardiovascular death, stroke or myocardial infarction 
Cardiovascular death, stroke or myocardial infarction is a composite of cardiovascular death, 
ischaemic or unspecified stroke and myocardial infarction and is defined as the first occurrence 
of the aforementioned events in follow up. 
Bleeding 
The definition of bleeding events evolves throughout this thesis.  
For the prognostic modelling chapter [chapter 5], three bleeding endpoints of varying 
incidence and severity were used. The definitions and codes used for the three bleeding 
endpoints in this study are shown in Table 3.5. 
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The first, fatal or hospitalised bleeding was intended to be a broader, more common less 
severe bleeding endpoint, followed by CALIBER major bleeding which was constructed emulate 
TIMI major bleeding, the primary safety endpoint of the PEGASUS-TIMI trial,17 as closely as 
possible by including intracranial bleeding, fatal bleeding, bleeding requiring transfusion and 
bleeding requiring an extended hospitalisation. Finally the fatal or intracranial bleeding was 
the rarest but most severe bleeding endpoint. 
In chapter 5, bleeding ICD-10 and Read codes were reviewed and a more comprehensive 
bleeding phenotype algorithm was developed (Figure 5.18). 
3.6 Limitations of CALIBER  
CALIBER is not without its limitations. The version of CALIBER used in this thesis covers records 
from 1997 to 2010, which may be considered out of date, especially for research in medical 
areas with newly approved treatments and changing guidelines. However, data updates are 
subject to the data licenses held by the Institute and can be a time consuming process. 
Linked data is only available for patients enrolled at CPRD general practices that consent to 
linkage. HES and ONS have national coverage and therefore the data for patients who are not 
enrolled at consenting practices is not available in CALIBER. 
Missing data is an issue for observational cohorts; in particular for electronic health records it 
is difficult to know what the missingness mechanism of data may be therefore not all methods 
for handling missing data may be appropriate. For example, a missing entry for a disease 
diagnosis may imply a patient does not have the disease, or that the patient has the disease 
but it has not been coded. Not all general practices receive electronic records for laboratory 
tests. Therefore missing data is common for clinical biomarkers. There are also cases where 
the data is genuinely missing for example missing discharge dates in HES records or missing 
procedure dates in OPCS-4 records.  
Administrative health data is not designed for research and therefore requires a great deal of 
cleaning and manipulation to create research ready datasets which is relatively time 
consuming. 
There are occasionally conflicts or discrepancies in data between the sources, for example the 
date or type of a single event may be recorded differently in CPRD and HES. It is up to 
researchers how to handle such issues. 
The gold-standard method for validating electronic health records and disease phenotypes is 
to compare them with manual charts and calculate statistics such as the positive predictive 
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value, sensitivity and specificity. However this process is beyond the scope of the CALIBER 
remit, and would require separate approvals to contact general practitioners, patients and to 
gain access to and review medical charts - a time consuming and expensive task. 
Recommendations 
CALIBER could benefit from widening available linkages to include HES outpatient data, HES 
accident and emergency data, prescriptions issued in hospitals, biomarker records captured 
during hospitalisation. These records could provide marginal improvements to case 
ascertainment and also widen the field of research available to CALIBER users. 
An automated data request and delivery process implemented via the CALIBER portal could 
potentially be more efficient than current ‘manual’ methods. Given that disease phenotypes 
are available on the portal, researchers could select the appropriate phenotypes to form their 
study population and the phenotypes required as study variables. The request could be sent 
via the data lab for their approval and an automated generation of the data can be carried out. 
A graphical user interface for generating top-level data summaries and visualisations from the 
CALIBER data, for example, to aid feasibility and exploratory analysis, may be useful. This 
would allow an overview of the data to be more accessible to researchers without a data 
science or statistical background. 
3.7 Conclusion 
In this chapter I described the approaches taken to prepare data from the CALIBER platform 
ready for analysis to answer the research questions in chapters 4 to 9.  
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3.8 Tables and figures 
Figure 3.1: The steps I took to plan and curate CALIBER linked electronic health records for statistical analysis 
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Figure 3.2: Demonstration of how linked data provides information across a patient’s medical journey 
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Figure 3.3: The process of phenotype development in the CALIBER platform 
 
Sourced from: Morley et al, 2014, Defining Disease Phenotypes Using National Linked 
Electronic Health Records: A Case Study of Atrial Fibrillation. PLOS ONE 9(11): e110900.  
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Figure 3.4: CALIBER data portal front page 
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Table 3.1: Estimated timeline for CALIBER data preparation 
Step 
Week  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Develop study protocol                 
Feasibility analysis                 
Define study population                 
Define study variables                 
ISAC approval                 
Request data          Data request 
being 
processed 
and fulfilled 
    
Receive data              
Construct cohort              
Develop phenotypes                 
Generate study exposures                 
Generate study endpoints                 
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Figure 3.5: Data request provided to the data manager for the bleeding phenotype study 
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Figure 3.6: Example of CALIBER cohort and variable files extracted 
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Table 3.2: Summary of study populations  
Chapter Study date 
range 
Entry criteria Cohort entry date 
4) Indications for 
antithrombotic 
therapies 
1997-2010 All patients with at least one 
prescription for an 
antithrombotic therapy 
The date of the 
first antithrombotic 
therapy 
prescription 
5) bleeding 
phenotypes; 6) 
bleeding incidence 
1997-2010 Patients with a diagnosis for 
atrial fibrillation, myocardial 
infarction, unstable angina 
or stable angina 
The date of the 
first diagnosis for 
any of the entry 
criteria diseases 
7) Development and 
validation of 
prognostic models 
1997-2010 Patients who survived event 
free for one year following a 
myocardial infarction 
The date one year 
following their 
index myocardial 
infarction record 
8) TTR; 9) Predictive 
value of INR control 
measures 
1997-2010 All patients with at least one 
oral anticoagulant 
prescription and at least 5 
consecutive INR records  
The date of the 
first INR record in 
the first valid INR 
spell 
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Table 3.3: Summary of data sources for CALIBER risk factor phenotypes 
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Demographics          
Age CPRD         
Sex CPRD         
Ethnicity CPRD         
Index of multiple deprivation ONS         
Practice region CPRD         
Behaviours          
Smoking status CALIBER composite x  x  x    
Alcohol consumption CALIBER composite x x       
Cardiovascular disease 
history 
         
Myocardial infarction CALIBER composite x    x x x  
Unstable angina CALIBER composite x    x  x  
Hypertension CALIBER composite x x x  x x   
Ischaemic Stroke CALIBER composite x    x    
Unspecified stroke CALIBER composite x    x    
Haemorrhagic stroke CALIBER composite x    x    
Atrial fibrillation CALIBER composite x  x  x    
Heart failure CPRD; HES x    x    
Peripheral arterial disease CALIBER composite x   x x x   
Venous thromboembolism CPRD; HES x    x    
Non-cardiovascular disease 
history 
         
Diabetes CALIBER composite x  x  x    
Renal disease CPRD; HES x    x    
Liver disease CPRD; HES x    x    
Cancer CPRD; HES x    x    
Chronic obstructive 
pulmonary disease 
CPRD; HES x    x    
Peptic ulcer CPRD; HES x    x    
Bleeding diatheses or 
coagulation disorders 
CPRD; HES x    x    
Chronic anaemia CPRD; HES x    x    
Procedures          
Revascularisation CPRD; OPCS    x  x   
Heart valve replacement CPRD; OPCS    x  x   
Transfusion CPRD; OPCS    x  x   
Surgical arrest of bleeding OPCS      x   
Bleeding cessation OPCS      x   
Haematoma evacuation CPRD; OPCS    x  x   
Endoscopy OPCS      x   
Clinical biomarkers          
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Systolic blood pressure CPRD  x       
Diastolic blood pressure CPRD  x       
Serum creatinine CPRD  x       
Body mass index CPRD  x       
Heart rate CPRD  x       
White blood cell count CPRD  x       
Total cholesterol CPRD  x       
HDL cholesterol CPRD  x       
eGFR CPRD  x       
Body mass index CPRD  x       
International normalised 
ratio 
CPRD  x       
Platelet count CPRD  x       
Hba1c CPRD  x       
Haemoglobin CPRD  x       
Prescribed medications          
Antiplatelet drugs CPRD   x      
Anticoagulants and 
protamine 
CPRD   x      
Statins CPRD   x      
Thiazides CPRD   x      
K-sparing diuretics and 
aldosterone 
CPRD   x      
K-sparing diuretics with 
other diuretics 
CPRD   x      
Beta blockers CPRD   x      
Ace inhibitors CPRD   x      
Angiotensin receptor 
blockers 
CPRD   x      
Calcium channel blockers CPRD   x      
Statins CPRD   x      
Insulin CPRD   x      
Anti-diabetics CPRD   x      
Digoxin CPRD   x      
Amiodarone CPRD   x      
Non-steroidal anti-
inflammatory drugs 
CPRD   x      
Antidepressants CPRD   x      
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Table 3.4: Defining all-cause mortality and atherothrombotic endpoints in CALIBER linked electronic health 
records 
 
Endpoint CPRD HES MINAP ONS 
All-cause 
mortality* 
Date of death   Date of death 
Cardiovascular 
death 
   I00-I02, I05-I09, 
I10-I15, I20-I25, 
I26-I28, I30-I52, 
I60-I69, I70-I79, 
I80-I89, I95-I99 
Cardiovascular 
death, stroke 
or MI 
 Ischaemic 
stroke 
 
Unspecified 
stroke 
 
Myocardial 
infarction 
STEMI 
NSTEMI 
I00-I02, I05-I09, 
I10-I15, I20-I25, 
I26-I28, I30-I52, 
I60-I69, I70-I79, 
I80-I89, I95-I99 
 
*if date of death appears in both CPRD and ONS with conflicting dates, the ONS date is used 
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Table 3.5: Defining three bleeding endpoints using codes in linked electronic health records 
Endpoint 
 
ICD-10 codes 
Fatal or 
hospitalised 
bleeding 
In hospital admissions (HES) OR death registry(ONS): 
I60 I61 I62 K250 K252 K254 K256 
K260 K262 K264 K266 K270 K272 K274 
K276 K280 K282 K284 K286 K290 K625 
K920 K921 K922 P261 R040 R041 R048 
R049 H356 H431 H450    
       
 
CALIBER major 
bleeding 
In hospital admissions (HES): 
I60 I61 I62 
 
In death registry (ONS): 
I60 I61 I62 K250 K252 K254 K256 
K260 K262 K264 K266 K270 K272 K274 
K276 K280 K282 K284 K286 K290 K625 
K920 K921 K922 P261 R040 R041 R048 
R049 H356 H431 H450    
 
Or all-cause mortality within 7 days of a hospital admission for any of the 
above codes  
 
Or any of the above codes in hospital admissions with primary admission 
and hospitalisation >14days 
 
Or any of the above codes in hospital admissions with a transfusion code 
in primary care (Read codes: 7L14.00, 7L14000, 7L14100, 7L14300, 
7L14311, 7L14y00, 7L14z00, TAy0.00, TB1y000, ZV58200) or hospital 
(OPCS codes X33, X331, X332, X333, X338, X339) within 30 days 
Fatal or intracranial 
bleeding 
In hospital admissions (HES): 
I60 I61 I62 
 
In death registry(ONS): 
I60 I61 I62 K250 K252 K254 K256 
K260 K262 K264 K266 K270 K272 K274 
K276 K280 K282 K284 K286 K290 K625 
K920 K921 K922 P261 R040 R041 R048 
R049 H356 H431 H450    
 
Or all-cause mortality within 7 days of a hospital admission for any of the 
above codes 
 
Note: the prefix of the code can identify the bleeding location: I=Intracranial, K=Gastrointestinal, P=pulmonary, 
R=respiratory, H= Eye; Fatal or hospitalised bleeding included fatal bleeding or hospitalisation of any duration with 
bleeding as a primary or secondary reason for admission; CALIBER major bleeding included fatal or intracranial 
bleeding, bleeding as a primary cause of hospitalisation with length of stay > 14 days or bleedings requiring 
transfusion. Bleeding requiring transfusion were identified as bleedings with a relevant transfusion record in either 
primary or secondary care within 30 days following the bleeding; Fatal or intracranial bleeding included fatal 
bleeding or intracranial bleeding only. Bleedings were considered fatal if there was a bleeding code recorded as the 
underlying cause of death or if a patient died from any cause within 7 days of hospitalised bleeding;
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Figure 3.7: An algorithm to determine patients’ history of excess alcohol consumption at baseline 
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4 Preliminary analysis of the CALIBER linked electronic health records: 
Antithrombotic drug use and inferring drug indications 
 
Chapter Summary 
Background 
Antithrombotic therapies are prescribed to prevent and treat a wide range of cardiovascular 
and non-cardiovascular conditions. In primary care electronic health records, the indication or 
reasons for prescribing drugs are not explicitly stated. The aim of this descriptive analysis was 
to use linked electronic health records to investigate the prevalence of antithrombotic 
prescribing and to infer indications for antithrombotic prescriptions. 
Methods 
Using CALIBER linked electronic health records I studied a population of patients prescribed at 
least one antithrombotic therapy between 1997 and 2010. I estimated the prevalence of 
antithrombotic prescribing over the duration of the study period. To infer indications for 
patients first antithrombotic prescription, I searched for 20 cardiovascular and non-
cardiovascular diseases in primary care and hospital admissions diagnosis records in a [-180, 
30] day window around the date of the prescription. 
Results 
In CALIBER, 277,598 patients were prescribed at least one antithrombotic therapy prescription 
between 1997 and 2010. The prevalence of antithrombotic prescribing increased over the 
course of the study period. I identified an indication for 45.7% of patients’ first antithrombotic 
therapy prescription. Overall, the most common indication was coronary heart disease 
however this differed when stratified by different antithrombotic agents. 
Conclusion 
Using linked electronic health records, I demonstrated a method to infer indications for 
antithrombotic therapies. More than half of patients, mostly those prescribed aspirin, did not 
have one of the investigated indications recorded in a time window around their prescription. 
Further work should be done to investigate the bleeding risks of these patients. 
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4.1 Background 
As described in chapter 2, various guidelines recommend antithrombotic drugs for 
atherothrombotic event prevention for a number of cardiovascular and non-cardiovascular 
diseases (Table 2.1).  
To date, studies of antithrombotic therapies in usual care settings have focused on single 
disease populations such as atrial fibrillation176 or acute coronary syndromes177 to analyse the 
uptake of the treatment within these particular patient populations or have focused on a 
subset of antithrombotic therapies such as oral anticoagulants178. No previous study has 
looked at the longitudinal prescribing trends of all types of antithrombotic therapies in an 
unselected national cohort. 
Clinical Practice Research Datalink (CPRD) prescription records do not explicitly state the 
indication for which they were prescribed, however it may be possible to infer the indications 
from diagnoses made around the time of the prescription. Attempts to determine indications 
in national electronic health records for other classes of drugs such as oral corticosteroids,179 
antibacterial,180 antidepressant181,182 and antipsychotic drugs183 have previously been made, to 
inform monitoring of drug use or over use and to identify the distribution of diseases amongst 
individuals prescribed the drugs. 
Antithrombotic therapies are associated with bleeding side effects which range from minor 
nosebleeds to serious gastrointestinal or intracranial haemorrhage. Therefore it is of interest 
which patients are prescribed these drugs and for what reason. 
The aims of this descriptive analysis were:  
 to investigate the prevalence of the antithrombotic therapy prescribing in England  
 to investigate the heterogeneity and distribution of cardiovascular and non-
cardiovascular diseases in patients prescribed antithrombotic therapies. 
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4.2 Methods 
4.2.1 Study population 
I used the CALIBER (CArdiovascular research using LInked Bespoke and Electronic health 
Records) research platform, consisting of EHR linkages between primary care data (Clinical 
Practice Research Datalink (CPRD)), secondary care data (Hospital Episode Statistics), disease 
registry data (Myocardial Ischaemia National Audit Project) and cause-specific mortality (Office 
for National Statistics) in England.8 The 4% sample of England’s population in CPRD available 
for linkage is unselected, representative in terms of age, sex and overall mortality.172-174 
The study population for this study included patients with at least one antithrombotic therapy 
prescription recorded in CPRD between 1997 and 2010. Patients were eligible for inclusion in 
the cohort if their first antithrombotic therapy prescription was recorded at least 180 days 
following registration at their general practice.  
Antithrombotic therapies include any of the substances in the BNF chapters: 2.8.1 parenteral 
anticoagulants, 2.8.2: oral anticoagulants or 2.9: antiplatelet drugs. 
4.2.2 Antithrombotic prescribing prevalence 
The prevalence of antithrombotic prescribing in CALIBER was examined graphically. The most 
prolific antithrombotic drugs aspirin, clopidogrel and warfarin were analysed individually. The 
remaining drugs were examined as groups: antiplatelet agents (dipyridamole, prasugrel, 
ticlopidine, tirofiban and abciximab), oral anticoagulants (acenocoumarol and phenindione), 
direct oral anticoagulants (dabigatran and rivaroxaban) and parenteral anticoagulants (heparin 
and low molecular weight heparin). 
Prevalence was calculated at monthly intervals from January 1998 to December 2009. The 
denominator was the total number of patients registered with their GP practices in CALIBER 
that month. The numerator was the monthly number of the patients with prescription records 
in primary care within each of the previously described antithrombotic therapy drug groups. 
4.2.3 Determining indications of antithrombotic therapy prescriptions 
Indications for cardiovascular and non-cardiovascular conditions were investigated and were 
based on those suggested for the various antithrombotic agents recorded in the BNF. The 
cardiovascular indications were atrial fibrillation, myocardial infarction, unstable angina, stable 
angina, heart valve disease or replacement, heart failure, unspecified coronary disease, 
transient ischemic attack, ischaemic or unspecified stroke, venous thromboembolism, 
peripheral arterial disease, cardiomyopathy, and a recorded international normalised ratio<2. 
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Non-cardiovascular indications included hip or knee replacement surgery, cancer, dialysis, 
systemic lupus erythematosus and rheumatoid arthritis. 
Phenotyping algorithms and codelists for the investigated indications were procured from the 
CALIBER portal [https://www.caliberresearch.org/portal] and have been validated in previous 
published studies.38-45,184-187 
The time window for indications around antithrombotic therapy prescriptions was defined as 
up to 180 days prior to the prescription to 30 days following the indication (to allow for 
potential time lag in recording), illustrated in Figure 4.1. 
4.3 Results 
4.3.1 Prevalence of antithrombotic therapy prescriptions 
In CALIBER there were 277,598 patients with at least one antithrombotic therapy prescription 
between 1997 and 2010, with their first prescription recorded at least 180 days following their 
general practice registration. The flow of patients into the study population is displayed in 
Figure 4.2. The mean (SD) age of these patients was 66.3 (14.8) and 138,573 (49.9%) were 
women (Table 4.1). The study cohort had a total of 8.6 million antithrombotic therapy 
prescription records between 1997 and 2010. 
Figure 4.3 (top panel) shows the changing prevalence of antithrombotic therapy prescriptions 
in CALIBER over time. Between 1997 and 2010  the prevalence of aspirin prescribing rose from 
about 1.5% to 4.5%, warfarin prescribing rose from 0.3% to 0.8% and clopidogrel which was 
approved for use in the UK in late 1998, rose to 0.5% by the start of 2010.  
A log transformation of the percentages shown in Figure 4.3 (bottom panel) enables us to 
visualise the changing trends over time particularly for the less commonly used drugs. We can 
see the introduction and approval of clopidogrel in 1998 and its overtaking of other 
antiplatelet agents as the platelet inhibitor of choice. Whilst warfarin prescriptions have risen, 
the prescribing of alternative oral anticoagulants has remained fairly constant. Finally, we can 
see the introduction of the novel oral anticoagulants, dabigatran and rivaroxaban which were 
first approved for prevention of thromboembolic disease following hip or knee replacement in 
2008 and subsequently approved for treating thromboembolic disease and preventing stroke 
in patients with non-valvular atrial fibrillation. 
4.3.2 Indication for first antithrombotic therapy prescription 
Index antithrombotic therapies in the study population comprised of 54 unique drug 
combinations. The distribution of the index antithrombotic therapies is shown in Figure 4.4. 
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266901 (96.1%)  patients were prescribed a single antithrombotic drug: 222962 (80.31%) 
patients were prescribed aspirin, 27436 (9.88%) patients were prescribed warfarin, 7772 
(2.80%) patients were prescribed clopidogrel, 6196 (2.23%) patients were prescribed a 
parenteral anticoagulant, 2413 (0.87%) patients were prescribed an antiplatelet other than 
aspirin or clopidogrel, 93 (0.03%) patients were prescribed a non-warfarin oral anticoagulant 
and 29 (0.01%) patients were prescribed a direct oral anticoagulant.  
The most common index antithrombotic therapy combination was two antiplatelets for 9631 
(3.47%) patients including 7136 (2.6%) prescribed aspirin and clopidogrel dual therapy. 
Furthermore, 683 (0.25%) patients were prescribed warfarin and one antiplatelet agent, 233 
(0.08%) patients were prescribed warfarin and one parenteral anticoagulant, 31 (0.01%) 
patients were prescribed warfarin and two antiplatelet agents and 119 (0.04%) patients were 
prescribed other combinations of antithrombotic therapies. 
The indications identified for the antithrombotic therapy groups are summarised in Table 4.2. 
Overall, we found an indication for 126923 (45.7%) index antithrombotic therapy prescriptions 
and 49635 (17.9%) patients had more than one indication recorded in the time window of 180 
days prior to up to 30 days following the date of their index antithrombotic therapy. 
Across all antithrombotic therapy agents the most common indications were stable angina, 
unspecified coronary heart disease, atrial fibrillation and myocardial infarction. Less than 50% 
of patients prescribed aspirin had a record of the investigated conditions in primary care or 
hospital admissions records and stable angina, unspecified coronary heart disease and 
myocardial infarction were the most common indications. The majority of patients prescribed 
clopidogrel (82.1%) were allocated an indication, with coronary disease (myocardial infarction, 
unspecified coronary disease, unstable angina, stable angina) being the most common. 
Patients prescribed other antiplatelet agents mainly had records for transient ischaemic attack, 
and ischaemic or unspecified stroke.  
 89.1% of patients prescribed warfarin had one of the investigated conditions recorded within 
the time window. Venous thromboembolism, atrial fibrillation, INR<2, heart failure, heart valve 
disease or replacement and cancer were among the most common indications. Indications 
were found for 74% of patients treated with other oral anticoagulants with venous 
thromboembolism, atrial fibrillation and INR<2 the most common. Only 29 patients were 
prescribed direct oral anticoagulants due to their approval for use for venous 
thromboembolism prevention occurring near the end of the study period. Most of these 
patients had a record for a hip or knee replacement procedure. 59.3% of patients prescribed 
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parenteral anticoagulants were allocated an indication. The most common indications for this 
group were venous thromboembolism, cancer, INR<2 and hip or knee replacement surgery. 
4.3.3 Characteristics of patients with and without an associated indication for their index 
antithrombotic therapy prescription 
Table 4.3 displays the characteristics of patients with and without an associated indication 
recorded between 180 days before and 30 days following their index ATT prescription. Patients 
without an indication had a lower mean age, 61.2 years (SD: 15.6), than patients with an 
indication, 64.6 years (SD: 14.1). The proportion of women was higher in the no indication 
group (52.4% vs. 46.9% in the indication group). There were also fewer smokers and ex-
smokers amongst the patients with no indication compared to those with an indication. Type 2 
diabetes was more common amongst patients with no indication (18.4% vs. 8.7% in the 
indication group). Patients did not appear to differ in terms of common cardiovascular clinical 
biomarkers such as body mass index, systolic blood pressure and cholesterol. 
4.4 Discussion 
Using linked electronic health records, we studied a cohort of 277,598 patients prescribed 
antithrombotic therapies. We identified a rising prevalence of antithrombotic prescribing and 
inferred cardiovascular and non-cardiovascular indications for 126923 (45.7%)patient’s first 
prescription in primary care. 
Antithrombotic therapy prescribing prevalence  
With the antithrombotic prescription records in captured in primary care records we identified 
rising prevalence amongst most of the antithrombotic subclasses, including aspirin, 
clopidogrel, other antiplatelet agents warfarin and parenteral anticoagulants. We also 
observed the rapid uptake of clopidogrel following its approval for use in 1998 for treating 
myocardial infarction and the introduction of direct oral anticoagulants in 2009 for venous 
thromboembolism prevention. This demonstrates that primary care prescription records may 
provide evidence of trends and changes in treatment practices over time. When linked to 
clinical outcome primary care and hospital admissions records, such data can be useful to 
evaluate the effectiveness of new treatments in a real-world setting. 
Index antithrombotic therapy indications  
Within each of the groups of antithrombotic therapies the most prevalent conditions identified 
within 180 days prior to and 30 days following index prescriptions were generally as expected, 
according to the guidelines (Table 2.1). For example, antiplatelet therapy is recommended for 
atherothrombotic prevention following coronary disease and almost half of patients (43.4%) 
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with a clopidogrel prescription had a myocardial infarction record in the time window. Atrial 
fibrillation and venous thromboembolism prevention are among the leading indications for 
warfarin and of the patients prescribed warfarin, 44.1% had a venous thromboembolism 
record and 31.8% had an atrial fibrillation record. This data suggests that antithrombotic 
prescribing in usual clinical care largely follows treatment guidelines. 
Patients with ‘no recorded indication’  
150675 (54.3%)patients had no record of the investigated indications in a time window around 
their index antithrombotic therapy. This was mostly attributable to patients with aspirin 
prescriptions, of which more 60% did not have a record of the investigated indications. 
However aspirin is associated with the lowest risk of bleeding and the broadest range of 
possible indications, for example general pain relief is a plausible reason that may not be 
recorded. 
Of the agents associated with higher bleeding risk and not recommended for general usage, 1 
in 5 patients prescribed clopidogrel and 1 in 10 patients prescribed warfarin did not have a 
recorded indication. 
The higher prevalence of diabetes in the ‘no indication’ group could indicate a group of high-
risk patient’s prescribed antithrombotic therapy, usually aspirin, for primary cardiovascular 
disease prevention. However some cardiovascular risk factors were less prevalent in the ‘no 
indication’ group, such as age, men and smokers. This may coincide with risk profiles of 
patients with lower bleeding risk, a consideration clinicians and patients take when prescribing 
antithrombotic therapies. 
Strengths and limitations 
To my knowledge, the first study of its kind for antithrombotic drugs. CALIBER allows a more 
comprehensive search of indications for prescriptions than if primary care data was used 
alone, with linkages to hospital admissions and myocardial infarction disease registry data. It 
has previously been demonstrated that no single EHR data source has complete coverage of 
diagnosis records.36  
There are further indications for antithrombotic therapies that may be investigated such as 
rare and/or genetic blood disorders that increase risk of thrombosis. Such conditions are not 
well coded in primary care or hospital admissions data at this time but may be explored in 
future with linkages to more specialised data e.g. disease registries. In this study, despite 
having linked records across primary and secondary care, only primary care prescriptions were 
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analysed. Aspirin is a common over the counter drug and whilst it was by far the most 
prescribed drug of the antithrombotic its use is likely under-represented in this study. 
Furthermore, in assessing aspirin prescriptions I did not differentiate between high-dose and 
low-dose aspirin, of which the former is not used as an antithrombotic therapy. High dose 
aspirin is indicated for general aches and has not been shown to be any more effective as an 
antithrombotic therapy than low-dose aspirin. 
Research implications 
Further potential areas of research include: 1) investigating duration of antithrombotic 
treatment within disease groups, 2) assessing the prevalence of contraindications in patients 
prescribed antithrombotic therapies, 3) estimating bleeding risks in patients prescribed 
antithrombotic therapy and the balance between benefits and harms in an unselected real-
world setting and 4) estimating interactions between antithrombotic therapies and blood 
pressure control in hypertensive patients. 
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4.5 Tables and Figures 
Figure 4.1: Illustrating the time window used to allocate indications for antithrombotic therapy 
prescriptions 
 
ATT= antithrombotic therapy; CPRD= Clinical Practice Research Datalink 
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Figure 4.2: Study population flowchart  
 
ATT= antithrombotic therapy  
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Table 4.1: Demographics of the study population 
 N=277,598 
Age (years) 66.3 (14.8) 
Women 138573 (49.9) 
Number of antithrombotic therapy 
prescriptions in follow up, median (IQR) 
19 (4, 45) 
Follow up time (years), median (IQR) 4.1 (1.8, 7.1) 
 
IQR= interquartile range 
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Figure 4.3: Prevalence of antithrombotic therapy prescribing captured in primary care electronic 
health records 1998-2009 
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Figure 4.4: The distribution of index antithrombotic therapy combinations  
 
Note: log scale (actual n displayed in chart above the bars) 
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Table 4.2: Distribution of the indications for 277,598 patient’s index antithrombotic prescription  
  Index antithrombotic therapy including any of: 
Indication1 Any ATT Aspirin Clopidogrel 
Other 
antiplatelet 
Warfarin 
Other oral 
anticoagulant 
Direct oral 
anticoagulant 
Parenteral 
anticoagulant 
N2 277598  233316  15027  4930  28384  96  29  6540  
Myocardial Infarction 18387 (6.6) 16633 (7.1) 6518 (43.4) 87 (1.8) 805 (2.8) 1 (1) 0 (0) 13 (0.2) 
Unspecified coronary heart 
disease 
25211 (9.1) 22173 (9.5) 6339 (42.2) 214 (4.3) 1308 (4.6) 0 (0) 1 (3.4) 37 (0.6) 
Unstable angina 7524 (2.7) 6650 (2.9) 2628 (17.5) 42 (0.9) 272 (1) 0 (0) 0 (0) 10 (0.2) 
Stable angina 32596 (11.7) 29454 (12.6) 4912 (32.7) 272 (5.5) 1142 (4) 3 (3.1) 0 (0) 46 (0.7) 
Atrial Fibrillation 24318 (8.8) 14772 (6.3) 1037 (6.9) 212 (4.3) 9034 (31.8) 17 (17.7) 0 (0) 110 (1.7) 
Ischaemic or unspecified stroke 12122 (4.4) 10245 (4.4) 681 (4.5) 1723 (34.9) 922 (3.2) 5 (5.2) 0 (0) 27 (0.4) 
Transient ischaemic attack 11757 (4.2) 10299 (4.4) 627 (4.2) 1192 (24.2) 375 (1.3) 0 (0) 0 (0) 14 (0.2) 
Haemorrhagic stroke 688 (0.2) 546 (0.2) 48 (0.3) 69 (1.4) 86 (0.3) 1 (1) 0 (0) 8 (0.1) 
Heart failure 10814 (3.9) 7867 (3.4) 1109 (7.4) 94 (1.9) 2604 (9.2) 1 (1) 0 (0) 45 (0.7) 
Heart valve disease or 
replacement 
5146 (1.9) 3334 (1.4) 497 (3.3) 61 (1.2) 1632 (5.7) 3 (3.1) 0 (0) 40 (0.6) 
Peripheral arterial disease 7453 (2.7) 6231 (2.7) 652 (4.3) 166 (3.4) 612 (2.2) 2 (2.1) 0 (0) 62 (0.9) 
Cardiomyopathy 97 (0) 59 (0) 15 (0.1) 0 (0) 31 (0.1) 0 (0) 0 (0) 2 (0) 
Venous thromboembolism 15041 (5.4) 749 (0.3) 62 (0.4) 19 (0.4) 12505 (44.1) 39 (40.6) 0 (0) 1965 (30) 
INR<2 10018 (3.6) 2208 (0.9) 281 (1.9) 98 (2) 7126 (25.1) 15 (15.6) 0 (0) 750 (11.5) 
Hip or knee replacement 5356 (1.9) 3248 (1.4) 122 (0.8) 24 (0.5) 1422 (5) 1 (1) 24 (82.8) 589 (9) 
Cancer 10123 (3.6) 5330 (2.3) 422 (2.8) 152 (3.1) 2729 (9.6) 6 (6.2) 0 (0) 1816 (27.8) 
Dialysis 517 (0.2) 394 (0.2) 38 (0.3) 8 (0.2) 92 (0.3) 0 (0) 0 (0) 10 (0.2) 
Systemic lupus erythematosus 215 (0.1) 148 (0.1) 10 (0.1) 6 (0.1) 44 (0.2) 0 (0) 0 (0) 12 (0.2) 
Rheumatoid arthritis 1657 (0.6) 1186 (0.5) 186 (1.2) 46 (0.9) 309 (1.1) 0 (0) 0 (0) 60 (0.9) 
None of the above 150675 (54.3) 141102 (60.5) 3129 (20.8) 1670 (33.9) 3095 (10.9) 25 (26) 5 (17.2) 2665 (40.7) 
1 49635 (17.9%) patients had more than one indication recorded in the time window of [-180, 30] days around their index antithrombotic prescription(s) 
2 55026 (19.7%) patients were prescribed more than one antithrombotic drug on their index date; 
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Table 4.3: Characteristics of patients with and without an allocated indication for their index 
antithrombotic therapy prescription 
 Indication No indication 
N 126923 150675 
Age; Mean (SD) 64.6 (14.1) 61.2 (15.6) 
Women 59545 (46.9) 79028 (52.4) 
Highest IMD Quintile 18734 (14.8) 22668 (15) 
Missing % 0.3 0.3 
Non-Smoker 55835 (44) 71230 (47.3) 
Ex-Smoker 27931 (22) 31551 (20.9) 
Smoker 21978 (17.3) 23872 (15.8) 
Missing % 16.7 15.9 
Type 1 Diabetes 794 (0.6) 2210 (1.5) 
Type 2 Diabetes 11022 (8.7) 27720 (18.4) 
Unspecified diabetes 1190 (0.9) 1813 (1.2) 
Body mass index; Mean (SD) 27.7 (5.72) 28.5 (5.90) 
Missing % 68 57.2 
Systolic blood pressure; Mean (SD) 142 (21.4) 143 (20.4) 
Missing % 25 19.7 
Low density lipoproteins; Mean (SD) 3.19 (1.11) 3.24 (1.10) 
Missing % 78.6 67.2 
High density lipoproteins; Mean (SD) 1.39 (0.438) 1.37 (0.419) 
Missing % 76.3 63.9 
Total cholesterol; Mean (SD) 5.36 (1.24) 5.43 (1.23) 
Missing % 63.2 50.9 
Creatinine; Mean (SD) 95.6 (29.9) 90.9 (24.8) 
Missing % 55.3 47.9 
Haemoglobin; Mean (SD) 13.6 (1.76) 14.0 (1.54) 
Missing % 61.2 61.2 
 
SD= standard deviation; IMD= Index of multiple deprivation; 
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5 Developing bleeding phenotypes in CALIBER 
Chapter Summary 
Background 
The main safety concern associated with the use of antithrombotic therapies is increased risk 
of bleeding. Bleeding harms can vary in presentation and severity. With the potential for such 
devastating treatment side effects, it is important to consider both the benefits and harms 
when studying antithrombotic therapies. To do this, standardised bleeding definitions for use 
in electronic health records are required. The objectives of this analysis were to determine 
whether bleeding endpoints used in clinical trials could be replicated using linked electronic 
health records and whether bleeding severity can be defined using supporting records such as 
transfusion. 
Methods 
First a review of bleeding diagnosis terms in Read and ICD-10 was performed, and bleeding 
code lists were developed. In the study population of 128815 patients with atrial fibrillation or 
coronary disease in CALIBER 1997-2010, the characteristics of the bleeding events were 
described. Potential markers of severity were assessed through their crude association with 
short term all-cause mortality using Kaplan-Meier plots. 
Results 
A bleeding phenotype algorithm was developed that identifies fatal bleeding, and bleeding 
with and without markers of severity in primary care and hospital admissions records. The 
markers of severity identified were bleeding anatomical site, transfusion recorded in hospital 
records, bleeding recorded as the primary reason for hospitalisation and duration of 
hospitalisation and the number of bleeding diagnosis codes recorded in one day. 
Conclusion 
Using linked electronic health records I constructed a scalable bleeding phenotype which 
identifies bleeding of differing severity, which can be used in studies of bleeding incidence and 
outcomes. No single source of data was sufficient to fully capture bleeding events in the study 
population. 
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5.1 Background 
5.1.1 Antithrombotic therapies and bleeding risks 
In common cardiac disorders, including atrial fibrillation (AF), acute coronary syndromes and 
stable coronary disease, antithrombotic drugs have been shown in randomised trials to be 
effective in reducing the risk of subsequent atherothrombotic events.188-190 There are 
increasing numbers of people with such common heart diseases on one, two or three 
antithrombotic agents because of better implementation of longstanding evidence trial 
evidence (e.g. aspirin for the secondary prevention of non-myocardial infarction (MI) coronary 
disease), the introduction of new antithrombotic drugs (e.g. novel oral anticoagulant’s 
[NOAC’s], ticagrelor) and the recognition of the role of prolonging dual antiplatelet therapy for 
MI (e.g. ticagrelor).17 Indeed prolonged (lifelong) treatment is now recommended not only for 
anticoagulation in AF but also in dual antiplatelet therapy following acute MI.17,191   
The main safety concern associated with the use of antithrombotic therapies is increased risk 
of bleeding. Bleeding harms can vary in their manifestation, ranging from minor nosebleeds to 
major or fatal intracranial haemorrhage. With the potential for such devastating treatment 
side effects, it is important for clinicians and patients to consider both the benefits and harms. 
5.1.2 Definitions for bleeding events in electronic health records 
Electronic health records (EHRs) have increasingly been used for medical research; however 
there has been a lack of standardised definitions to measure bleeding occurrence and severity 
using national population based primary care and hospital admission records. This limits the 
comparability and interpretation of EHR studies investigating harms associated with the use of 
antithrombotic therapies.  
Previous EHR studies of bleeding endpoints have been confined to hospitalised patients,75-77 or 
one anatomical site (e.g. upper gastrointestinal bleeding70,71,73), or based on commercially 
insured or administrative claims data72,74 (Table 5.1). 
5.1.3 Disease phenotypes in CALIBER linked electronic health records 
The CALIBER platform provides linkages between primary care, hospital admissions, 
myocardial infarction registry, and cause of death sources. 
Within CALIBER high resolution disease phenotypes are developed using the linked data 
through collaborations between clinicians, epidemiologists and statisticians. The disease 
phenotypes can be granular enough to include categories, or sub-phenotypes which classify for 
example, disease subtype (e.g. ST-elevation or non-ST elevation myocardial infarction), 
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severity of the condition (e.g. mild, moderate or severe renal disease) or disease status (e.g. 
history of, possible diagnosis, confirmed diagnosis). 
An example of the approach to phenotyping in CALIBER has been demonstrated for atrial 
fibrillation.38 Atrial fibrillation cases were defined in primary care and hospitalisations. 
Additional cases were inferred for those without a diagnosis code in primary care or hospital 
admissions, but with prescriptions for drugs commonly used by atrial fibrillation patients 
(warfarin and digoxin) and no diagnosis for any of the other indications for the prescriptions. 
Within CALIBER there is information on bleeding diagnosis, and other relevant data that might 
be used to assess severity across primary and hospital care (e.g. site, fatality, length of hospital 
stay, haemoglobin, transfusion, endoscopy, surgical interventions). 
Using the CALIBER data I sought to address the following questions:   
First to what extent can population-based electronic health records (EHR) replicate the 
definitions of bleeding used in trials? Secondly, can bleeding severity be defined using 
information on bleeding diagnosis, site, fatality, length of stay, haemoglobin, transfusion, 
endoscopy, surgical interventions using linked primary care and hospital admissions EHR.  
5.2 Methods 
5.2.1 Reviewing code lists for bleeding and related procedures 
Bleeding diagnosis terms in Read and ICD-10 were reviewed for defining bleeding in primary 
care and hospital admissions and determine which are relevant to antithrombotic use. I 
identified 96 ICD-10 codes (Supplementary appendix 11.2.1) and 215 Read codes 
(Supplementary appendix 11.2.2) for bleeding events which I categorised into a total of 18 
anatomical sites:  
 Intracranial (Intracerebral; Subarachnoid; Extradural; Subdural; Unspecified) 
 Gastrointestinal (Upper; Lower; Unspecified) 
 Respiratory (Upper; Lower; Unspecified) 
 Ruptured aortic aneurysm or haemopericardium  
 Genitourinary 
 Bleeding disorders 
 Ocular  
 Ear  
 Renal  
 Unspecified 
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MINAP has one field related to bleeding complications which consists of 6 categories 
pertaining to bleeding location and haemoglobin drop. (Supplementary appendix 11.2.3) 
Furthermore I reviewed primary care Read codes and OPCS codes for hospital procedures 
related to bleeding that may provide supporting evidence for bleeding events:  
 Transfusion (Read codes: Supplementary appendix 11.2.5; OPCS codes: 
Supplementary appendix 11.2.4) 
 Haematoma evacuation or aspiration (OPCS codes: Supplementary appendix 11.2.6) 
 Surgical arrest for bleeding ( OPCS codes: Supplementary appendix 11.2.7) 
 Endoscopy (OPCS code: Supplementary appendix 11.2.8)  
5.2.2 Study Population 
The study population consisted of patients with either coronary disease or atrial fibrillation, i.e. 
those who were potential candidates for antithrombotic therapy, in CALIBER during 1997-
2010. To define this population I used pre-existing validated disease phenotypes in CALIBER 
described in Chapter 3. Patients were eligible if they were aged 18 years and above and 
entered the cohort at their first diagnosis of atrial fibrillation, myocardial infarction, unstable 
angina or stable angina, and were followed up until death or transfer out of their primary care 
practice (i.e. loss to follow-up). 
5.2.2.1 Patient characteristics 
I examined the characteristics, (demographics, behaviours, medical history) of the population 
in stratified by their disease diagnosis at cohort entry. Using prescribing data I summarised 
duration (median and interquartile range days) of antithrombotic use between cohort entry 
and first bleeding event. Prescriptions were assumed to last a maximum of 90 days as this is 
the longest allowed duration of prescriptions in the UK. Antithrombotic therapies were 
grouped as aspirin monotherapy, adenosine diphosphate (ADP) receptor monotherapy, dual 
antiplatelet therapy, vitamin K antagonist (VKA) monotherapy, VKA and one antiplatelet 
(aspirin or ADP receptor inhibitor) and VKA and two antiplatelets (aspirin and ADP receptor 
inhibitor). 
5.2.3 Developing the phenotype 
Based on a combination of the exploratory analyses of bleeding codes, their characteristics, 
severity markers and consensus amongst the study team I iteratively developed an algorithm 
to define bleeding in linked electronic health records. Bleeding was grouped as with or without 
markers of severity within primary care or hospital admissions or as inferred. 
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I assessed how well bleeding events are captured amongst the data sources using a Venn 
diagram. I allowed a minimum of 30 days between records from different data sources to 
consider events to be unique, to allow for time lag in events being recorded. 
5.2.3.1 Bleeding characteristics 
I performed preliminary analysis of the bleeding records in the study population to determine 
which data are viable for use in the final algorithm.  
I examined the characteristics of bleeding records stratified by anatomical bleeding site. For 
hospitalised bleeding I calculated the length of hospitalisation and the proportion of records 
with primary diagnosis position. I investigated the presence of procedures records, transfusion 
(recorded in primary care and hospital admissions), bleeding surgical arrest, haematoma 
evacuation and endoscopy, at different time intervals (on the same day, within 7 days and 
within 30 days) of bleeding records in primary care and hospital admissions.  
I examined the availability of haemoglobin values captured in primary care at various time 
intervals (acute: same day, +/-1 day, +/7 days, and chronic:  in the year prior and in the year 
post) to determine whether it is possible identify haemoglobin levels dropping due to a 
bleeding event. Haemoglobin drop related to a bleeding event was then calculated as the peak 
haemoglobin value within 365 to 7 days prior to bleeding minus the lowest haemoglobin value 
recorded within 7 days of bleeding for patients with a minimum of 2 haemoglobin values 
recorded in primary care. 
5.2.3.2 Indicators of bleeding severity 
To assess the suitability of indicators for bleeding severity I used Kaplan Meier plots to 
examine short term (30 day) all-cause and bleeding specific mortality following bleeding with 
and without the indicators. Guided by current clinical bleeding definitions that are used to 
assess bleeding at the point of care (Table 5.2) and availability of data within CALIBER the 
following severity indicators were considered: 
 Anatomical site  
 Presence of a transfusion record  
 Presence of surgical interventions  
 Haemoglobin drop   
 Presence of multiple bleeding records on a single date.  
 For hospitalised bleeding records I considered primary versus secondary diagnosis 
position and length of hospitalisation. 
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5.2.3.3 Inferring bleeding cases 
Using the information gained through analysing the characteristics of bleeding events, I 
attempted to capture potential bleeding cases in patients with no bleeding code in primary 
care or hospital admissions through the following pathways: 
 Surgical procedures (surgical arrest, haematoma evacuation) recorded in primary care 
and hospital admissions 
 Transfusion with 
o Iron deficiency anaemia record in primary care or hospital admissions within 
30 days 
o Low haemoglobin (<10g/dL) and endoscopy within 30 days and without 
cancer, liver disease, renal disease diagnosis 1 year prior 
 Low haemoglobin (<10g/dL ) with 
o Iron deficiency anaemia record in primary care or hospital admissions and 
endoscopy within 30 days and without cancer, liver disease, renal disease 
diagnosis 1 year prior 
5.3 Results 
5.3.1 Study population 
The study population consisted of 128815 patients in 224 general practices with a new 
diagnosis of at least one of diagnosis of atrial fibrillation, acute myocardial infarction, unstable 
angina or stable angina from 1997-2010. They were followed up for a total of 559,161 person-
years, a median of 3.7 years (IQR: 5.4 1.5, 6.9), and were 48.5% women and had a mean age of 
71.5 years old at cohort entry. 
Patient characteristics stratified by cardiac disease are shown in Table 5.3. Atrial fibrillation 
patients were older than the coronary disease patients and were majority women, whereas 
the coronary disease patients were mostly men. The atrial fibrillation patients also had higher 
prevalence of history of stroke, renal disease, cancer and chronic anaemia. The majority of 
patients in all four disease groups were prescribed at least 1 antithrombotic therapy during 
follow up.  
Around 70% of patients with coronary diseases (acute myocardial infarction, stable or unstable 
angina) were prescribed aspirin in follow up for median durations near to 2 years suggesting it 
was generally prescribed for long term treatment and/or secondary prevention. Dual 
antiplatelet therapy was most common in myocardial infarction patients (34.6%), and was 
prescribed for a median duration of just under a year (349 days) which corroborates with 
151 
 
current guidelines for the treatment of acute myocardial infarction. The most aggressive form 
of antithrombotic therapy, triple therapy (VKA + 2 antiplatelets) was uncommon. Around 1% of 
patients in each cardiac disease group were prescribed triple therapy and the median 
durations of around 60-70 days suggest it was generally for short term treatment. 
5.3.2 Phenotype Development 
5.3.2.1 Characteristics of bleeding events in HES, CPRD and MINAP 
During follow up 16087 (12.5%) patients had a hospitalisation bleeding record in HES (23719 
bleeding records in total), 17716 (13.8%) patients had a primary care bleeding record in CPRD 
(30107 bleeding records in total), 1494 (1.2%) patients had bleeding recorded as underlying 
cause of death in ONS, 2405 (1.9%) patients had bleeding recorded as a secondary cause of 
death in ONS and 797 (0.6%) patients had a bleeding complication recorded in MINAP (823 
bleeding complications in total).  
5.3.2.2 Bleeding anatomical site 
Distribution across data sources 
The distribution of bleeding anatomical sites is presented in Table 5.4. Within each data 
source, the most common anatomical bleeding sites were genitourinary (31.1%), lower 
gastrointestinal (31.1%), ruptured aortic aneurysm or haemopericardium (36.6%), unspecified 
gastrointestinal (30.6%) and unspecified site (93.8%) in HES, CPRD, ONS (underlying cause of 
death), ONS (other cause of death) respectively and MINAP. Gastrointestinal bleeding 
(including upper, lower and unspecified) was the most common bleeding site accounting for 
40.9% of bleeding events across HES, CPRD and ONS. Intracranial bleeding and ruptured aortic 
aneurysm or haemopericardium were relatively uncommon outside of the death registry. 
Bleeding respiratory sites was most commonly found in primary care records, in particular 
upper respiratory (15.1%). Bleeding related to the eyes, ears, renal system or bleeding 
disorders were uncommon in primary care and hospital admissions and were never recorded 
as an underlying or other cause of death in ONS. 
Anatomical site and short term mortality 
In both HES (Figure 5.1) and CPRD (Figure 5.2) ruptured aortic aneurysm or haemopericardium 
were related with the highest 30 day mortality: 53.2% in HES and 22.8% in CPRD. Intracranial 
bleeding was also associated with high short term mortality. In MINAP (Figure 5.3) intracranial 
bleeding was associated with 60.7% 30 day mortality, the highest amongst the available 
categories. Bleeding requiring hospitalisation in general had higher 30 day mortality than 
bleeding events captured in primary care.  
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5.3.2.3 Length of hospitalisation and primary reason for admission 
Distribution across bleeding anatomical sites 
Descriptive statistics for length of stay and reason for admission for hospitalised bleeding is 
shown in Table 5.5. 
The median length of stay for bleeding events that required hospitalisation was 3 days (IQR: 0, 
10 days). Intracranial bleeding was associated with longest length of stay, with median 
hospitalisation days ranging from 9 (3, 21) to 13.5 (5.8, 25.5) amongst the subgroups. 
Genitourinary and ocular bleeding had median hospitalisations of 0 days.  
Overall, 14846 (62.6%) hospitalised bleeding events were recorded as the primary reason for 
hospitalisation. The vast majority of intracranial bleeding events were the primary reason for 
hospital admission; in particular 85.2% of intracerebral, 84.6% of subarachnoid and 80.8% of 
subdural were coded as such. Ruptured aortic aneurysm and haemopericardium also were 
mostly primary admission events (81.1%). Bleeding disorders and unspecified bleeding events 
were rarely coded as the primary reason for hospitalisation, 33% and 25.2% respectively. 
Length of hospitalisation, reason for admission and short term mortality 
Patients hospitalised for longer durations had higher mortality at discharge (Figure 5.4). At 
discharge the risk of all-cause mortality was 4.5%, 11.6%, 15.1%, 20.6%, 23.3% for 0-3, 3-7, 7-
14, 14-30 and >30 days hospitalisation respectively. At 30 days following discharge the risk of 
all-cause mortality was  6.3%, 15.1%, 20.0%, 28.5% and 32.3% for 0-3, 3-7, 7-14, 14-30 and >30 
days hospitalisation respectively. 
Hospital admissions primarily for bleeding had lower 30 day all-cause mortality than 
admissions where bleeding was not the primary event (8.7% [8.2, 9.1%] vs. 13.5% [12.8, 
14.2%]). However it was considered that this comparison may have been confounded by there 
being more severe non-bleeding primary events in the cases that bleeding is secondary. 
Therefore I considered the same comparison but with a bleeding specific cause of mortality 
outcome. Here I saw that when bleeding is the primary reason for admission the risk of 30 day 
bleeding mortality is higher than when it was not the primary reason for admission (4.5% [4.2, 
4.8%] vs. 3.7% [3.3, 4.1%]) (Figure 5.5). 
5.3.2.4 Transfusion  
Distribution of transfusion events around HES and CPRD bleeding events 
Of the HES bleeding events, 0.4% had a transfusion record in CPRD and 2.3% had a transfusion 
record in OPCS on the same day. Expanding the time window to +/-30 days around the 
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bleeding event increased the capture of potentially related transfusions to 1.6% in CPRD and 
7.5% in OPCS (Table 5.6). Transfusion records appeared to mostly coincide with 
gastrointestinal bleeding events – 13% upper GI, 10.4% lower GI and 15.1% unspecified GI 
bleeding events had a transfusion record in OPCS within 30 days. 
CPRD bleeding events had fewer related transfusion events in CPRD and OPCS (Table 5.7). 
0.4% had a transfusion record in CPRD and 0.4% had a transfusion record in OPCS on the same 
day. Expanding the time window to +/-30 days around the bleeding event increased the 
capture of potentially related transfusions to 1% in CPRD and 2.8% in OPCS. Transfusion 
records appeared to mostly coincide with gastrointestinal bleeding events – 13% upper GI, 
10.4% lower GI and 15.1% unspecified GI bleeding events had a transfusion record in OPCS 
within 30 days. Similarly to HES, transfusion records were most commonly associated with 
gastrointestinal bleeding events.  
Transfusion and short term mortality 
Amongst HES bleeding events (Figure 5.6), 90 day mortality was highest in the group with a 
transfusion record in OPCS within 30 days of their bleeding event (30.1%), followed by 
bleeding events with transfusion recorded in both CPRD and OPCS within 30 days (16.7%), 
bleeding events with no transfusion (16.5%) and bleeding events with transfusion captured in 
CPRD within 30 days (10.0%). 
Amongst CPRD bleeding events (Figure 5.7), 90 day mortality was highest in the group with 
transfusion record in OPCS within 30 days of a bleeding event (18.7%), followed by bleeding 
events with transfusion recorded in both OPCS and CPRD within 30 days (18.3%), bleeding 
events with transfusion captured in CPRD within 30 days (10.9%) and bleeding events with no 
transfusion record within 30 days (4.8%). 
5.3.2.5 Haemoglobin 
Recording of haemoglobin in CPRD general practices 
The total number of haemoglobin records per year in each of the 224 general practices over 
the course of the study period (1997-2010) is shown in Supplementary appendix 11.2.9. All 
224 general practices had at least one haemoglobin record and in total, 811218 haemoglobin 
values were recorded. Under half (42.4%) of the general practices received at least one 
haemoglobin lab result per year for the entire study period and many practices increased 
recording haemoglobin values over time. On average, general practices had 293 haemoglobin 
records per year (median 249, IQR: 87, 434) 
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Capture of acute and chronic haemoglobin values around bleeding events 
891(3.8%) bleeding events in HES had a haemoglobin value recorded in CPRD within +/- 1 day 
(Table 5.8). The mean (SD) haemoglobin in these cases was 10.2 (2.9) g/dL. Increasing the time 
window to +/- 7 days improved the capture of acute haemoglobin to 9.2%, with a mean (SD) of 
11.0 (2.7) g/dL. Gastrointestinal and upper respiratory bleeding events and bleeding disorders 
had the highest relative availability of haemoglobin within +/- 7 days (Supplementary 
appendix 11.2.10). Chronic haemoglobin data availability was better. In the year prior, 61.3% 
HES bleeding events had a haemoglobin record, mean (SD): 12.7 (2.2) g/dL and the year 
following, 47.3%, 12.3 (2.0) g/dL. 
2542 (8.4%) bleeding events in CPRD had a haemoglobin value recorded in CPRD within +/- 1 
day (Table 5.9). The mean (SD) haemoglobin in these cases was 12.3 (2.4) g/dL. Increasing the 
time window to +/- 7 days improved the capture of acute haemoglobin to 18.1%, with a mean 
(SD) of 12.4 (2.3) g/dL. Gastrointestinal, genitourinary and upper respiratory bleeding events 
and bleeding disorders had the highest availability of haemoglobin within +/- 7 days. In the 
year prior, 60.9% CPRD bleeding events had a haemoglobin record, mean (SD): 13.1 (1.9) g/dL 
and the year following, 59.0%, 12.8 (2.0) g/dL.  
Estimating haemoglobin drop due to bleeding 
The average chronic haemoglobin values were consistently higher than the acute values in 
both CPRD and HES, suggesting some degree of a haemoglobin drop can be detected but only 
in a limited number of patients. I was able to calculate haemoglobin drop for 1636 (6.9%) of 
bleeding events in HES and the average drop was 1.3 (2.3) g/dL. I was able to calculate 
haemoglobin drop for 3720 (12.3%) of bleeding events in CPRD for which the average drop was 
1.1 (1.8) g/dL.  The average haemoglobin drop was highest amongst unspecified 
gastrointestinal bleeding events in both HES and CPRD, 2.7 (2.5) g/dL and 2.4 (2.7) g/dL 
respectively. The distribution of estimated haemoglobin drops are shown in Figure 5.8. 
Haemoglobin drop and short term mortality 
Following HES bleeding 30 day all-cause mortality was similar amongst events with 
haemoglobin drop ≤3d/dL (9.95%),>3g/dL (10.8%) and no data (10.5%) (Figure 5.9). 
Differences in 30 day mortality between the groups were more apparent following CPRD 
bleeding (Figure 5.10). Those with a higher haemoglobin drop (>3 g/dL) had 30 day mortality 
risk of 5.14%, while those with ≤3g/dL and no data had risks of 2.07% and 2.28% respectively. 
In MINAP a small number of bleeding events were coded with haemoglobin drop information 
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(Figure 5.3). 30 day all-cause mortality risk was 17.2%, 15.9% and 13.3% following bleeding 
events with >5g/dL, 3-5 g/dL and >3 g/dL respectively. 
5.3.2.6 Examinations and interventions 
For hospitalised bleeding events, endoscopic examinations (Table 5.10) were recorded in OPCS 
on the same day for 22.6%, within 7 days for 33.2% and within 30 days for 39.7%. Endoscopies 
were found to be mostly associated with gastrointestinal (present for 36.1%, 51.1%, 40.5% of 
upper, lower and unspecified gastrointestinal bleeding events respectively), lower respiratory 
(31.9%) and genitourinary (55.1%) within 30 days of hospitalised bleeding. Surgical arrest of 
bleeding (Table 5.10) was observed to be associated with upper respiratory bleeding events. 
11.2% and 22.7% upper respiratory bleeding events had a surgical arrest procedure record on 
the same day or within 30 days respectively. Surgical arrest procedures were otherwise rare to 
be recorded within 30 days of bleeding from any other anatomical site. Similarly, haematoma 
evacuation or aspiration records appeared almost exclusively around subdural intracranial 
bleeding events. 6.6% and 41% of subdural intracranial bleeding events had a haematoma 
evacuation or aspiration procedure on the same day or within 30 days respectively. Prescribed 
medication that may be related to bleeding cessation or bleeding recovery (antifibrinolytics, 
haemostatics and vitamin K) (Table 5.10) were uncommon. Overall, prescription records for 
antifibrinolytic or haemostatic drugs were present for 0.7% bleeding events within 30 days and 
vitamin K prescriptions were present for 0.07% bleeding events within 30 days. 
Examinations, interventions and short-term mortality 
The examinations and interventions investigated appeared to have a protective effect. 
Gastrointestinal, genitourinary and lower respiratory bleeding events that had a record of 
endoscopic examination within 30 days were associated with lower 90 day all-cause mortality 
than those that were not (9.0% vs. 22.9%) (Figure 5.11). Upper respiratory bleeding that 
required surgical arrest was associated with 5.3% 90 day all-cause mortality compared with 
11.3% for those that had no record of surgical arrest procedures within 30 days (Figure 5.12). 
Subdural intracranial bleeding that had a record of haematoma evacuation or aspiration within 
30 days had 18.3% 90 day all-cause mortality compared with 48.0% for those that didn’t 
(Figure 5.13). 
5.3.2.7 Number of bleeding codes recorded on a single date 
There were 1323 occurrences in HES of more than one bleeding ICD-10 code being recorded 
on the same date for a single patient. In 1192 cases 2 codes were recorded, in 113 cases 3 
codes were recorded and in 18 cases 4 codes were recorded. The combinations of anatomical 
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sites in each of these cases are shown in Figure 5.14. Combinations of codes including upper, 
lower and unspecified gastrointestinal and genitourinary bleeding were the most common. 
There were 1063 occurrences in CPRD of more than one bleeding Read code being recorded 
on the same date for a single patient. In 1007 cases 2 codes were recorded, in 53 cases 3 codes 
were recorded and in 3 cases 4 codes were recorded. The combinations of anatomical sites in 
each of these cases are shown in Figure 5.15. In the majority of these cases the codes recorded 
belonged to the same anatomical site category. There was much less variation in the 
anatomical sites captured in these cases in CPRD compared with HES. 
Multiple bleeding codes and short-term mortality 
Cases in HES with >1 ICD-10 bleeding code recorded on the same date had higher 30 day 
mortality than cases with a single code, 15.9% vs. 9.8% (Figure 5.16). Cases in CPRD with > 1 
Read bleeding code recorded on the same date also had higher 30 day mortality than cases 
with a single code, 3.0% vs. 2.2% (Figure 5.17) 
5.3.3 Inferring bleeding events 
Of the 128815 patients in the study cohort, 27249 had at least one bleeding record in HES, 
CPRD or ONS. I examined the records of the remaining 101566 patients to determine whether 
any patients had evidence of a bleeding event that had not been captured in the bleeding 
codes. Through the pathways described in Section 5.2.3.3, I identified 477 surgical arrest or 
haematoma evacuation procedures in 451 patients; 689 cases in 514 patients of a transfusion 
code in OPCS accompanied by an iron deficiency anaemia diagnosis in HES or CPRD within 30 
days; 77 cases in 62 patients of a transfusion code in OPCS accompanied by a haemoglobin 
value of <10g/dL in CPRD within 30 days, an endoscopic examination within 30 days and no 
history of cancer, liver or renal disease in the year prior to transfusion; and 249 cases in 182 
patients of haemoglobin <10g/dL in CPRD, an endoscopic examination within 30 days and no 
history of cancer, liver or renal disease in the year prior to the haemoglobin record. That is, 
overall 1492 potential bleeding events identified in 1144/101566 patients with no bleeding 
record in HES or CPRD. 
5.3.4 The CALIBER bleeding phenotype 
Based on the results in Section 5.3.2 I determined that the following characteristics were 
appropriate to incorporate into the algorithm to define non-fatal bleeding severity: 
 Anatomical site: Intracranial or ruptured aortic aneurysm or haemopericardium 
 Transfusion record in hospital admissions (OPCS) within 30 days 
 Primary reason for hospitalisation AND >14 days stay 
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 >1 bleeding code  recorded on a single date in a single data source  
Fatal bleeding events were determined by bleeding records in ONS (underlying or other cause 
of death) or bleeding records in HES or CPRD followed by all-cause mortality within 7 days. 
The CALIBER bleeding phenotype algorithm is presented in Figure 5.18. When identifying 
bleeding events first search we for fatal bleeding events in ONS, followed by bleeding in 
hospital admissions and determine whether it was fatal or non-fatal event and check for 
markers of bleeding severity. Then we search for bleeding in primary care and determine 
fatality or severity markers as applicable. Otherwise we search for evidence of bleeding 
outside of the bleeding codes. The algorithm is scalable and may be adapted to researchers’ 
needs, for example if they are interested in non-fatal bleeding events only, or if they only have 
access to a single data source e.g. hospital admission records in HES. 
Applying the algorithm to the cohort (n=128815) there were 39804 bleeding events in 27259 
patients (21.2%) from primary care, hospital admissions and death registry records. 1492 
bleeding events were inferred in 1144 (0.9%) patients with no bleeding code in primary care or 
hospital admissions. 59.4% of coded bleeding events were captured in primary care, 50.2% in 
hospital admissions, and 3.8% events in the death registry. However, allowing a 30 day 
window, only 13.2% of coded bleeding events were captured in 2 or more data sources. The 
overlap of bleeding events between the data sources used is shown in Figure 5.19. 
5.4 Discussion 
Based on the electronic health records of 128815 patients with newly diagnosed atrial 
fibrillation, myocardial infarction, unstable angina or stable angina, I developed a 
comprehensive bleeding phenotype algorithm (Figure 5.18). The established phenotype 
identified bleeding events and markers of bleeding severity using combinations of diagnoses, 
procedures, transfusion and haemoglobin in primary care and hospital admissions records.  
5.4.1 Developing a bleeding phenotype in linked electronic health records 
In developing the bleeding phenotype I carried out a comprehensive assessment of bleeding 
record distribution in primary care and hospital admission data and concurrent records of 
relevant events such as transfusion, haemoglobin and drug prescriptions various time windows 
which to my knowledge has not been carried out previously in linked electronic health records. 
Unlike previous EHR studies which used simple code lists for bleeding, I demonstrated the 
depth of information readily available within linked electronic health records and the capability 
to achieve a more granular case definition. The results highlighted the importance of using 
multiple linked data sources for defining bleeding phenotype in electronic health records. No 
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individual data source used in this study had complete coverage of coded bleeding diagnoses, 
transfusions, causes of death and other bleeding relevant data, and only 13.2% of bleeding 
cases were captured in multiple data sources (Figure 5.19). However, although the phenotype 
was developed in linked electronic health records; it may be adapted for use in non-linked 
sources, but with careful interpretation given the differences in incidence and outcomes 
associated with bleeding in primary care and hospital admissions. CALIBER includes linkages to 
MINAP, a national myocardial infarction registry. However, bleeding records in these 
myocardial infarction patients were sparse and details of bleeding anatomical site were largely 
absent therefore the decision was made not to include these records in the overall phenotype. 
5.4.2 Markers of bleeding severity 
I identified markers of bleeding severity available within the linked EHRs, which corroborate 
with bleeding definitions used in clinical trials (Table 5.2). In addition to fatality, 
hospitalisation, transfusion and anatomical bleeding site which are commonly adopted within 
bleeding definitions, I found evidence to incorporate mode of hospital admission, length of 
hospitalisation and the presence of multiple bleeding records as markers of severity. It is 
important that bleeding severity is accurately captured within phenotype algorithms due to 
the heterogeneous nature of bleeding and the outcomes following bleeding. The prognostic 
importance of haemoglobin falling below the normal range in stable coronary disease and 
myocardial infarction patients has previously been demonstrated.192 With inevitable future 
availability of data such as hospital haemoglobin records, and amount of blood transfused I 
envision the definition of severity may be further refined. 
5.4.3 Inferring bleeding events  
A previous study showed that it is appropriate to infer disease cases in electronic health 
records where diagnosis codes are absent.38 I identified 1144 patients with no coded bleeding 
diagnosis present but exhibited signs or symptoms of bleeding, such as low haemoglobin, iron 
deficiency anaemia or had a bleeding related procedure, with careful scrutiny to rule out cases 
where bleeding may not be the cause of these signs, symptoms and procedures, such as 
cancer, liver and renal diseases. This suggests the importance of looking beyond diagnosis 
codes in electronic health records for case finding. Identifying further bleeding events may 
ameliorate the underestimation of bleeding risk and improve statistical power in current safety 
studies of antithrombotic use.  
5.4.4 Addition to previous implementations of bleeding phenotypes in EHRs 
While some previous bleeding definitions have been limited to single disease areas in 
particular gastrointestinal bleeding,70,72-74 I was fully inclusive with regards to anatomical site. 
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Indeed I found gastrointestinal bleeding records were among the most common in CPRD and 
HES. However clinically relevant bleeding from upper respiratory and genitourinary sites were 
also common within a population that is at relatively high risk of bleeding due to their 
eligibility for antithrombotic therapy. 
5.4.5 Limitations of EHRs 
Our EHR lacked sufficient data for acute haemoglobin or the number of units transfused 
support the classification of bleeding severity. These are markers commonly used to assess 
bleeding severity in practice and will likely made a significant contribution in providing greater 
refinement to bleeding definitions in EHRs when the data inevitably becomes available. Due to 
the fully anonymised data in CALIBER, I was unable to validate bleeding cases using a gold-
standard measure, such as manual review of hospital charts. However individual components 
of the phenotype, such as subgroups of the bleeding codes, have been validated in previous 
studies in CPRD, HES73 and other electronic health record systems70,72,74-76 and the analysis of 
outcomes following bleeding adequately reflected expected results across levels of bleeding 
severity. 
5.4.6 Conclusion 
In linked electronic health records I have developed bleeding phenotypes with distinct levels of 
severity which may be useful and informative for studies of bleeding incidence and outcomes. 
No single source of data was sufficient to fully capture bleeding events in the study population. 
  
160 
 
5.5 Tables and Figures 
Table 5.1: Bleeding phenotypes developed using electronic health records 
Author Year Bleeding 
endpoint(s) 
evaluated 
No. of 
anatomical 
sites 
Data 
source(s) 
Setting Study Population Coding 
system  
(n codes) 
Supporting 
EHR data used 
in case 
definition 
Algorithm 
figure 
reported 
Assessment of 
phenotype 
accuracy 
Raiford et 
al70 
 
1996 Upper GI bleeding 
or perforation 
1 Saskatchewan 
Hospital 
Services Plan 
Hospital 
admissions 
Patients 
hospitalised for 
upper GI bleeding 
ICD-9 (30) No No Site specific codes 
PPV: 91% 
Nonspecific codes 
PPV: 68% 
De Abajo et 
al71 
1999 Upper GI bleeding 1 GPRD 
 
(UK) 
Primary 
care 
Patients with a 
record for acute 
upper GI bleeding 
Read 
(codes not 
stated)  
No No PPV: 95/96 
Arnason et 
al75 
2006 Any bleeding  
Major bleeding  
8 A university 
hospital, 
Ottawa 
Hospital 
admissions 
Patients with a 
record for 
thromboembolism 
or bleeding 
ICD-9 (81) No  
(information 
from patient 
charts were 
used to classify 
severity) 
No Definite bleeding 
PPV: 91%; NPV: 
91% 
Major bleeding 
PPV: 87%; NPV: 
92% 
Wahl et al72  2010 Severe upper GI 
bleeding 
1 HealthCore 
Integrated 
Research 
Database 
(USA) 
Hospital 
admissions 
Patients with a 
record for upper 
GI bleeding 
ICD-9 
(original:75; 
refined:33)  
Procedure 
codes 
No PPV:  
original: 56.5% 
refined: 87.8%  
Cunningham 
et al76 
2011 Serious bleeding 
related to oral 
anticoagulation 
>4 Tennessee 
Medicaid 
program 
Hospital 
admissions 
Medicaid enrolees 
>30 years old 
ICD-9 (39) No  
(information 
from patient 
charts were 
used to classify 
severity) 
No PPV assessed for 
individual codes 
ranged from 71.4% 
to 100% (>5 charts) 
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Author Year Bleeding 
endpoint(s) 
evaluated 
No. of 
anatomical 
sites 
Data 
source(s) 
Setting Study Population Coding 
system  
(n codes) 
Supporting 
EHR data used 
in case 
definition 
Algorithm 
figure 
reported 
Assessment of 
phenotype 
accuracy 
Crooks et 
al73  
2012 Upper GI bleeding 1 CPRD 
HES 
ONS 
 
(UK) 
Primary 
care 
Hospital 
admissions 
Death 
registry 
Patients with a 
record for acute 
upper GI bleeding 
Read (46) 
ICD-10 (22) 
Causes, 
symptoms, 
endoscopy, 
death, 
transfusion, 
procedures, 
alcohol, 
anaemia, 
coagulation, 
collapse, other 
Yes None 
Valkhoff et 
al74  
2014 Upper GI bleeding 1 IPCI 
(Netherlands) 
HSD (Italy) 
ARS (Italy) 
Aarhus 
(Denmark) 
Primary 
care 
Hospital 
admissions 
Patients with a 
record for upper 
GI bleeding 
IPCI (4) 
ICD-9 (26) 
ICD-10 (16) 
No No IPCI - PPV: 21% 
HSD - PPV: 78% 
ARS - PPV: 72% 
Aarhus - PPV: 77% 
Friberg et 
al77 
 
2016 Fatal 
Non-fatal major 
Hospitalised 
Minor 
4 Swedish 
Patient 
register 
Hospital 
admissions 
Hospital 
outpatients 
Death 
registry 
Atrial fibrillation 
patients 
ICD-10 (38) Anatomical site 
(intracranial) 
Transfusion 
Hospitalisation 
Diagnosis 
position 
No Fatal 
PPV: 88.1%; NPV: 
99.7% 
Non-fatal major 
PPV: 90.6%; NPV: 
91.5% 
Hospitalised 
PPV: 65.1%; NPV: 
97.5% 
Minor 
PPV: 84.2%; NPV: 
98.9% 
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Author Year Bleeding 
endpoint(s) 
evaluated 
No. of 
anatomical 
sites 
Data 
source(s) 
Setting Study Population Coding 
system  
(n codes) 
Supporting 
EHR data used 
in case 
definition 
Algorithm 
figure 
reported 
Assessment of 
phenotype 
accuracy 
CALIBER – 
present 
study 
2017 Fatal 
Hospitalised with 
markers of 
severity 
Hospitalised 
Primary care with 
markers of 
severity 
Primary care 
Inferred 
18 CPRD 
HES 
ONS 
Primary 
care 
Hospital 
admissions 
Death 
registry 
Coronary disease 
and atrial 
fibrillation 
patients 
Read (201) 
ICD-10(96) 
 
Yes: 
Transfusion, 
anatomical site; 
procedures;  
Yes Validated bleeding 
severity through 
assessment of  
prognosis following 
bleeding 
GI=Gastrointestinal; PPV= positive predictive value; NPV= negative predictive value
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Table 5.2: Components of bleeding definitions used in randomised trials of antithrombotic therapies and the CALIBER bleeding phenotype 
Component Bleeding Academic 
Research Consortium 
(BARC) 
International Society 
on Thrombosis and 
Haemostasis (ISTH) 
Thrombosis In 
Myocardial Infarction 
(TIMI) 
CALIBER 
bleeding phenotype 
Fatality ● ● ● ● 
Anatomic bleeding site ● 
Intracranial 
Intraocular 
● 
Intracranial 
Intraspinal 
Intraocular 
Retroperitoneal 
Intraarticular 
Pericardial 
Intramuscular w. 
compartment 
syndrome 
● 
Intracranial 
● 
Intracranial   
Gastrointestinal  
Respiratory  
Ruptured aortic 
aneurysm or 
haemopericardium  
Genitourinary 
Bleeding disorders 
Ocular  
Ear  
Renal  
Unspecified 
 
Haemoglobin drop ● 
3 - <5g/dL 
≥5g/dL 
● 
≥2 g/dL 
● 
3 - <5g/dL 
≥5g/dL 
○ 
Hospitalisation ● ● ○ ● 
Mode of hospital admission ○ ○ ○ ● 
Length of hospitalisation ○ ○ ○ ● 
Blood transfusion ● ● ● ● 
Number of units transfused ● ● ○ ○ 
Medical/surgical consultation ● ● ● ● 
Medical or surgical intervention ● ● ● ● 
Multiple bleeding codes ○ ○ ○ ● 
Haemodynamic compromise ○ ● ○ ○ 
Change in antithrombotic therapy ○ ● ● ○ 
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Table 5.3: Baseline patient characteristics in 4 common cardiac diseases 
 
Atrial 
Fibrillatio
n 
(n= 
27061) 
Acute 
Myocardial 
Infarction 
(n=25031) 
Unstable 
Angina 
(n=9500) 
Stable 
Angina 
(n= 
67223) 
Demographics and behaviours at cohort 
entry 
    
Age (years), mean (SD) 76.6 (12.8) 69.9 (13.5) 
69.1 
(13.2) 
70.4 
(12.3) 
Women, n (%) 
14266 
(52.7) 
9206 (36.8) 
4169 
(43.9) 
31365 
(46.7) 
Highest quintile of deprivation (most 
deprived) 
5137 (19) 4758 (19.1) 
1947 
(20.5) 
13837 
(20.6) 
Smoking status, n (%)     
 Non-Smoker 
11938 
(44.1) 
8895 (35.5) 
3851 
(40.5) 
28721 
(42.7) 
 Smoker 2277 (8.4) 3691 (14.7) 
1058 
(11.1) 
6229 
(9.3) 
 Ex-smoker 7531 (2.8) 6355 (25.4) 
2634 
(27.7) 
19743 
(29.4) 
 Missing, (%) 19.6 24.3 20.6 18.6 
History of alcohol abuse, n (%) 2627 (9.7) 2430 (9.7) 908 (9.6) 
6459 
(9.6) 
Medical history  
(Any record ever prior to entry) 
    
Diabetes, n (%)     
 Type 1 153 (0.6) 277 (1.1) 99 (1) 609 (0.9) 
 Type 2 2695 (10) 2922 (11.7) 
1222 
(12.9) 
8728 (13) 
 Unspecified type 486 (1.8) 448 (1.8) 220 (2.3) 1352 (2) 
Ischaemic or unspecified stroke, n (%) 2169 (8) 1462 (5.8) 558 (5.9) 
3435 
(5.1) 
Peripheral arterial disease, n (%) 2276 (8.4) 2147 (8.6) 865 (9.1) 
6199 
(9.2) 
Renal disease, n (%) 2570 (9.5) 1731 (6.9) 694 (7.3) 
4351 
(6.5) 
Non-metastatic cancer, n (%) 
5427 
(20.1) 
3158 (12.6) 
1155 
(12.2) 
8701 
(12.9) 
Metastatic cancer, n (%) 526 (1.9) 209 (0.8) 74 (0.8) 520 (0.8) 
Peptic ulcer, n (%) 1814 (6.7) 1713 (6.8) 753 (7.9) 
5074 
(7.5) 
Bleeding diatheses and coagulation 
disorders, n (%) 
312 (1.2) 175 (0.7) 77 (0.8) 534 (0.8) 
Chronic anaemia, n (%) 
4982 
(18.4) 
2808 (11.2) 
1198 
(12.6) 
8125 
(12.1) 
Biomarkers 
(Nearest record to entry within 1 year 
prior to entry) 
    
SBP (mmHg), mean (SD) 140 (21.8) 143 (21.2) 142 (21.2) 
142 
(20.5) 
 Missing, (%) 29.7 33.2 25.8 21.6 
BMI, mean (SD) 27.2 (6.19) 27.7 (5.44) 
28.4 
(5.73) 
28.5 
(5.60) 
BMI, n (%)     
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Atrial 
Fibrillatio
n 
(n= 
27061) 
Acute 
Myocardial 
Infarction 
(n=25031) 
Unstable 
Angina 
(n=9500) 
Stable 
Angina 
(n= 
67223) 
 Underweight 378 (1.4) 194 (7.8) 67 (0.7) 420 (0.6) 
 Normal 2609 (9.6) 2145 (8.6) 832 (8.8) 
6411 
(9.5) 
 Overweight 2556 (9.4) 2909 (11.6) 
1219 
(12.8) 
9997 
(14.9) 
 Obese 2024 (7.5) 2078 (8.3) 
1053 
(11.1) 
8440 
(12.6) 
 Missing, (%) 72 70.7 66.6 62.4 
Haemoglobin (g/dL), mean (SD) 12.9 (1.97) 13.5 (1.91) 
13.5 
(1.75) 
13.6 
(1.69) 
 Missing, (%) 56.2 65.9 62 59.1 
Creatinine (mol/l), mean (SD) 107 (59.1) 108 (56.1) 105 (55.9) 
102 
(46.1) 
 Missing, (%) 49.5 57.6 54.1 49.7 
Antithrombotic therapies (n, %) and 
duration (median, IQR) 
(Between cohort entry and 1st bleeding 
event or end of follow-up) 
    
Any antithrombotic therapy 
16868 
(62.3) 
19950 (79.7) 
7947 
(83.7) 
55619 
(82.7) 
Aspirin monotherapy 
10787 
(39.9) 
16511 (66) 
6695 
(70.5) 
48262 
(71.8) 
 Duration (days) 
382 (114,  
908) 
791 (267, 1742) 
765 (268, 
1691) 
842 (305, 
1752) 
ADP receptor inhibitor monotherapy 1264 (4.7) 3683 (14.7) 1425 (15) 
7351 
(10.9) 
 Duration (days) 
150 (46, 
486) 
 94 (30, 376) 
121 (42, 
495) 
181 (52, 
652) 
Dual antiplatelet therapy 1594 (5.9) 8673 (34.6) 
2417 
(25.4) 
9539 
(14.2) 
 Duration (days) 
186 (90, 
426) 
349 (143, 478) 
272 (98, 
488) 
261 (90, 
476) 
VKA monotherapy 
7149 
(26.4) 
1666 (6.7) 853 (9) 
6287 
(9.4) 
 Duration (days) 
427 (146, 
1083) 
216 (82,  626) 
318 (110,  
844) 
344 (113,  
938) 
VKA + 1 antiplatelet 
3003 
(11.1) 
1426 (5.7) 637 (6.7) 
3892 
(5.8) 
 Duration (days) 
 85 (51, 
163) 
106 (55, 262) 
 90 (54, 
228) 
 90 (51, 
214) 
VKA + 2 antiplatelets 266 (1) 321 (1.3) 102 (1.1) 430 (0.6) 
 Duration (days) 
68.5 (39,  
93.2) 
68.0 (43, 116.0) 
62.5 (39,  
90.0) 
57.0 (35,  
84.0) 
Note: SD=standard deviation, SBP=systolic blood pressure, BMI= body mass index, IQR= interquartile 
range, ADP=adenosine diphosphate, VKA=vitamin K antagonist 
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Table 5.4: Distribution of records of bleeding in various anatomical sites in each data source 
 
CPRD  
 
(Primary 
care) 
HES 
 
(Hospital 
admissions) 
ONS - 
underlying 
cause 
(Death 
registry) 
ONS - other 
cause 
(Death 
registry) 
MINAP 
 
(MI 
registry) 
 n=30107 n=23719 n= 1494 n= 2405 n=823 
 Intracranial       
(Any 
intracranial) 
28 (3.40) 
Intracerebral 226 (0.75) 715 (3.01) 365 (24.43) 445 (18.5) 
Subarachnoid 137 (0.46) 201 (0.85) 92 (6.16) 94 (3.91) 
Extradural 1 (0.00) 22 (0.09) 0 (0) 1 (0.04) 
Subdural 83 (0.28) 442 (1.86) 56 (3.75) 92 (3.83) 
Unspecified 5 (0.02) 55 (0.23) 42 (2.81) 54 (2.25) 
Gastrointestinal     
(Retro-
peritoneal) 
23 (2.79) 
 Upper 1455 (4.83) 3142 (13.25) 192 (12.85) 133 (5.53) 
Lower 
9365 
(31.11) 
5806 (24.48) 7 (0.47) 25 (1.04) 
Unspecified 1062 (3.53) 1530 (6.45) 182 (12.18) 735 (30.56) 
Respiratory     
Upper 
4543 
(15.09) 
2207 (9.30) 0 (0) 4 (0.17) 
Lower 1579 (5.24) 1281 (5.40) 6 (0.40) 42 (1.75) 
Unspecified 0 (0) 26 (0.11) 1 (0.07) 31 (1.29) 
Ruptured aortic 
aneurysm or 
haemopericardium 
57 (0.19) 280 (1.18) 546 (36.55) 596 (24.78) 
Genitourinary 9032 (30.0) 7378 (31.11) 1 (0.07) 18 (0.75) 
Ocular 703 (2.34) 263 (1.11) 0 (0) 0 (0) N/A 
Ear 0 (0) 5 (0.02) 0 (0) 0 (0) N/A 
Renal 2 (0.01) 0 (0) 0 (0) 0 (0) N/A 
Bleeding disorders 33 (0.11) 227 (0.96) 0 (0) 0 (0) N/A 
Unspecified 1824 (6.06) 139 (0.59) 4 (0.27) 135 (5.61) 772 (93.80) 
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Figure 5.1: 30 day mortality following bleeding captured in HES stratified by anatomical site 
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Figure 5.2: 30 day mortality following bleeding captured in CPRD stratified by anatomical site 
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Figure 5.3: 30 day mortality following bleeding captured in MINAP stratified by MINAP 
bleeding category 
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Table 5.5: Length of hospitalisation and reason for admission for 23719 HES bleeding codes in 16087 patients by bleed location 
 
*ruptured abdominal or thoracic aortic aneurysm or haemopericardium 
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Figure 5.4: The association between length of hospitalisation and 30 day mortality 
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Figure 5.5: The association between the reason for hospitalisation and 30 day mortality 
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Table 5.6: HES bleeding (n= 23719 bleeding events in 16087 patients) and transfusions 
 
*ruptured abdominal or thoracic aortic aneurysm or haemopericardium 
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Table 5.7: CPRD bleeding (n=30107 bleeding events in 17716 patients) and transfusions 
 
*ruptured abdominal or thoracic aortic aneurysm or haemopericardium 
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Figure 5.6: The association between HES bleeding requiring transfusion and short term all-
cause mortality 
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Figure 5.7: The association between CPRD bleeding requiring a transfusion and short term 
mortality 
.
177 
 
Table 5.8: HES bleeding (n= 23719 bleeding events in 16087 patients) and haemoglobin  
 
*ruptured abdominal or thoracic aortic aneurysm or haemopericardium 
**Haemoglobin drop defined as max haemoglobin in year prior to bleed minus min haemoglobin recorded within 7 days of bleed 
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Table 5.9: CPRD bleeding (n=30107 bleeding events in 17716 patients) and haemoglobin  
 
IC= intracranial; GI= gastrointestinal; NOS= not otherwise specified; SD= standard deviation 
*ruptured abdominal or thoracic aortic aneurysm or haemopericardium 
**Haemoglobin drop defined as max haemoglobin in year prior to bleed minus min haemoglobin recorded within 7 days of bleed 
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Figure 5.8: Distribution of estimated haemoglobin drop around bleeding events in HES and CPRD 
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Figure 5.9: Association between haemoglobin drop and short term mortality following HES bleeding 
 
hb= haemoglobin  
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Figure 5.10: Association between haemoglobin drop and short term mortality following CPRD bleeding 
 
hb= haemoglobin 
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Table 5.10: Examinations and interventions and HES bleeding (n= 23719 bleeding events in 16087 patients) 
 
IC= intracranial; GI= gastrointestinal; NOS= not otherwise specified; rx= prescription 
*ruptured abdominal or thoracic aortic aneurysm or haemopericardium; 
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Figure 5.11: The association between bleeding requiring endoscopic examination and short 
term all-cause mortality 
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Figure 5.12: The association between bleeding requiring surgical arrest and short term all-
cause mortality 
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Figure 5.13: The association between bleeding requiring haematoma evacuation or 
aspiration and short term all-cause mortality 
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Figure 5.14: The anatomical site combinations for cases with multiple bleeding codes 
recorded in HES on a single date (1323 cases: 1192 with 2 codes, 113 with 3 codes, 18 with 4 
codes recorded) 
 
GI= gastrointestinal; IC= intracranial;  
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Figure 5.15: The distribution of anatomical site combinations for cases with multiple 
bleeding codes recorded in CPRD on a single date (1063 cases: 1007 with 2 codes, 53 with 3 
codes, 3 with 4 codes recorded)  
 
GI= gastrointestinal; IC= intracranial; 
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Figure 5.16: The association between number of ICD-10 bleeding codes recorded and 30 day 
mortality 
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Figure 5.17: The association between number of Read bleeding codes recorded and 30 day 
all-cause mortality 
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Figure 5.18: Phenotype algorithm showing the use of CPRD (primary care), HES (hospital admissions) and ONS (death registry) to define major and minor bleeding in primary 
care and hospital admissions and infer additional bleeding events 
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Figure 5.19: Overlap of 39,804 bleeding recorded in CPRD (primary care), HES (hospital care) and ONS (death registry) and the number of inferred bleeding 
cases in patients without a bleeding record in primary or hospital care (n= 128,815 patients) 
14802 18819 
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6 Incidence and prognosis of bleeding events in four common 
cardiovascular diseases  
 
Chapter Summary 
Background 
There are increasing numbers of patients being treated with antithrombotic therapies, new 
agents being approved and guidelines recommending lifetime treatment to reduce risk of 
subsequent atherothrombotic events. In the previous chapter I developed a bleeding 
phenotype algorithm. In this chapter my objectives were to determine the incidence of major 
and any bleeding in atrial fibrillation and coronary disease patients, to investigate the 
incidence of antithrombotic prescribing and bleeding over time and to investigate the effect of 
bleeding on long term prognosis. 
Methods 
In a study population of 128815 patients with atrial fibrillation or coronary disease in CALIBER 
from 1997-2010, 5 year incidence of bleeding events was assessed using Kapan-Meier plots. 
Cox proportional hazard models were used to estimate hazard ratios for the association 
between antithrombotic therapies and the risk of bleeding. Bleeding and antithrombotic 
prescribing prevalence was by counting the number of events and prescriptions per patient in 
CALIBER at monthly intervals between 1997 and 2010. Cox proportional hazard models were 
used to estimate hazard ratios for the associations between bleeding severity and the risk of 
all-cause mortality and atherothrombotic events. 
Results 
The overall 5 year risk of any bleeding was 24.2% (95% CI: 23.9, 24.5%) and fatal or bleeding 
with markers of severity was 6.5% (5.4, 6.7%). Bleeding risk was higher in atrial fibrillation 
patients compared with coronary disease patients. More intense antithrombotic regimens 
were associated with increased bleeding risk; patients prescribed triple therapy versus aspirin 
had more than 3 times the risk of any bleeding event. The rate of hospitalised bleeding 
increased over the duration of the study period. Bleeding recorded in both primary care and 
hospitalised settings were associated with increased risk of all-cause mortality and 
atherothrombotic events. 
Conclusion 
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Bleeding is a major public health problem; it is common, increasing hospitalisations and 
associated with high mortality. With linked electronic health records I have developed and 
validated a comprehensive and reproducible bleeding phenotype with 3 distinct levels of 
severity that is can be used and further developed. 
 
6.1 Background 
In common cardiac disorders, including atrial fibrillation, acute coronary syndromes and stable 
coronary disease, antithrombotic drugs have been shown to be effective in reducing the risk of 
subsequent atherothrombotic events in randomised trials.188-190 Yet, major and minor bleeding 
is the main safety concern of different antithrombotic drug classes in clinical trials. Clinical 
bleeding scores7 have been incorporated into guidelines and bleeding prognostic models have 
been developed186 to aid assessment of patients bleeding risk prior to making treatment 
decisions. However such tools are limited by miscalibration when applied to new 
populations.193 
There are increasing numbers of people with such common heart diseases on one, two or 
three antithrombotic agents because of better implementation of longstanding trial evidence, 
(e.g. aspirin in the secondary prevention of non-myocardial infarction coronary disease), the 
introduction of new antithrombotic drugs (e.g. direct  oral anticoagulants (DOACs), ticagrelor) 
and the recognition of the benefit of prolonging dual antiplatelet therapy post-MI (e.g. 
ticagrelor).17 Indeed prolonged (lifelong) treatment is now recommended not only for 
anticoagulation in atrial fibrillation but also in dual antiplatelet therapy following acute 
myocardial infarction.17,191,194  
For the bleeding risk associated with antithrombotic therapy, it remains unclear the modern 
population burden of bleeding in people with common cardiac disorders. While previous 
studies reported bleeding risk of atrial fibrillation81, acute coronary syndromes195, and stable 
coronary disease66, there are no studies which compare across common cardiac disorders; and 
the bleeding definitions used within single disease studies differ. While small regional studies 
of intracerebral haemorrhage suggest increased incidence84,196 there has been a lack of 
understanding of time trend in bleeding among other cardiac disorders. 
In the previous chapter I developed a bleeding phenotype using linked electronic heath 
records (CALIBER). The bleeding phenotype was developed with a view to encourage 
standardised bleeding definitions within electronic health record studies with bleeding 
endpoints and enable monitoring patients at risk of bleeding (e.g. those treated with 
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antithrombotic therapies). The assessment of the incidence and prognosis of bleeding in the 
study population can contribute towards demonstrating the validity of the phenotypes whilst 
estimating the burden of bleeding in populations indicated for antithrombotic therapies in 
England. 
There has been a lack of research in large scale population based samples of patients with 
common cardiac disorders evaluating the incidence of bleeding, time trends and prognosis. I 
sought to address the following questions:   
First, what is the long term incidence of major bleeding and any bleeding across patients with 
atrial fibrillation, acute myocardial infarction, unstable and stable angina who are on different 
antiplatelet and anticoagulation regimens?  There are no studies which compare across 
common cardiovascular disorders; and bleeding definitions differ.  
Second to what extent has the incidence of bleeding increased over time with the changes in 
antithrombotic management? Small regional studies of intracerebral haemorrhage suggest an 
increase incidence.  
Third how does major, minor bleeding impact on long term prognosis in terms of all-cause 
mortality, a composite of cardiovascular mortality, MI and stroke and recurrent bleeding? 
6.2 Methods 
6.2.1 Study population 
The study population consisted of patients with either coronary disease or atrial fibrillation, i.e. 
those who were potential candidates for antithrombotic therapy, in CALIBER during 1997-
2010. To define this population I used pre-existing validated disease phenotypes in CALIBER. 
Patients were eligible if they were aged 18 years and above and entered the cohort at their 
first diagnosis of atrial fibrillation, acute myocardial infarction, unstable angina or stable 
angina. If patients were diagnosed with more than one of the aforementioned diseases on 
their index date they were placed into a group using the ranking 1) atrial fibrillation, 2) 
myocardial infarction, 3) unstable angina, and 4) stable angina. Patients were followed up until 
death, transfer out of their primary care practice (i.e. loss to follow-up), or the date of 
administrative censoring (March 2010). 
I analysed baseline characteristics of patients stratified baseline bleeding risk. Patients 
bleeding risk was calculated using a previously validated prognostic model which uses baseline 
characteristics to determine long term risks186. Multiple imputation197 was used to impute 
missing systolic blood pressure, creatinine and smoking status data that was required in order 
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to apply the prognostic model and calculate individual predictions. Ten imputed data sets were 
generated. The prognostic model was applied to each imputed data set and the calculated 
linear predictors were averaged for each patient. Using the 16%, 50% and 84% cut points from 
the prognostic model development,186 patients were grouped as low, medium low, medium 
high and high bleeding risk. 
Using prescribing data I summarised duration (median and interquartile range days) of 
antithrombotic use between cohort entry and first bleeding event. To calculate duration, a 
patient’s prescription was assumed to be continuous if issued within 90 days of the previous 
one (90 days is the longest allowed duration of prescriptions in the UK). Antithrombotic 
therapies were grouped as aspirin monotherapy, adenosine diphosphate (ADP) receptor 
inhibitor monotherapy, dual antiplatelet therapy (aspirin and ADP receptor inhibitor), vitamin 
K antagonist (VKA) monotherapy, VKA and one antiplatelet (aspirin or ADP receptor inhibitor) 
and triple therapy (VKA, aspirin and ADP receptor inhibitor). 
6.2.2 Classification of bleeding events 
Bleeding events were defined using the algorithm defined in the previous chapter. Non-fatal 
bleeding events were classified as hospitalised or primary care with markers of severity 
(referred to as hospitalised+ and primary care+), and hospitalised or primary care without 
markers of severity (referred to as hospitalised and primary care). For patients with no 
bleeding code in either primary care or hospital records, bleeding events may be inferred 
where there are records that provide evidence suggesting bleeding, for example transfusions 
and low haemoglobin. 
6.2.3 Bleeding incidence 
The incidence of any bleeding and fatal, hospitalised+ and primary care+ bleeding events was 
assessed using Kaplan-Meier plots stratified by cardiovascular disease group (atrial fibrillation, 
acute myocardial infarction, unstable angina and stable angina) and by bleeding risk group 
(high, medium high, medium low and low). Follow-up was capped at 5 years. 
6.2.4 The association between antithrombotic therapy prescribing and the risk of bleeding 
Cox proportional hazard models were used to estimate hazard ratios for the association 
between antithrombotic therapies and first bleeding event of any severity and fatal or 
bleeding+ event. Antithrombotic therapy prescriptions were included in the models as a time-
dependent variable due to the dynamic nature of such treatment within individuals. Possible 
states were no antithrombotic therapy (reference group), aspirin, ADP receptor inhibitor, dual 
antiplatelet therapy, VKA monotherapy, VKA and one antiplatelet (aspirin or ADP receptor 
inhibitor) and triple therapy. Patients were followed up until their first bleeding event of any 
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severity and until their first fatal or bleeding+ event. Models were also adjusted for age, sex, 
bleeding risk group, and initial cardiovascular disease. 
6.2.5 Time trends in bleeding and antithrombotic therapy prescribing 
I estimated the change in prevalence of primary care, hospitalised and fatal bleeding within 
the study population at monthly intervals between 1997 and 2010. To do this I calculated the 
number of bleeding events in primary care, secondary care and death registry per active 
patients in each month and fitted local regression (LOESS) smoothed lines to assess the trends. 
I also investigated the trends in antithrombotic therapy prescribing (aspirin, ADP receptor 
inhibitor and VKAs) using the same methods. 
Bleeding and antithrombotic therapy prescribing rates were also assessed in the initial 
cardiovascular disease subgroups: atrial fibrillation, myocardial infarction, unstable angina and 
stable angina. 
6.2.6 Prognosis following non-fatal bleeding events 
Cox proportional hazard models were used to estimate hazard ratios for the association 
between first bleeding events and all-cause mortality and atherothrombotic events (composite 
of cardiovascular death, ischaemic or unspecified stroke, or myocardial infarction). Bleeding 
severity (hospitalised +, primary care +, hospitalised, primary care and inferred) was treated as 
a time-dependent variable in the models to prevent immortal time bias. The bleeding variable 
could have the states no bleeding, primary care, primary care+, hospitalised or hospitalised+. 
Models were also adjusted for age, sex and baseline disease history (diabetes, stroke, 
peripheral arterial disease, cancer, renal disease, peptic ulcer, bleeding diatheses, chronic 
anaemia). The risk of recurrent bleeding events (at least 30 days following initial bleeding 
event to ensure the recurrent bleeding is a new event and not a continuation of the initial 
bleeding) following non-fatal bleeding events of any severity and primary care+ or 
hospitalised+ bleeding was examined using Kaplan-Meier plots. 
6.3 Results 
6.3.1 Study Population baseline characteristics 
The baseline characteristics of the 128815 patients in the study population, stratified by 
bleeding risk group are presented in Table 6.1. By nature of the risk prediction model, patients 
were on average older in the higher risk groups. Large proportions of the high risk patients had 
comorbidities such as atrial fibrillation (31.9% vs. 12.8% low risk patients), ischaemic or 
unspecified stroke (18.9% vs. 0.4%), type 2 diabetes (22.1% vs. 3.5%), cancer (36.4% vs 1.4%) 
and chronic anaemia (34.2% vs. 4.7%). Patients in the low risk group had a higher average BMI. 
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14.9% of patients in the low risk group were classified as obese compared with 6.7% of the 
patients in high risk group. Average systolic blood pressure and creatinine was higher and 
haemoglobin was lower in the higher risk groups.  
The percentage of patients prescribed antithrombotic therapy during follow-up was lowest in 
the high bleeding risk group (65.9%) compared with the medium high risk group (78.4%), the 
medium low risk group (85.5%) and the low risk group (72.0%). Aspirin monotherapy was less 
common in the high risk group compared with the other groups. The percentage of patients 
prescribed dual antiplatelet therapy increased across risk groups (6.6% in the low risk group vs. 
14.6% in the high risk group). The median duration of dual antiplatelet therapy was similar 
across the risk groups, approximately a year, which aligns with guidelines that were in place 
during the study period. VKA monotherapy prescribing was highest in the medium low (21.3%) 
and low (18.4%) risk groups. Prescribing VKAs with 1 or 2 antiplatelets concurrently was most 
common in the medium high and medium low risk groups. 
6.3.2 Long term risk of bleeding 
At 5 years the overall risk of any bleeding event in the study population was 24.2% (95% CI: 
23.9, 24.5%) and the 5 year risk of fatal, hospitalised+ or primary care+ bleeding events was 
6.5% (95% CI: 6.4, 6.7%). 
The Kaplan-Meier curves of CALIBER bleeding events, stratified by initial cardiovascular disease 
are shown in Figure 6.1. At 5 years 29.1% (95% CI: 28.2, 29.9%) of atrial fibrillation patients, 
21.9% (95% CI: 21.2, 22.5%) of myocardial infarction patients, 25.3% (95% CI: 24.2, 26.3%) of 
unstable angina patients and 23.4% (95% CI: 23.0, 23.8%) of stable angina had bleeding of any 
kind. At 5 years fatal, hospital+ or primary care+ bleeding risks were 9.9% (95% CI: 9.3, 10.4%) 
for atrial fibrillation patients, 6.1% (95% CI: 5.8, 6.5%) for myocardial infarction patients, 6.8% 
(95% CI: 6.0, 7.2%) for unstable angina patients and 5.7% (95% CI: 5.5, 5.9%) for stable angina.  
At 5 years any bleeding risks were 16.8% (95% CI: 16.0, 17.5%), 19.5% (95% CI: 19.0, 19.9%), 
27.2% (95% CI: 26.7, 27.7%) and 37.1% (95% CI: 36.0, 18.1%) for patients in the low, medium, 
medium high and high bleeding risk groups respectively. Fatal, hospital+ or primary care+ 
bleeding event risks were 2.0% (95% CI: 1.8, 2.3%), 3.6% (95% CI: 3.4, 3.8%), 8.2%, (95% CI: 7.9, 
8.5%) and 15.1% (95% CI: 14.3, 15.9%) for patients in the low, medium, medium high and high 
bleeding risk groups respectively. 
The increasing incidence of bleeding across bleeding risk groups was consistent within each 
cardiovascular disease group Table 6.2. The 5 year risk of fatal, hospitalised+ or primary care+ 
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bleeding in patients with atrial fibrillation and classified as high bleeding risk was 17.5% (15.6, 
19.3%), and for patients with stable angina classified as low bleeding risk 1.85% (1.00, 2.70%). 
6.3.3 The association between antithrombotic prescriptions and bleeding 
Patients prescribed with more aggressive antithrombotic therapies (dual antiplatelet therapy, 
vitamin K antagonists, and triple therapy) had significantly higher risk of bleeding events 
compared with to those not prescribed antithrombotic therapies (Figure 6.2). Patients who 
were prescribed triple therapy had 3.3 (95% CI: 2.6, 4.4) times increased risk of any bleeding 
and 5.2 (95% CI: 3.4, 9.0) times increased risk of fatal, hospitalised+ or primary care+ bleeding 
events compared with those not prescribed antithrombotic therapies. 
6.3.4 Time trends in bleeding incidence and antithrombotic prescribing 
In Figure 6.3 estimated time trends in bleeding incidence and antithrombotic prescribing are 
shown. The estimated number of hospitalised+ bleeding events per 1000 active patients 
increased from 0.32 (95% CI: 0.24, 0.40) in January 1998 to 0.54 (95% CI: 0.45, 0.62) in 
December 2009. Primary care+ bleeding events per 1000 active patients decreased from 0.80 
(95% CI: 0.70, 0.91) in January 1998 to 0.34 (95% CI: 0.23, 0.45) in December 2009, and fatal 
bleeding remained steady. There were increases in hospitalised and primary care bleeding 
events without markers of severity. The estimated number of hospitalised bleeding events per 
1000 active patients increased from 1.02 (95% CI: 0.83, 1.22) in January 1998 to 2.68 (95% CI: 
2.49, 2.88) in December 2009. The estimated number of primary care bleeding events per 
1000 active patients increased from 1.70 (95% CI: 1.44, 1.95) in January 1998 to 3.31 (95% CI: 
3.06, 3.57) in December 2009. Rates of prescribed antithrombotic therapies also rose over the 
study period. The number of aspirin prescriptions issued per 1000 active patients rose from 
147.9 (95% CI: 127.4, 168.3) in January 1998 to 465.1 (95% CI: 444.6, 485.6) in December 2009. 
ADP receptor inhibitor prescriptions per 1000 active patients rose from 2.8 (95% CI: 0.2, 5.4) in 
January 1998 to 94.8 (95% CI: 92.2, 97.4) in December 2009. VKA prescriptions per 1000 active 
patients rose from 22.7 (95% CI: 19.2, 26.1) in January 1998 to 83.7 (95% CI: 80.2, 87.1) in 
December 2009.  
The rates of fatal, hospitalised+ and primary care+ stratified by cardiovascular disease are 
displayed in Supplementary appendix 11.3.1. The increasing rates of hospitalised and primary 
care bleeding events appeared to be similar amongst the cardiovascular diseases 
(Supplementary appendix 11.3.2). 
Antithrombotic therapy prescribing rates differed amongst the cardiovascular diseases, in 
particular between atrial fibrillation and the coronary diseases (Supplementary appendix 
11.3.3). The rates of prescribing of each drug class increased in all four diseases, and the 
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prescribing of aspirin was consistently higher than those of vitamin K antagonists and ADP 
receptor inhibitors. However the prescribing of vitamin K antagonists was highest for atrial 
fibrillation patients and the prescribing of ADP receptor inhibitors was highest for myocardial 
infarction, unstable angina and stable angina patients. 
6.3.5 Death, atherothrombotic events and recurrent bleeding following first bleeding 
event 
Patients were at increased risk of all-cause mortality and cardiovascular death, stroke or 
myocardial infarction following their first bleeding event and this association was observed 
across all bleeding severities (Figure 6.4). Compared with patients with no bleeding, risk of all-
cause mortality was highest in patients following hospitalised+ bleeding (adjusted HR: 2.97; 
95% CI: 2.84, 3.12). Similarly, risk of cardiovascular death stroke or MI events increased the 
most following hospitalised+ bleeding (adjusted HR: 2.55; 95% CI: 2.38, 2.74). Following 
primary care bleeding, patients were also at significantly increased risk of all-cause mortality 
(adjusted HR: 1.23; 95% CI: 1.19, 1.27) and cardiovascular death, stroke or MI events (adjusted 
HR: 1.08; 95% CI: 1.04, 1.13) although to a lesser extent. 
The estimates of prognosis were largely consistent between atrial fibrillation (Supplementary 
appendix 11.3.4), myocardial infarction (Supplementary appendix 11.3.5), unstable angina 
(Supplementary appendix 11.3.6) and stable angina (Supplementary appendix 11.3.7). All 
bleeding events were associated with increased risk of all-cause mortality within each of the 
cardiovascular diseases. For atrial fibrillation patients the risk of cardiovascular death, stroke 
or MI was not significantly increased following primary care bleeding events (adjusted HR: 
1.03; 95% CI: 0.93, 1.15). Similarly, unstable angina patients were not at increased risk of 
cardiovascular death, stroke or MI following primary care (adjusted HR: 0.98; 95% CI: 0.84, 
1.14) and inferred bleeding events (adjusted HR: 1.41; 95% CI: 0.93, 2.13). 
Following an initial bleeding event patients were at high risk of further bleeding in the long 
term (Figure 6.5). The risks were greater if the initial bleeding event was major. Patients who 
had a bleeding event of any kind were at 32.4% (95% CI: 31.8, 33.0) risk of 5 year any recurrent 
bleeding and 8.3% (95% CI: 7.9, 8.6) risk of 5 year fatal or major bleeding. Patients who 
experienced major bleeding had 37.4% (95% CI: 36.0, 38.8) 5 year risk of any further bleeding 
and 23.1% (95% CI: 21.9, 24.3) 5 year risk of fatal or major bleeding. 
6.3.6 Classification of bleeding severity 
Through the assessment of prognosis following bleeding (Figure 6.4) I identified 3 distinct 
levels of severity amongst the bleeding types defined in the phenotype. I therefore classify 
non-fatal bleeding severity as:  
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• I: Hospitalised + bleeding  
• II: Hospitalised bleeding; primary care + bleeding; inferred bleeding  
• III: Primary care bleeding 
6.4 Discussion 
6.4.1 Bleeding incidence in cardiovascular disease populations 
In this chapter I demonstrated a direct comparison of bleeding within four common 
cardiovascular diseases with varying degrees of antithrombotic use. Atrial fibrillation had 
highest bleeding 5-year rates both for any bleeding (29.1%) and for fatal or major bleeding 
(9.9%). This may be indicative of higher prevalence and longer durations of prescribed 
aggressive ATT treatment (VKA, dual, triple therapy) in atrial fibrillation patients. However the 
incidence of bleeding in myocardial infarction, unstable angina and stable angina patients was 
still relatively high.  
6.4.2 Time trends in bleeding rates over the study period (1997-2010) 
So far as I am aware there have been no previous studies which have evaluated the time 
trends in bleeding incidence.  It was hypothesised that the increased use of antithrombotic 
therapies during this period would be associated with an increased incidence of bleeding.  
Increases in major and minor hospitalised bleeding and minor primary care bleeding events 
over time were identified. It is unknown whether the increase in bleeding incidence is directly 
attributable to increasing range of available antithrombotic therapies and widening indications 
for their use over time, but there was an increase in antithrombotic prescribing in the 
coinciding timeframe. These bleeding events are associated with poor outcomes indicating an 
increasing burden bleeding may have on healthcare systems and costs in England. 
6.4.3 Prognosis following bleeding 
The analysis of prognosis following a non-fatal bleeding event identified 3 distinct levels of 
severity; I: Major bleeding requiring hospitalisation, II: Minor bleeding requiring 
hospitalisation, major bleeding in primary care, or inferred bleeding and III: Minor bleeding in 
primary care. This contrasts with the usual dichotomised major/minor bleeding used in 
outcome studies. Increased bleeding severity was strongly associated with increased risks of 
all-cause mortality and atherothrombotic events. ‘Type III’ bleeding though the least severe, 
significantly increased risk of death suggesting all types of bleeding captured by the phenotype 
are clinically important. The association between bleeding and subsequent atherothrombotic 
events could be due to cessation of ATT following a bleeding event and thus exposing patients 
to increased risk of atherothrombotic events. Patients at highest risk of atherothrombotic 
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events may be treated more aggressively with ATT and therefore at a high risk of bleeding. 
Furthermore there are a number of common risk factors, such as age and comorbidities, for 
both the propensity to bleeding and the progression from one cardiac to disease to fatal or 
non-fatal atherothrombotic events. 
6.4.4 Phenotype validity 
The gold standard method for validating phenotypes in electronic health records is to compare 
manually with patient charts. Such information is not available within the CALIBER platform. 
However the analyses performed in this study demonstrate the characteristics of the bleeding 
events defined by the phenotype and previous studies have demonstrated the good validity of 
many of the bleeding codes used in the present study.74,77 
6.4.5 Clinical implications 
This study provides an analysis of bleeding incidence, risks and prognosis from a public health 
perspective. The rise of bleeding and adverse prognosis following bleeding of any kind suggests 
an iatrogenic epidemic. A potential action to stem this problem is more stringent checking of 
bleeding risks prior to prescribing antithrombotic therapies. For example risk scores for 
cardiovascular and bleeding events integrated into general practice systems can help 
determine suitability for antithrombotic therapy and the phenotype can be used for continual 
monitoring and automated flagging-up of bleeding events. With growing ability replicating trial 
populations within real world data in linked electronic health records to estimate real-world 
impact of interventions phenotypes such as ours allow us to closely match the endpoints used 
in trials. 
6.4.6 Future research 
The phenotype should be validated in further electronic health record populations to ensure 
generalisability. The phenotype should also be applied to more recent populations including 
patients prescribed newer antithrombotic agents such as novel oral anticoagulants and 
ticagrelor. It is not known if the wider range of available antithrombotic agents has had an 
impact on incidence and severity of bleeding events. 
6.4.7 Conclusion 
Bleeding is a major public health problem; it is common, increasing hospitalisations and 
associated with high mortality. With linked electronic health records I have developed and 
validated a comprehensive and reproducible bleeding phenotype with 3 distinct levels of 
severity that is can be used and further developed for use in electronic health record studies of 
bleeding outcomes or antithrombotic safety. 
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6.5 Tables and Figures 
Table 6.1: Baseline characteristics stratified by bleeding risk group 
 High 
(n= 21101) 
Medium high 
(n=53362) 
Medium low 
(n= 40950) 
Low 
(n=13402) 
Demographics and 
behaviours at cohort entry 
    
Age (years), mean (SD) 83.8 (7.95) 77.2 (8.17) 64.9 (8.12) 49.6 (8.85) 
Women, n (%) 9184 (43.5) 25697 (48.2) 17892 (43.7) 6233 (46.5) 
Highest quintile of 
deprivation, n (%) 
4059 (19.3) 10422 (19.6) 8109 (19.9) 3089 (23.1) 
Missing % 0.3 0.3 0.3 0.3 
Smoking status, 
n (%)               
Smoker 2207 (10.5) 4716 (8.8) 4697 (11.5) 1635 (12.2) 
Ex-Smoker 5760 (27.3) 14842 (27.8) 12204 (29.8) 3457 (25.8) 
Non-Smoker 9524 (45.1) 23379 (43.8) 15580 (38.0) 4922 (36.7) 
Missing % 17.1 19.5 20.7 25.3 
History of alcohol abuse, n 
(%) 
2928 (13.9) 5197 (9.7) 3727 (9.1) 572 (4.3) 
Medical history prior to 
cohort entry a 
    
Atrial fibrillation, n (%) 6622 (31.4) 13007 (24.4) 5711 (13.9) 1721 (12.8) 
Myocardial infarction, n 
(%) 
4938 (23.4) 9970 (18.7) 7790 (19) 2333 (17.4) 
Unstable angina, n (%) 1236 (5.9) 3536 (6.6) 3311 (8.1) 1417 (10.6) 
Stable angina, n (%) 8305 (39.4) 26849 (50.3) 24138 (58.9) 7931 (59.2) 
Ischaemic or unspecified 
stroke, n (%) 
3988 (18.9) 3073 (5.8) 514 (1.3) 49 (0.4) 
Peripheral arterial disease, 
n (%) 
5048 (23.9) 4983 (9.3) 1348 (3.3) 108 (0.8) 
Diabetes, n (%) Type 2 4671 (22.1) 7148 (13.4) 3273 (8) 475 (3.5) 
Type 1 58 (0.3) 263 (0.5) 430 (1.1) 387 (2.9) 
Unspecified 533 (2.5) 1119 (2.1) 706 (1.7) 148 (1.1) 
Renal disease, n (%) 3862 (18.3) 3885 (7.3) 1314 (3.2) 285 (2.1) 
Non-metastatic cancer, n 
(%) 
7691 (36.4) 8506 (15.9) 2062 (5) 182 (1.4) 
Metastatic cancer, n (%) 984 (4.7) 308 (0.6) 36 (0.1) 1 (0) 
Peptic ulcer, n (%) 2174 (10.3) 4131 (7.7) 2526 (6.2) 523 (3.9) 
Bleeding diatheses and 
coagulation disorders, n 
(%) 
662 (3.1) 330 (0.6) 87 (0.2) 19 (0.1) 
Chronic anaemia, n (%) 7217 (34.2) 7088 (13.3) 2183 (5.3) 625 (4.7) 
Biomarkers at cohort 
entry b 
    
BMI, Mean (SD) 26.3 (4.93) 27.5 (5.37) 29.0 (5.74) 30.7 (6.78) 
Underweight, n (%) 264 (1.3) 539 (1.0) 221 (0.5) 35 (0.2) 
Normal, n (%) 2708 (12.8) 5465 (10.2) 3091 (7.5) 733 (5.5) 
Overweight, n (%) 2637 (12.5) 7132 (13.4) 5533 (13.5) 1379 (10.3) 
Obese, n (%) 1413 (6.7) 4921 (9.2) 5259 (12.8) 2002 (14.9) 
Missing % 66.7 66.2 65.6 69 
SBP (mmHg), mean (SD) 146 (26.2) 143 (21.1) 139 (17.7) 133 (15.8) 
 Missing % 23.8 24.5 26 34.1 
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 High 
(n= 21101) 
Medium high 
(n=53362) 
Medium low 
(n= 40950) 
Low 
(n=13402) 
Haemoglobin (g/dL), mean 
(SD) 
12.4 (1.98) 13.3 (1.75) 14.0 (1.51) 14.1 (1.49) 
 Missing % 50.2 59.2 63.7 67.8 
Creatinine (mmol/l), mean 
(SD) 
139.8 (91.1) 101.9 (34.8)  89.4 (21.8)  81.4 (19.6) 
 Missing % 42 49.6 54.5 65.1 
Antithrombotic therapies 
(n, %) and duration 
(median, IQR) during 
follow-upc 
    
Any antithrombotic 
therapy, n (%) 
13898 (65.9) 41835 (78.4) 34999 (85.5) 9652 (72.0) 
Aspirin monotherapy, n 
(%) 
9991 (47.3) 33921 (63.6) 30103 (73.5) 8240 (61.5) 
 Duration (days) 416 (137,  944) 718 (253, 1532) 965 (357, 1949) 714 (218, 1698) 
ADP receptor inhibitor 
monotherapy, n (%) 
1779 (8.4) 5409 (10.1) 5057 (12.3) 1478 (11) 
 Duration (days) 151 (41, 516) 145 (42, 561) 135 (42, 551) 142 (47, 463) 
Dual antiplatelet therapy, 
n (%) 
3086 (14.6) 7531 (14.1) 4455 (10.9) 883 (6.6) 
 Duration (days) 343 (112, 856) 372 (124, 990) 362 (120, 999) 331 (126, 954) 
VKA monotherapy, n (%) 2537 (12) 8502 (15.9) 8715 (21.3) 2469 (18.4) 
 Duration (days) 229 ( 90, 448) 292 (101, 482) 316 (118, 477) 305 (114, 471) 
VKA + 1 antiplatelet, n (%) 1253 (5.9) 4328 (8.1) 2914 (7.1) 463 (3.5) 
 Duration (days) 90 (53, 236) 90 (51, 205) 90 (54, 198) 90 (49, 189) 
VKA + 2 antiplatelets, n (%) 159 (0.8) 547 (1) 363 (0.9) 50 (0.4) 
 Duration (days) 65.0 (35.0,  90) 61.0 (38.5,  90) 63.0 (34.0,  90) 74.5 (55.5, 108) 
Note: SD=standard deviation, SBP=systolic blood pressure, BMI= body mass index, IQR= interquartile 
range, ADP=adenosine diphosphate, VKA=vitamin K antagonist 
a Any record prior to cohort entry 
b Nearest record to entry within 1 year prior to entry 
c Between cohort entry and 1st bleeding event or end of follow-up
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Figure 6.1: Five year risk of CALIBER bleeding from time of initial atrial fibrillation, acute myocardial infarction, unstable angina or stable angina (n= 128,815 patients); A: any 
bleeding, B: Fatal bleeding or bleeding with further markers of severity) 
 
Note: In panel A ‘Any bleeding’ includes fatal, hospitalised +, hospitalised, primary care + and primary care bleeding events; in panel B ‘Fatal bleeding or bleeding +’ includes fatal, 
hospitalised + and primary care+ bleeding events only 
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Table 6.2: Kaplan-Meier estimates (95% confidence interval) for 5 year any bleeding (top row) and fatal bleeding, primary care+ bleeding or hospitalised+ bleeding (bottom 
row) stratified by baseline bleeding risk group and initial cardiovascular disease 
Bleeding risk group Atrial fibrillation Myocardial infarction Unstable angina Stable angina Overall 
Low 
16.05 (13.90 18.14) 
3.17 (2.20 4.12) 
12.14 (10.55 13.70) 
2.10 (1.41 2.78) 
16.87 (14.51 19.17) 
1.83 (1.50 2.16) 
18.05 (17.09 18.99) 
1.85 (1.00 2.70) 
16.8 (16.0 17.5) 
2.0 (1.8 2.3) 
Medium low 
23.53 (22.11 24.93) 
5.96 (5.17 6.74) 
16.70 (15.71 17.68) 
3.05 (2.59 3.50) 
21.53 (19.90 23.11) 
4.02 (3.24 4.78) 
19.15 (18.58 19.71) 
3.21 (2.96 3.46) 
19.5 (19.0 19.9) 
3.6 (3.4 3.8) 
Medium high 
31.40 (30.16 32.62) 
10.92 (10.10 11.73) 
24.47 (23.35 25.57) 
7.32 (6.64 7.98) 
29.46 (27.55 31.31) 
8.90 (7.72 10.06) 
26.39 (25.75 27.03) 
7.51 (7.12 7.89) 
27.2 (26.7 27.7) 
8.2 (7.9 8.5) 
High 
40.08 (37.56 42.50) 
17.48 (15.62 19.31) 
37.41 (34.98 39.75) 
15.11 (13.33 16.86) 
38.00 (33.88 41.86) 
16.17 (13.06 19.16) 
35.62 (34.14 37.06) 
13.80 (12.73 14.85) 
37.1 (36.0 18.1) 
15.1 (14.3 15.9) 
Overall 
29.1 (28.2 29.9) 
9.9 (9.3 10.4) 
21.9 (21.2 22.5) 
6.1 (5.8 6.5) 
25.3 (24.2 26.3) 
6.8 (6.0 7.2) 
23.4 (23.0 23.8) 
5.7 (5.5 5.9) 
24.2 (23.9 24.5) 
6.5 (6.4 6.7) 
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Figure 6.2: The association between antithrombotic therapy prescribing and any bleeding and fatal or bleeding + events 
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Figure 6.3: Time trends of fatal, hospitalised and primary care bleeding events and antithrombotic prescribing 1998-2010 in CALIBER.  
 
A: Fatal, hospitalised + and primary care+ bleeding events; B: Hospitalised and primary care bleeding events; C: Prescriptions for ADP receptor inhibitors, 
aspirin and vitamin K antagonists. 
Note: Fitted lines are loess smoothed curved with shaded 95% confidence intervals 
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Figure 6.4: The association between non-fatal bleeding severity classes and time to all-cause mortality and cardiovascular death, stroke or myocardial infarction 
 
Note: Adjusted estimates are adjusted for age, sex and comorbidities; CV= cardiovascular; MI= myocardial infarction   
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Figure 6.5: Five year risk of recurrent bleeding stratified by initial bleeding type: any bleeding or bleeding with further markers of severity (bleeding +). 
 
Note: ‘Any bleeding’ includes hospitalised, hospitalised +, primary care, primary care + and inferred bleeding. ‘Bleeding +’ includes hospitalised + or primary care + 
bleeding. 
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7 Personalising the decision for prolonged dual antiplatelet therapy: 
Development and validation of prognostic models for 
atherothrombotic and bleeding events in stable myocardial 
infarction survivors 
This work in this chapter has been published:  
Pasea, L., Chung, S.C., Pujades-Rodriguez, M., Moayyeri, A., Denaxas, S., Fox, K.A., 
Wallentin, L., Pocock, S.J., Timmis, A., Banerjee, A., Patel, R. and Hemingway, H., 2017. 
Personalising the decision for prolonged dual antiplatelet therapy: development, validation and 
potential impact of prognostic models for cardiovascular events and bleeding in myocardial 
infarction survivors. European heart journal, 38(14), pp.1048-1055. 
https://doi.org/10.1093/eurheartj/ehw683 
Chapter Summary 
Background 
Recent trials have examined the efficacy of prolonging dual antiplatelet therapy in myocardial 
infarctions survivors for continued reduction of atherothrombotic risk 
Methods 
Using CALIBER linked electronic health records prognostic models for patients who survived 
one year following a myocardial infarction were developed (n=12694) and validated (n=5613) 
for all-cause mortality, atherothrombotic and bleeding events. Trial effect estimates for 
prolonged dual antiplatelet therapy with ticagrelor were applied to predicted risks of 
atherothrombotic and bleeding events in the validation cohort to estimate the net clinical 
benefit of treatment. A web application was developed to produce predicted risks of 
atherothrombotic and bleeding events given a set of baseline characteristics. 
Results 
Prognostic models were developed including covariates for patient demographics, behaviours, 
cardiovascular and non-cardiovascular medical history, clinical biomarkers and prescribed 
medication. In external validation the models performed well in terms of discrimination (c 
indexes ranged from 0.67 to 0.81 across the studied endpoints) and calibration. In the highest 
risk groups we estimated, for every 10,000 patients treated per year 249 (95% CI: 228, 269) 
cardiovascular events may be prevented and 134 (95% CI: 87,181) major bleeding events may 
be caused, whereas in the lowest risk groups 28 (95% CI: 19, 37) cardiovascular events may be 
prevented and 9 (95% CI: 0, 20) major bleeding events may be caused. Depending on the 
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weighting of benefits versus harms there was a net clinical benefit in favour of dual 
antiplatelet therapy for 63 to 99% of patients in the validation cohort. 
Conclusion 
I developed and validated prognostic models for benefits and different bleeding harms, 
relevant to the decision to prolong DAPT in patients stable 1 year after an acute MI. 
Personalised treatment decisions, based on individual patient risk profiles, can inform 
decision-making. 
7.1 Introduction 
Among patients who survived a year since their last acute myocardial infarction (MI), 
subsequent major cardiovascular events, all-cause mortality and major bleeding risks are 
high.198,199 In unselected populations in USA, Sweden, England and France 20% of such patients 
experienced subsequent MI, stroke or died during the following 3 years.199 Prolonged 
secondary prevention therapy in such patients is already recommended for 4 classes of drugs 
(statins, beta-blockers, ACE inhibitors and aspirin). Recent trials17,200 examined addition of an 
extra antiplatelet. The PEGASUS-TIMI 54 trial17 found prolonged dual antiplatelet therapy 
(DAPT) using aspirin and ticagrelor compared with aspirin alone in patients 1-3 years since 
their last acute MI reduced the risk of cardiovascular death, stroke or MI by 16% but increased 
major bleeding twofold. In light of this evidence, 2015 European Society of Cardiology 
guidelines recommend prolonged DAPT may be ‘considered after careful assessment of 
ischaemic and bleeding risks’.191,201  
How to make this ‘careful assessment’ is unclear. Risk prediction modelling has proven 
invaluable in conditions such as atrial fibrillation where similar decisions on benefits and harm 
need to be weighed.7 Indeed, such models for bleeding and subsequent MI have been 
developed to guide use of bivalirudin202, the choice of P2Y12 inhibitor203 and duration of 
DAPT.204,205 An existing model intended to guide the duration of DAPT is based on patients 
undergoing drug eluting stent placement and selected into a trial and uses patient 
characteristics at the time of percutaneous coronary intervention.205 Currently, no prognostic 
models evaluate the long-term risks of bleeding and cardiovascular events using updated 
clinical information one year after acute MI, to support the key clinical decision on prolonging 
DAPT.   
In this context, unselected populations are important to provide realistic estimates of long-
term cardiovascular and bleeding risks; these estimates are often substantially higher than 
those observed in the placebo arms of trials.187,206,207 Linked electronic health records (EHRs) 
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are ideal sources of data to derive such ‘real life’ estimates of risks and harms, at scale. The 
CALIBER dataset,8 validated for cardiovascular prognostic research,40,41,184 is a 2 million person 
resource of linked primary-secondary and mortality data in England including 18,307 MI 
survivors.  
Among these stable MI survivors, I sought to first, develop and validate prognostic models for 
major cardiovascular and bleeding endpoints. I used prognostic factors present one year 
following acute MI and widely recorded as part of guideline recommended care. Secondly, to 
demonstrate how predicted benefits and harms may aid treatment and clinical decisions I 
applied PEGASUS-TIMI 54 trial17 relative risks of efficacy and safety to estimate potential 
numbers of cardiovascular events prevented and harms caused by prolonged DAPT, and net 
clinical benefits for individuals. 
7.2 Methods 
The models were developed and validated in line with TRIPOD (Transparent Reporting of a 
multivariable prediction model for Individual Prognosis Or Diagnosis) guidelines.102 (See 
supplementary appendix 11.4.1 for the completed TRIPOD checklist). 
7.2.1 Linked electronic health records  
I used the CALIBER (CArdiovascular research using LInked Bespoke and Electronic health 
Records) research platform, consisting of EHR linkages between primary care data (Clinical 
Practice Research Datalink (CPRD)), secondary care data (Hospital Episode Statistics), disease 
registry data (Myocardial Ischaemia National Audit Project) and cause-specific mortality (Office 
for National Statistics) in England.8 The 4% sample of England’s population in CPRD available 
for linkage is unselected, representative in terms of age, sex and overall mortality.172-174 
Furthermore, there is extensive evidence of risk factor and cardiovascular and non-
cardiovascular disease endpoint validity in CALIBER.36,38-42,184,185 The study was approved by the 
Independent Scientific Advisory Committee of the Medicines and Health care products 
Regulatory Agency in the UK and the MINAP Academic Group. 
The full details of the data used for this work is described in Chapter 3. 
7.2.2 Study Population 
Patients in CALIBER alive 1 year after their last acute MI (i.e. their index acute MI) were 
included in the study. I studied patients from 2000-2010, before the introduction of ticagrelor, 
and when prolonged DAPT was rare. Follow-up started at 1 year after index acute MI, and 
patients were censored at the earliest date of the endpoints of interest, primary care practice 
transfer, death, or 5 years of follow-up. I evaluated prescriptions indicating prolonged 
clopidogrel use in follow up in the cohort to ensure they were untreated with long-term dual 
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antiplatelet therapy i.e. the decision the models aimed to aid. Patients were split into model 
development and validation cohorts using a pre-specified geographical divide.208 The North of 
England has well documented higher rates of cardiovascular mortality compared to the 
South.209 Based on the 10 administrative areas in the National Health Service I chose 6 in the 
South for model development cohort and 4 in the North for model validation cohort.   
7.2.3 Potential prognostic factors 
In model development I considered a priori prognostic factors including demographics, 
behaviours, cardiovascular and non-cardiovascular medical history, medications and clinical 
biomarkers. Each patient’s most recent biomarker records in the year from index acute MI to 
follow-up start were used. Medications were defined as having ≥1 prescription of a drug in the 
year prior to follow-up start. As a patient’s risk profile evolves with time (risk at index event 
and at one year may differ) I also analysed risk characteristics at the time of hospital discharge 
from index acute MI. Patients characteristics at hospital discharge and at one year post-MI 
were summarised as mean and standard deviation (SD) or median and interquartile range 
(IQR) for continuous variables and percentages for categorical variables. 
7.2.4 Endpoints 
The primary endpoint relating to potential benefits of prolonged DAPT, a composite of 
cardiovascular death, MI or ischemic or unspecified stroke, have validated phenotypes in 
CALIBER.36,40,184 For examining potential harms of prolonged DAPT, I evaluated three severe 
bleeding endpoints with differing incidence: 1) fatal or hospitalised  bleeding; 2) CALIBER major 
bleeding (a composite of fatal bleeding, intracranial bleeding, hospitalised bleeding with length 
of stay exceeding 14 days and bleeding requiring transfusion); and 3) fatal or intracranial 
bleeding. Models were also evaluated for all-cause mortality and cardiovascular death.   
7.2.5 Statistical analysis 
7.2.5.1 Model development  
I evaluated associations between endpoints and prognostic factors using proportional hazards 
models with Weibull baseline hazards. Univariable models were used to detect nonlinear 
trends and inform inclusion of prognostic factors in multivariable models. Nonlinear 
continuous prognostic factors were included in the model using restricted cubic splines with 
three knot points. I chose the number of knots based on descriptive plots in the univariable 
analysis to provide a sufficient balance between capturing accurate shape and without 
overfitting.210 I used 3 knots (a sensitivity analysis using 5 knots resulted in very similar 
predictions). Proportional hazards assumptions were checked using residual and log(-log) 
plots. For non-normally distributed continuous prognostic factors, sensible functional form was 
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obtained by log transformation. For parsimony, backwards selection methods were employed 
for constructing multivariable models, in which all prognostic factors were initially included 
and removed stepwise if p>0.1. Variance inflation factors were calculated to detect evidence 
of multicollinearity problems in the model selection process. If variables were deemed to be 
collinear (variance inflation factor>3) then a decision was made to remove one of the 
offending variables. Known important prognostic factors (age, gender, smoking status, index 
acute MI subtype, diabetes, history of MI prior to index acute MI and stroke) were retained in 
all models.   
Missing values for clinical biomarkers and patient behaviours (smoking status and alcohol 
consumptions) were multiply imputed using MICE (Multiple Imputation by Chained 
Equations).211 I used multiple imputation to allow the use of all available patient data in the 
analyses and potentially increase the precision of estimates. If the analyses was restricted to 
complete cases, the sample size would be reduced and would likely not be representative of 
the study population. Multiple imputation assumes data is missing at random – i.e. the missing 
data is not associated with the value of the missing data itself and violation of this assumption 
may result in biased imputations and model estimates. Prognostic factors with more than 50% 
data missing were not considered for multiple imputation or inclusion in the models. 30 
imputed sets were generated using all baseline covariates (demographics and behaviours, 
disease history, clinical biomarkers and prescribed drugs) and study endpoints as predictors in 
the imputation models. Coefficient estimates from models fitted to imputed data sets were 
combined using Rubin’s rules; which uses average coefficients and variances account for 
between and within imputation variability.  
7.2.5.2 Risk groups 
Unequal sized groups can minimise information loss when categorising compared with equal 
groupings,212 I therefore grouped patients according into four risk groups (highest, high, low, 
lowest) using cut-points at the 16th, 50th and 84th percentiles of the model weighted sum of 
covariates in the development cohort.89 These cut points split the validation cohort into risk 
groups for each outcome Therefore in validation, a well calibrated model would place 16%, 
34%, 34% and 16% of patients into the high, medium high, medium low and low risk groups 
respectively.  
7.2.5.3 Model validation 
The developed models were initially validated internally in the development population.  
Bootstrap estimates of Harrell c-indexes were calculated and the observed events in the 
development population were compared with model predictions stratified by risk group. 
Models were then validated using the geographically external North of England population. 
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Harrell’s C-indexes and 95% confidence intervals were used to estimate the discriminative 
ability of each model. Hazard ratios for each of the endpoints between risk groups, using the 
lowest risk groups being as reference, were calculated as a further measure of discrimination. 
Model calibration was assessed visually by comparing plots of model expected events with 
validation cohort observed events, stratified by risk group.  
7.2.5.4 Model application 
I applied the relative risks for efficacy (cardiovascular death, stroke or MI, cardiovascular death 
and all-cause mortality) and safety (TIMI major bleeding and fatal or intracranial bleeding) of 
ticagrelor 60mg versus placebo estimated in the PEGASUS-TIMI 54 trial17 to the validation 
cohort stratified by predicted risk groups to calculate the potential events prevented and 
harms caused per 10,000 patients treated per year (Equation 1). I assumed constant treatment 
effect across risk groups.  
 
Equation 1: Calculating potential events prevented and harms caused with prolonged dual antiplatelet therapy 
〖𝑃𝑜𝑡𝑒𝑛𝑡𝑖𝑎𝑙 𝑒𝑣𝑒𝑛𝑡𝑠 𝑝𝑟𝑒𝑣𝑒𝑛𝑡𝑒𝑑 𝑝𝑒𝑟 10,000 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑝𝑒𝑟 𝑦𝑒𝑎𝑟〗_𝑖𝑗 = 10000 × [
〖𝑚𝑜𝑑𝑒𝑙 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 3 𝑦𝑒𝑎𝑟 𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑟𝑖𝑠𝑘〗_𝑖𝑗 −  (〖𝑃𝐸𝐺𝐴𝑆𝑈𝑆 𝑇𝐼𝑀𝐼 54 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑟𝑖𝑠𝑘〗
_(𝑖 ) ×〖 𝑚𝑜𝑑𝑒𝑙 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 3 𝑦𝑒𝑎𝑟 𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑟𝑖𝑠𝑘〗_𝑖𝑗 )]/3  
𝑖 ∈ {𝐶𝑉 𝑑𝑒𝑎𝑡ℎ, 𝑠𝑡𝑟𝑜𝑘𝑒 𝑜𝑟 𝑀𝐼} 
𝑗 ∈  {ℎ𝑖𝑔ℎ𝑒𝑠𝑡 𝑟𝑖𝑠𝑘; ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘; 𝑙𝑜𝑤 𝑟𝑖𝑠𝑘; 𝑙𝑜𝑤𝑒𝑠𝑡 𝑟𝑖𝑠𝑘} 
 
𝑃𝑜𝑡𝑒𝑛𝑡𝑖𝑎𝑙 ℎ𝑎𝑟𝑚𝑠 𝑐𝑎𝑢𝑠𝑒𝑑 𝑝𝑒𝑟 10,000 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑝𝑒𝑟 𝑦𝑒𝑎𝑟𝑖𝑗 = 
 10000 × [(〖𝑃𝐸𝐺𝐴𝑆𝑈𝑆 𝑇𝐼𝑀𝐼 54 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑟𝑖𝑠𝑘〗_(𝑖 ) ×〖
 𝑚𝑜𝑑𝑒𝑙 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 3 𝑦𝑒𝑎𝑟 𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑟𝑖𝑠𝑘〗_𝑖𝑗 ) −  
〖𝑚𝑜𝑑𝑒𝑙 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 3 𝑦𝑒𝑎𝑟 𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑟𝑖𝑠𝑘〗_𝑖𝑗 ]/3    
𝑖 ∈ {𝑚𝑎𝑗𝑜𝑟 𝑏𝑙𝑒𝑒𝑑𝑖𝑛𝑔; 𝑓𝑎𝑡𝑎𝑙 𝑜𝑟 𝑖𝑛𝑡𝑟𝑎𝑐𝑟𝑎𝑛𝑖𝑎𝑙 𝑏𝑙𝑒𝑒𝑑𝑖𝑛𝑔} 
𝑗 ∈  {ℎ𝑖𝑔ℎ𝑒𝑠𝑡 𝑟𝑖𝑠𝑘; ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘; 𝑙𝑜𝑤 𝑟𝑖𝑠𝑘; 𝑙𝑜𝑤𝑒𝑠𝑡 𝑟𝑖𝑠𝑘} 
 
I calculated net cardiovascular death, stroke or MI and net CALIBER major bleeding risks with 
treatment for each individual in the validation cohort using the trial relative risk estimates 
(Equation 2). I evaluated predicted net benefit in patients (i.e. estimated cardiovascular risk 
decrease exceeds bleeding risk increase) under three different benefit and harm weighting 
scenarios:99,203 1) patients view benefits and harms equally, 2) patients are more concerned 
about preventing atherothrombotic events than potential harms and 3) patients are more 
concerned about potential harms than preventing atherothrombotic events. 
 
216 
 
Equation 2: Calculating individual net benefits for prolonged dual antiplatelet therapy 
𝑁𝑒𝑡 𝑏𝑒𝑛𝑒𝑓𝑖𝑡𝑖 = [𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝐶𝑉 𝑟𝑖𝑠𝑘𝑖 − (𝑃𝐸𝐺𝐴𝑆𝑈𝑆 𝑇𝐼𝑀𝐼 54 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐶𝑉 𝑟𝑖𝑠𝑘 ×
𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝐶𝑉 𝑟𝑖𝑠𝑘𝑖)] − [𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑏𝑙𝑒𝑒𝑑𝑖𝑛𝑔 𝑟𝑖𝑠𝑘𝑖 − (𝑃𝐸𝐺𝐴𝑆𝑈𝑆 𝑇𝐼𝑀𝐼 54 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑏𝑙𝑒𝑒𝑑𝑖𝑛𝑔 𝑟𝑖𝑠𝑘 ×
𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑏𝑙𝑒𝑒𝑑𝑖𝑛𝑔 𝑟𝑖𝑠𝑘)]  
 
𝑖 ∈ {1 …  𝑛} 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 
7.2.6 Web app development 
I used the RShiny package [https://shiny.rstudio.com/] to develop a user friendly web app to 
calculate risks of atherothrombotic and bleeding risks given patient baseline characteristics. I 
used the effect estimates of prolonged dual antiplatelet therapy from the PEGASUS TIMI 54 
trial to show potential changes of risk with further treatment (Equation 1). 
7.2.7 Assessment of simplified approaches for risk stratification 
I assessed simple methods of risk stratification. I compared the model predicted 3 years risks 
of cardiovascular death, stroke or MI and CALIBER major bleeding amongst patients in the 
validation cohort with and without binary factors determined by the PEGASUS-TIMI 54 trial to 
indicate patients at the highest risk: age≥ 65, diabetes (any of types 1, 2 or unspecified type), 
history of MI prior to their index MI and history of renal disease. I applied commonly used 
point-base risk scores, CHA2DS2-VASc6 for atherothrombotic risk and HASBLED7 for bleeding 
risk to the validation cohort. The CHA2DS2-VASc scheme scores patients 1 point each for age 
65-74 years, female gender, histories of heart failure, hypertension, diabetes and vascular 
disease and 2 points for age≥75 years and history of stroke. Patients risk increases with higher 
values of the CHA2DS2-VASc score and the scores range is 0-9. The HASBLED scheme scores 
patients 1 point each for hypertension, abnormal liver function, abnormal renal function, 
stroke, bleeding, labile international normalised ratio (time in therapeutic range <60), age>65 
years, prescriptions for antiplatelets or non-steroidal anti-inflammatory drugs and history of 
alcohol abuse.  Patients risk increases with higher values of the HASBLED score and the scores 
range is 0-9. I assessed the performance of CHA2DS2-VASc and HASBLED risk stratification 
schemes using c-indexes and 5 year Kaplan-Meier event estimates for patients with each score 
value. 
7.3 Results  
7.3.1 Baseline characteristics and overall event rates 
I identified 18307 patients in CALIBER who had survived 1 year following their index MI (Figure 
7.1). The model development cohort consisted of 12,694 patients (mean age 70.1 years, 66.1% 
male) from 159 general practices, median follow-up of 3.1 years (range: 0-9.8) and 27% 
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followed-up for at least 5 years (Table 7.1). The validation cohort consisted of 5,613 patients 
(mean age 69 years, 64.4% male) from 61 general practices. Histories of stroke, heart failure, 
peripheral arterial disease, renal disease, chronic obstructive pulmonary disease, dementia, 
chronic anaemia, peptic ulcer and hospitalised bleeding were more prevalent in the model 
validation cohort compared with the development cohort. Approximately 3% of patients had 
prolonged clopidogrel use in follow-up.  
Patient characteristics of the cohorts changed from acute MI discharge to the study baseline 
date of 1 year post-MI (Supplementary appendix 11.4.2) including increased heart failure 
(18.2% to 23.5% in the development cohort and 21.4% to 28.0% in the validation cohort) and 
renal disease (8.7% to 13.6% in the development cohort and 9.5% to 14.8% in the validation 
cohort) prevalence and changed smoking statuses. There was also a reduction in mean blood 
pressure of 12mmHg in both groups (145 (SD: 16.3) to 133(SD: 18.6) in the development 
cohort and 144(SD: 17.0) to 132 (SD: 18.4) in the validation cohort. 
Using Kaplan-Meier curved I observed higher 5 year event rates in the validation cohort than in 
the development cohort  for all endpoints expect cardiovascular death stroke or MI (Figure 
7.2). At 5 years in the development cohort 2683 (30.1%) had died, 1913 (22.4%) had 
cardiovascular death, stroke or MI events and 188 (2.5%) had major bleeding events. Whereas 
in the validation cohort at 5 years 1252 (30.6%) patients had died, 936 (23.8%) had 
cardiovascular death, stroke or MI and 188 and 98 (2.7%) had major bleeding events. 
7.3.2 Development of prognostic models  
In univariable modelling (Univariable log hazard ratio estimate shown in Supplementary 
appendix 11.4.3) I found increasing risk of all events with age and women were at greater risk 
than men of all-cause mortality, cardiovascular events and fatal or hospitalised bleeding. 
Patients whose index MI was STEMI or unspecified had lower risks of all endpoints compared 
with NSTEMI patients. All investigated cardiovascular and non-cardiovascular comorbidities 
were associated with increased risks of events or had non-significant associations. In particular 
patients with histories of heart failure, atrial fibrillation, stroke, peripheral arterial disease, 
type 2 diabetes, renal disease, cancer, chronic anaemia, bleeding disorders and hospitalised 
bleeding were at increased risk of all six endpoints. Underweight patients had greater risks of 
all-cause mortality and cardiovascular events compared with normal weight patients. Patients 
who had been prescribed oral anticoagulants were at increased risk of cardiovascular and 
bleeding events. 
Checks of the proportional hazards assumptions (Supplementary appendix 11.4.4) showed no 
violations. The curves in log(-log) plots for categorical prognostic factors were parallel and time 
dependent coefficients for continuous prognostic factors were constant over time. 
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In multivariable (Log hazard ratios displayed in Figure 7.3; hazard ratio estimates given in 
Supplementary appendix 11.4.5) modelling, I identified 20 prognostic factors for inclusion in 
the cardiovascular death, stroke or MI model, 22 for inclusion in the cardiovascular death 
model, 24 for inclusion in the all-cause mortality model , 17 for CALIBER major bleeding, 17 for 
fatal or hospitalised bleeding and 16 for fatal or intracranial bleeding. There was no evidence 
of problematic multicollinearity between the prognostic factors in the multivariable models 
(variance inflation factors < 3). While the presence and direction of prognostic factor 
associations with cardiovascular events and bleeding outcomes were mostly concordant, the 
magnitude of prognostic factor associations (e.g. history of MI, stroke, diabetes) differed 
across endpoints. Systolic blood pressure was also included in all models and was modelled 
using restricted cubic splines due to a nonlinear relationship with the endpoints. An example 
curve demonstrating the association of systolic blood pressure with the risk of CV death, stroke 
or MI is shown in Figure 7.4. Patients with very low or very high systolic blood pressure had 
increased risk of events. The functions estimated for systolic blood pressure in each model are 
provided in Supplementary appendix 11.4.6.  
7.3.3 Risk groups for all-cause mortality, atherothrombotic and bleeding events 
The 16th, 50th and 84th percentiles of the linear predictors for each endpoint in the 
development cohort were used to split the patients into risk groups. These cut points were 
(−1,746, −2.972, and −4.077) for all-cause mortality, (−2.198, −3.298, and −4.252) for 
cardiovascular death, stroke or MI, (−2.439, −3.792, and −4.995) for cardiovascular death, 
(−4.159, −5.040 and −5.879) for fatal or intracranial bleeding, (−4.178, −5.118 and −5.989) for 
CALIBER major bleeding and (−3.437, −4.128 and −4.728) for hospitalised bleeding. The 
proportions of patients assigned to each risk group are shown in Table 7.2. By design 16%, 
34%, 34% and 16% of patients in the development cohort were classified as highest, high, low 
and lowest risk respectively for each endpoint. When the cut points were applied to the 
validation cohort for all endpoints fewer than 16% patients were classified as lowest risk (from 
14.5% for cardiovascular death, stroke or MI and cardiovascular death to 15.4% fatal or 
intracranial bleeding). More than 16% patients were assigned to the highest risk group for all 
endpoints (from 16.1% for fatal or intracranial bleeding to 18.5% for hospitalised bleeding). 
The expected numbers of patients were assigned to the high and low risk groups. This 
indicates worse outcomes and higher risks in the validation cohort compared with the 
development cohort. 
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In Figure 7.5 I show the risk groupings for cardiovascular death, stroke or MI and CALIBER 
major bleeding across their respective linear predictor distributions in the validation cohort 
and the corresponding cumulative probability of events. 
7.3.4 Internal validation 
In internal validation, the models demonstrated high levels of discrimination and calibration 
(Figure 7.6). The c-indexes for all models were at least 0.70. The cardiovascular death model 
had the best discriminative ability (c-index=0.82). The observed event Kaplan-Meier curves 
were largely within the bounds of the model predicted values 95% confidence intervals for all 
risk groups in each of the endpoints. 
7.3.5 Geographical validation - model discrimination 
In the validation cohort the models discriminated risk well, c-index estimates were 0.81 [95% 
CI: 0.80, 0.82] for all-cause mortality, 0.75 [95% CI: 0.74, 0.77] for cardiovascular death, stroke 
or MI, 0.81 [95% CI: 0.80, 0.83] for cardiovascular death, 0.67 [95% CI: 0.64, 0.70] for fatal or 
hospitalised bleeding, 0.72 [95% CI: 0.67, 0.77] for CALIBER major bleeding, and 0.68 [95% CI: 
0.61, 0.75] for fatal or intracranial bleeding. The hazard ratios for events across risk groups 
(Table 7.3) also demonstrated good discriminative ability of the models. The hazard ratios for 
the predicted highest: lowest risk group contrast were 41.0 [95% CI: 26.2, 64.0] for all-cause 
mortality, 11.5 [95% CI: 8.40, 15.5] for cardiovascular death, stroke or MI, 33.0 [95% CI: 18.9, 
57.4] for cardiovascular death, 6.3 [95% CI: 3.7, 10.6] for hospitalised bleeding, 13.3 [95% CI: 
4.8, 37.3] for CALIBER major bleeding and 3.1 [95% CI: 1.7, 5.9] for fatal or intracranial 
bleeding.  For cardiovascular death, stroke or MI, CALIBER major bleeding, and fatal or 
intracranial bleeding the 95% confidence intervals for the hazard ratios comparing risks of 
events between low risk and lowest risk patients contain 1. This suggests that for these 
endpoints the models may struggle to distinguish between patients with lower risks. 
7.3.6 Geographical validation - model calibration 
The models were well calibrated (Figure 7.7), in particular, models for all-cause mortality and 
cardiovascular death had very similar predicted and observed events in the validation cohort. 
The cardiovascular death, stroke or MI model underestimated events for patients in the lowest 
risk group. Patients in the low and lowest risk groups had very similar event rates. The fatal or 
hospitalised bleeding and fatal or intracranial bleeding models overestimated events for 
patients in the highest risk group and underestimated events for low risk patients. The CALIBER 
major bleeding model underestimated events for low risk patients. 
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7.3.7 Potential absolute benefits and harms in risk groups 
I observed higher event rates in the validation cohort compared with the trial placebo group 
for all studied endpoints: cardiovascular death, stroke or MI (16.5% versus 9.04%), 
cardiovascular death (11.5% versus 3.39%), all-cause mortality (20.3% versus 5.16%), major 
bleeding (CALIBER 1.7% versus TIMI 1.26%) and fatal or intracranial bleeding (0.9% versus 
0.6%). Table 7.4 shows on an intention-to-treat basis in highest risk groups, for every 10,000 
patients treated per year, 249 (95% CI: 228, 269) cardiovascular events may be prevented and 
134 (95% CI: 87,181) major bleeding events may be caused, whereas in the lowest risk groups 
28 (95% CI: 19, 37) cardiovascular events may be prevented and 9 (95% CI: 0, 20) major 
bleeding events may be caused. In the absence of risk stratification, overall an estimated 89 
(95% CI: 83, 94) cardiovascular events prevented and 42 (95% CI: 32, 51) harmed patients per 
10,000 treated per year. I also identified wide ranges in cardiovascular death and all-cause 
mortality events that may be prevented depending on risk. In their respective highest risk 
groups, the 3 year cumulative risk of fatal or intracranial bleeding was 2.2% and of fatal or 
hospitalised bleeding was 10.5%.  
7.3.8 Potential net clinical benefits in individuals 
A positive net clinical benefit was estimated in 93.5% of patients when cardiovascular death, 
stroke or MI events and CALIBER major bleeding were weighted equally, 63% if avoiding major 
bleeding was valued twice more than preventing cardiovascular events and 99.1% if 
preventing cardiovascular events was valued twice as high as avoiding major bleeding (Figure 
7.8, panel A). The importance of using clinical characteristics updated at 1 year after acute MI 
compared with characteristics at acute MI discharge for 5 typical patients is illustrated in 
Figure 7.8, panel B. For example, using characteristics at discharge patient 5 would be 
considered suitable for prolonged DAPT under all weighting options (point ‘▽’ on the figure), 
whereas using updated information 1 year post MI this patient would only be considered 
suitable for prolonged DAPT if they valued potential benefits over potential harms of 
treatment (point ‘▼’ on the figure). 
7.3.9 Web application  
I developed a web-based tool which calculates personalised risk predictions following the input 
of baseline characteristics: 
http://www.caliberresearch.org/prolonged_dapt_benefits_harms_risks 
An example of the output from the web app is shown in Figure 7.9 for an male patient aged 
68, non-smoker, whose index MI was a STEMI and has type 2 diabetes, is overweight, systolic 
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blood pressure: 139mmHg, creatinine: 151mmol/L, haemoglobin: 14.3g/dL, white blood cell 
count: 9.3 109/L and HDL: total cholesterol ratio: 0.4.  
The output displays that 90 out of 1000 patients with these characteristics would be expected 
to have cardiovascular death, stroke or MI at 3 years, which reduces to 76 out of 1000 when 
the PEGASUS-TIMI 54 estimates of the effect of prolonged dual antiplatelet therapy are 
applied. 9 out of 1000 patients with these characteristics would be expected to experience 
major bleeding at 3 years which increases to 21 out of 1000 when accounting for the 
estimated harms of prolonged dual antiplatelet therapy.  This information is also displayed 
with Kaplan-Meier curves, with the option to overlay the predicted curves accounting for 
treatment effects and to display the expected event rates at different time points between 1 
and 5 years. 
7.3.10 Simplified approaches for risk stratification 
Very little discrimination between predicted risks of events amongst patients with and without 
single high-risk factors for cardiovascular death, stroke or MI and CALIBER major bleeding 
endpoints was observed (Figure 7.10). 
The distributions of HASBLED and CHA2DS2-VASc scores in the validation cohort are shown in 
(Figure 7.11). The c-index for HASBLED was 0.64 (95% CI: 0.58, 0.70) and for CHA2DS2-VASc was 
0.71 (95% CI: 0.69, 0.72). I observed generally increasing risks of cardiovascular death, stroke 
or MI and CALIBER major bleeding with increasing CHA2DS2-VASc and HASBLED scores 
respectively. However there were no bleeding events amongst patients with a HASBLED score 
of 0, 7 or 8 so I was unable to calculate Kaplan-Meier estimates for these groups. 
7.4 Discussion 
Using population-based linked electronic health records, I developed and validated prognostic 
models providing personalised estimates of risks of major cardiovascular and bleeding events 
in patients 12 months after an acute MI. With trial relative risks I estimated potential benefits 
and harms of prolonged DAPT across risk groups. In individuals, potential net clinical benefit 
was observed for the majority of patients, even when avoiding bleeding is considered twice as 
important as preventing cardiovascular events. However the magnitude of benefit must also 
be considered.  
7.4.1 Potential benefits of prolonged dual antiplatelet therapy   
The unselected study cohort experienced a much higher cardiovascular event rate than the 
PEGASUS-TIMI 54 trial placebo group despite the trial inclusion criteria enriching for high 
risk.187 Thus the potential absolute benefit of prolonged DAPT may be greater than reported in 
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the trial. Importantly, potential benefits are comparable when the unselected real-world study 
population reported here is restricted to those meeting the trial inclusion and exclusion 
criteria (89 vs 101 events potentially prevented per 10,000 treated per year, respectively).187 
The models widely separated the risk of events: a clinician may treat nine times (28/249) as 
many patients in the lowest-risk, compared to the highest-risk group, to prevent one 
cardiovascular event. The models help clarify limitations of ignoring individual patient 
characteristics evaluated during the stable phase post-acute MI.  
7.4.2 Potential bleeding harms of prolonged dual antiplatelet therapy 
In balancing potential harms from prolonged DAPT, I show the importance of considering 
different bleeding endpoints. While all bleeding events studied may be considered serious 
(they all required hospitalisation), their event rates and potential harms vary significantly. I 
sought to approximate the PEGASUS-TIMI 54 trial primary safety endpoint, TIMI major 
bleeding, and successfully defined fatal bleeding, intracranial bleeding and transfusions, but 
not, in currently available EHR, acute haemoglobin change. Nonetheless, incidence of CALIBER 
major bleeding was comparable with TIMI major bleeding in the trial placebo arm.  
7.4.3 Balancing potential benefits and harms in individuals 
Patients and clinicians differ in how they value different benefits and harms, and I derived net 
clinical benefit estimates under different weighting scenarios. These can inform patient 
counselling and patient-doctor discussions tailored to patients risk covariates. Cost-
effectiveness considerations are additionally important in determining the magnitude of net 
clinical benefit a given health system is willing to pay for.213,214   
7.4.4 Need for multivariable risk prediction 
The importance of tailoring risk to multiple patient characteristics, as opposed to single risk 
factors (e.g. the high-risk factors specified in the PEGASUS-TIMI 54 trial: age, diabetes, history 
of MI and renal disease)215 is illustrated in Figure 7.10. In each case the risk distribution largely 
overlaps among people with and without simple binary prognostic factors. Furthermore, while 
simple, point-based scores for predicting bleeding risk prove valuable for other diseases,6,216 
they are unlikely to be useful for this population.  For example, HASBLED7 and CHA2DS2-VASc6 
did not perform as well as my models (Figure 7.11). It is well-known categorising clinical 
information loses predictive value and systolic blood pressure has nonlinear U-shaped 
associations with endpoints (Figure 7.4).217 Nonetheless in practice some simplification of the 
models will occur as absolute contraindications are established (e.g. although history of 
bleeding was adjusted for in the models, patients who bleed in the first year should be 
excluded from the prolonged DAPT treatment option). 
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7.4.5 Application in clinical practice   
I demonstrate marked changes in the year following acute MI in the prevalence of major 
prognostic factors, including heart failure, renal disease and smoking, with consequent 
changes in net benefits. Good clinical practice dictates thorough evaluation of patients at the 
time of decision-making including up-to-date medical history and biomarkers. The models can 
be readily implemented in health systems with EHR.90 I present a web-based tool to aid 
calculation of personalised atherothrombotic and bleeding risk predictions at: 
http://www.caliberresearch.org/prolonged_dapt_benefits_harms_risks. I envision that the risk 
prediction tool could be used by clinicians to assess their patients one year following an MI. 
This will aid clinicians to identify patients that are candidates for prolonged dual antiplatelet 
therapy and decisions could be made taking into account patients values towards treatment 
benefits and harms. 
7.4.6 Methodological strengths  
Few, if any, previous studies evaluated prognostic relevance of clinical data available at the 
decision point of surviving 1 year following an acute MI. Previous studies focused on factors 
measured in the acute hospitalised phase. Unlike voluntary disease registries or trial 
populations which may not reflect the entire population at risk, CALIBER is population-based. 
Therefore, estimates of risk obtained are likely to be representative of those observed in usual 
clinical practice. Routinely collected clinical information readily available in EHR enabled 
estimation of changing net clinical benefit of prolonged DAPT during patient journeys.   
7.4.7 Limitations  
The study has limitations. First, the information that is recorded as part of usual clinical 
practice is unlikely to have the same precision as that recorded as part of standardised 
research protocols. If the quality of information recording is low this will diminish the ability of 
the models to discriminate risk. Second, current large-scale population-based EHR data lack 
information on left ventricular function, number of diseased vessels, coronary stent type and 
diameter. However it is not known if such factors remain prognostically relevant when 
included in models with updated clinical information at one year post-MI. There is extensive 
evidence that stent type (bare metal, drug eluting, bioabsorbable) is an important predictor of 
prognosis from the time of acute myocardial infarction, and this study was unable to evaluate 
whether, in the stable phase 12 months after acute myocardial infarction, at a time when I 
demonstrate that clinical factors have changed, stent characteristics continue to provide 
incremental discrimination of risk. Previous nationwide studies of angiographic findings 
suggest only a modest predictor of subsequent events in stable patients.218 Furthermore I did 
not validate the models in different health systems. However a study of 140,000 unselected 
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stable post-MI patients found similar rates of cardiovascular and bleeding events in England, 
France, Sweden and USA199 and the effects of multiple prognostic factors reported in the 
present study were consistent across these 4 countries, suggesting potential geographic 
transportability of the models. I used multiple imputations where appropriate and the 
complete-case sensitivity analysis showed no important difference to the presented models. 
Multiply imputing MI type for those unspecified did not show any difference to the ST-
elevation MI versus non ST-elevation MI contrast presented in the multivariable models. 
7.4.8 Future research 
I propose three major avenues for future research.  First, further validation studies are 
recommended in populations differing in background, treatment strategies and event rates to 
ensure generalisability.218 I selected a study period to provide a relatively pure population, 
prior to the UK approval of ticagrelor and widespread occurrences of prolonged DAPT. Further 
research is required to test the models in more recent cohorts with a mix of clopidogrel, 
ticagrelor and prasugrel users  and risk prediction models may be required for other harms 
(e.g. dyspnea in patients taking ticagrelor). Second, as with any prognostic model the question 
arises of what is their impact on clinical outcomes and costs213,214 when implemented in clinical 
care.193 This would involve developing clinical decision support systems using prognostic 
models, and evaluation through a cluster randomised controlled trial. Third, there is a need to 
identify biomarkers which distinguish bleeding from cardiovascular event risks and may further 
aid decision-making.  
7.5 Conclusion 
Using population-based EHRs I developed and validated prognostic models for benefits and 
different bleeding harms, relevant to the decision to prolong DAPT in patients stable 1 year 
after an acute MI. Personalised treatment decisions, based on individual patient risk profiles, 
can inform decision-making.  
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7.6 Tables and Figures 
Figure 7.1: Study population flow diagram, endpoints and 3 & 5 year event rates 
 
Note: MI= myocardial infarction, STEMI=ST-elevation myocardial infarction, NSTEMI= non-ST-elevation myocardial infarction, 
NOS=not otherwise specified, CV=cardiovascular 
  
Prognostic model validation population 
(n= 5,613 in 61 general practices from 
East Midlands and North England) 
 
Patients with an acute MI recorded in 
CALIBER 2000-2010 
(n= 48,222) 
Patients stable 1 year post-MI 
(n=18,307) 
Index acute MI subtype: 
 STEMI (n= 3,127) 
 NSTEMI (n= 5,712) 
 Unclassified (n= 9,468) 
Excluded (n= 29,915) due to: 
 Fatal index acute MI or recurrent 
MI within 365 days (n=13,843) 
 Died prior to 1 year/ transferred 
out of CPRD practice (n= 8,860) 
 Less than 1 year at CPRD 
practice prior to index acute MI 
(n= 7,212) 
 
Prognostic model development 
population (n= 12,694 in 159 general 
practices from South England, London, 
East England and West Midlands)  
 
Endpoints 
from 1 year 
post MI 
3 year 
events, n 
(%) 
5 year 
events, n 
(%) 
All-cause mortality 
 1,943 (18.7) 2,683 (30.1) 
CV death or ischaemic/ NOS stroke or MI 
 1,469 (14.6) 1,913 (22.4) 
CV death   
 1,020 (10.2)  1,374 (16.5) 
Fatal or hospitalised bleeding 
 408 (4.3)  556 (7.3) 
CALIBER major bleeding 
 141 (1.5) 188 (2.5) 
Fatal bleeding or intracranial bleeding 
 78 (0.9 ) 112 (1.6) 
 
Endpoints 
from 1 year 
post MI 
3 year 
events, n 
(%) 
5 year 
events, n 
(%) 
All-cause mortality 
 943 (20.3) 1,252 (30.6) 
CV death or ischaemic/ NOS stroke or MI 
 745 (16.5) 936 (23.8) 
CV death   
 507 (11.5)  650 (16.9) 
Fatal or hospitalised bleeding 
 211 (4.9)  292 (8.4) 
CALIBER major bleeding 
 72 (1.7) 98 (2.7) 
Fatal bleeding or intracranial bleeding 
 39 (0.9 ) 61 (1.9) 
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Table 7.1: Characteristics of population based samples at baseline defined as 1 year after their last 
acute MI 
 Development cohort 
(n=12,694) 
Validation cohort 
(n=5,613) 
Demographics and behaviours   
Age (years) 70.1 (12.7) 69.1 (12.8) 
Women 33.9% 35.6% 
Ethnicity   
 Asian 2.0% 1.1% 
 Black 0.5% 0.1% 
 Other 17.0% 14.1% 
 White 80.4% 84.6% 
Index of multiple deprivation  
(highest quartile- most deprived) 
15.4% 30.3% 
 Missing 0.1% 0.5% 
Smoking status   
 Ex-Smoker 45.5% 45.4% 
 Non-Smoker 33.9% 31.1% 
 Smoker 12.9% 14.3% 
 Missing 7.6% 9.1% 
Excess alcohol 10.8% 15.4% 
Cardiovascular diseases   
Index acute MI subtype   
 NSTEMI 32.1% 29.1% 
 STEMI 17.4% 16.4% 
 Unspecified 50.5% 54.5% 
MI (prior to index acute MI) 34.7% 38.7% 
Revascularisation (any) 43.5% 33.0% 
 Primary PCI for index acute MI 24.8% 18.8% 
 PCI at any time prior to 1 year post 
MI 
39.4% 31.0% 
 CABG at any time to 1 year post MI 4.1% 2.0% 
Stroke 6.9% 8.1% 
Atrial fibrillation 18.0% 17.9% 
Heart failure 23.5% 28.0% 
Peripheral arterial disease 9.8% 13.1% 
Renal disease 13.6% 14.8% 
Recent hospitalisation  for acute renal disease 1.3% 1.0% 
Non-cardiovascular diseases   
Diabetes   
 Type 1  1.2% 0.9% 
 Type 2  16.7% 17% 
 Unspecified 1.5% 1.7% 
COPD 9.1% 12.8% 
Recent hospitalisation  for acute COPD 1.1% 2.2% 
Liver disease 0.4% 0.5% 
Non-metastatic cancer 14.4% 13.2% 
Metastatic cancer 1.0% 1.2% 
Dementia 1.3% 2.0% 
Chronic anaemia 14.3% 17.9% 
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 Development cohort 
(n=12,694) 
Validation cohort 
(n=5,613) 
Peptic ulcer 7.3% 10.2% 
Bleeding diatheses and coagulation disorders 1.1% 1.1% 
Hospitalised bleeding 6.5% 8.2% 
Treatments prescribed   
Aspirin 87.0% 86.2% 
Clopidogrel 50.5% 47.8% 
 Prolonged clopidogrel, post-baseline 2.7% 3.4% 
Oral anticoagulant  9.9% 9.5% 
Statin  88.5% 88.6% 
Anti-hypertensive 96.4% 96.0% 
Biomarkers*   
BMI (Continuous) (kg/m2) 27.8 (5.1) 27.7 (5.1) 
BMI (Categorical)   
 Underweight 0.9% 1.1% 
 Normal 16.2% 17.3% 
 Overweight 23.3% 25.7% 
 Obese 16.1% 16.9% 
 Missing 43.5% 39.1% 
SBP (mmHg) 133 (18.6) 132 (18.4) 
 Missing 5.4% 6.1% 
DBP (mmHg) 75.3 (10.4) 74.6 (10.1) 
 Missing 5.4% 6.1% 
Haemoglobin (g/dL) 13.4 (1.6) 13.3 (1.6) 
 Missing 43.3% 45.0% 
White blood cell count (109/L) 7.60 (2.3) 7.68 (2.3) 
 Missing 45.4% 46.9% 
Total cholesterol (mmol/L) 4.17 (1.0) 4.17 (1.0) 
 Missing 18.4% 18.0% 
HDL cholesterol (mmol/L) 1.28 (0.4) 1.26 (0.4) 
 Missing 40.7% 40.1% 
Creatinine (μmol/l) Median (IQR) 98 (84, 114) 99 (86, 117) 
 Missing 21.6% 21.8% 
eGFR (ml/min) 65.5 (20.3) 64.7 (20.7) 
eGFR < 60 ml/min 29.3% 31.4% 
 Missing 24.3% 23.7% 
 
Note: *values are mean (SD) except where stated; MI=myocardial infarction, STEMI=ST-elevation myocardial infarction, 
NSTEMI=non-ST-elevation myocardial infarction, PCI= Percutaneous coronary intervention, CABG= Coronary artery bypass graft, 
COPD=chronic obstructive pulmonary disease, BMI= body mass index, SBP=systolic blood pressure, DBP= diastolic blood pressure, 
HDL= high-density lipoprotein, eGFR= estimated glomerular filtration rate 
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Figure 7.2: Comparison of all-cause mortality, cardiovascular and bleeding events in patents included in the development (n=12,694) and validation (n=5,613) cohorts 
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Figure 7.3: Prognostic factors (multivariable) for 5-year all-cause mortality, cardiovascular and bleeding endpoints 
 
Note: CV= cardiovascular, MI= myocardial infarction, NSTEMI= non-ST-elevation myocardial infarction, STEMI= ST-elevation myocardial infarction, PCI= percutaneous coronary 
intervention, CABG= coronary artery bypass graft, BMI= body mass index, HDL= high-density lipoprotein; log hazard ratios compared with [ref] group for categorical factors or per 
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unit increase for continuous factors; For hazard ratios and 95% confidence intervals see Supplementary appendix 11.4.5. Systolic blood pressure was included in all models using 
restricted cubic splines [see Supplementary Appendix 11.4.6] 
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Figure 7.4: U-shaped association of systolic blood pressure (SBP) and 5 year cardiovascular death, 
stroke or myocardial infarction (MI) events [n=12,694, events=1,913] 
 
Note: Systolic blood pressure reference value = 136mmHg  
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Table 7.2: N(%) of patients allocated to each risk group in the development (n=12694) and validation 
(n=5613) cohorts for each endpoint  
  Risk Group 
Endpoint Cohort Highest High Low Lowest 
All-cause 
mortality 
Development 2031 (16.0) 4316 (34.0) 4316 (34.0) 2031 (16.0) 
Validation 974 (17.4) 1941 (34.6)  1874 (33.4) 824 (14.7) 
Cardiovascular 
death, stroke 
or MI 
Development 2031 (16.0) 4316 (34.0) 4316 (34.0) 2031 (16.0) 
Validation 993 (17.7) 1922 (34.2) 1886 (33.6) 812 (14.5) 
Cardiovascular 
death 
Development 2031 (16.0) 4316 (34.0) 4316 (34.0) 2031 (16.0) 
Validation 973 (17.3) 1933 (34.4) 1894 (33.7) 813 (14.5) 
Hospitalised 
bleeding 
Development 2031 (16.0) 4316 (34.0) 4316 (34.0) 2031 (16.0) 
Validation 1037 (18.5) 1880 (33.5) 1866 (33.2) 830 (14.8) 
CALIBER 
major 
bleeding 
Development 2031 (16.0) 4316 (34.0) 4316 (34.0) 2031 (16.0) 
Validation 939 (16.7) 1878 (33.5) 1940 (34.6) 856 (15.3) 
Fatal or 
intracranial 
bleeding 
Development 2031 (16.0) 4316 (34.0) 4316 (34.0) 2031 (16.0) 
Validation 901 (16.1) 1892 (33.7) 1958 (34.9) 862 (15.4) 
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Figure 7.5: Cumulative probability of cardiovascular death, stroke or MI (top) and CALIBER major 
bleeding (bottom) across their respective linear predictors in the validation cohort (n= 5613) 
 
Note: CV= cardiovascular; MI= myocardial infarction
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Figure 7.6: Internal validation: comparing observed events with model predictions in the development cohort 
 
Note: CV=cardiovascular; MI= myocardial infarction; CI= confidence interval
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Table 7.3: Hazard ratios comparing patient risk groups in development and validation cohorts for all-
cause mortality, cardiovascular and bleeding end-points 
 Hazard ratio (95% CI) 
 Highest vs. 
Lowest 
High vs. Lowest Low vs. Lowest 
Potential Benefits    
All-cause mortality    
 Development 54.9 (39.7, 75.8) 15.1 (10.9, 20.9) 2.9 (2.1, 4.1) 
 Validation 41.0 (26.2, 64.0) 11.8 (7.5, 18.4) 2.5 (1.6, 4.1) 
Cardiovascular death, stroke or MI    
 Development 19.6 (15.3, 25.1) 5.8 (4.5, 7.4) 1.7 (1.3, 2.2) 
 Validation 11.5 (8.4, 15.5) 3.3 (2.5, 4.5) 1.2 (0.9, 1.7) 
Cardiovascular death    
 Development 59.8 (37.4, 95.5) 14.5 (9.1, 23.2) 2.5 (1.5, 4.1) 
 Validation 33.0 (18.9, 57.4) 8.2 (4.7, 14.3) 1.7 (1.0, 3.2) 
Potential harms    
Fatal or hospitalised bleeding    
 Development 11.2 (7.5, 16.6) 4.8 (3.3, 7.1) 2.2 (1.5, 3.3) 
 Validation 6.3 (3.7, 10.6) 3.9 (2.4, 6.5) 2.1 (1.2, 3.5) 
CALIBER major bleeding    
 Development 32.1 (11.8, 87.6) 10.1 (3.7, 27.5) 2.6 (0.9, 7.5) 
 Validation 13.3 (4.8, 37.3) 3.7 (1.2, 10.6) 2.6 (0.9, 7.6) 
Fatal bleeding or intracranial 
bleeding 
   
 Development 28.9 (9.0, 92.7) 7.6 (2.4, 24.6) 2.0 (0.6, 7.1) 
 Validation 3.1 (1.7, 5.9)a 1.3 (0.7, 2.3)b - 
a Highest vs Low: No fatal bleeding or intracranial bleeding events in the validation cohort lowest risk 
group, thus we obtain inflated hazard ratio estimates when using lowest risk as the reference group. The 
low risk group is used as the reference group instead. 
b High vs Low: No fatal bleeding or intracranial bleeding events in the validation cohort lowest risk 
group, thus we obtain inflated hazard ratio estimates when using lowest risk as the reference group. The 
low risk group is used as the reference group instead 
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Figure 7.7: Geographical validation: comparing observed events with model predictions in the validation cohort 
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Table 7.4: Estimated events prevented and harms caused per 10,000 patients treated per year with prolonged dual antiplatelet therapy by predicted risk groups compared 
with all risk groups combined and the trial population. Calculated using PEGASUS-TIMI 54 trial relative risk estimates 
 
Note: PEGASUS-TIMI 54 trial estimated relative risks [ticagrelor 60mg versus placebo; intention-to-treat (ITT) and on treatment (OT) estimates where available] for cardiovascular death, stroke or MI 
[ITT: 0.84 (95% CI: 0.74, 0.95), main report], cardiovascular death [ITT: 0.83 (95% CI: 0.68, 1.01), main report], all-cause mortality [ITT: 0.89 (0.76, 1.04), main report], TIMI major bleeding [ITT: 1.75 
(95% CI: ), appendix E; OT: 2.32 (95% CI: 1.68, 3.21), main report], fatal bleeding or intracranial bleeding [OT:1.20 (95% CI:0.73, 1.97), main report] were used to calculate CV events potentially 
prevented and bleeding harms potentially caused per 10,000 treated per year; *TIMI-Major bleeding; †No broad/ composite bleeding endpoint reported in PEGASUS-TIMI 54  
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Figure 7.8: Net predicted risk for cardiovascular death, stroke or MI and CALIBER major bleeding with prolonged dual antiplatelet therapy 
 
MI= Myocardial infarction; CV=cardiovascular; DAPT= dual antiplatelet therapy; The straight lines correspond to different scenarios of how patients or clinicians may value (or weight) benefits and 
harms. All patients to the right of a line applicable to their values would be estimated to have a positive net benefit with prolonged DAPT. 
Panel A. Net benefit for 5613 patients under different benefit vs. harm weighting scenarios. Panel B. Timing of clinical characteristic assessment may impact treatment decisions shows the net 
benefits calculated using patient characteristics at discharge from acute MI and at 1 year post-acute MI for 5 typical patients in the validation cohort.
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Figure 7.9: Screenshots of risk prediction application displaying 3 year predicted risks of CV death, 
stroke or MI and major bleeding for patient without prolonged dual antiplatelet therapy (top) and 
with prolonged dual antiplatelet therapy (bottom) 
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Figure 7.10: Overlap of 3 year predicted risks in the validation cohort (n=5613) based on multivariable models in those with and without categorical risk factors: age≥ 65, 
diabetes, history of MI and renal disease (used to define high risk in the PEGASUS-TIMI 54 trial) 
 
Note: Each panel shows the distribution of predicted 3-year CV or bleeding risks in patients with and without 4 binary indicators of high CV risk (Age, diabetes, MI history, renal 
disease). The dotted curve is the distribution of risk for patients with the high risk factor and the solid curve is the distribution of risk without the high risk factor. I demonstrated that 
these ‘high risk’ factors alone are insufficient to separate patients who are truly at higher and lower risks. CV= cardiovascular; MI= myocardial infarction  
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Figure 7.11: The distribution of CHA2DS2-VASc and HASBLED scores and their observed risks of cardiovascular death, stroke or MI and CALIBER major bleeding respectively in 
the validation cohort (n=5613) 
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8 Predictors and outcomes of INR time in therapeutic range: a linked-
electronic health record study 
 
Chapter Summary 
Background 
Oral anticoagulants (OAC) are a widely used class of drugs primarily for stroke prevention in 
atrial fibrillation and treating venous thromboembolism. The therapeutic range for OAC 
treatment is particularly narrow. If overtreated, patients are at increased risk of major 
bleeding or if undertreated patients may be at increased risk of atherothrombotic events. The 
international normalised ratio (INR) is a widely used biomarker for patients being treated with 
OAC in order to measure treatment control. The most common measure of INR control is 
percent time in therapeutic range (TTR). The objectives of this analysis were to describe INR 
and TTR data within CALIBER within 4 disease populations indicated for oral anticoagulation, to 
assess patient baseline characteristics associated with time in therapeutic range, to determine 
whether a risk score developed for predicting treatment control are effective in the study 
population and to assess the association between TTR and risk of all-cause mortality, 
atherothrombotic and bleeding events. 
Methods 
Using CALIBER linked electronic health records, the study population comprised of 18823 
patients prescribed OAC and at least 5 consecutive INR records sorted into atrial fibrillation, 
venous thromboembolism, heart valve replacement or other indication groups. The 
distribution of INR records and TTR in the study population was examined. The SAME-TT2R2 
score was applied to the study population and their predicted INR control was compared 
observed TTR values. A wide range of clinical risk factors were assessed for association with 
TTR using linear regression models. Cox proportional hazard models were used to investigate 
association between TTR and the risk of outcomes. 
Results 
Of the 541770 INR records included in this analysis 309097 (57.1%) were in the range of 2-3. 
The mean (SD) TTR was 62.8% (21.4) and 9800 (52.1%) patients had a TTR greater than 65%. 
TTR varied across the indication groups from 66.2% (19.8) in atrial fibrillation patients to 51.2% 
(22.7) in heart valve replacement patients. The SAME-TT2R2 score did not perform well in the 
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study population (c-index≤0.55 in all models stratified by indication and with different TTR cut-
offs). Older patients were found to have higher TTR, whilst higher deprivation, smoking and a 
number of comorbidities were associated with lower TTR. Patients with TTR>65% were found 
to be at lower risk of all-cause mortality, atherothrombotic events and bleeding compared to 
those with TTR≤65%. 
Conclusion 
In the absence of guidelines recommended targets for TTR amongst patients venous 
thromboembolism, heart valve replacement and other indications for oral anticoagulation, the 
study results supports maintaining treatment control as measured by TTR above 65%. 
 
8.1 Introduction 
Oral anticoagulants are a widely used class of drugs primarily for stroke prevention in atrial 
fibrillation, treating venous thromboembolism and prevent atherothrombotic events in 
patients who underwent heart valve replacement. Vitamin K antagonists (VKA) are currently 
the class of oral anticoagulants most commonly used for long-term treatment. The guidelines 
for VKA therapy control in atrial fibrillation, venous thromboembolism and heart valve 
replacement patients are summarised in the literature chapter (Table 2.7).  
The therapeutic range for VKA treatment is particularly narrow. If over treated with VKAs, 
patients are at increased risk of major bleeding or if undertreated patients may be at increased 
risk of atherothrombotic events. VKAs are particularly sensitive drugs and their effectiveness 
may be altered by comorbidities, concomitant medications, diet and alcohol consumption103. 
Guidelines for treatment of patients with venous thromboembolism33,34,106 suggests initial 3 
months of VKA therapy with the potential to extend the duration for long term secondary 
prevention of atherothrombotic events in high risk patients. Patients with mechanical heart 
valve replacements are recommended to undergo lifelong VKA therapy.107,108 Patients with bio-
prosthetic heart valve replacements are recommended to undergo 3 months of VKA 
therapy.107,108 The intensity of treatment defined by the therapeutic range is dependent on the 
presence of additional risk factors for atherothrombotic events. 
The international normalised ratio (INR) is widely used biomarker for patients being treated 
with VKAs in order to measure treatment control and requires patients to undergo regular 
blood tests.  The most common measure of INR control is percent time in therapeutic range 
(TTR). In calculating TTR a commonly used assumption is linear change between consecutive 
INR measures, known as Rosendaals method.105 The SAME-TT2R2 score117 is a clinical prediction 
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tool that was developed to estimate the likelihood of achieving good anticoagulation control 
defined by TTR in individual patients.  
NICE4 and ESC5 guidelines for treating atrial fibrillation differ in recommending an ideal 
minimum TTR threshold, ranging from  65% to 70%. However there are no such 
recommendations for TTR for other diseases indicated to be treated with VKAs, such as venous 
thromboembolism and heart valve replacement. 
The objectives of this chapter is to address the following objectives: First, to describe INR and 
TTR data within CALIBER within 4 distinct populations indicated for oral anticoagulation with 
VKA therapy (AF, VTE, heart valve replacement and other indications).,second to assess patient 
baseline characteristics associated with time in therapeutic range in the study population and 
whether my results agree with the results of previous studies, third to determine whether the 
SAME-TT2R2 score is effective for predicting TTR in the study population and fourth I will assess 
the association between TTR and outcomes (all-cause mortality, atherothrombotic events and 
bleeding). 
8.2 Methods 
8.2.1 Study population and index INR spells 
I used CALIBER (1997-2010) linked electronic health records. Patients were included if they had 
at least one prescription for a VKA: warfarin, phenindione or acenocoumarol and a minimum 
of five consecutive INR records. INR records with value over 20 were not included in this 
analysis and INR values were considered to be consecutive if they were within 90 days. 
Sensitivity analyses were carried out in choosing this cut-off. Examples of INR spells with 50 
day and 90 day cut-offs between consecutive INR records are shown in Figure 8.1. For patients 
1 and 2 we see that a 50 day cut-off between consecutive INR records is not sufficient to 
capture their entire INR spells. For patient 3, although 50 days appears to be sufficient cut-off, 
the 90 day cut-off is not excessively long and the three distinct spells of INR monitoring are 
kept as such. 
For patients with multiple valid spells of INR monitoring I used their first as their index INR 
spell. 
8.2.2 Indication for oral anticoagulation and INR monitoring 
Patients’ indication for oral anticoagulation and INR monitoring was determined by records for 
atrial fibrillation, venous thromboembolism and heart valve replacement days prior to the 
start of the index INR spell using the following hierarchy: 
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1) Venous thromboembolism - a venous thromboembolism record in primary care or 
hospital admission records within 30 days prior to the start of the index INR spell 
2) Heart valve replacement – a heart valve replacement record in primary care or 
hospital procedure records at any time prior to the start of the index INR spell 
3) Atrial fibrillation – an atrial fibrillation record in primary care or hospital admissions 
records at any time prior to the start of the index INR spell 
4) Other indication – none of the indications as described above 
The other indication group represents patients treated with vitamin K therapy for less common 
indications. In the UK, small numbers of patients with chronic rheumatic heart disease, 
antiphospholipid syndromes and cardiomyopathy may be recommended to undergo 
anticoagulation therapy. The phenotypes for venous thromboembolism, heart valve 
replacement and atrial fibrillation are described in the Data chapter. 
8.2.3 Overall distribution of INR data 
I assessed the overall distribution of INR records in the study population. I also assessed the 
frequency of monitoring by estimating the mean time between INR tests at each individual INR 
value. 
8.2.4 Time in therapeutic range 
The time in therapeutic range (TTR) is the percent of a patient’s INR spell spent within their 
given prescribed therapeutic range. Within electronic health records, data on the therapeutic 
range assigned to patients is not available. I therefore assumed a range of 2 to 3 for all patients 
since this is the most commonly used range for treating and preventing atherothrombotic 
events. High risk patients with heart valve replacements can be indicated to receive more 
intense VKA therapy, so in a sensitivity analysis I calculated the TTR using a range of 2.5 to 3.5 
in this subgroup. Using Rosendaal’s method105 I applied linear interpolation between 
consecutive INR records. Assuming a linear trajectory we can estimate the number of days 
each patient spent within the therapeutic range and the TTR is expressed as the percentage of 
the INR spell spent within range. Examples of TTR calculated in three INR spells is shown in 
Figure 8.2. 
I assessed the distribution of TTR for the index INR spells to provide an overview of the level of 
anticoagulation control within the study population as a whole and within each indication for 
oral anticoagulation. 
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8.2.5 Baseline characteristics 
I described the characteristics of the study cohort at baseline as a whole and stratified by 
indication for oral anticoagulation. Broadly, the characteristics investigated were 
demographics and behaviours, characteristics of their index INR spell and vitamin K antagonist 
prescribing, cardiovascular and non-cardiovascular medical history, clinical biomarkers and 
prescribed medications prior to and during INR spell. Baseline characteristics were described 
using mean and standard deviation (SD) or median and interquartile range (IQR) for 
continuous variables and frequencies and percentages for categorical variables. Details of the 
phenotypes for the characteristics are described in the data chapter. 
8.2.5.1 Application of the SAME-TT2R2 score 
I calculated the SAME-TT2R2 score117 (Table 8.1) for each patient at baseline, prior to the start 
of their INR spell. A single point is scored for each of the following patient characteristics: sex 
(female), age<60years, medical history (at least two of hypertension, diabetes, coronary 
disease, myocardial infarction, peripheral arterial disease, congestive heart failure, stroke, 
pulmonary disease, hepatic or renal disease), treatment with interacting drugs (amiodarone, 
calcium channel blockers, beta-blockers or digoxin). Two points are scored for current tobacco 
use and non-Caucasian race. The SAME-TT2R2 score is the sum of the awarded points. The 
score therefore ranges from 0 to 8 and a high score represents poor predicted anticoagulation. 
I described the distribution of the SAME-TT2R2 score in the study population produced boxplots 
of TTR stratified by SAME-TT2R2 score. 
8.2.6 Endpoints 
Patients were followed up for all-cause mortality, cardiovascular death stroke or MI, any 
bleeding and major bleeding. The composition of the phenotypes for these endpoints is 
described in the Chapter 3.  
8.2.7 Statistical analysis 
8.2.7.1 Predictors of TTR 
Univariable linear regression models were used to assess the association between baseline 
characteristics and the time in therapeutic range for index INR spells. This included 
demographics, behaviours, medical history, clinical biomarkers and prescribed medications 
prior and during index INR spells. The effect estimates were calculated within indication 
subgroups and in the cohort as a whole. 
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8.2.7.2 Outcomes following first INR spell 
I assessed the incidence of all-cause mortality, cardiovascular death, stroke or MI, any bleeding 
and major bleeding following INR monitoring stratified by TTR (≤65%, >65%) using Kaplan-
Meier plots. The risk of 1 year outcomes was estimated using Cox proportional hazards 
models. TTR was fitted in models using restricted cubic splines to allow for non-linear effects. 
The number of spline knot points to be used in each model will be checked in sensitivity 
analyses. The models were also adjusted for age, gender and length of index INR spell. 
Modelling assumptions 
The presence of collinear variables in the multivariable models was checked using variance 
inflation factor estimates and any offending variables were removed. 
In Cox proportional hazards models, the proportional hazards assumption was checked using 
log(-log) plots for categorical variables and plots of time dependent coefficients for continuous 
variables. 
Missing Data 
Missing covariate data was multiply imputed using the MICE (multiple imputation with chained 
equations).211 10 imputed data sets were generated. 
8.3 Results 
8.3.1 Study Population and characteristics by indication 
The flow of patients into the study population is displayed in Figure 8.3. In CALIBER 46568 
patients had at least one oral anticoagulant prescription. Of these patients, 18823 had at least 
one spell of at least 5 consecutive (within 90 days of each other) INR records in primary care 
data. Their first valid INR spell was used in the analysis consisting of 541770 INR records in 
total. The determined indication for oral anticoagulation and INR monitoring was atrial 
fibrillation for 10132 (53.8%) patients, venous thromboembolism for 3471 (18.4%) patients, 
heart valve replacement for 744 (4.0%) patients and other indication for 4476 patients 
(23.8%).  
The characteristics of the study population are shown in Table 8.2. Overall the mean age of the 
study population was 69.8 year and 45.4% were women. Atrial fibrillation patients were older 
(mean age: 73.6 years) than venous thromboembolism, heart valve replacement and other 
indication patients. More than half of venous thromboembolism patients were women, 
compared with 42.6% of atrial fibrillation patients, 21.8% of heart valve replacement patients 
and 28% of other indication patients. Smokers were more prevalent in the venous 
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thromboembolism and other indication groups compared with the atrial fibrillation and heart 
valve replacement groups. 
Medical histories differed amongst the indication groups. 61% of patients with atrial fibrillation 
had a history or hypertension compared with 55.2% of heart valve replacement patients, 
42.6% of other indication patients and 39.7% of venous thromboembolism patients. 10% of 
atrial fibrillation and other indication patients had history of myocardial infarction compared 
4.7% venous thromboembolism patients and 7.8% heart valve replacement patients.  Heart 
failure was more common in heart valve replacement (33.1%) and atrial fibrillation (22.5%) 
patients than venous thromboembolism (6.5%) and other indication (13%) patients. Across all 
patients, history of any or major bleeding was 26.5% and 1.6% respectively, however the heart 
valve replacement patients had higher prevalence of bleeding history. Patients with venous 
thromboembolism had a lower prevalence of diabetes.  More than 20% of venous 
thromboembolism and other indication patients had a history of cancer, compared with 16.3% 
atrial fibrillation patients and 9.1% heart valve replacement patients. Chronic obstructive 
pulmonary disease and renal disease was more prevalent in atrial fibrillation patients. 
Clinical biomarker levels were generally similar amongst patients. The overall mean (SD) body 
mass index was 29kg/m2 (6.23) and the mean (SD) systolic blood pressure was 136mmHg 
(18.8). 
More than half of atrial fibrillation patients had been prescribed antiplatelets prior to their 
index INR spell compared with 27.4% of venous thromboembolism patients, 47.4% of heart 
valve replacement patients and 32.2% of other indication patients. Antiplatelet prescriptions 
were less common during index INR spells, 12.4% across all patients. Prescriptions for 
antiarrhythmic drugs digoxin and amiodarone were similar prior to and during index INR spells 
across all indications. Overall, 66.7% patients had a prescription for nonsteroidal anti-
inflammatory drugs prior to their index INR spell compared to 8.5% during index INR spells. 
30.5% of patients had a prescription for an antidepressant prior to their index INR spell and 
17.4% had an antidepressant prescription during their index INR spell. 
8.3.2 INR data in CALIBER 
Of the 541770 INR records included in this analysis 309097 (57.1%) were in the range of 2-3. 
The distribution of INR records, stratified by indication is shown in Figure 8.4. The distribution 
of INR records was similar amongst the atrial fibrillation, venous thromboembolism and other 
indications, whereas for heart valve replacement patients the distribution was comparatively 
skewed to the right. 
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The mean number of days between INR records by INR value is displayed in Figure 8.5. Time 
between INR tests was highly variable but peaked between INR values of 2 and 3 (i.e. 
therapeutic range) and was generally lower at the extreme ends of the INR range.  For INR 
records between 2 and 3, the mean (SD) time until next INR test was 26.8 (18.9) days. For INR 
records lower than 1 the mean (SD) time until next INR test was 9.2 (11.0) days and for INR 
records greater than 5 the mean (SD) time until the next INR test was 6.0 (7.2) days. 
8.3.3 Index INR spell characteristics and time in therapeutic range 
Overall the mean (SD) TTR was 62.8% (21.4) and 9800 (52.1%) patients had a TTR greater than 
65%. The TTR varied across the indications, from 66.2% (19.8) in atrial fibrillation patients to 
51.2% (22.7) in heart valve replacement patients. This is reflected in Figure 8.6 where it is 
shown that the distribution of TTR for atrial fibrillation patients is more skewed to the right 
than for heart valve replacement patients.  
Further characteristics of index INR spells are described in Table 8.3. In a sensitivity analysis, a 
therapeutic range of 2.5-3.5 was applied to heart valve replacement patients and the mean 
(SD) TTR was 49.5% (21.4).  
The duration of index INR spells (time difference between first and last INR record in a spell) 
was variable amongst the indications. The median (IQR) duration was longest for atrial 
fibrillation and heart valve replacement patients, 477 (196, 959) and 582 (236, 1269) days 
respectively. For venous thromboembolism patients the median (IQR) duration was 162 (97, 
239) days and for other indication the median (IQR) duration was 233 (118, 652) days. Overall 
the median (IQR) number of INR records in each INR spell was 17 (9, 35). Atrial fibrillation and 
heart valve replacement patients had higher numbers of INR records per spell compared with 
venous thromboembolism and other indication patients. 
Heart valve replacement and atrial fibrillation patients had higher mean time prescribed to 
vitamin K antagonists prior to their index INR spell compared with venous thromboembolism 
and other indication patients. The duration of vitamin K antagonist prescribing was very similar 
to the duration of index INR spell duration. Overall patients were prescribed vitamin K 
antagonists for a median of 310 (167, 707) days during their index INR spell. 
8.3.4 Application of the SAME-TT2R2 score 
The majority of the study population had a SAME-TT2R2 score of 2 or 3 (Table 8.4). No patients 
were allocated the maximum score of 8 which indicates very high risk of poorly controlled 
anticoagulation, and only 4 patients (1 atrial fibrillation and 3 other indication) were scored 7. 
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No venous thromboembolism or heart valve replacement patients were allocated a score 
higher than 5. 
For all indications there appeared to be a slight deceasing trend in mean TTR with increasing 
SAME-TT2R2 score (Figure 8.7), with the exception that the mean (95% CI) TTR for other 
indication patients and a SAME-TT2R2 score of 7 was 71.7% (42.7, 100%), the highest of all of 
the subgroups. The mean (95% CI) TTR for patients with a SAME-TT2R2 score of zero was 68.5% 
(67.5, 69.6%) for atrial fibrillation patients, 62.9% (61.2, 64.6%) for venous thromboembolism 
patients, 51.4% (46.9, 55.8%) for heart valve replacement patients and 62.5% (60.9, 64.1%) for 
other indication patients. The mean (95% CI) TTR for patients with a SAME-TT2R2 score of five 
was 61.2% (57.8, 64.6%) for atrial fibrillation patients, 55.8% (46.9, 64.7%) for venous 
thromboembolism patients, 31.6% (23.8, 39.4%) for heart valve replacement patients and 
52.4% (45.9, 58.9%) for other indication patients 
C-indexes were estimated for logistic regression models using the SAME-TT2R2 score to predict 
patients achieving TTR>60, 65 and 70 across all patients and within the indication subgroups 
(Table 8.5). None of the models had a c-index higher than 0.55, suggesting that the SAME-
TT2R2 score was not much better than chance at predicting TTR in the study population. 
8.3.5 Predictors of time in therapeutic range 
In using univariable linear regression models I assessed predictors of time in therapeutic range. 
The effect estimates for demographic and behaviour variables are shown in Figure 8.8. 
Patients in age categories >40 years had mean TTR approximately 10 points higher than 
patients aged 40 or below. This held true in the atrial fibrillation, venous thromboembolism 
and other indication populations. Women generally had lower TTR than men, across all 
patients the difference in mean TTR (95% CI) was -1.4 (-2.0, -0.8). Non-white patients had 
lower mean TTR than white patients, across all patients the difference was -3.5 (-6.4, -
0.5).There did not appear to be any regional variation in mean TTR across England. Patients in 
the highest quintile of deprivation had lower mean TTR than patients with lower degrees of 
deprivation, -2.5 (-3.2, -1.7). 
Smokers had lower mean TTR than non-smokers, -5.3 (-6.4, -4.3) and patients with a history of 
alcohol abuse had lower mean TTR than patients without a history of alcohol abuse, -2.1 (-3.0, 
-1.2). 
The effect estimates for medical history variables are shown in Figure 8.9. Patients with 
hypertension had a higher mean TTR than patients without hypertension, 2.1 (1.5, 2.7). This 
difference was particularly apparent in the other indication group, 2.6 (1.3, 4.0). Atrial 
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fibrillation patients with a history of myocardial infarction had a lower mean TTR -2.3 (-3.6, -
1.0), whereas other indication patients with a history of myocardial infarction had a higher 
mean TTR, 2.4 (0.2, 4.7). Similarly, atrial fibrillation and venous thromboembolism patients 
with a history of heart failure had a lower mean TTR, -2.4 (-3.3, -1.5) and -3.8 (-6.8, -0.9) 
respectively, whereas other indication patients with a history of heart failure had a higher 
mean TTR 2.2 (0.2, 4.2). Patients with a history of unstable angina had lower mean TTR. Type 1 
diabetes patients had mean TTR -9.9 (-14.1, -5.6) points lower than patients without diabetes. 
Patients with a history of liver disease had a lower mean TTR, -5.4 (-8.7, -2.1), particularly in 
the heart valve replacement and other indications subgroups. Patients with a history of chronic 
obstructive pulmonary disease in the atrial fibrillation and venous thromboembolism 
subgroups had lower mean TTR, -6.2 (-7.5, -5.0) and -3.7 (-6.4, -0.9) respectively. Overall, 
patients with a history of cancer had a lower mean TTR, -2.5 (-3.2, -1.7), however in the heart 
valve replacement subgroup patients with cancer had a higher mean TTR, 2.9 (-2.7, 8.7). 
Patients with a history of chronic anaemia had lower mean TTR, -3.4 (-4.4, -2.5), however 
histories of either any bleeding or major bleeding did not appear to be associated with TTR. 
The effect estimates for clinical biomarker variables are shown in Figure 8.10. BMI did not 
appear to be associated with TTR. There appeared to be a ‘J-curve’ association between both 
systolic and diastolic blood pressure and TTR. That is patients with low blood pressure 
(SBP≤120 mmHg, DBP≤60 mmHg) and high blood pressure (SBP>160 mmHg, DBP>100 mmHg) 
had lower TTR compared with patients with normal blood pressure (SBP 121-140mmHg, DBP 
81-90 mmHg). There was an increasing association between haemoglobin and TTR. Compared 
to patients with haemoglobin 13-14g/dL, patients with haemoglobin ≤12g/dL had lower mean 
TTR, -4.8 (-5.9, -3.7), and patients with haemoglobin >14g/dL had higher mean TTR, 3.0 (2.2, 
3.9). High white blood cell counts (>11 109/L vs. 5-11 109/L) and platelet counts (>450 109/L vs. 
151-450 109/L) were associated with lower TTR, -3.4 (-4.8, -2.0) and -6.5 (-8.6, -4.3) 
respectively. Patients with low creatinine (≤80mmol/l vs. 81-110mmol/l) had lower mean TTR, 
-2.5 (-3.3, -1.6). Patients with high total cholesterol (>6.3 vs. ≤5.2) had lower mean TTR, -2.6 (-
3.9, -1.3). 
K-sparing diuretics, loop diuretics, insulin, antidiabetics and antidepressants prescribed prior to 
index INR spells were associated with lower TTR. On the contrary, antiplatelets, thiazides, 
ARBs, beta blockers, CCBs, statins and digoxin prescribed prior to the index INR spell were 
associated with higher TTR (Figure 8.11).  Similarly, thiazides, ace inhibitors, ARBs, beta 
blockers, CCBs, statins and digoxin prescribed during index INR spells were associated with 
higher TTR, whereas prescriptions during index INR spells for insulin, amiodarone and 
antidepressants were associated with lower TTR (Figure 8.12). 
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8.3.6 The association between TTR and outcomes  
All-cause mortality incidence was higher in patients whose TTR was ≤65% compared with 
patients whose TTR was>65% in the year following INR monitoring. The overall risk of 1 year 
all-cause mortality was 22.97% (95% CI: 21.97, 23.95%) for patients with TTR≤65% and 15.99 
(95% CI: 15.08, 16.89) for patients with TTR>65%. The difference between the groups was 
similar across the indication subgroups (Figure 8.13).  
There was a small difference in 1 year cardiovascular death, stroke or MI incidence between 
patients with TTR≤65% and TTR>65%, 10.69% (95% CI: 9.93, 11.44%) and 9.09% (95% CI: 8.37, 
9.80%) respectively. The difference between TTR groups was more apparent for the subgroups 
of patients with atrial fibrillation and heart valve replacement than for patients with venous 
thromboembolism or other indications (Figure 8.13). The risk of 1 year cardiovascular death, 
stroke or MI in atrial fibrillation patients was 14.96% (95% CI: 13.62, 16.27%) and 11.42 (95% 
CI: 10.34, 12.49%) for TTR≤65% and TTR>65% respectively. For venous thromboembolism 
patients the risk of 1 year cardiovascular death, stroke or MI was 4.78% (95% CI: 3.70, 5.85%) 
and 3.85% (95% CI: 2.74, 4.94%) for TTR≤65% and TTR>65% respectively. 
The incidence of bleeding events in the year following INR monitoring was similar in the TTR 
groups, 11.95% (95% CI: 11.12, 12.77%) and 11.48% (95% CI: 10.65, 12.31%) for TTR≤65%, and 
TTR>65% respectively. In the heart valve replacement subgroup, patients with TTR>65% had 
slightly higher incidence of bleeding at 1 year than patients with TTR≤65% (Figure 8.14). 
Similarly, for major bleeding events, one year incidence did not differ greatly between the TTR 
groups, 3.69% (3.23, 4.15%). Incidence of one year major bleeding was higher for patients with 
TTR>65% compared with patients with TTR≤65% in the heart valve replacement subgroup 
(Figure 8.14). 
In multivariable analysis I assessed the risk of 1 year events across the full range of TTR values. 
TTR was fitted in the Cox proportional hazards models using restricted cubic splines with three 
knots and models were adjusted for age, gender and index INR spell duration. 
In all indication subgroups, the risk of one all-cause mortality was approximately halved for 
patients with 100% TTR compared to patients with 65% TTR (Figure 8.15). The risk of one year 
all-cause mortality for atrial fibrillation, heart valve replacement and other indication patients 
peaked and plateaued at TTR of 50% or less. However, there was a more linear association 
between TTR and all-cause mortality for venous thromboembolism. The risks of cardiovascular 
death stroke or MI associated with TTR (Figure 8.15) were similar to those for all-cause 
mortality within the indication subgroups. 
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The association between TTR and bleeding events are shown in Figure 8.16. The risk of any 
bleeding or major bleeding in atrial fibrillation patients is similar for TTR between 0 and 65% 
and TTR>65% is associated with decreasing risk. The association between TTR and bleeding 
events appeared to have a reversed J-curve shape for patients with venous thromboembolism. 
That is, patients had increasing risk from 65% TTR to 0% TTR. For example patients with 20% 
TTR were estimated to have 2 times the risk of any bleeding and 3 times the risk of major 
bleeding compared to patients with 65% TTR. There also appeared to be increasing risks of 
bleeding events from 65% TTR to 100% TTR. Heart valve replacement patients had a similar 
shaped association between TTR and bleeding events, although the magnitude of effect 
estimates were much lower.  TTR had a linear association with risks of bleeding events for 
patients with other indications. 
8.4 Discussion 
In this study I used linked electronic health record to investigate patterns and outcomes of TTR 
in a population-based cohort of patients in 4 disease populations indicated for oral 
anticoagulation. The average TTR was 62.8% across the study population. The highest mean 
TTR was observed in atrial fibrillation patients, who on average spent two thirds of their INR 
monitoring time within therapeutic range. Distribution of TTR for atrial fibrillation patients was 
skewed to the right, indicating more patients with higher TTR during their treatment 
monitoring period. The lowest TTR was observed in heart valve replacement patients, who on 
average spent only half the time within therapeutic range. 
Similar to previous literature, demographic factors of age >40 years, men, white, and a lower 
deprivation were associated with higher TTR. Lifestyle factors of smoking and history of alcohol 
abuse were associated with lower TTR. In terms of clinical history, patients with hypertension 
had a higher TTR, as summarised in the literature (Figure 2.2). There appeared to be a ‘J-curve’ 
association between both systolic and diastolic blood pressure and TTR. Other disease histories 
(type 1 diabetes, liver disease, COPD, anaemia) were associated with lower TTR. It is notable 
that the association between a CVD history (myocardial infarction, heart failure) and TTR was 
different among patients with atrial fibrillation, compared with patients with other indications.  
It may be related to the observation that the prescriptions of K-sparing diuretics, loop 
diuretics, prescriptions prior to index INR spells were associated with lower TTR. This is 
however to be examined in future. The prescriptions of anti-hypertensive treatment, such as 
thiazides, ARBs, beta blockers, CCBs, statins, digoxin were associated with higher TTR. Anti-
diabetic drug treatment, for example insulin, was associated with lower TTR.  
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The SAME-TT2R2 score did not perform well to predict patients TTR in the data, as increasing in 
SAME-TT2R2 score was observed with little to null change in TTR (c-indexes ranging from 0.52-
0.55 across the studied disease populations and TTR cut-off values). However, I found that the 
predictors used to define the SAME-TT2R2 score were associated with lower TTR. The simple 
point-based scheme and weighting of predictors in SAME-TT2R2 may not be sufficient to detect 
small changes in TTR. 
Patients with a TTR lower than the guideline recommended threshold of 65% had a higher risk 
of all-cause mortality and cardiovascular death, stroke or MI and this was evident across each 
of the studied disease populations. There was a small bleeding risk increase in patients with 
TTR lower than 65%. TTR above guideline recommended threshold appeared to be effective in 
indicating beneficial oral anticoagulation, suggested by a higher atherothrombotic risk 
reduction and lower bleeding risk. 
The real-world data of CALIBER has the strength to compare TTR amongst 4 disease 
populations indicated for oral anticoagulants. A limitation is not all CPRD general practices 
electronically receive INR records from anticoagulation clinics, therefore the depth and quality 
of INR data in CALIBER may be lower compared with studies set in anticoagulation clinics. 
While I restricted the analysis to patients with at least 5 consecutive INR records (the median 
number of records per patient spell was 17 (IQR: 9, 35)), the TTR estimates for patients with 
fewer INR records in their oral anticoagulation spell may still not be as accurate as for patients 
with a larger number of INR records. This is in particular because initially in oral 
anticoagulation, INR may not be stable until a patients’ therapeutic dose is determined. 
However this data reflects real-world practice and we do not have sufficient evidence to 
recommend that patients should be monitored more frequently. The precise INR therapeutic 
range for the patients in the study population was assumed to be 2-3 for all patients. This may 
have resulted in misspecification of TTR for some heart valve replacement patients whose 
recommended therapeutic range can vary between 2-3 or 2.5-3.5 depending on their type of 
valve replacement and their risk profile. However, in my sensitivity analysis, a shifted 
therapeutic range of 2.5-3.5 was applied to the heart valve replacement population and the 
change in TTR was small.   
My study observed that for patients who maintained a TTR of 65% or greater had improved 
long term prognosis and reduced bleeding risk. This was true not only for atrial fibrillation 
patients, but also for patients with venous thromboembolism, heart valve replacements and 
other indications for oral anticoagulation. In the absence of guidelines recommended targets 
for TTR amongst these patient groups, the study results supports maintaining oral 
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anticoagulation treatment control as measured by TTR above 65%. Future randomised clinical 
trials should investigate thresholds of TTR for effective oral anticoagulation and treatment 
strategies to improve and maintain a high TTR. 
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8.5 Tables and Figures 
Figure 8.1: INR spells with 50 vs. 90 day cut-off for consecutive INR records 
Note: Green dots represent records for oral anticoagulant prescriptions, orange dots represent 
records for antiplatelet prescriptions;   
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Figure 8.2: Examples of time in therapeutic range calculated for three patients 
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Table 8.1: Same-TT2R2 score  
Risk factor Points 
Sex (female) 1 
Age (<60 years) 1 
Medical history (at least two of: hypertension, diabetes, myocardial 
infarction, peripheral arterial disease, congestive heart failure, 
history of stroke, pulmonary disease, liver disease, renal disease) 
1 
Treatment (interacting medications e.g. amiodarone 1 
Tobacco use (within two years) 2 
Race (non-Caucasian) 2 
  
259 
 
Figure 8.3: Flow of patients into the study population 
  
Note: INR= international normalised ratio; SD= standard deviation; TTR= time in therapeutic 
range  
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Table 8.2: Baseline characteristics of the study population (n=18823) stratified by indication 
  
Atrial 
fibrillation 
(n= 10132) 
Venous 
thrombo-
embolism 
(n= 3471) 
Heart valve 
replacement 
(n= 744) 
Other 
indication 
(n= 4476) 
All patients 
(n=18823) 
Demographics and behaviours 
Age (Years)  73.6 (9.95) 65.0 (15.61) 64.9 (12.01) 65.8 (15.35) 69.8 (13.3) 
Women  4316 (42.6) 1832 (52.8) 244 (32.8) 2147 (48) 8539 (45.4) 
Ethnicity: Non-
white 
 89 (0.9) 44 (1.3) 14 (1.9) 50 (1.1) 197 (1) 
Ethnicity: White  7729 (76.3) 2664 (76.8) 627 (84.3) 3356 (75) 14376 (76.4) 
 Missing % 22.8 22 13.8 23.9 22.6 
Practice region North West 1038 (10.2) 245 (7.1) 84 (11.3) 403 (9) 1770 (9.4) 
 North East 212 (2.1) 65 (1.9) 11 (1.5) 55 (1.2) 343 (1.8) 
 
Yorkshire & 
The Humber 
575 (5.7) 136 (3.9) 45 (6) 224 (5) 980 (5.2) 
 
West 
Midlands 
1091 (10.8) 327 (9.4) 91 (12.2) 420 (9.4) 1929 (10.2) 
 
East 
Midlands 
538 (5.3) 142 (4.1) 30 (4) 278 (6.2) 988 (5.2) 
 
East Of 
England 
1415 (14) 496 (14.3) 97 (13) 581 (13) 2589 (13.8) 
 London 457 (4.5) 84 (2.4) 33 (4.4) 174 (3.9) 748 (4) 
 South West 2426 (23.9) 1178 (33.9) 180 (24.2) 1256 (28.1) 5040 (26.8) 
 South Central 1399 (13.8) 500 (14.4) 113 (15.2) 648 (14.5) 2660 (14.1) 
 
South East 
Coast 
981 (9.7) 298 (8.6) 60 (8.1) 437 (9.8) 1776 (9.4) 
Highest quintile of deprivation 
(IMD) 
1941 (19.2) 655 (18.9) 144 (19.4) 1002 (22.4) 3742 (19.9) 
 Missing % 0.4 0.2 0.4 0.5 0.4 
Alcohol abuse  1408 (13.9) 445 (12.8) 104 (14) 559 (12.5) 2516 (13.4) 
 Missing % 0.3 0.2 0.1 0.3 0.3 
Smoking status Non-Smoker 4421 (43.6) 1570 (45.2) 309 (41.5) 1847 (41.3) 8147 (43.3) 
 Ex-Smoker 4104 (40.5) 1170 (33.7) 298 (40.1) 1514 (33.8) 7086 (37.6) 
 Smoker 718 (7.1) 405 (11.7) 64 (8.6) 493 (11) 1680 (8.9) 
 Missing % 8.8 9.4 9.8 13.9 10.1 
Medical history 
Hypertension  6194 (61.1) 1377 (39.7) 411 (55.2) 1906 (42.6) 9888 (52.5) 
Myocardial 
infarction 
 975 (9.6) 164 (4.7) 58 (7.8) 449 (10) 1646 (8.7) 
Heart failure  2279 (22.5) 224 (6.5) 246 (33.1) 581 (13) 3330 (17.7) 
Unstable angina  534 (5.3) 97 (2.8) 60 (8.1) 166 (3.7) 857 (4.6) 
Ischaemic or unspecified stroke 685 (6.8) 170 (4.9) 52 (7) 386 (8.6) 1293 (6.9) 
Peripheral arterial disease 1117 (11) 116 (3.3) 34 (4.6) 385 (8.6) 1652 (8.8) 
Any bleeding  2726 (26.9) 875 (25.2) 236 (31.7) 1156 (25.8) 4993 (26.5) 
Major bleeding  137 (1.4) 65 (1.9) 24 (3.2) 81 (1.8) 307 (1.6) 
Chronic anaemia  1074 (10.6) 443 (12.8) 140 (18.8) 551 (12.3) 2208 (11.7) 
Diabetes Unspecified 74 (0.7) 15 (0.4) 5 (0.7) 34 (0.8) 128 (0.7) 
 Type 1 41 (0.4) 11 (0.3) 4 (0.5) 40 (0.9) 96 (0.5) 
 Type 2 1275 (12.6) 292 (8.4) 86 (11.6) 453 (10.1) 2106 (11.2) 
Cancer  1652 (16.3) 746 (21.5) 68 (9.1) 941 (21) 3407 (18.1) 
Chronic obstructive pulmonary 
disease 
979 (9.7) 259 (7.5) 60 (8.1) 352 (7.9) 1650 (8.8) 
Renal disease  1441 (14.2) 382 (11) 87 (11.7) 459 (10.3) 2369 (12.6) 
Liver disease  59 (0.6) 45 (1.3) 10 (1.3) 52 (1.2) 166 (0.9) 
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Atrial 
fibrillation 
(n= 10132) 
Venous 
thrombo-
embolism 
(n= 3471) 
Heart valve 
replacement 
(n= 744) 
Other 
indication 
(n= 4476) 
All patients 
(n=18823) 
Clinical biomarkers 
Body mass index  28.8 (6.08) 29.8 (6.65) 28.7 (5.66) 29.1 (6.40) 29 (6.23) 
 Missing % 58.4 66.5 61.7 66.5 61.9 
Systolic blood pressure (mmHg) 137 (18.7) 136 (18.1) 134 (18.1) 136 (19.8) 136 (18.8) 
 Missing % 12 29.8 13.4 28 19.1 
Diastolic blood pressure (mmHg) 79.2 (10.9) 79.1 (10.7) 75.9 (10.8) 78.8 (10.6) 79 (10.8) 
 Missing % 12 29.8 13.4 28 19.1 
Heart rate (bpm)  80.8 (19.7) 80.1 (17.7) 78.6 (18.7) 81.2 (18.7) 80.7 (19.3) 
 Missing % 78.9 89.3 85.8 88.8 83.4 
Haemoglobin 
(g/dL) 
 13.9 (1.61) 13.2 (1.85) 13.2 (1.93) 13.4 (1.87) 13.7 (1.75) 
 Missing % 41.8 47.7 46.4 48.9 44.8 
Total white blood cell count (109/L) 7.49 (2.47) 7.89 (3.13) 7.62 (2.49) 7.63 (2.71) 7.59 (2.66) 
 Missing % 43.8 49.9 48.4 50.8 46.7 
Platelets (109/L)  248 (79.9) 281 (107.1) 267 (112.3) 271 (99.6) 259 (92) 
 Missing % 43.7 49.8 48.5 51.4 46.9 
Creatinine (mmol)  101.9 (32.5)  96.9 (35.0) 101.8 (44.7)  99.2 (36.8) 101 (34.4) 
 Median (IQR) 97 (84, 112) 90 (78, 107) 97 (85, 111) 94 (80, 110) 95 (82, 111) 
 Missing % 28.2 45.3 36.3 43.7 35.3 
Hba1c (mmol/mol)  55.1 (15.4) 57.0 (18.0) 55.5 (13.6) 58.5 (17.7) 56.1 (16.3) 
 Missing % 87.4 92.3 89.8 90.1 89 
High-density 
lipoproteins 
(mmol) 
 1.39 (0.419) 1.43 (0.474) 1.36 (0.405) 1.39 (0.457) 1.39 (0.433) 
 Missing % 60.4 77.7 62.4 74.7 67.1 
Total cholesterol (mmol) 4.72 (1.11) 5.14 (1.17) 4.71 (1.13) 4.96 (1.28) 4.82 (1.16) 
 Missing % 44.8 68.9 43.1 63.3 53.6 
Prescribed medication before and during INR spell 
Antiplatelets pre 5914 (58.4) 950 (27.4) 353 (47.4) 1443 (32.2) 8660 (46) 
 during 1437 (14.2) 252 (7.3) 132 (17.7) 521 (11.6) 2342 (12.4) 
Digoxin pre 4546 (44.9) 118 (3.4) 159 (21.4) 406 (9.1) 5229 (27.8) 
 during 4863 (48) 155 (4.5) 144 (19.4) 478 (10.7) 5640 (30) 
Amiodarone pre 1353 (13.4) 42 (1.2) 153 (20.6) 117 (2.6) 1665 (8.8) 
 during 1354 (13.4) 40 (1.2) 125 (16.8) 181 (4) 1700 (9) 
Thiazides pre 4355 (43) 1005 (29) 228 (30.6) 1336 (29.8) 6924 (36.8) 
 during 2187 (21.6) 445 (12.8) 109 (14.7) 658 (14.7) 3399 (18.1) 
Loop diuretics pre 4034 (39.8) 833 (24) 400 (53.8) 1370 (30.6) 6637 (35.3) 
 during 4287 (42.3) 714 (20.6) 341 (45.8) 1307 (29.2) 6649 (35.3) 
K-sparing diuretics 
and aldosterone 
antagonists 
pre 1468 (14.5) 290 (8.4) 207 (27.8) 519 (11.6) 2484 (13.2) 
 during 1324 (13.1) 165 (4.8) 161 (21.6) 458 (10.2) 2108 (11.2) 
K-sparing diuretics 
with other 
diuretics 
pre 1217 (12) 297 (8.6) 146 (19.6) 403 (9) 2063 (11) 
 during 458 (4.5) 87 (2.5) 70 (9.4) 146 (3.3) 761 (4) 
Beta blockers pre 6074 (59.9) 1022 (29.4) 410 (55.1) 1588 (35.5) 9094 (48.3) 
 during 5190 (51.2) 536 (15.4) 337 (45.3) 1180 (26.4) 7243 (38.5) 
Ace inhibitors pre 6078 (60) 1447 (41.7) 466 (62.6) 2145 (47.9) 10136 (53.8) 
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Atrial 
fibrillation 
(n= 10132) 
Venous 
thrombo-
embolism 
(n= 3471) 
Heart valve 
replacement 
(n= 744) 
Other 
indication 
(n= 4476) 
All patients 
(n=18823) 
 during 4940 (48.8) 722 (20.8) 395 (53.1) 1514 (33.8) 7571 (40.2) 
Angiotensin 
receptor blockers 
pre 1544 (15.2) 292 (8.4) 107 (14.4) 419 (9.4) 2362 (12.5) 
 during 1692 (16.7) 242 (7) 114 (15.3) 416 (9.3) 2464 (13.1) 
Calcium channel 
blockers 
pre 4281 (42.3) 788 (22.7) 252 (33.9) 1191 (26.6) 6512 (34.6) 
 during 3244 (32) 465 (13.4) 144 (19.4) 817 (18.3) 4670 (24.8) 
Statins pre 4350 (42.9) 826 (23.8) 399 (53.6) 1392 (31.1) 6967 (37) 
 during 4916 (48.5) 748 (21.5) 458 (61.6) 1527 (34.1) 7649 (40.6) 
Insulin pre 626 (6.2) 160 (4.6) 44 (5.9) 293 (6.5) 1123 (6) 
 during 621 (6.1) 131 (3.8) 53 (7.1) 275 (6.1) 1080 (5.7) 
Anti-diabetics pre 945 (9.3) 209 (6) 56 (7.5) 378 (8.4) 1588 (8.4) 
 during 1063 (10.5) 192 (5.5) 60 (8.1) 372 (8.3) 1687 (9) 
Nonsteroidal anti-
inflammatory 
drugs 
pre 6699 (66.1) 2543 (73.3) 429 (57.7) 2889 (64.5) 12560 (66.7) 
 during 858 (8.5) 293 (8.4) 67 (9) 385 (8.6) 1603 (8.5) 
Antidepressants pre 2695 (26.6) 1270 (36.6) 215 (28.9) 1570 (35.1) 5750 (30.5) 
 during 1564 (15.4) 646 (18.6) 126 (16.9) 931 (20.8) 3267 (17.4) 
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Figure 8.4: Distribution of 541770 INR records for 18823 patients stratified by indication 
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Figure 8.5: Mean days to next INR test by INR value from 541770 INR records for 18823 patients. 
 
Note: INR= International normalised ratio; grey lines represent 95% confidence interval; INR 
values only captured once in the data do not have a confidence interval   
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Figure 8.6: The distribution of percent time in therapeutic range for 18823 patients stratified by 
indication 
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Table 8.3: Characteristics of index INR spells and vitamin K antagonist prescribing prior to and during index INR spells 
  
Atrial fibrillation 
(n= 10132) 
Venous 
thrombo-
embolism 
(n= 3471) 
Heart valve 
replacement 
(n= 744) 
Other indication 
(n= 4476) 
All patients 
(n=18823) 
Index INR spell characteristics 
Time in therapeutic 
range (2-3)  
66.2 (19.8) 59.4 (21.6) 51.2 (22.7) 59.6 (23.1) 62.8 (21.4) 
 Median (IQR) 69.3 (55.5, 80.2) 61.3 (44.9, 75.5) 53.7 (32.0, 68.9) 63.0 (44.8, 76.3) 66.1 (50.1, 78.3) 
Time in therapeutic 
range (2.5-3.5)  
36.3 (19.8) 32.6 (21.7) 49.5 (21.4 34.8 (21.7) 35.8 (20.9) 
 Median (IQR) 35.8 (23.0, 48.3) 30.6 (15.7, 46.2) 50.7 (35.9, 63.4) 30.6 (15.7, 46.2) 35.1 (21.0, 48.9) 
Index INR spell duration 
(days) 
698 (687) 294 (449) 908 (894) 532 (684) 592 (679) 
 Median (IQR) 477 (196, 959) 162 (97, 239) 582 (236, 1269) 233 (118, 652) 312 (142, 798) 
Number of INR records  31.5 (30.7) 19.4 (22.9) 47.2 (51.0) 26.8 (33.6) 28.8 (31.8) 
 Median (IQR) 21.0 (11, 41) 13.0 9, 19) 27.5 (13, 61) 14.0 (8, 31) 17 (9, 35) 
Mean time between 
INR records (days) 
24.3 (12.61) 15.3 ( 7.41) 21.9 (10.86) 21.1 (11.60) 21.8 (12) 
 Median (IQR) 22.0 (15.4, 30.5) 13.9 (10.2, 18.7) 19.7 (14.4, 27.2) 18.8 (12.9, 26.8) 19.4 (13.2, 27.5) 
Vitamin K antagonist prescribing 
Prior to INR spell (days) 366.1 (601.4)  53.6 (88.3) 516.5 (787.4) 294.2 (511.6) 297 (546) 
 Median (IQR) 90 (90, 410)  0 (0,  90) 90 (0, 698) 90 (90, 266) 90 (0, 246) 
During INR spell (days) 643 (606) 304 (394) 785 (756) 478 (563) 547 (586) 
 Median (IQR) 449 (211,  868) 196 (137,  267) 544 (229, 1072) 244 (144,  575) 310 (167, 707) 
INR= international normalised ratio; Mean (SD) for continuous variables unless stated otherwise 
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Table 8.4: The distribution of the SAME-TT2R2 score within the study population 
SAME-TT2R2 score Atrial fibrillation 
(n= 10132) 
Venous 
thrombo-
embolism 
(n= 3471) 
Heart valve 
replacement 
(n= 744) 
Other indication 
(n= 4476) 
All patients 
(n=18823) 
0 1337 (13.2) 605 (17.4) 119 (16) 736 (16.4) 2797 (14.9) 
1 3099 (30.6) 1451 (41.8) 247 (33.2) 1737 (38.8) 6534 (34.7) 
2 3365 (33.2) 944 (27.2) 218 (29.3) 1334 (29.8) 5861 (31.1) 
3 1751 (17.3) 295 (8.5) 114 (15.3) 404 (9) 2564 (13.6) 
4 414 (4.1) 163 (4.7) 30 (4) 213 (4.8) 820 (4.4) 
5 147 (1.5) 13 (0.4) 16 (2.2) 44 (1) 220 (1.2) 
6 18 (0.2) 0 (0) 0 (0) 5 (0.1) 23 (0.1) 
7 1 (0) 0 (0) 0 (0) 3 (0.1) 4 (0) 
 
Reported numbers are n (%) 
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Figure 8.7: Mean (95% CI) time in therapeutic range across the range of SAME-TT2R2 scores stratified by indication 
 
Note: The SAME-TT2R2 score is specified in Table 8.1. No confidence interval for atrial fibrillation and SAME-TT2R2 score 7 due to there being only one patient in this 
subgroup. CI= confidence interval; TTR= time in therapeutic range (%) 
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Table 8.5: C-indexes for models using the SAME-TT2R2 score to predict TTR>60, 65 and 70 in the study population 
Endpoint All patients 
Atrial 
fibrillation 
Venous 
thromboembolism 
Heart valve 
replacement 
Other 
indication 
TTR>60 0.53 0.54 0.54 0.53 0.55 
TTR>65 0.53 0.55 0.55 0.52 0.55 
TTR>70 0.54 0.55 0.55 0.54 0.54 
270 
 
Figure 8.8: Univariable linear regression estimates for the difference (95% CI) in TTR in demographics and behaviour subgroups 
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Figure 8.9: Univariable linear regression estimates for the difference (95% CI) in TTR in medical history subgroups 
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Figure 8.10: Univariable linear regression estimates for the difference (95% CI) in TTR in clinical biomarker subgroups 
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Figure 8.11: Univariable linear regression estimates for the difference (95% CI) in TTR in subgroups defined by prescribed medication prior to index INR spell  
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Figure 8.12: Univariable linear regression estimates for the difference (95% CI) in TTR in subgroups defined by prescribed medication during index INR spells 
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Figure 8.13: All-cause mortality and cardiovascular death, stroke or MI events stratified by TTR above and below 65% 
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Figure 8.14: Any bleeding and major bleeding events stratified by TTR above and below 65% 
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Figure 8.15: Risk of all-cause mortality and cardiovascular death, stroke or MI by index INR spell time in therapeutic range 
  
Hazard ratios estimated for 1 year endpoints using Cox proportional hazards models adjusted for age, gender and length of index INR spell. Time in therapeutic range was fitted 
using restricted cubic splines with 3 knot points in each model. The reference value for time in therapeutic range is 65%.  
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Figure 8.16: Risk of any bleeding and major bleeding death, stroke or MI by index INR spell time in therapeutic range 
  
Hazard ratios estimated for 1 year endpoints using Cox proportional hazards models adjusted for age, gender and length of index INR spell. Time in therapeutic range was fitted 
using restricted cubic splines with 3 knot points in each model. The reference value for time in therapeutic range is 65%. 
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9 The predictive value of measures of INR control for atherothrombotic 
and bleeding outcomes: a population-based linked electronic health 
record study 
 
Chapter Summary 
Background 
In the previous chapter I examined the association between TTR and all-cause mortality, 
atherothrombotic events and bleeding and found patients with higher TTR have lower risks of 
events. Despite this association prognostic models seldom use measures of INR control as a 
covariate for assessing atherothrombotic and bleeding risk in the relevant patient populations. 
Measures of INR control beyond TTR, such as INR variability, have also been shown to be 
associated with outcomes. The objectives of this chapter were to illustrate INR control within 
the study population, to estimate predictors of INR variability, and to estimate the predictive 
value of range of measures of INR control in prognostic models for atherothrombotic and 
bleeding events. 
Methods 
Using CALIBER linked electronic health records, the study population comprised of 18823 
patients prescribed OAC and at least 5 consecutive INR records. I examined the distribution of 
a range of measures of INR control, including TTR, INR variability, INR trajectory,. A linear 
regression model was used to estimate associations between baseline risk factors and INR 
variability. Prognostic models were constructed using logistic regression for one year 
outcomes, adjusting for standard cardiovascular risk factors and each measure of INR control 
in turn. Net reclassification improvement and integrated discrimination improvement statistics 
were used to estimate the predictive value of each measure of INR control. 
Results 
Smoking, excess alcohol consumption, prior heart valve replacement, cancer were among the 
risk factors found to be associated with increased INR variability during oral anticoagulation. 
Over-anticoagulation, high INR variability, high maximum INR and an increasing INR trajectory 
were found to be associated with higher risks of all-cause mortality, atherothrombotic and 
bleeding events. In the presence of standard cardiovascular risk factors INR variability, % time 
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above therapeutic range, improved the predictive performance of prognostic models for the 
studied endpoints. 
Conclusions 
I demonstrated that measures of INR control, such as INR variability, maximum INR and TTR 
can improve the predictive performance of prognostic models for all-cause mortality, 
atherothrombotic and bleeding events in patients previously treated with oral anticoagulants. 
Such measures would be can be implemented within electronic health records with simple 
algorithms to enable continuous monitoring and updating of patients risks. 
 
9.1 Introduction 
Oral anticoagulants are a widely used class of drugs primarily for stroke prevention in atrial 
fibrillation and other cardiovascular diseases. The international normalised ratio (INR) is a 
regular blood test for patients being treated with vitamin K antagonists (VKA) a class of oral 
anticoagulants in order to observe treatment control. INR is a standardised calculation of 
prothrombin time: the time taken for blood to clot. In healthy people not treated with oral 
anticoagulants a normal INR is between 0.8 and 1.2. For patients being treated with oral 
anticoagulants the therapeutic range for most diseases is between 2 and 3. If over treated 
patients are at risk of major bleeding, and if under treated patients are at risk of blood clotting 
which could result in stroke or other serious atherothrombotic events. Given the severity of 
outcomes associated with unstable INR, patients are monitored regularly for the duration of 
their treatment with oral anticoagulants. The frequency of INR tests is dependent on the stage 
of anticoagulation, presence of bleeding risk factors, concomitant prescriptions with known 
interactions with oral anticoagulants, and poor INR stability.104 Depending on the indication for 
oral anticoagulation patients may be treated from 3 months (e.g. venous thromboembolism) 
to lifelong (e.g. for atrial fibrillation with high stroke risk). 
There are many ways repeated INR tests may be summarised for assessment, the most 
common being percent time in therapeutic range (TTR). Cohort studies have shown that sub-
therapeutic INR and INR stability is associated with increased risks of all-cause mortality, 
atherothrombotic events, and bleeding events.112,171 Prognostic models and risk scores have 
widely been adopted for assessing patient’s risks associated with oral anticoagulation. 
However within such risk assessments, measures of INR are seldom included as a prognostic 
factor. HAS-BLED,7 a simple point-based bleeding risk score includes labile INR (defined as 
TTR<65%) as a risk factor. It has been shown that modification of the risk scores, ATRIA, 
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HEMORR2HAGES and ORBIT to include labile INR resulted in improvement in prediction of 
major bleeding events in atrial fibrillation patients.146 Previous studies of INR variability140-143 
and wider ranges of measures of INR control139,144,145 have demonstrated scope for improving 
upon TTR; in particular INR variability has shown stronger associations with bleeding and 
atherothrombotic events. However the value these measures may add to prognostic models 
with standard cardiovascular and bleeding risk factors is unknown. 
Using an unselected cohort from primary care-hospital-death registry linked electronic health 
records I sought to investigate which measures of INR control are optimal to predict the risks 
of both the benefits and harms of oral anticoagulation therapy. The objectives of the study 
were 1) To illustrate overall distribution of INR control within the study population, 2) To 
estimate predictors of INR variability and 3) To estimate the predictive value of a range of 
measures of INR control for atherothrombotic and bleeding events; Is TTR the best measure 
and do measures of INR control work well for predicting both bleeding and atherothrombotic 
endpoints and add value to standard risk factors? 
9.2 Methods 
9.2.1 Study population and index INR spell 
I used CALIBER (1997-2010) linked electronic health records. Patients were included if they had 
at least one prescription for an oral anticoagulant (vitamin K antagonists: warfarin, 
phenindione or acenocoumarol) and a minimum of five consecutive INR records. INR values 
were considered to be consecutive if they were within 90 days. If a patient had multiple valid 
spells of INR monitoring I used their first as their index INR spell. 
9.2.2 Measures of INR control 
The measures of INR control investigated in the study are described below including how to 
calculate them and the rationale for their inclusion. 
9.2.2.1 Time in therapeutic range, above range and below range 
The time in therapeutic range (TTR) is the percent of the INR spell spent within the range of 2 
to 3. The trajectory between adjacent INR measures is assumed to be linear following 
Rosendaal’s method.105 The time above therapeutic range (TAR) is the percent of the INR spell 
spent >3. This is calculated in a similar manner to TTR except any time below therapeutic range 
(<2) is not considered. The time below therapeutic range (TBR) is the percent of the INR spell 
spent <3. This is calculated in a similar manner to TTR except any time above therapeutic range 
(<3) is not considered. 
Examples of TTR, TAR and TBR are shown in Tables and Figures 
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Figure 9.1. 
9.2.2.2 TTR control group 
I grouped patients by TTR whilst utilising information on whether patients out of range INR 
measures were predominantly above range or below range. Patients with a TTR ≥ 80% were 
grouped as stable. Patients with TTR<80% and all of their out of range INR measures >3 were 
grouped as over-anticoagulated. Patients with TTR<80% and all of their out of range INR 
measures <2 were grouped as under-anticoagulated. The remaining patients with TTR<80% 
and a mixture of out of range INR values >3 and <2 were grouped as erratic. 
The advantage of this grouping method compared with TTR alone is that it accounts for the 
direction of patients out of range measures. 
Examples of index INR spells for patients in each TTR control group are shown in Figure 9.2. 
9.2.2.3 Mean INR and INR variability 
I used the mean INR as a measure of average location of INR values within spells. The 
variability of INR spells was calculated using the standard deviation of the measures within a 
spell. 
Examples of patients with different means and standard deviation for their INR spells are 
shown in Figure 9.3. 
9.2.2.4 Single INR values 
I also used single values within INR spells to determine whether they alone held any predictive 
value for future events, rather than ‘time consuming’ summaries of longitudinal data. I 
analysed the first, last, minimum and maximum values individually from each INR spell. An 
example of these single INR values for a patient’s INR spell is shown in Figure 9.4. 
9.2.2.5 INR trajectory  
I estimated the trajectory of INR spells by fitting linear models to the INR measures by time. I 
initially fitted quadratic models. If the quadratic coefficient for time was significant (p<0.05) I 
used the sign of coefficients to determine if the trajectory was upwards quadratic or 
downwards quadratic. For INR spells with a non-significant quadratic coefficient for time I fit a 
simple linear model for INR measures vs. time. If the coefficient for time was significant 
(p<0.05) I used the sign of the coefficient to determine if the trajectory was increasing or 
decreasing. The trajectories of INR spells with non-significant coefficients for time were 
classified as stable. 
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However this method does not account for the location of INR measures. For example for a 
patient with an increasing trajectory, this method does not capture if the INR is increasing 
having started low, or was initially high and continued to increase, the latter of which might 
considered to be a significantly worse scenario.  
Examples of patients INR spells with the different trajectories described are shown in Figure 
9.5. 
9.2.3 Baseline characteristics 
I described the characteristics of the study cohort at baseline stratified by TTR control group 
(stable, erratic, over anticoagulated, under anticoagulated). Broadly, the characteristics 
investigated were demographics and behaviours, characteristics of their index INR spell and 
oral anticoagulant exposure, cardiovascular and non-cardiovascular medical history, clinical 
biomarkers and prescribed medications prior to and during INR spell. Baseline characteristics 
were described using mean and standard deviation (SD) or median and interquartile range 
(IQR) for continuous variables and frequencies and percentages for categorical variables. 
The phenotypes for the characteristics are described in chapter 3. 
9.2.4 Endpoints 
Patients were followed up for 1 year for all-cause mortality, cardiovascular death stroke or MI, 
any bleeding and major bleeding. The composition of the phenotypes for these endpoints is 
described in chapter 3.  
9.2.5 Statistical analysis 
9.2.5.1 Baseline predictors of measures of INR variability 
Multivariable linear regression models were used to estimate the effects of baseline 
characteristics on INR variability. The model was adjusted for demographics and behaviours, 
characteristics of their index INR spell and oral anticoagulant exposure, cardiovascular and 
non-cardiovascular medical history, clinical biomarkers and prescribed medications prior to 
and during INR spell. 
9.2.5.2 Outcomes following first INR spell 
To estimate the association of the measures of INR control with 1 year mortality, 
cardiovascular and bleeding endpoints following an INR spell I used multivariable logistic 
regression models to calculate odds ratios and 95% confidence intervals (CI), adjusted for 
standard cardiovascular risk factors and confounders measured prior to and during INR spells: 
Demographics and behaviours (Age, sex, index of multiple deprivation, smoking status and 
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history of excess alcohol consumption), INR spell characteristics (length of index INR spell and 
exposure to oral anticoagulants prior to index INR spell), cardiovascular disease history (atrial 
fibrillation, myocardial infarction, heart failure, heart valve replacement, unstable angina, 
peripheral arterial disease, venous thromboembolism, ischaemic or unspecified stroke, 
bleeding and major bleeding), non-cardiovascular disease history (diabetes, cancer, chronic 
obstructive pulmonary disease and renal disease) and clinical biomarkers (BMI, systolic blood 
pressure, high density lipoproteins, serum creatinine, haemoglobin and white blood cell 
count). 
9.2.5.3 Estimating the predictive value of measures of INR control 
In order to evaluate the change in performance of prediction models with the inclusion of each 
of the measures of INR control I first fit a multivariable logistic ‘base model’ adjusting for the 
standard risk factors and confounders only (described in chapter 9.2.5.2). Next models were 
fitted that comprised of the base model with the inclusion each of the measures of INR 
control. For ease of interpretation and presentation the continuous measures of INR control 
were categorised into quintiles, with the middle quintile being used as the reference group. 
For the measures of INR control that were already categorical, TTR control group and INR 
trajectory, their respective ‘Stable’ groups were used as reference categories in multivariable 
models.  I compared each of the new models with the base model using the net reclassification 
improvement and the integrated discrimination improvement measures. 
The net reclassification improvement219-221 (NRI) is the sum of the net change in proportion of 
patients correctly reclassified upwards (i.e. patients that did have an event and are predicted 
to have no event with the base model and predicted to have an event with the new model) 
and the net change in proportion of patients correctly reclassified downwards (i.e. patients 
that did not have an event and are predicted to have am event with the base model and 
predicted to have no event with the new model).  
Let M1 and M2 denote the individual predicted probabilities of events estimated from model 1 
(base model) and model 2 (base model plus measure of INR control) respectively. The NRI is 
calculated as follows: 
𝑁𝑅𝐼 = 𝑃(𝑀2 > 𝑀1|𝑒𝑣𝑒𝑛𝑡) − 𝑃(𝑀2 < 𝑀1|𝑒𝑣𝑒𝑛𝑡) +  𝑃(𝑀2 < 𝑀1|𝑛𝑜 𝑒𝑣𝑒𝑛𝑡)
− 𝑃(𝑀2 > 𝑀1|𝑛𝑜 𝑒𝑣𝑒𝑛𝑡) 
Note that this is the continuous version of NRI as opposed to the category-based NRI which 
requires the specification of cut-points and risk groups. 
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The Integrated discrimination improvement219 (IDI) is the difference in discrimination slope 
between a model with and without an added risk factor. The discrimination slope of a model is 
the difference in mean predicted probabilities between those that do and don’t have the event 
of interest. The IDI therefore can be expressed as: 
𝐼𝐷𝐼 = (?̅?𝑒𝑣𝑒𝑛𝑡 − ?̅?𝑛𝑜 𝑒𝑣𝑒𝑛𝑡)𝑀2 − (?̅?𝑒𝑣𝑒𝑛𝑡 − ?̅?𝑛𝑜 𝑒𝑣𝑒𝑛𝑡)𝑀1   
Model prediction comparison 
To visualise the changes in individual patient’s predictions with the additions of measures of 
INR control, I plotted predictions from the base model versus predictions for measure of INR 
control models. 
Model calibration 
The calibration of all models was assessed using Hosmer-Lemeshow tests and plots of 
observed events versus model predictions in decile groups. 
Modelling assumptions 
In univariable analyses evidence of non-linear associations between dependent and 
independent variables was checked and where appropriated fitted in the multivariable models 
using restricted cubic splines. Presence of collinear variables in the multivariable models was 
checked and any offending variables were removed. 
Missing Data 
Missing covariate data was multiply imputed using the MICE (multiple imputation with chained 
equations).211 10 imputed data sets were generated. 
9.3 Results 
9.3.1 Demographics and baseline characteristics of study population 
I identified 18823 patients in CALIBER who had been prescribed an oral anticoagulant and had 
at least 5 consecutive (within 90 days) INR records (Figure 9.6). Of these patients, 11677 had 
an index INR spell classed as erratic, 4123 were stable, 2168 were under anticoagulated and 
855 were over anticoagulated (Table 9.1). Patients in the erratic and stable groups were on 
average older, 70.1 years and 71.2 years respectively, than those who were over-
anticoagulated or under-anticoagulated, 68.7 and 66.0 years respectively. The majority of all 
four groups were men; however women were slightly more prevalent in the erratic and under-
anticoagulated groups. Patients in the erratic group had higher proportions of excess alcohol 
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consumption history (14.3%) and current smokers (10.6%) compared with those in the stable 
group (11.7% and 7.5%). 
A history of atrial fibrillation was most prevalent in the stable group (64.5%), whilst a history of 
myocardial infarction was most prevalent in the over anticoagulated group (10.3%). Heart 
failure history was most prevalent in the erratic (19.3%) and over-anticoagulated groups 
(19.2%). More than 25% of patients had a bleeding event of any severity prior to their index 
INR spell whilst 2% or less had experienced major bleeding in each group. Chronic anaemia 
was most common in the over-anticoagulated group (14.6%). Type 2 diabetes, cancer and 
chronic obstructive pulmonary disease were more prevalent in the erratic group than the 
others. 
At baseline the levels of clinical biomarkers, including systolic blood pressure, body mass 
index, haemoglobin, and creatinine were similar amongst the groups.  
The stable group had lower percentages of patients who had a history of prescriptions for 
antidepressants, anti-diabetics and insulin prior to index INR spells compared with the other 
groups. A history of antiplatelet prescribing was highest in the stable and erratic groups. 
Across most classes of drugs, prescribing was markedly lower during index INR spells 
compared with prior to INR spells in all groups. Exceptions to this were increased prescribing of 
angiotensin receptor blockers, statins and anti-diabetics in both the stable and erratic groups 
and insulin in the erratic group. 10% of the erratic group were prescribed nonsteroidal anti-
inflammatory drugs (NSAIDs) during their index INR spell compared with <7% in the three 
remaining groups. The erratic group also had higher prescribing of antiplatelets, K-sparing 
diuretics, loop diuretics, ace inhibitors, calcium channel blockers and antidepressants during 
index INR spells compared with the other groups. Patients in the stable group had a higher 
percentage of prescriptions for thiazides and beta blockers during index INR spells compared 
with the other groups. 
9.3.2 Characteristics of index INR spells and oral anticoagulation 
The median duration of INR monitoring for patients in the stable and erratic TTR control 
groups were the longest of the four groups with both exceeding a year at 425 (IQR: 174, 896) 
and 399 (IQR: 168, 936) days respectively, whilst the median duration was less than 6 months 
for the over-anticoagulated and under-anticoagulated group, at 154 (IQR: 82.5, 344) and 120 
(IQR: 70, 184) days respectively.  As a result the exposure to oral anticoagulants during index 
INR spells was also highest in the erratic and stable TTR control groups. Median duration of 
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oral anticoagulant exposure prior to the start of index INR spells was highest in the over-
anticoagulated group. 
9.3.3 Measures of INR control 
The distributions and relationships between the continuous measures of INR control are 
shown in a matrix plot, Supplementary appendix 11.5.1. The distribution of INR trajectories in 
the study population were 13462 (71.5%) stable, 1731 (9.2%) increasing, 1092 (5.8%) upwards 
quadratic, 862 (4.6%) decreasing and 1676 (8.9%) downwards quadratic. 
For the regression analysis the continuous measures of INR control were grouped into quintiles 
(Table 9.2). 
9.3.4 The association between baseline characteristics and INR variability 
The associations between patient baseline characteristics and log INR spell standard deviation 
were estimated using a multivariable linear regression model and the exponentiated 
coefficients are shown in Figure 9.7. 
Smokers compared with non-smokers had a 7.5% (95% CI: 4.7%, 10.3%) increase in INR SD. 
Patients with a history of excess alcohol consumption had a 6.7% increase in INR SD (95% CI: 
4.6%, 8.9%). Having a history of heart valve replacement was associated with a 11.3% (95% CI: 
7.4%, 15.3%) increase in INR SD. Other cardiovascular an non-cardiovascular disease histories 
associated with a significant increase in INR SD included peripheral arterial disease 3.0% (95% 
CI: 0.3%, 5.8%), major bleeding 6.1% (95% CI: 0.6%, 11.9%), chronic anaemia 2.6% (95% CI: 
0.3%, 4.9%), cancer 6.5% (95% CI: 4.6%, 8.4%) and chronic obstructive pulmonary disease 9.2% 
(95% CI: 6.5%, 11.9%). One unit increase in haemoglobin was associated with a small decrease 
in INR SD 0.989 (95% CI: 0.982, 0.997). 
Patients had increased INR SD if prior to their index INR spell they add a history of 
prescriptions for loop diuretics 3.2% (95% CI: 1.1%, 5.2%), antiplatelets 5.4% (95% CI: 3.8%, 
7.1%) and antidepressants 1.9% (95% CI: 0.2%, 3.6%). Patients had lower INR SD if they were 
prescribed at any time prior to INR index spell statins 0.959 (95% CI: 0.939, 0.979), digoxin 
0.963 (95% CI: 0.942, 0.985) or amiodarone 0.963 (95% CI: 0.937, 0.989). 
The drugs prescribed during INR spells that were associated with increased variability were 
loop diuretics 3.1% (95% CI: 1.1%, 5.1%), k-sparing diuretics and aldosterone antagonists 5.1% 
(95% CI: 2.2%, 8.2%), ace inhibitors 5.6% (95% CI: 2.5%, 8.8%), nonsteroidal anti-inflammatory 
drugs 7.1% (95% CI: 4.6%, 9.7%),  antidepressants 7.0% (95% CI: 5.0%, 9.1%), digoxin 3.8% 
(95% CI: 1.6%, 6.1%) and amiodarone 15.2% (95% CI: 12.2%, 18.3%). Only hypertension and 
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heart failure drugs were associated with lower INR SD (0.947 (95% CI: 0.918, 0.977)) when 
prescribed during the INR spells  
9.3.5 The base prognostic models 
At one year following the end of their index INR spell 2686 (14.3%) patients had died, 1304 
(6.9%) had cardiovascular death, stroke or MI, 1446 (7.7%) had any bleeding and 478 (2.5%) 
had major bleeding. Multivariable logistic ‘base’ prognostic models were developed for each 
endpoint which included covariates for demographics and cardiovascular risk factors and no 
measures of INR control. Systolic blood pressure and body mass index were modelled using 
restricted cubic splines with 3 knots. The base models estimates are displayed in 
Supplementary appendix 11.5.2. 
9.3.6 The association between measures of INR control and one year endpoints 
Each of the measures of INR control was included in each base model in turn. The adjusted 
odds ratios for the association between measures of INR control and all-cause mortality and 
cardiovascular death, stroke or MI are shown in Figure 9.8 and for any bleeding and major 
bleeding are shown in Figure 9.9.  
9.3.6.1 Time in therapeutic range stability group 
Patients had higher odds of all-cause mortality and cardiovascular death, stroke or MI one year 
after their index INR spell if their INR spell was classed as erratic or over-anticoagulated 
compared to those whose INR spells were stable. Odds of any bleeding did not differ 
significantly between TTR stability groups, however patients had nearly double the odds of 
major bleeding if their INR spell was classed as over-anticoagulated compared with stable, OR: 
1.90 (95% CI: 1.24, 2.91). 
9.3.6.2 Time in therapeutic range 
There was a decreasing trend in the odds of all four investigated endpoints as TTR increased 
and the trend appeared to be most pronounced for all-cause mortality. Patients in the lowest 
quintile of TTR [0.0%, 45.4%), compared to those in the 3rd quintile [60.5%, 70.9%) had 
significantly higher odds of all-cause mortality, OR: 1.47 (95% CI: 1.28, 1.69), any bleeding, OR: 
1.32 (95% CI: 1.11, 1.58) and major bleeding, OR: 1.38 (95% CI: 1.02, 1.87). Patients in the 
highest quintile of TTR [81.0%, 100%], compared to those in the 3rd quintile had significantly 
lower odds of all-cause mortality, OR: 0.50 (95% CI: 0.43, 0.58) and cardiovascular death stroke 
or MI OR: 0.60 (95% CI: 0.49, 0.73). 
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9.3.6.3 Time above therapeutic range 
There was an increasing trend association between % time above therapeutic range and the 
odds of the four investigated endpoints. These trends appeared to be modest for the bleeding 
endpoints compared with the clearer trends for all-cause mortality and cardiovascular death, 
stroke or MI endpoints. Patients in the 1st quintile [0.0%, 1.5%) of time above therapeutic 
range compared with the 3rd quintile [8.5%, 14.9%) had significantly lower odds of all-cause 
mortality and major bleeding. Patients in the 5th quintile [25.4, 100.0] compared with the 3rd 
quintile had significantly higher odds of all-cause mortality and cardiovascular death stroke or 
MI. 
9.3.6.4 Time below therapeutic range 
There were no apparent trends between % time below therapeutic range and the one year 
endpoints. The odds of cardiovascular death, stroke or MI, any bleeding and major bleeding 
did not differ significantly between the quintiles of % time below therapeutic range. However 
the 1st quintile [0.0%, 5.0%) and 5th quintile [33.8%, 100.0%] had lower odds of one year all-
cause mortality when compared to the 3rd quintile, OR’s: 0.84 (95% CI: 0.73, 0.97) and 0.86 
(95% CI: 0.74, 0.99) respectively. 
9.3.6.5 Mean INR 
Patients with mean INR in the 4th quintile [2.5, 2.7) and 5th quintile [2.7, 8.2) had higher odds of 
one year all-cause mortality OR: 1.34 (95% CI: 1.17, 1.54) and 2.27 (95% CI: 1.98, 2.60) 
respectively compared with patients in the 3rd quintile [2.4, 2.5). The odds of one year 
cardiovascular death, stroke or MI was also significantly higher in patients whose mean INR 
was in the 5th quintile. The odds of any bleeding and major bleeding did not differ significantly 
amongst the mean INR quintiles. 
9.3.6.6 INR standard deviation 
Increasing INR standard deviation was associated with higher odds of one year events. Patients 
in whose INR standard deviation was in the 1st quintile [0.000, 0.458) had lower odds of all-
cause mortality OR: 0.66 (95% CI: 0.56, 0.78) and cardiovascular death, stroke or MI OR: 0.74 
(95% CI: 0.60, 0.92) than patients in the 3rd quintile [0.584, 0.710). Patients with greatest 
variability during their INR spell, in the 5th quintile [0.922, 5.917], had increased odds of all-
cause mortality OR: 2.67 (95% CI: 2.34, 3.05), cardiovascular death, stroke or MI OR:  1.80 (95% 
CI: 1.51, 2.14), any bleeding OR: 1.32 (95% CI: 1.11, 1.57) and major bleeding OR: 1.59 (95% CI: 
1.19, 2.12). 
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9.3.6.7 Minimum INR 
There were no distinct trends between minimum INR values and one year outcomes. Patients 
whose minimum INR fell within the range of the 2nd quintile [1.11, 1.31) had increased odds of 
one year all-cause mortality, OR: 1.17 (95% CI: 1.02, 1.34) compared with those whose 
minimum INR was in the 3rd quintile [1.31, 1.51). Patients with minimum INR values in the 4th 
quintile [1.51, 1.71) and 5th quintile [1.71, 4.00] had reduced odds of one year all-cause 
mortality. There was no significant association between minimum INR values and 
cardiovascular death, stroke or MI or the bleeding outcomes. 
9.3.6.8 Maximum INR 
Increasing maximum INR values was associated with higher odds of one year outcomes. 
Patients whose INR exceeded 5.21 (i.e. 5th quintile) during their index INR spell had increased 
odds of one year all-cause mortality OR: 3.01 (95% CI: 2.63, 3.44), cardiovascular death, stroke 
or MI 2.15 (95% CI: 1.81, 2.57), any bleeding OR: 1.18 (95% CI: 1.00, 1.39) and major bleeding 
OR: 1.54 (95% CI: 1.17, 2.02) compared with patients whose maximum INR value was in the 3rd 
quintile [3.61, 4.22). Patients whose maximum INR value did not exceed 3.1 (1st quintile) had 
lower odds of one year all-cause mortality OR: 0.67 (95% CI: 0.57, 0.79), any bleeding OR: 0.84 
(95% CI: 0.70, 1.00) and major bleeding OR: 0.67 (95% CI: 0.48, 0.95) compared with patients 
whose maximum INR value was in the 3rd quintile. 
9.3.6.9 First INR 
The first INR measure in patients index INR spells showed no significant association with one 
year cardiovascular death, stroke or MI and the bleeding outcomes. However patients whose 
first INR was in the 5th quintile [2.91, 18.10] had increased odds of one year all-cause mortality 
OR: 1.24 (95% CI: 1.08, 1.43) compared with patients whose first INR was in the 3rd quintile 
[1.91, 2.31). 
9.3.6.10 Last INR 
The last INR measure in index INR spells appeared to have a U-shaped relationship with one 
year outcomes. Patients whose last INR value was in the 1st quintile [0.6, 2.0) (i.e. below range) 
had increased odds of one year all-cause mortality OR: 1.38 (95% CI: 1.18, 1.61) and 
cardiovascular death, stroke or MI, OR 1.22 (95% CI: 1.00, 1.49) compared with patients whose 
last INR was in the 3rd quintile [2.31, 2.51). Patients whose last INR value was in the 5th quintile 
[2.91, 19.20] (i.e. above range) had increased odds of all-cause mortality, OR: 2.83 (95% CI: 
2.43, 3.29), cardiovascular death, stroke or MI, OR: 1.89 (95% CI: 1.55, 2.31), any bleeding OR: 
1.58 (95% CI: 1.31, 1.91) and major bleeding OR: 2.34 (95% CI: 1.68, 3.26). 
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9.3.6.11 INR trajectory 
Patients with decreasing or downwards quadratic INR trajectory had lower odds of one year 
all-cause mortality OR: 0.79 (95% CI: 0.62, 0.99) and 0.67 (95% CI: 0.56, 0.81) respectively 
compared with patients who had a stable INR trajectory. Patients who had an increasing or 
upwards quadratic trajectory had higher odds of one year all-cause mortality OR: 1.33 (95% CI: 
1.15, 1.54) and 1.64 (95% CI: 1.39, 1.93) respectively. Upwards quadratic INR trajectories were 
also associated with increased odds of cardiovascular death, stroke or MI OR: 1.34 (95% CI: 
1.07, 1.69) and downwards quadratic INR trajectories were associated with lower odds of any 
bleeding, OR: 0.80 (95% CI: 0.65, 0.99) compared with stable trajectories. The odds of major 
bleeding did not differ significantly between the INR trajectory groups. 
9.3.7 The predictive value of measures of INR control 
The IDI (Figure 9.10) and NRI (Figure 9.11) estimates for measures of INR control 
demonstrated the additional predictive value compared with the base models. The breakdown 
of estimated IDI and NRI values by events and non-events are displayed in Supplementary 
appendix 11.5.3 for all-cause mortality, Supplementary appendix 11.5.4 for cardiovascular 
death, stroke or MI, Supplementary appendix 11.5.5 for any bleeding and Supplementary 
appendix 11.5.6 for major bleeding. 
9.3.7.1 All-cause mortality 
The inclusion of each of the measures of INR control resulted in a statistically significant 
improvement to the one year all-cause mortality model, according to both IDI and NRI metrics. 
The inclusion of maximum INR value and INR standard deviation into the all-cause mortality 
model gave the largest IDI estimates, 0.0375 (95% CI: 0.0337, 0.0413) and 0.0353 (95% CI: 
0.0317, 0.0388) respectively. For both of these measures their inclusion in the model increased 
the mean predicted probability for patients that died at one year by ≈0.03 and decreased the 
mean predicted probabilities for patients that did not die at one year by 0.005. Similarly, NRI 
estimates for maximum INR (0.48 (95% CI: 0.44, 0.52)) and INR standard deviation (0.46 (95% 
CI: 0.42, 0.50)) were the largest of the measures of INR control. With maximum INR included in 
the model there were net increases of 0.12 (95% CI: 0.08, 0.15) of the patients that died at one 
year who had a higher predicted probability and 0.36 (95% CI: 0.35, 0.38) of patients that were 
alive at one year had a lower predicted probability, compared with predicted probabilities 
from the base model. With INR standard deviation included in the model there were net 
increases of 0.15 (95% CI: 0.11, 0.18) of the patients that died at one year had a higher 
predicted probability and 0.31 (95% CI: 0.30, 0.33) of patients that were alive at one year had a 
lower predicted probability. Time in therapeutic range had modest predictive value, IDI: 
0.0159 (95% CI: 0.0137, 0.0181) and NRI: 0.30 (95% CI: 0.27, 0.34). Percent time below 
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therapeutic range, minimum INR, first INR and INR trajectory yielded the smallest IDI and NRI 
estimates.  
9.3.7.2 Cardiovascular death, stroke or MI 
All measures of INR control provided significant improvement to the cardiovascular death, 
stroke or MI model, except first percent time below therapeutic range according to the IDI 
estimate (0.0004 (95% CI: 0.0000, 0.0008)), first INR and INR trajectory according to the NRI 
estimates, 0.03 (95% CI: -0.02, 0.09) and 0.04 (95% CI: 0.00, 0.08), respectively. Maximum INR 
and INR standard deviation had the largest IDI, 0.0102 (95% CI: 0.0078, 0.0125) and 0.0093 
(95% CI: 0.0071, 0.0116) respectively. Both variables were associated with an increase in mean 
predicted probability of around 0.009 for patients who had cardiovascular death, stroke or MI 
at one year and a decrease in mean predicted probability of 0.0007 in patients who did not 
have an event. However, according to the NRI estimates both maximum INR and INR standard 
deviation increased misspecification of patients who had events but had large increases in 
correctly reclassifying patients who did not have an event. For example, with INR standard 
deviation included in the model, of patients that had an event there was a net decrease, -0.18 
(95% CI:-0.24, -0.13), of patients with higher predicted values compared with the base model. 
This was countered by a net increase of 0.41 (95% CI: 0.40, 0.42) of patients who did not have 
an event who had a decreased predicted value in the new model resulting in an overall NRI 
value of 0.23 (95% CI: 0.17, 0.28) for INR standard deviation. TTR group had a large net 
increase for events 0.52 (95% CI: 0.47, 0.56) countered by a large net decrease for non-events -
0.30 (95% CI: -0.31, -0.29). 
9.3.7.3 Any bleeding 
Of the measures of INR control, last INR had the best predictive value in the any bleeding 
model according to the IDI estimates. The mean predicted probability for those who had any 
bleeding at one year increased by 0.0020 and for those who did not experience any bleeding 
decreased by 0.0002, overall IDI: 0.0021 (95% CI: 0.0013, 0.0030). The next best measures of 
INR control by the IDI estimates were time in therapeutic range, 0.0009 (95% CI: 0.0003, 
0.0014), and INR standard deviation, 0.0008 (95% CI: 0.0003, 0.0014). The NRI estimates 
suggest INR standard deviation had the biggest impact on predictive value for any bleeding. 
While there was a net decrease of proportion of patients who had a bleeding event and a 
larger prediction in the INR standard deviation model compared with the base model, -0.07 
(95% CI: -0.12, -0.02), there was a net increase, 0.20 (95% CI: 0.19, 0.22), of proportion of 
patients who didn’t have a bleeding event and had lower predictions. Therefore the overall 
NRI estimate was 0.13 (95% CI: 0.08, 0.18). According to both IDI and NRI estimates, percent 
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time below therapeutic range, mean INR and minimum INR added no statistically significant 
predictive value to the base model.  
9.3.7.4 Major bleeding 
Both IDI and NRI estimates suggested that of the measures of INR control, last INR was the 
best addition to the major bleeding base model. With the inclusion of last INR in the base 
model patients that had major bleeding at one year had a 0.0031 increase in mean predicted 
probability and patients that did not have major bleeding at one year had a 0.0001 decrease in 
mean predicted probability, overall IDI: 0.0032 (95% CI: 0.0019, 0.0044). The NRI estimate for 
last INR suggested no significant net increase in the proportion of patients who had a major 
bleeding event and higher predictions, -0.03 (95% CI: -0.12, 0.06) but a net increase in the 
proportion of patients who did not have a major bleeding event and had lower predictions, 
0.28 (95% CI: 0.27, 0.29), therefore the overall NRI was 0.25 (95%CI: 0.16, 0.34). The predictive 
values of TTR group, time above therapeutic range and INR standard deviation for major 
bleeding were also reasonable. The IDI estimates suggested time in therapeutic range, time 
below therapeutic range, mean INR and minimum INR did not add any statistically significant 
predictive value to the base model, while NRI estimates suggested only time in therapeutic 
range and minimum INR added no predictive value. 
9.3.8 Comparison of predictions between models with different measures of INR control 
Figure 9.12 displays the individual model predictions compared between base models for all-
cause mortality and cardiovascular death, stroke or MI and their respective models adjusted 
for selected measures of INR control. The line through y=x represents no change in predicted 
probability between the base model and the models including measures of INR control. Points 
above the line represent increased predicted probabilities and points below the line represent 
decreased predicted probabilities from the base model to the new model. 
The predictions from models including measures of INR control with poorer predictive value - 
TBR for all-cause mortality and first INR for cardiovascular death, stroke or MI – did not differ 
greatly than those from the base models. For the all-cause mortality adjusted for INR standard 
deviation compared with the base model there were general increases in predicted probability 
for patients that had events and decreases in probability for patients that did not have events. 
The individual model predictions compared between base models for any bleeding and major 
bleeding and their respective models adjusted for selected measures of INR control are 
displayed in Supplementary appendix 11.5.7. 
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9.3.9 Model calibration 
There was evidence of miscalibration in the all-cause mortality base model; however 
calibration improved with the inclusion of measures of INR control, in particular INR standard 
deviation. The cardiovascular death, stroke or MI base model was well calibrated and 
calibration was further improved with the inclusion of maximum INR in the model. However 
calibration was slightly worsened when adjusting for TTR. 
The any bleeding models were well calibrated. However calibration appeared slightly worse in 
models adjusted with measures of INR control compared with the base model. The major 
bleeding models had good calibration and improved with the inclusion of measures on INR 
control.  
The calibration of the base models and a selection of models adjusted for measures of INR 
control are displayed in Supplementary appendix 11.5.8 (all-cause mortality and 
cardiovascular death, stroke or MI) and Supplementary appendix 11.5.9 (any bleeding and 
major bleeding). 
9.4 Discussion 
In the analysis of 18823 patients undergoing INR monitoring for oral anticoagulation, using 
linked electronic health records, I sought to estimate the associations between patient 
characteristics and INR stability and to assess the predictive value of various measures of INR 
control, some of which have not previously been investigated, for all-cause mortality, 
atherothrombotic and bleeding outcomes.  
9.4.1 Overall distribution of TTR and INR control and their predictors 
The majority of index INR spells in the study population were classed as erratic and over 20% 
were classed as stable. Under or over-anticoagulation for the entire duration of an INR spell 
was much less frequent. Prior heart valve replacement, although uncommon in the study 
population, was associated with higher INR variability. Smoking, as a modifiable factor was an 
important predictor of INR control. Patients who were recorded as smokers at the time of their 
index INR spell had higher variability compared with non-smokers, whilst ex-smokers did not 
differ significantly from non-smokers in INR variability. Major bleeding and chronic anaemia 
was associated with worse INR variability. A number of drugs were associated with lower INR 
variability when prescribed during the index INR spells however it is unlikely a causal 
relationship. Due to warfarin’s known interaction with other drugs, patients on concomitant 
medication may have been subject to more intense monitoring during anticoagulation.  
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Knowledge of the patient characteristics which may influence the maintenance of INR control 
and high INR variability can help target patients for closer monitoring during anticoagulation. 
9.4.2 Predictive value of measures of INR control for and bleeding and major bleeding 
As previous studies have shown TTR and INR variability are associated with increased odds 
bleeding events140-143,145 and shown their predictive value within a small anticoagulation clinic 
based cohort.144 I have demonstrated this in CALIBER data for two bleeding endpoints, any 
bleeding and major bleeding at one year following oral anticoagulation. I also identified 
increased odds of any bleeding and major bleeding events using simpler point estimates of INR 
spells: a maximum INR record greater than 5 and a final INR record greater than 2.9 i.e. outside 
of therapeutic range.  
Further to demonstrating the independent associations of measures of INR control with 
bleeding events I examined and quantified how model predictions may be improved with their 
inclusion. According to the NRI estimates, inclusion of measures of INR control such as TTR, 
INR standard deviation, maximum INR and last INR improved the predictions for patients that 
didn’t have events, whilst there were negligible changes to predictions for patients who had 
bleeding events. Identifying patients who are at low risk of bleeding is important and may 
prevent patients being removed from oral anticoagulation prematurely. Categorised TTR 
stability group was the only measure of INR control which improved predictions for patients 
that had any bleeding or major bleeding events. 
9.4.3 Predictive value of measures of INR control for atherothrombotic events and all-
cause mortality 
I found evidence of associations between all-cause mortality and cardiovascular death, stroke 
or MI and each of the investigated measures of INR control. Previous studies have shown 
associations between INR variability and TTR and risks of death and thrombotic events.140-143,145 
However no studies have investigated whether INR control provides predictive value to in 
addition to standard risk factors for atherothrombotic events. This was demonstrated in the 
analyses and furthermore I found a high initial INR value (>2.9 compared with 2.3-2.5) is 
associated with increased odds of all-cause mortality. The most novel summary measure, INR 
trajectory also had an association with all-cause mortality and atherothrombotic events.   
Further to estimating relative risks, I assessed and quantified how the measures of INR control 
improved predictions of all-cause mortality and cardiovascular death, stroke or MI. For all-
cause mortality, addition of INR standard deviation, maximum INR or time above range  to the 
base model improved predicted probabilities for both patients that did and didn’t have events. 
For cardiovascular death, stroke or MI the addition of INR standard deviation and maximum 
296 
 
INR improved predictions predominantly for those that did not have events and performed 
better than the standard measure of INR control, TTR. 
9.4.4 Electronic health record implications 
The use of electronic health records for research has become increasingly widespread. 
However such resources are often designed for administrative purposes and have to be 
adapted for use in research. It is important to generate useful and valid algorithms for defining 
diseases within electronic health records.38 In this study I have demonstrated a number of 
ways to harness INR data for analysis in the linked electronic health records. This can aid future 
studies of INR in electronic health records - in particular the development of risk prediction 
models for anticoagulated patients which utilise INR data tailored to the endpoints of interest.  
Within electronic health records calculating time in therapeutic range may be inaccurate due 
to patients prescribed therapeutic ranges not be specified in the data. Researchers can 
reasonably assume a therapeutic range depending on the indication for oral anticoagulation 
however in EHR it may be more appropriate to use measures of INR control that are not 
dependent on the unspecified time in therapeutic range, such as variability. 
9.4.5 Clinical implications 
Current guidelines suggest for atrial fibrillation patients with vitamin K antagonists advise 
maintaining a TTR above 65%.4,5 In this study I have found that alternative measures of INR 
control, such as INR variability, % time above range and maximum INR may be improved 
predictors of adverse events associated with oral anticoagulation. 
While it may seem time intensive for clinicians to assess a range of non-standard measures of 
INR control, algorithms could be implemented within primary care EHR systems to provide up-
to-date measures of INR control within electronic health records. This would provide clinicians 
with a more thorough overview of patients anticoagulation resulting in more effective 
monitoring during and post-anticoagulation. Examples of this may be flagging patients who 
have an INR record exceeding 5, have high INR variability, a final INR record outside of the 
therapeutic range, and overall TTR indicating whether out of range measures are primarily 
above or below range. 
9.4.6 Limitations 
This study had important limitations. Not all CPRD general practices electronically receive INR 
records from anticoagulation clinics, therefore the depth and quality of INR data in CALIBER 
may be lower compared with studies set in anticoagulation clinics. The precise indication for 
anticoagulation for the patients in the study population was unknown. As a result the 
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therapeutic range for patients was unknown and assumed to be 2-3 for all patients. This may 
have resulted in misspecification of some patients INR stability groups, TTR, TAR and TBR. Last 
INR was one of the stronger performing measures of INR control across the investigated 
endpoints. However there is potential that its effect may be biased due to reverse causality i.e. 
patients had an event and were subsequently discontinued from anticoagulation, a problem 
worsened by lag in updating electronic health records. I did not include a washout period 
between the end of anticoagulation and the start of follow-up. However <1% of patients had 
recorded events within 7 days of their last INR record. The use of NRI and IDI measures have 
been criticised for their potential to provide false positive results within incorrectly specified 
prediction models222,223 However in this study I aimed to demonstrate and compare the 
relative contribution to prediction models amongst a multiple measures of INR control as 
opposed to showing the absolute predictive value of a single measure. 
9.4.7 Further work 
Further avenues of research in this area that I propose includes assessing the predictive value 
of measures of INR control within relevant subgroups, such as diseases (e.g. atrial fibrillation 
and venous thromboembolism) and age groups. A previous study has shown the use of 
electronic health records to dynamically update patients predicted survival as blood pressure 
records were updated using joint modelling longitudinal and survival analysis. I demonstrated 
the trajectory of INR enhanced prediction of our endpoints. Therefore it may be appropriate to 
carry out such analysis with INR data, and develop models which dynamically assess patients 
risks of adverse events during anticoagulation. Genotypes (CYP2CP*3) have also been shown 
to be associated with increased bleeding risks in patients treated with warfarin224 and 
therefore an assessment of their predictive value in prognostic models would be of interest. 
9.5 Conclusion 
Where INR data is available it should be used for more accurate prognostic assessment of 
patients for bleeding, atherothrombotic and all-cause mortality risks. In particular INR 
variability and maximum INR improved the specificity of models, ensuring better 
discrimination of lower risk patients. Such measures would be can be implemented within 
electronic health records with simple algorithms to enable continuous monitoring and 
updating of patients risks. 
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9.6 Tables and Figures 
Figure 9.1: Examples of calculating time in therapeutic range, time above therapeutic range and time below therapeutic range 
 
 INR= international normalised ratio; TTR= Time in therapeutic range; TAR= time above therapeutic range; TBR= time below therapeutic range
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Figure 9.2: Examples of time in therapeutic range control groups 
 
INR= international normalised ratio; TTR= Time in therapeutic range   
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Figure 9.3: Examples of mean INR and INR variability (standard deviation) 
 
INR= international normalised ratio; SD= standard deviation   
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Figure 9.4: Examples of single INR values 
 
INR= international normalised ratio; TTR= Time in therapeutic range  
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Figure 9.5: Examples of INR trajectory groups 
 
INR= international normalised ratio; TTR= Time in therapeutic range   
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Figure 9.6: Study population flow diagram 
 
 
INR= international normalised ratio  
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Table 9.1: Study population baseline characteristics by TTR control group 
 
Erratic  
 
(n=11677) 
Over- 
anticoagulated 
(n=855) 
Stable  
 
(n=4123) 
Under-
anticoagulated 
(n=2168) 
Demographics and behaviours     
Age (Years) 70.1 (13.2) 68.7 (13.4) 71.2 (11.3) 66.0 (16.0) 
Women 5432 (46.5) 359 (42.0) 1743 (42.3) 1005 (46.4) 
Highest quintile of deprivation 2358 (20.2) 177 (20.7) 738 (17.9) 469 (21.6) 
Excess alcohol 1661 (14.2) 111 (13.0) 482 (11.7) 262 (12.1) 
Missing % 0.3 0.2 0.2 0.2 
Smoking status  Non-Smoker 4835 (41.4) 376 (44.0) 1951 (47.3) 985 (45.4) 
Ex-Smoker 4469 (38.3) 321 (37.5) 1550 (37.6) 746 (34.4) 
Smoker 1105 (9.5) 61 (7.1) 282 (6.8) 232 (10.7) 
Missing % 10.9 11.3 8.2 9.5 
Index INR spell characteristics and 
oral anticoagulation 
    
Number of INR readings in index 
spell 
35.2 (35.65) 13.5 (16.02) 23.5 (23.66) 10.1 (5.68) 
Median (IQR) 22 (12, 44) 8 (6, 14) 15 (8, 29) 9 (6, 12) 
Duration of index INR spell (days) 673 (722) 298 (394) 651 (670) 160 (154) 
Median (IQR) 399 (168.0, 936) 154 (82.5, 344) 425 (174.0, 896) 120 (70.0, 184) 
VKA exposure prior to INR spell 
(days) 
232 (506) 477 (773) 338 (612) 122 (349) 
Median (IQR) 28 (0, 152) 56 (28, 626) 28 (28, 364) 28 (0,  28) 
VKA exposure during INR spell 
(days) 
550 (618) 239 (344) 543 (592) 131 (139) 
Median (IQR) 310 (127, 755) 118 (55, 288) 338 (139, 736) 92 (49, 163) 
Time in therapeutic range (%) 57.3 (16.87) 49.6 (22.88) 88.3 (5.96) 49.0 (22.98) 
Median (IQR) 60.9 (47.3, 70.6) 55.4 (31.2, 69.5) 87.1 (83.2, 92.4) 54.5 (33.2, 67.9) 
Medical history     
Atrial Fibrillation 6755 (57.8) 387 (45.3) 2658 (64.5) 962 (44.4) 
Myocardial infarction 1066 (9.1) 88 (10.3) 339 (8.2) 153 (7.1) 
Heart failure 2248 (19.3) 164 (19.2) 656 (15.9) 262 (12.1) 
Heart valve replacement 511 (4.4) 128 (15.0) 77 (1.9) 36 (1.7) 
Unstable angina 584 (5) 40 (4.7) 157 (3.8) 76 (3.5) 
Ischaemic or unspecified stroke 1010 (8.6) 64 (7.5) 405 (9.8) 173 (8) 
Peripheral arterial disease 868 (7.4) 73 (8.5) 227 (5.5) 125 (5.8) 
Venous thromboembolism 3741 (32) 321 (37.5) 1169 (28.4) 944 (43.5) 
Any bleeding 3145 (26.9) 240 (28.1) 1059 (25.7) 549 (25.3) 
Major bleeding 207 (1.8) 17 (2) 45 (1.1) 38 (1.8) 
Chronic anaemia 1441 (12.3) 125 (14.6) 420 (10.2) 222 (10.2) 
Diabetes  Unspecified 90 (0.8) 5 (0.6) 23 (0.6) 10 (0.5) 
Type 1 70 (0.6) 5 (0.6) 11 (0.3) 10 (0.5) 
Type 2 1372 (11.7) 87 (10.2) 422 (10.2) 225 (10.4) 
Cancer 2246 (19.2) 137 (16) 650 (15.8) 374 (17.3) 
Chronic obstructive pulmonary 
disease 
1175 (10.1) 66 (7.7) 251 (6.1) 158 (7.3) 
Renal disease 1521 (13) 113 (13.2) 505 (12.2) 230 (10.6) 
Clinical biomarkers     
Body mass index 28.9 (6.26) 29.4 (6.53) 29.2 (5.88) 29.0 (6.68) 
Missing % 61.9 64.9 60.6 63.6 
Systolic blood pressure (mmHg) 136 (19.2) 135 (18.4) 136 (17.9) 135 (18.5) 
305 
 
 
Erratic  
 
(n=11677) 
Over- 
anticoagulated 
(n=855) 
Stable  
 
(n=4123) 
Under-
anticoagulated 
(n=2168) 
Missing % 18.7 23.2 17.2 23.9 
Diastolic blood pressure (mmHg) 78.9 (11.0) 78.3 (11.1) 79.5 (10.4) 79.0 (10.5) 
Missing % 18.7 23.2 17.2 23.9 
Heart rate (bpm) 81.1 (19.5) 78.1 (18.4) 80.5 (19.2) 80.3 (18.0) 
Missing % 83.4 84 81.8 86.3 
Haemoglobin (g/dL) 13.6 (1.78) 13.4 (1.88) 14.0 (1.57) 13.6 (1.80) 
Missing % 43.7 49.7 45.5 47.3 
Total white blood cell count (109/L) 7.65 (2.77) 7.75 (2.66) 7.38 (2.27) 7.65 (2.66) 
Missing % 45.8 51 47.3 49 
Platelets (109/L) 261 (93.3) 267 (97.4) 248 (83.3) 268 (96.4) 
Missing % 45.9 51.2 47.5 49.2 
Creatinine (mmol) 101.1 (36.4) 103.5 (40.5) 99.9 (26.2) 97.7 (35.1) 
Median (IQR) 95 (82, 111) 98 (83, 114) 96 (84, 111) 93 (79, 107) 
Missing % 34.4 41.8 33.4 41.5 
Hba1c (mmol/mol) 56.8 (16.9) 52.8 (13.7) 54.2 (13.7) 57.2 (17.5) 
Missing % 88.5 89.2 89.6 90.4 
High-density lipoproteins (mmol) 1.40 (0.442) 1.35 (0.390) 1.38 (0.421) 1.39 (0.427) 
Missing % 67.7 67.7 63.9 69.6 
Total cholesterol (mmol) 4.82 (1.16) 4.83 (1.16) 4.78 (1.12) 4.87 (1.25) 
Missing % 53.6 56.5 50 59.2 
Prescribed medication pre- and 
during INR spell 
    
Thiazides pre 4375 (37.5) 290 (33.9) 1578 (38.3) 681 (31.4) 
during 2139 (18.3) 127 (14.9) 869 (21.1) 264 (12.2) 
K-sparing diuretics and 
aldosterone antagonists 
pre 1644 (14.1) 132 (15.4) 489 (11.9) 219 (10.1) 
during 1536 (13.2) 81 (9.5) 375 (9.1) 116 (5.4) 
K-sparing diuretics with 
other diuretics 
pre 1361 (11.7) 106 (12.4) 405 (9.8) 191 (8.8) 
during 536 (4.6) 32 (3.7) 154 (3.7) 39 (1.8) 
Loop diuretics pre 4447 (38.1) 324 (37.9) 1303 (31.6) 563 (26.0) 
during 4675 (40.0) 261 (30.5) 1254 (30.4) 459 (21.2) 
Beta blockers pre 5657 (48.4) 408 (47.7) 2156 (52.3) 873 (40.3) 
during 4658 (39.9) 263 (30.8) 1730 (42) 592 (27.3) 
Hypertension and heart 
failure drugs 
pre 7147 (61.2) 517 (60.5) 2492 (60.4) 1211 (55.9) 
during 6420 (55) 398 (46.5) 2290 (55.5) 802 (37) 
Ace inhibitors pre 6428 (55) 457 (53.5) 2172 (52.7) 1079 (49.8) 
during 5012 (42.9) 302 (35.3) 1669 (40.5) 588 (27.1) 
Angiotensin receptor 
blockers 
pre 1446 (12.4) 103 (12) 591 (14.3) 222 (10.2) 
during 1596 (13.7) 86 (10.1) 618 (15) 164 (7.6) 
Calcium channel 
blockers 
pre 4121 (35.3) 282 (33) 1458 (35.4) 651 (30) 
during 2992 (25.6) 160 (18.7) 1141 (27.7) 377 (17.4) 
Antiplatelets pre 5552 (47.5) 333 (38.9) 1944 (47.2) 831 (38.3) 
during 1560 (13.4) 68 (8) 451 (10.9) 263 (12.1) 
Statins pre 4325 (37) 336 (39.3) 1603 (38.9) 703 (32.4) 
during 4940 (42.3) 333 (38.9) 1787 (43.3) 589 (27.2) 
Insulin pre 730 (6.3) 58 (6.8) 202 (4.9) 133 (6.1) 
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Erratic  
 
(n=11677) 
Over- 
anticoagulated 
(n=855) 
Stable  
 
(n=4123) 
Under-
anticoagulated 
(n=2168) 
during 768 (6.6) 39 (4.6) 186 (4.5) 87 (4) 
Anti-diabetics pre 1053 (9) 69 (8.1) 289 (7) 177 (8.2) 
during 1144 (9.8) 58 (6.8) 333 (8.1) 152 (7) 
Nonsteroidal anti-
inflammatory drugs 
pre 7831 (67.1) 548 (64.1) 2727 (66.1) 1454 (67.1) 
during 1174 (10.1) 42 (4.9) 283 (6.9) 104 (4.8) 
Antidepressants pre 3752 (32.1) 244 (28.5) 1047 (25.4) 707 (32.6) 
during 2355 (20.2) 123 (14.4) 507 (12.3) 282 (13) 
Digoxin pre 3307 (28.3) 194 (22.7) 1341 (32.5) 387 (17.9) 
during 3735 (32) 179 (20.9) 1361 (33) 365 (16.8) 
Amiodarone pre 1089 (9.3) 94 (11) 345 (8.4) 137 (6.3) 
during 277 (10.9) 74 (8.7) 239 (5.8) 110 (5.1) 
 
Mean (standard deviation) for continuous variables and n (%) for categorical variables unless otherwise 
stated; INR= international normalised ratio 
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Table 9.2: Quintiles of measures of INR control  
Measure of INR control Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Time in therapeutic 
range (%) 
[0.0, 45.4) [45.4, 60.5) [60.5, 70.9) [70.9, 81.0) [81.0, 100.0] 
Time above therapeutic 
range (%) 
[0.0, 1.5) [1.5, 8.5) [8.5, 14.9) [14.9, 25.4) [25.4, 100.0] 
Time below therapeutic 
range (%) 
[0.0, 5.0) [5.0, 12.5) [12.5, 20.6) [20.6, 33.8) [33.8, 100.0] 
Mean INR [0.9, 2.2) [2.2, 2.4) [2.4, 2.5) [2.5, 2.7) [2.7, 8.2] 
INR standard deviation [0.00, 0.46) [0.46, 0.58) [0.58, 0.71) [0.71, 0.92) [0.92, 5.92] 
Minimum INR [0.0, 1.1) [1.1, 1.3) [1.3, 1.5) [1.5, 1.7) [1.7, 4.0) 
Maximum INR [0.9, 3.1) [3.1, 3.6) [3.6, 4.2) [4.2, 5.2) [5.2, 20.0) 
First INR [0.6, 1.4) [1.4, 1.9) [1.9, 2.3) [2.3, 2.9) [2.9, 18.1) 
Last INR [0.9, 2.0) [2.0, 2.3) [2.3, 2.5) [2.5, 2.9) [2.9, 19.2) 
 
INR= International normalised ratio
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Figure 9.7: Association between baseline characteristics and INR standard deviation 
 
OAC= oral anticoagulant; HDL= high-density lipoproteins; pre= drugs at least one prescription at any time prior to index INR spell; during= drugs prescribed during: index INR spell
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Figure 9.8: Association between measures of INR control and one year all-cause mortality (2686 events) and 
cardiovascular death, stroke or myocardial infarction (1304 events) 
  
INR= international normalised ratio; TTR= time in therapeutic range; MI= myocardial infarction; OR= 
odds ratio; CI= confidence interval  
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Figure 9.9: Association between measures of INR control with any bleeding (1446 events) and major bleeding 
(478 events) 
  
INR= international normalised ratio; TTR= time in therapeutic range; OR= odds ratio; CI= confidence 
interval 
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Figure 9.10: Integrated discrimination improvement with the inclusion of measures of INR control in models for 1 year all-cause mortality, cardiovascular death, stroke or MI, any bleeding and 
major bleeding events 
 
INR= international normalised ratio; TTR= time in therapeutic range; SD= standard deviation; IDI= integration discrimination improvement; CI= confidence interval; MI= myocardial 
infarction 
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Figure 9.11: Net reclassification improvement with the inclusion of measures of INR control in models for 1 year all-cause mortality, cardiovascular death, stroke or MI, any bleeding and major 
bleeding events 
 
INR= international normalised ratio; TTR= time in therapeutic range; SD= standard deviation; NRI= net reclassification improvement; CI= confidence interval; MI= myocardial 
infarction 
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Figure 9.12: Predicted all-cause mortality and cardiovascular death, stroke or MI; comparing base models with models including measures of INR control 
  
TBR= time below therapeutic range; NRI= net reclassification improvement; IDI= integrated discrimination improvement; TTR= time in therapeutic range; SD= standard deviation; CV= cardiovascular; 
MI= myocardial infarction;  
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10 Conclusion 
10.1 Thesis overview 
In my thesis, using routinely collected linked electronic health records (EHR) in England, I 
performed analyses that address the gaps in our current understanding of the benefits and 
harms associated with antithrombotic therapies with a focus on approaches to personalise 
treatment strategies. 
I undertook a review on the current literature to identify relevant areas of research relating to 
antithrombotic therapies, summarising the various study designs and populations, therapeutic 
intervention, exposures, primary and secondary outcomes, analytical methods, conclusion and 
implications.   
I provided an overview of the CALIBER linked electronic health records platform and each of 
the data sources linked data sources: primary care data from CPRD, hospital admissions from 
HES, myocardial infarction disease registry data from MINAP and cause-specific mortality data 
from ONS.  I described accessing the data through applying and gaining study approval from 
the Independent Science Advisory Committee (ISAC) and the methods employed to curate the 
routinely collected patient information into research ready datasets. 
10.2 Summary of key findings and impact  
10.2.1 Chapter 4: Antithrombotic drug use and inferring drug indications 
In Chapter 4 my aims were (1) to investigate the prevalence of antithrombotic therapy 
prescribing in CALIBER; (2) to determine how many of patient’s first antithrombotic 
prescription had an indication recorded within a reasonable timeframe. 
Through cross-referencing 20 cardiovascular and non-cardiovascular indications for prescribing 
antithrombotic therapies, against the first antithrombotic therapy prescription for 277,598 
patients I was able to infer an indication for 45.7%, using clinical diagnosis codes recorded 
within the time frame of 180 days prior to, to 30 days following the prescription. To my 
knowledge, this was the first study of its kind for antithrombotic drugs with a more 
comprehensive search of indications for prescriptions through the use of linked EHR compared 
with using a single data source. My findings can inform monitoring of antithrombotic drug use, 
the patients issued prescriptions and for what reason. This is important due to the potentially 
serious bleeding side effects associated with antithrombotic drugs. 
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10.2.2 Chapter 5: Developing bleeding phenotypes in CALIBER 
My objectives in this chapter were (1) to determine the extent  that population-based EHRs 
can replicate the definitions of bleeding used in trials; (2) to determine if bleeding severity can 
be defined using bleeding diagnosis codes and other supporting information available within 
EHR.  
I presented and applied methodology to develop phenotyping algorithms in EHR which define 
bleeding events and determine which available data were useful and usable markers of 
bleeding severity. The identified markers of bleeding severity were bleeding anatomical site 
(intracranial or ruptured abdominal aortic aneurysm), hospitalisation, duration of 
hospitalisation, transfusion and number of bleeding records on a single date. Amongst patients 
with no bleeding diagnosis in primary care or hospital records, I inferred a small number of 
bleeding cases using transfusion, iron deficiency anaemia, haemoglobin and endoscopy 
records. Of the bleeding events identified within the study population only 13.2% were 
identified in more than one of primary care, hospital records and death registry records, 
highlighting the importance of using linked electronic health records to improve case 
ascertainment.  
The bleeding phenotyping algorithms offer a scalable approach to the analysis of harms of 
antithrombotic therapies using EHR. The algorithms could potentially be integrated within EHR 
systems used by general practitioners and clinicians to aid monitoring of bleeding in the 
general population.  
10.2.3 Chapter 6: Incidence and prognosis of bleeding events in four common 
cardiovascular diseases 
The objectives of this chapter were (1) to estimate the incidence of major bleeding and any 
bleeding across patients with atrial fibrillation, acute myocardial infarction, unstable and stable 
angina who are on different antiplatelet and anticoagulation regimens;  (2) to assess time 
trends in bleeding incidence along with the changes in antithrombotic management (3) to 
evaluate the association between bleeding severity and long term prognosis in terms of all-
cause mortality, atherothrombotic events and recurrent bleeding. 
Applying the bleeding phenotypes developed in chapter 5 I found that amongst 128815 
patients, 27259 (21.2%) had at least one bleeding event, with 5 year risks of bleeding of 29.1%, 
21.9%, 25.3% and 23.4% following diagnoses of atrial fibrillation, acute myocardial infarction, 
unstable angina and stable angina respectively. Incidence of bleeding doubled between 1998 
and 2010. Patients with hospitalised bleeding and primary care bleeding, with or without 
markers of severity, were at increased risk of all-cause mortality and atherothrombotic events 
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compared to those with no bleeding. Patients with bleeding diagnosed in primary care 
presenting with markers of bleeding severity had doubled risk of all-cause mortality compared 
with patients with no bleeding record. The prognosis was worse for patients with bleeding 
diagnosed in hospital care. This study demonstrated that bleeding is a commonly occurring 
public health problem among atrial fibrillation and coronary disease patients. It is associated 
with high mortality. Closer monitoring of individual patient bleeding risks using prognostic 
models may contribute to the prevention of avoidable harms associated with antithrombotic 
therapies. 
10.2.4 Chapter 7: Development and validation of prognostic models for atherothrombotic 
events and bleeding in stable myocardial infarction survivors 
The objectives of the chapter were to (1) develop and validate prognostic models for 
atherothrombotic and bleeding risks using a cohort of patients who were atherothrombotic 
event-free one year following a MI and (2) demonstrate how these models may be used to aid 
treatment decisions. 
Using population-based electronic health records (EHRs) for patients evaluated 1 year after 
acute myocardial infarction (MI), I developed (n = 12694 patients) and validated (n = 5613) 
prognostic models for cardiovascular (cardiovascular death, MI or stroke) events and three 
different bleeding endpoints. I applied trial effect estimates to determine potential benefits 
and harms of dual antiplatelet therapy (DAPT) and the net clinical benefit of individuals. 
Prognostic models for cardiovascular events (c-index: 0.75 (95% CI: 0.74, 0.77)) and bleeding (c 
index 0.72 (95% CI: 0.67, 0.77)) were well calibrated. 3-year risk of cardiovascular events was 
5.2% in the lowest and 46.7% in the highest-risk individuals, while for major bleeding, it was 
0.3% in the lowest and 5.4% in the highest-risk patients. For every 10000 patients treated per 
year, we estimated 249 (95% CI: 228, 269) cardiovascular events prevented and 134 (95% CI: 
87, 181) major bleeding events caused in the highest-risk patients, and 28 (95% CI: 19, 37) 
cardiovascular events prevented and 9 (95% CI: 0, 20) major bleeding events caused in the 
lowest-risk patients. There was a net clinical benefit of prolonged DAPT in 63–99% patients 
depending on how benefits and harms were weighted. 
Given patients baseline characteristics change over the one year following an acute MI, the 
developed and validated prognostic models may help to personalise decisions for prolonged 
DAPT 1-year following acute MI using up to date information. Web calculators and web tools 
integrated within EHR systems used by clinicians can easily compute the estimated risks based 
on individual patient profiles. 
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10.2.5 Chapter 8: Predictors and outcomes of INR time in therapeutic range 
The objectives of this chapter were (1) to describe the international normalised ratio (INR) and 
time in therapeutic range (TTR) data available within CALIBER within 4 distinct populations 
indicated for oral anticoagulation with vitamin K antagonist (VKA) therapy (atrial fibrillation, 
venous thromboembolism, heart valve replacement or other indication); (2) to assess patient 
baseline characteristics associated with time in therapeutic range in our study population and 
whether they agree with the conclusions made in previous literature; (3) to assess the strength 
of the SAME-TT2R2 score for predicting TTR in our population; (4) to assess all-cause mortality, 
atherothrombotic and bleeding outcomes following  oral anticoagulation with TTR below the 
recommended levels. 
I found that the average TTR was 62.8% across the study population. The highest mean TTR 
was observed in atrial fibrillation patients, who on average spent two thirds of their INR 
monitoring time within therapeutic range. Similar to previous literature, demographic factors 
of age >40 years, men, white, and a lower deprivation were associated with higher TTR. I found 
that SAME-TT2R did not perform well to predict patients TTR in my data, as the simple point-
based scheme and weighting of predictors in SAME-TT2R2 may not be sufficient to detect small 
changes in TTR.  
My study observed that for patients who maintained a TTR of 65% or greater had improved 
long term prognosis and reduced bleeding risk. This was true not only for atrial fibrillation 
patients, but also for patients with venous thromboembolism, heart valve replacements and 
other indications for oral anticoagulation. In the absence of guidelines recommended targets 
for TTR amongst the non-atrial fibrillation patient groups, the study results supports 
maintaining oral anticoagulation treatment control as measured by TTR above 65%.  
10.2.6 Chapter 9: The predictive value of measures of INR control for atherothrombotic and 
bleeding outcomes 
The objectives in this chapter were (1) To illustrate overall distribution of INR control within 
our cohort; (2) To estimate predictors of INR variability and (3) To estimate the predictive 
value of a range of measures of INR control for atherothrombotic and bleeding events; Is TTR 
the best measure and do measures of INR control work well for predicting both bleeding and 
atherothrombotic endpoints and add value to standard risk factors? 
In my analysis of 18823 patients undergoing INR monitoring during oral anticoagulation, I 
investigated the INR control measures of time in therapeutic range (%), time above 
therapeutic range (%), time below therapeutic range (%), mean INR, INR variability, minimum 
INR, maximum INR, first INR, last INR. 
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The majority of index INR spells in our study population were classed as erratic and over 20% 
were classed as having stable INR control. Lower TTR and higher INR variability were 
associated with increased odds of bleeding and major bleeding defined by the algorithm 
developed in chapter 5. We found evidence of associations between all-cause mortality and 
cardiovascular death, stroke or MI and each of the investigated measures of INR control. 
Where INR data is available it should be used for more accurate prognostic assessment of 
patients for bleeding, atherothrombotic and all-cause mortality risks. In particular INR 
variability and maximum INR improved the specificity of models, ensuring better 
discrimination of lower risk patients. Such measures would be can be implemented within 
electronic health records with simple algorithms to enable continuous monitoring and 
updating of patients risks. 
10.3 Limitations 
Further to the limitations identified within each chapter there were broad limitations 
encountered within this thesis. The version of CALIBER used in this thesis covers records from 
1997 to 2010, which may be considered out of date, especially for research in medical areas 
with ever-changing guidelines and recommended treatments. 
The studies are observational in design, and are subject to bias, such as misclassification of 
exposures, information bias or confounding that failed to be accounted in the analysis. Missing 
data is an issue for observational cohorts; in particular for electronic health records it is 
difficult to know what the missingness mechanism of data may be therefore not all methods 
for handling missing data may be appropriate.  
Aspirin prescribing and therefore antithrombotic prescribing will have been underestimated in 
our data, due to the fact that aspirin may be bought over the counter.  
10.4 Overall impact 
The thesis addressed the many considerations regarding the prescribing and use of 
antithrombotic therapies in clinical practice, using real-world population based linked 
electronic health records. The bleeding phenotypes are scalable and may be used by 
researchers in future electronic health record studies. The prognostic models developed may 
be used in clinical practice to aid refinement of long-term treatment decisions for myocardial 
infarction survivors. I have highlighted the prognostic importance of measures of INR control 
and recommend their use in models for cardiovascular events and bleeding where the data is 
available. 
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Beyond the theme of antithrombotic therapy, this thesis demonstrates a framework on how 
population-based linked electronic health records may be harnessed to study a widely used 
class of medication, procedures or interventions, develop definitions for related clinical events, 
and investigate ways to personalise and optimise treatment strategies through increasing 
benefits and reducing harms in the relevant populations.  
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11 Supplementary appendix 
This chapter contains the supplementary material for chapters 3, 5 and 7. 
11.1 Supplementary Appendix (Chapter 3) 
11.1.1 CALIBER data dictionary 
CPRD patient and general practice data fields: 
patid: Encrypted CPRD patient identifier 
pracid: unique CPRD general practice identifier 
prac_region: the UK region in which the general practice is situated 
prac_lcd: date of last data collection from general practice 
prac_uts: date at which general practice data considered to be of up-to-standard 
research quality 
gender: patient gender 
dob: patient date of birth 
frd: patients date of first registration with the general practice 
crd: patients date of current registration with the general practice 
tod: date of transfer out of CPRD general practice 
toreason: patient transfer out reason 
deathdate: patient date of death 
date_entry: the date which is the latest of crd, prac_uts 
date_exit: the date which is the earliest of tod, deathdate, prac_lcd 
ethnicity: patient ethnicity 
CPRD diagnosis data fields: 
patid: Encrypted CPRD patient identifier 
eventdate: date of record 
medcode: CPRD unique diagnosis code 
CPRD prescription data fields: 
patid: Encrypted CPRD patient identifier 
eventdate: date of record 
consid: The identifier for the consultation, used in combination with pracid  
prodcode: CPRD unique product code 
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staffid: The identifier for the staff at the general practice who input the data 
textid: The identifier for freetext information regarding the prescription, if available 
bnfcode: code referring to the BNF chapter and section 
qty: The quantity of the product prescribed 
ndd: The numeric daily dose prescribed 
numdays: Length of prescription/ therapy (days) 
numpacks: The number of product packs prescribed 
packtype: The size or type of pack 
issueseq: The sequence number for repeat prescriptions 
CPRD clinical biomarkers data fields: 
patid: Encrypted CPRD patient identifier 
eventdate: date of record 
data1: depending on data type – usually biomarker measurement 
data2: depending on data type – usually biomarker measurement units 
HES admission data fields: 
patid: Encrypted CPRD patient identifier  
date_admission: date of hospital admission 
date_discharged: date of hospital discharge  
icd: ICD10 code for the hospital admission 
epi_primary: Indicates if the ICD-10 code is the primary diagnosis in the episode 
hosp_primary: Indicates if the ICD-10 code is the primary diagnosis in the 
hospitalisation  
HES procedure data fields: 
patid: Encrypted CPRD patient identifier 
date_admission: date of hospital admission 
date_procedure: date of procedure 
date_discharged: date of hospital discharge 
opcs: OPCS-4 code for the procedure 
ONS mortality data fields: 
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patid: Encrypted CPRD patient identifier 
dod: date of death 
cod: ICD-10 code recorded as the underlying cause of death 
cod1-cod15: ICD-10 codes for up to 15 secondary causes of death 
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11.1.2 My ISAC application for the prognostic modelling study 
 
ISAC APPLICATION FORM 
PROTOCOLS FOR RESEARCH USING THE CLINICAL PRACTICE RESEARCH DATALINK (CPRD) 
 
ISAC use only: 
Protocol Number 
Date submitted 
 
............................. 
............................. 
IMPORTANT 
If you have any queries, please contact ISAC 
Secretariat  
 
1. Study Title  
Prognostic models for risk of serious atherothrombotic and bleeding events and death in 
patients who survived after myocardial infarction 
2. Principal Investigator (full name, job title, organisation & e-mail address for correspondence 
regarding this protocol) 
3. Affiliation (full address) 
4. Protocol’s Author (if different from the principal investigator) 
5. List of all investigators/collaborators (please list the names, affiliations and e-mail addresses* of all 
collaborators, other than the principal investigator) 
 
*Please note that your ISAC application form and protocol must be copied to all e-mail addresses listed above at 
the time of submission of your application to the ISAC mailbox. Failure to do so will result in delays in the processing 
of your application. 
 
6. Type of Institution (please tick one box below) 
 
Academia  Research Service Provider  Pharmaceutical Industry  
NHS  Government Departments  Others    
 
7. Financial Sponsor of study 
Pharmaceutical Industry (please specify)   AstraZeneca Academia(please specify)  
      
Government / NHS (please specify)          None    
Other (please specify)           
 
8. Data source  (please tick one box below)      
 
Sponsor has on-line access   Purchase of ad hoc dataset   
Commissioned study    
Other      (please specify)        
 
9. Has this protocol been peer reviewed by another Committee? 
Yes*    No   
* Please state in your protocol the name of the reviewing Committee(s) and provide an outline of the 
review process and outcome. 
 
10. Type of Study (please tick all the relevant boxes which apply) 
Adverse Drug Reaction/Drug Safety  Drug Use   Disease Epidemiology
  
Drug Effectiveness   Pharmacoeconomic          Other 
Prognostic modelling 
 
11. This study is intended for: 
Publication in peer reviewed journals   Presentation at scientific conference 
  
Presentation at company/institutional meetings  Other    
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12. Does this protocol also seek access to data held under the CPRD Data Linkage Scheme? 
 
Yes    No   
 
 
13. If you are seeking access to data held under the CPRD Data Linkage Scheme*, please 
select the source(s) of linked data being requested. 
 
 Hospital Episode Statistics                Cancer Registry Data**               
 MINAP                                              ONS Mortality Data    
 Index of Multiple Deprivation/ Townsend Score  
 Mother Baby Link                  Other: (please specify)   
 
* As part of the ISAC review of linkages, the protocol may be shared - in confidence - with a 
representative of the requested linked data set(s) and summary details may be shared - in 
confidence - with the Confidentiality Advisory Group of the Health Research Authority.   
 
**Please note that applicants seeking access to cancer registry data must provide consent for 
publication of their study title and study institution on the UK Cancer Registry website. Please 
contact the CPRD Research Team to discuss this requirement further. 
 
 
14. If you are seeking access to data held under the CPRD Data Linkage Scheme, have you 
already discussed your request with a member of the Research team?  
 
Yes    No*   
 
*Please contact the CPRD Research Team to discuss your requirements before submitting your 
application. 
 
Please list below the name of the person/s at the CPRD with whom you have discussed your 
request. 
  
15. If you are seeking access to data held under the CPRD Data Linkage Scheme, please 
provide the following information: 
 
The number of linked datasets requested: 4 
 
A synopsis of the purpose(s) for which the linkages are required:  
The study requires description of patient characteristics, medication use, anthropometric 
measurements and laboratory tests included in CPRD.      
Further, the study requires details of hospital admissions, length of stay and reason for 
admission provided by HES.  
Finally, it requires cause-specific mortality from ONS to assess fatalities and causes of death. 
 
Is linkage to a local dataset with <1 million patients being requested?  
 
Yes*  No  
 
* If yes, please provide further details: 
            
            
 
16. If you have requested linked data sets, please indicate whether the Principal Investigator 
or any of the collaborators listed in response to question 5 above, have access to any of 
the linked datasets in a patient identifiable form, or associated with a patient index.  
 
Yes*    No   
 
* If yes, please provide further details: 
           
           
 
17. Does this protocol involve requesting any additional information from GPs?  
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Yes*   No   
 
 * Please indicate what will be required:  
Completion of questionnaires by the GP    Yes      No   
Provision of anonymised records (e.g.  hospital discharge summaries)  Yes      No   
Other (please describe)       
 
 Any questionnaire for completion by GPs or other health care professional must be approved 
by ISAC before circulation for completion.   
18. Does this protocol describe a purely observational study using CPRD data (this may include 
the review of anonymised free text)? 
 
Yes*   No**   
 
 * Yes: If you will be using data obtained from the CPRD Group, this study does not require 
separate ethics approval from an NHS Research Ethics Committee. 
** No: You may need to seek separate ethics approval from an NHS Research Ethics 
Committee for this study. The ISAC will provide advice on whether this may be needed. 
 
19. Does this study involve linking to patient identifiable data from other sources? 
 
Yes    No   
 
20. Does this study require contact with patients in order for them to complete a 
questionnaire? 
 
Yes    No   
 
N.B. Any questionnaire for completion by patients must be approved by ISAC before circulation 
for completion.   
21. Does this study require contact with patients in order to collect a sample? 
 
Yes*   No   
 
* Please state what will be collected         
 
22. Experience/expertise available  
 
Please complete the following questions to indicate the experience/expertise available within 
the team of researchers actively involved in the proposed research, including  analysis of data 
and interpretation of results 
 Previous GPRD/CPRD Studies  Publications using GPRD/CPRD data 
 
None      
1-3       
> 3       
 
Is statistical expertise available within the research team?   Yes      No    
                
Is statistical expertise available within the research team?  Yes      No  
 
                           If yes, please outline level of experience  
 
      
   
Is experience of handling large data sets (>1 million records)  
available within the research team?     Yes      No  
                            If yes, please outline level of experience         
The team at UCL has used the CALIBER dataset previously demonstrating their experience of 
handling large datasets.  
 
Is UK primary care experience available within the research team?  Yes      No  
                                                       If yes, please outline level of experience 
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The researchers in the team have conducted many research projects in UK primary care and 
using linked electronic health records through CALIBER (dataset linking CPRD, HES, MINAP 
and ONS data). 
 
23.  References relating to your study 
 
Please list up to 3 references (most relevant) relating to your proposed study. 
 
           
1. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, et al. A Risk 
Score to Predict Bleeding in Patients With Acute Coronary Syndromes. Journal of the American 
College of Cardiology. 2010;55(23):2556-66. 
2. Ducrocq G, Wallace JS, Baron G, Ravaud P, Alberts MJ, Wilson PWF, et al. Risk score 
to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. European 
heart journal. 2010;31(10):1257-65. 
3. Rapsomaniki E, Shah A, Perel P, Denaxas S, George J, Nicholas O, et al. Prognostic 
models for stable coronary artery disease based on electronic health record cohort of 102 023 
patients. European heart journal. 2013. 
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PROTOCOL CONTENT CHECKLIST 
In order to help ensure that protocols submitted for review contain adequate information for protocol 
evaluation, ISAC have produced instructions on the content of protocols for research using CPRD data. 
These instructions are available on the CPRD website (www.cprd.com/ISAC). All protocols using CPRD data 
which are submitted for review by ISAC must contain information on the areas detailed in the instructions.  
IF you do not feel that a specific area required by ISAC is relevant for your protocol, you will need to justify 
this decision to ISAC.  
 
Applicants must complete the checklist below to confirm that the protocol being submitted includes all the 
areas required by ISAC, or to provide justification where a required area is not considered to be relevant for 
a specific protocol.  Protocols will not be circulated to ISAC for review until the checklist has been completed 
by the applicant.  
 
Please note, your protocol will be returned to you if you do not complete this checklist, or if 
you answer ‘no’ and fail to include justification for the omission of any required area. 
 
 Included in 
protocol? 
 
Required area Yes No If no, reason for 
omission 
Lay Summary (max.200 words)         
Background         
Objective, specific aims and rationale         
Study Type 
Descriptive 
Hypothesis Generating 
Hypothesis Testing 
   
 
 
 
 
      
      
Study Design         
Sample size/power calculation  
(Please provide justification of  
sample size in the protocol) 
        
Study population  
(including estimate of expected number of  
relevant patients in the CPRD)  
 
 
 
 
 
      
Selection of comparison group(s) or controls   N/A 
Exposures, outcomes and covariates 
Exposures are clearly described  
Outcomes are clearly described 
 
 
 
 
 
 
      
      
Use of linked data  
(if applicable) 
        
Data/ Statistical Analysis Plan 
There is plan for addressing confounding  
There is a plan for addressing missing data 
 
 
 
 
 
 
      
      
Patient/ user group involvement †         
Limitations of the study design, data sources  
and analytic methods 
        
Plans for disseminating and communicating study 
results 
        
 
† It is expected that many studies will benefit from the involvement of patient or user groups 
in their planning and refinement, and/or in the interpretation of the results and plans for 
further work. This is particularly, but not exclusively true of studies with interests in the 
impact on quality of life.   Please indicate whether or not you intend to engage patients in any 
of the ways mentioned above. 
 
Voluntary registration of ISAC approved studies:  
Epidemiological studies are increasingly being included in registries of research around the world, including 
those primarily set up for clinical trials. To increase awareness amongst researchers of ongoing research, 
ISAC encourages voluntary registration of epidemiological research conducted using MHRA databases. This 
will not replace information on ISAC approved protocols that may be published in its summary minutes or 
annual report. It is for the applicant to determine the most appropriate registry for their study. Please 
inform the ISAC secretariat that you have registered a protocol and provide the location. 
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Prognostic models for risk of serious atherothrombotic and bleeding events 
and death in patients who survived after myocardial infarction 
 
Lay Summary 
Patients who survive a heart attack (acute myocardial infarction) have an increased risk of death in the 
following years. This risk is largely due to another heart attack or other causes related to their heart and 
circulatory disease. National guidelines recommend that specific medicines are prescribed to patients 
following a heart attack to reduce the risk of further attacks, other circulatory disease and death. One of 
these recommendations is that all patients receive medicines that decrease the formation of blood clots 
(antiplatelet) either aspirin and/or another antiplatelet. However, one of the side effects of these drugs is 
bleeding. 
 
This proposed observational study will use linked data covering hospital admissions and primary care data 
to develop algorithms (prognostic models) that can be used to predict the risk of cardiovascular mortality 
and morbidity and bleeding among patients who survived a heart attack. The purpose of the study 
proposed is to inform clinicians on the safety to continue therapy when monitoring this type of patients. 
 
 
Background 
 
Post-myocardial infarction (MI) patients are at high risk of further cardiovascular disease (CVD) events and 
death. Antiplatelet agents (e.g. aspirin, clopidogrel) are amongst the front-line treatments recommended 
for the management of atherothrombotic risk in after MI. However, their use is associated with increased 
risk of bleeding. Thus clinicians with their patients have to continuously weigh the benefits of antiplatelet 
therapies against the risk of bleeding, particularly as their improved survival post-MI as a result of medical 
advances exposes them to long periods of antiplatelet treatment. 
 
Existing prognostic models for bleeding in post-MI survivors are restricted to short-term / in-hospital 
bleeds (e.g. ACUITY/HORIZONS-AMI (1)), have been developed for different populations (e.g. HAS-BLED 
(2)  for patients with atrial fibrillation), or lacked data for important prognostic factors (e.g. REACH(3) 
lacked data on antiplatelet use and International Normalised Ratio [INR] levels). Previous models for 
MI/coronary death and all-cause mortality have been developed for stable angina patients and  patients 
who survived after acute coronary syndrome ([ACS], MI or unstable angina) in CALIBER (4), but it is not 
known whether better performance might be achieved if models were restricted to post-MI survivors .  
 
Using contemporary, linked electronic health record data (study period 2000-2014) we aim to develop 
algorithms to predict atherothrombotic and bleeding risks in post-MI survivors over a much longer period 
than previously possible. When making treatment decisions clinicians and patients need to be able to 
weight up the risk of bleeding against the risk of further CV events. We will thus enable evaluation of 
these risks separately and by combining them under a competing risks framework. 
 
The new models for atherothrombotic and bleeding outcomes will be extended to dynamic risk models. 
The majority of prognostic models developed to date are limited to estimating baseline risks. However, 
dynamic models will allow doctors to monitor the changing risks of bleeding with time to make up-to-date 
decisions with respect to the safety of continuing therapy or receiving coronary artery bypass graft 
(CABG).  
 
We will evaluate the performance of the new models in the extended coronary artery disease (CAD) 
survivor population that covers stable angina and patients who survived ACS, different time periods 
(depending on availability of data at the time of submission), and in patients from electronic health 
records of one or more other countries. 
 
 
 
 
Overall aim 
To develop and validate prognostic risk models of atherothrombotic events and bleeding for post-MI 
survivors. 
 
Specific objectives 
 
1) Simple prognostic model development in the post-MI survivor population: 
a) To develop a simple prognostic model for atherothrombotic events using clinical covariates that 
are readily available in UK general practice. 
b) To develop a simple prognostic model for bleeding events using clinical covariates that are readily 
available in UK general practice. 
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c) To demonstrate how these risks can be used to aid treatment and procedure decisions, that take 
into account both the potential benefits and harms of interventions. 
d) To assess the clinical utility of the models using hypothetical cost effectiveness scenarios. 
 
2) Validation of simple prognostic models developed  
a) To validate the simple prognostic models internally 
b) To validate the simple prognostic models internally on a wider stable cohort following various 
cardiovascular events and/or procedures. 
 
 
3) Dynamic prognostic model development in the post-MI survivor population: 
a) To extend the simple prognostic models that use baseline information into dynamic prognostic 
models and utilise routinely collected, continuous biomarker trajectories to estimate changing 
risks over time. 
b) To compare dynamic prognostic models with simple prognostic models – in particular, the 
differences in utility. 
 
4) External validation of prognostic models developed  
a) To validate the  prognostic models using international electronic health record cohorts 
compromising of patients with stable angina and/or stable post-MI (i.e. extended stable CAD 
population) 
b) To validate the prognostic models in trial data (Thrombolysis in Myocardial Infarction [TIMI] trial) 
 
  
Study Type 
 
Prognostic model development and validation. 
 
Study Design 
 
A retrospective observational cohort study using primary care data from Clinical Practice Research Datalink 
(CPRD) linked to secondary care data from Hospital Episode Statistics (HES) and Office for National 
Statistics (ONS) mortality. 
 
The overall cohort will be patients registered at CPRD practices to permit data linkage who were 
discharged alive from hospital following admission for MI between January 2000 and July 2014. The post-
MI patients will be those diagnosed with an MI in HES between January 2000 and July 2014, registered in 
a linked CPRD general practice at least 12 months previously and with no subsequent myocardial 
infarction within the first 12 months. This cohort will be used to assess outcomes and costs. 
 
Sample Size 
 
Between 2000 and 2010 there were 35,858 patients with MI in CALIBER (linked electronic heath records 
of CPRD, HES, MINAP and ONS) (5), of which approximately 16,000 had continuous registration for >12 
prior to and after their index MI, and survived with no recurrent MI for the 12 month period following their 
index MI. These 16,000 post-MI 1-year survivors experienced approximately 2,400 CVD events and 1,300 
non-CVD deaths over a mean follow-up of 3 (SD=2) years. The sample size and number of events will be 
considerably higher when data up to July 2014 is used. 
 
Study Population 
 
The model development study population consists of patients aged ≥18 years who had an MI and did not 
have a recurrent MI or were deregistered from the GP practice in the 12 months following their index MI. 
Patients must also have had continuous registration in a participating primary practice for the 12 months 
prior to their index MI. 
 
In addition to internal validation on the model development population, the model will also be validated on 
wider cohort including those with stable angina, stable following a stroke or transient ischaemic attack, 
peripheral arterial disease, abdominal aortic aneurysm, chronic heart disease and heart failure.  
 
Outcomes 
 
1) Atherothrombotic events within 1 year after index MI 
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 Composite of CVD death, non-fatal MI or non-fatal ischemic/unspecified stroke (ICD 10 codes are 
listed in Appendix 1) 
 Cardiovascular death 
These events have established phenotypes in the CALIBER dataset. 
 
2) All-cause mortality within 1 year after index MI 
 
3) Long-term severe/moderate bleeding events 
Long term (>1 year after index myocardial infarction) bleeding that required transfusion or hospitalisation 
(ICD 10 codes are listed in Appendix 2). 
 
Risk factors/ Covariates  
 
We will evaluate which covariates are good predictors of cardiovascular outcomes and mortality. 
Covariates will be defined according to methods agreed among the CALIBER research group and 
documented in the CALIBER data manual. 
 
Demographics Age, sex, ethnicity, smoking status, year of entry into study population 
Clinical diagnoses/ 
procedures 
Previous major bleed, previous coronary intervention, diabetes, chronic 
obstructive pulmonary disease (COPD), history of heart failure, renal disease, 
cancer, peripheral arterial disease, peptic ulcer, atrial fibrillation, dementia 
Pharmacological 
interventions 
Aspirin use, antiplatelet use, oral anticoagulant use, duration of 
antithrombotic therapy (ATT) use, antihypertensive drug use, statin therapy, 
ACE inhibitors, beta-blockers 
Biomarkers Systolic blood pressure, diastolic blood pressure, body mass index (BMI), 
heart rate, haemoglobin, white blood cell count, total and high-density 
lipoprotein (HDL) cholesterol, creatinine, estimated glomerular filtration rate 
(eGFR), INR 
 
 
 
Use of linked data 
 
CPRD Gold: all tables from all practices. 
Linked with HES inpatient admissions including primary discharge diagnosis per hospitalization and 
procedure information. 
Linked with ONS mortality including underlying and ranked causes of death. 
Linked with ONS socioeconomic status (IMD score) 
 
 
Data analysis 
 
A. Primary analyses 
 
PROGRESS guidance (6) for prognostic model development and validation will be followed in this study. 
 
 Prognostic model development 
Preliminary univariate analyses using Cox models will be carried out to determine the effect of each 
variable on atherothrombotic and bleeding risk and to inform initial inclusion of variables in the 
multivariate model.  
 
For the multivariate regression model stepwise selection methods will be employed to ensure parsimony, 
with  age, sex and year of entry being kept in the model regardless of their significance.  
 
For model adjustment, we will examine covariate missing data patterns. We will impute baseline 
covariates with non-informative missing patterns based on multiple imputation. As a sensitivity analysis, to 
take full advantage of the longitudinal nature of the data we will use multi-level imputation, as 
implemented in the R package ‘mice’ for continuous covariates, based on a multivariate normal 
assumption.  
 
 
Clinical utility will be assessed by estimating the event-free years per number of life years saved in general 
practices that use the prognostic models.  
 
 
 Internal validation of prognostic models 
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The performance of the models developed will be examined internally (with cross-validation to correct for 
‘optimism’) in terms of their calibration and discrimination (Harrell’s C-index).  
 
To determine the generalizability of our developed models, we will also internally validate them using a 
wider cohort including those with stable angina, stable following a stroke or transient ischaemic attack, 
peripheral arterial disease, abdominal aortic aneurysm, chronic heart disease and heart failure.  
 
 
 Development of dynamic prognostic models 
Joint modeling of longitudinal and survival data allows us make predictions using a longitudinal biomarker 
(modeled using linear mixed effects models) on a survival outcome – in this case, time until bleeding and 
atherothrombotic events.  
Graphical methods will be used to determine which longitudinal risk factors may indicate changing risk 
over time.  Due to computationally intensive methods we will use high performance computing resources 
available at the Farr Institute where necessary. 
 
 External validation of prognostic models  
The developed models will be externally validated using data from international (Sweden, TIMI trial) 
electronic health records in order to demonstrate the generalizability of the models. The external 
validation population will compromise of the extended stable CAD population – that is, patients with stable 
angina and/or stable post-MI. 
 
B. Secondary analyses 
 
To account for changing guidelines between 2000 and 2014 analyses restricted to the 2005-2014 period 
will be performed. This will entail developing and validating the models described above on the subcohort 
identified for that period. 
 
Limitations 
 
 The nature of the electronic health record data has limitations, in particular, not all MIs will have 
been coded and therefore some patients eligible for inclusion may be missed out and not all the 
event will have been coded. 
 Not all CPRD practices have given permission for linkage outside primary care (i.e. to HES) and 
this will reduce potential sample size. 
 CPRD only include records of prescription issued and not whether the patient collected the 
medicine from pharmacy. 
 Costs are not captured in CPRD so unit prices will be multiplied with resource use and based on 
national listings and published literature. Unit prices from one calendar year will be used.  
 
 
Plans for disseminating and communicating study results 
 
We will publish the results of these studies in peer reviewed medical journals. Additional strategies will 
also be applied for communicating study results to the general public, including: 
 
 
 Study results will be included in the Farr 'Citizen Science' initiative - in which general public are 
invited to take part in analysing and visualising health record data.  
 Study results will contribute to current projects of the Farr Institute in the development of a 
European Roadmap on eHealth Innovations enabling patient and citizen in health. 
 Study results will be communicated to our partners from charities for patient wellbeing, such as 
the National Voices and British Heart Foundation, to be used for information, services and 
training provided for heart disease patients and their family. 
 Media and web-based social media campaign strategies will be applied for disseminating research 
results to the general public. 
 
Results of the proposed studies will be presented through national and international conferences in 
informatics (including those hosted by Farr Institute), and in national and international clinical meetings 
(for example, European Society of Cardiology, America Heart Association). 
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11.2 Supplementary Appendix (Chapter 5) 
11.2.1 Bleeding ICD-10 codes 
code term Anatomical site 
D683 Haemorrhagic disorder due to circulating anticoagulants blood 
D69 Purpura and other haemorrhagic conditions blood 
D698 Other specified haemorrhagic conditions blood 
D699 Haemorrhagic condition, unspecified blood 
I230 
Haemopericardium as current complication following acute myocardial 
infarction circulatory 
I312 Haemopericardium, not elsewhere classified circulatory 
I711 Thoracic aortic aneurysm, ruptured circulatory 
I713 Abdominal aortic aneurysm, ruptured circulatory 
I715 Thoracoabdominal aortic aneurysm, ruptured circulatory 
I718 Aortic aneurysm of unspecified site, ruptured circulatory 
H922 Otorrhagia ear 
N02 Recurrent and persistent haematuria genitourinary 
N026 Recurrent and persistent haematuria, dense deposit disease genitourinary 
N028 Recurrent and persistent haematuria, other genitourinary 
N029 Recurrent and persistent haematuria, unspecified genitourinary 
N421 Congestion and haemorrhage of prostate genitourinary 
N501 Vascular disorders of male genital organs genitourinary 
N836 Haematosalpinx genitourinary 
N837 Haematoma of broad ligament genitourinary 
N857 Haematometra genitourinary 
N897 Haematocolpos genitourinary 
N898 Other specified noninflammatory disorders of vagina genitourinary 
N908 Other specified noninflammatory disorders of vulva and perineum genitourinary 
N921 Excessive and frequent menstruation with irregular cycle genitourinary 
N925 Other specified irregular menstruation genitourinary 
N926 Irregular menstruation, unspecified genitourinary 
N93 Other abnormal uterine and vaginal bleeding genitourinary 
N938 Other specified abnormal uterine and vaginal bleeding genitourinary 
N939 Abnormal uterine and vaginal bleeding, unspecified genitourinary 
N950 Postmenopausal bleeding genitourinary 
R31 Unspecified haematuria genitourinary 
R31X Unspecified haematuria genitourinary 
K625 Haemorrhage of anus and rectum GI (lower)  
K921 Melaena GI (lower)  
K922 Gastrointestinal haemorrhage, unspecified GI (unspecified) 
I850 Oesophageal varices with bleeding GI (upper) 
I983 Oesophageal varices with bleeding in diseases classified elsewhere GI (upper) 
K250 Gastric ulcer ;  Acute with haemorrhage GI (upper) 
K252 Gastric ulcer ;  Acute with both haemorrhage and perforation GI (upper) 
K254 Gastric ulcer ;  Chronic or unspecified with haemorrhage GI (upper) 
K256 
Gastric ulcer ;  Chronic or unspecified with both haemorrhage and 
perforation GI (upper) 
K260 Duodenal ulcer ;  Acute with haemorrhage GI (upper) 
K262 Duodenal ulcer ;  Acute with both haemorrhage and perforation GI (upper) 
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code term Anatomical site 
K264 Duodenal ulcer ;  Chronic or unspecified with haemorrhage GI (upper) 
K266 
Duodenal ulcer ;  Chronic or unspecified with both haemorrhage and 
perforation GI (upper) 
K270 Peptic ulcer, site unspecified ;  Acute with haemorrhage GI (upper) 
K272 
Peptic ulcer, site unspecified ;  Acute with both haemorrhage and 
perforation GI (upper) 
K274 Peptic ulcer, chronic or unspecified with haemorrhage GI (upper) 
K276 Chronic or unspecified with both haemorrhage and perforation GI (upper) 
K280 Gastrojejunal ulcer ;  Acute with haemorrhage GI (upper) 
K282 Gastrojejunal ulcer ;  Acute with both haemorrhage and perforation GI (upper) 
K284 Gastrojejunal ulcer ;  Chronic or unspecified with haemorrhage GI (upper) 
K286 
Gastrojejunal ulcer ;  Chronic or unspecified with both haemorrhage and 
perforation GI (upper) 
K290 Acute haemorrhagic gastritis GI (upper) 
K661 Haemoperitoneum GI (upper) 
K920 Haematemesis GI (upper) 
I61 Intracerebral haemorrhage IC (intracerebral) 
I610 Intracerebral haemorrhage in hemisphere, subcortical IC (intracerebral) 
I611 Intracerebral haemorrhage in hemisphere, cortical IC (intracerebral) 
I612 Intracerebral haemorrhage in hemisphere, unspecified IC (intracerebral) 
I613 Intracerebral haemorrhage in brain stem IC (intracerebral) 
I614 Intracerebral haemorrhage in cerebellum IC (intracerebral) 
I615 Intracerebral haemorrhage, intraventricular IC (intracerebral) 
I616 Intracerebral haemorrhage, multiple localized IC (intracerebral) 
I618 Other intracerebral haemorrhage IC (intracerebral) 
I619 Intracerebral haemorrhage, unspecified IC (intracerebral) 
I60 Subarachnoid haemorrhage IC (subarachnoid) 
I600 Subarachnoid haemorrhage from carotid siphon and bifurcation IC (subarachnoid) 
I601 Subarachnoid haemorrhage from middle cerebral artery IC (subarachnoid) 
I602 Subarachnoid haemorrhage from anterior communicating artery IC (subarachnoid) 
I603 Subarachnoid haemorrhage from posterior communicating artery IC (subarachnoid) 
I604 Subarachnoid haemorrhage from basilar artery IC (subarachnoid) 
I605 Subarachnoid haemorrhage from vertebral artery IC (subarachnoid) 
I606 Subarachnoid haemorrhage from other intracranial arteries IC (subarachnoid) 
I607 Subarachnoid haemorrhage from intracranial artery, unspecified IC (subarachnoid) 
I608 Other subarachnoid haemorrhage IC (subarachnoid) 
I609 Subarachnoid haemorrhage, unspecified IC (subarachnoid) 
I62 Other nontraumatic intracranial haemorrhage IC (subarachnoid) 
I620 Subdural haemorrhage (acute)(nontraumatic) IC (subdural) 
I621 Nontraumatic extradural haemorrhage IC (extradural) 
I629 Intracranial haemorrhage (nontraumatic), unspecified IC (unspecified) 
S064 Epidural haemorrhage IC (extradural) 
R233 Spontaneous ecchymoses NOS 
R58 Haemorrhage, not elsewhere classified NOS 
R58X Haemorrhage, not elsewhere classified NOS 
T81 Haemorrhage and haematoma complicating a procedure NEC NOS 
H313 Choroidal haemorrhage and rupture ocular 
H356 Retinal haemorrhage ocular 
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code term Anatomical site 
H431 Vitreous haemorrhage ocular 
H450 Vitreous haemorrhage in diseases classified elsewhere ocular 
J942 Haemothorax respiratory (lower) 
R040 Epistaxis respiratory (upper) 
R041 Haemorrhage from throat respiratory (upper) 
R042 Haemoptysis respiratory (lower) 
R048 Haemorrhage from other sites in respiratory passages 
respiratory 
(unspecified) 
R049 Haemorrhage from respiratory passages, unspecified 
respiratory 
(unspecified) 
 
GI= gastrointestinal; IC=intracranial; NOS= not otherwise specified 
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11.2.2 Bleeding Read codes 
code term Anatomical site 
D31..00 Purpura and other haemorrhagic conditions blood 
D31X.00 Haemorrhagic condition, unspecified blood 
D31y.00 Other specified haemorrhagic conditions blood 
D31yz00 Other specified haemorrhagic condition NOS blood 
D31z.00 Haemorrhagic condition NOS blood 
Dyu3300 [X]Other specified haemorrhagic conditions blood 
G360.00 Haemopericardium/current comp folow acut myocard infarct circulatory 
G530.00 Haemopericardium circulatory 
G711.00 Thoracic aortic aneurysm which has ruptured circulatory 
G711.11 Ruptured thoracic aortic aneurysm circulatory 
G713.00 Abdominal aortic aneurysm which has ruptured circulatory 
G713.11 Ruptured abdominal aortic aneurysm circulatory 
G713000 Ruptured suprarenal aortic aneurysm circulatory 
G715.00 Ruptured aortic aneurysm NOS circulatory 
G715000 Thoracoabdominal aortic aneurysm, ruptured circulatory 
G723500 Ruptured popliteal artery aneurysm circulatory 
7303000 Drainage of haematoma of external ear ear 
7303200 Drainage haematoma ext ear control cavity c bolster suture ear 
F501G00 Haemorrhagic otitis externa ear 
F503100 Haematoma of pinna ear 
C063000 Thyroid haemorrhage endocrine 
C12y100 Haemorrhage of parathyroid endocrine 
1584 Heavy episode of vaginal bleeding genitourinary 
1A45.00 Blood in urine - haematuria genitourinary 
K167.00 Haemorrhage into bladder wall genitourinary 
K16y200 Bladder haemorrhage genitourinary 
K197.00 Haematuria genitourinary 
K197000 Painless haematuria genitourinary 
K197100 Painful haematuria genitourinary 
K197300 Frank haematuria genitourinary 
K197400 Clot haematuria genitourinary 
K19y400 Bleeding from urethra genitourinary 
K19y411 Urethral bleeding genitourinary 
K221100 Prostatic haemorrhage genitourinary 
K275100 Corpus cavernosum haematoma genitourinary 
K275200 Corpus cavernosum haemorrhage genitourinary 
K286100 Scrotal haemorrhage genitourinary 
K286400 Testicular haemorrhage genitourinary 
K286v00 Male genital haematoma NOS genitourinary 
K286w00 Male genital haemorrhage NOS genitourinary 
K537.00 Haematoma of the broad ligament genitourinary 
K55y300 Haemorrhage of cervix genitourinary 
K566.00 Vaginal haematoma genitourinary 
K56y100 Haemorrhage of vagina genitourinary 
K575.00 Haematoma of vulva genitourinary 
K59yx00 Dysfunctional uterine haemorrhage NOS genitourinary 
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code term Anatomical site 
K59yy00 Functional uterine haemorrhage NOS genitourinary 
K5E..00 Other abnormal uterine and vaginal bleeding genitourinary 
K5E0.00 Abnormal uterine bleeding unrelated to menstrual cycle genitourinary 
K5E1.00 Abnormal uterine bleeding, unspecified genitourinary 
K5E2.00 Abnormal vaginal bleeding, unspecified genitourinary 
K5Ez.00 Abnormal uterine and vaginal bleeding, unspecified genitourinary 
Kyu9D00 [X]Other specified abnormal uterine and vaginal bleeding genitourinary 
196B.00 Painful rectal bleeding GI (lower) 
196C.00 Painless rectal bleeding GI (lower) 
19E4.12 C/O - melaena GI (lower) 
19E6.00 Blood in faeces GI (lower) 
19E6.11 Blood in faeces symptom GI (lower) 
4737.11 Melaena - O/E of faeces GI (lower) 
4762 Faeces: fresh blood present GI (lower) 
4762.11 Blood in faeces GI (lower) 
479..11 Faeces occult blood test GI (lower) 
J510900 Bleeding diverticulosis GI (lower) 
J573.00 Haemorrhage of rectum and anus GI (lower) 
J573000 Rectal haemorrhage GI (lower) 
J573011 Rectal bleeding GI (lower) 
J573012 PRB - Rectal bleeding GI (lower) 
J573100 Anal haemorrhage GI (lower) 
J573z00 Haemorrhage of rectum and anus NOS GI (lower) 
J681.00 Melaena GI (lower) 
J681.11 Blood in stool GI (lower) 
J681.12 Altered blood in stools GI (lower) 
J681.13 Blood in stools altered GI (lower) 
J68z100 Intestinal haemorrhage NOS GI (lower) 
S740100 Liver haematoma and contusion without open wound into cavity GI (lower) 
SE22300 Haematoma of rectus sheath GI (lower) 
SE23111 Perianal haematoma GI (lower) 
J68..00 Gastrointestinal haemorrhage GI (NOS) 
J68z.00 Gastrointestinal haemorrhage unspecified GI (NOS) 
J68z.11 GIB - Gastrointestinal bleeding GI (NOS) 
J68zz00 Gastrointestinal tract haemorrhage NOS GI (NOS) 
1994 Vomiting blood - fresh GI (upper) 
1994.11 Blood in vomit - symptom GI (upper) 
1995 Vomiting blood - coffee ground GI (upper) 
4A23.00 Vomit: frank blood present GI (upper) 
4A23.11 Blood in vomit O/E GI (upper) 
4A5..00 Vomit occult blood GI (upper) 
4A5..11 Occult blood in vomit GI (upper) 
4A51.00 Vomit occult blood positive GI (upper) 
4A5Z.00 Vomit occult blood NOS GI (upper) 
7619100 Gastrotomy and ligation of bleeding point of stomach GI (upper) 
G850.00 Oesophageal varices with bleeding GI (upper) 
G852000 Oesophageal varices with bleeding in diseases EC GI (upper) 
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J10y000 Haemorrhage of oesophagus GI (upper) 
J110100 Acute gastric ulcer with haemorrhage GI (upper) 
J110111 Bleeding acute gastric ulcer GI (upper) 
J110300 Acute gastric ulcer with haemorrhage and perforation GI (upper) 
J111100 Chronic gastric ulcer with haemorrhage GI (upper) 
J111111 Bleeding chronic gastric ulcer GI (upper) 
J111300 Chronic gastric ulcer with haemorrhage and perforation GI (upper) 
J11y100 Unspecified gastric ulcer with haemorrhage GI (upper) 
J11yy00 Unspec gastric ulcer; unspec haemorrhage and/or perforation GI (upper) 
J120100 Acute duodenal ulcer with haemorrhage GI (upper) 
J120300 Acute duodenal ulcer with haemorrhage and perforation GI (upper) 
J121100 Chronic duodenal ulcer with haemorrhage GI (upper) 
J121111 Bleeding chronic duodenal ulcer GI (upper) 
J121300 Chronic duodenal ulcer with haemorrhage and perforation GI (upper) 
J12y100 Unspecified duodenal ulcer with haemorrhage GI (upper) 
J12y300 Unspecified duodenal ulcer with haemorrhage and perforation GI (upper) 
J12yy00 Unspec duodenal ulcer; unspec haemorrhage and/or perforation GI (upper) 
J130100 Acute peptic ulcer with haemorrhage GI (upper) 
J130300 Acute peptic ulcer with haemorrhage and perforation GI (upper) 
J131100 Chronic peptic ulcer with haemorrhage GI (upper) 
J13y100 Unspecified peptic ulcer with haemorrhage GI (upper) 
J13y300 Unspecified peptic ulcer with haemorrhage and perforation GI (upper) 
J140100 Acute gastrojejunal ulcer with haemorrhage GI (upper) 
J14y100 Unspecified gastrojejunal ulcer with haemorrhage GI (upper) 
J150000 Acute haemorrhagic gastritis GI (upper) 
J680.00 Haematemesis GI (upper) 
J680.11 Vomiting of blood GI (upper) 
J68z000 Gastric haemorrhage NOS GI (upper) 
J68z200 Upper gastrointestinal haemorrhage GI (upper) 
G620.00 Extradural haemorrhage - nontraumatic IC (extradural) 
S626.00 Epidural haemorrhage IC (extradural) 
G600.00 Ruptured berry aneurysm IC (intracerebral) 
G61..00 Intracerebral haemorrhage IC (intracerebral) 
G610.00 Cortical haemorrhage IC (intracerebral) 
G611.00 Internal capsule haemorrhage IC (intracerebral) 
G612.00 Basal nucleus haemorrhage IC (intracerebral) 
G613.00 Cerebellar haemorrhage IC (intracerebral) 
G614.00 Pontine haemorrhage IC (intracerebral) 
G615.00 Bulbar haemorrhage IC (intracerebral) 
G616.00 External capsule haemorrhage IC (intracerebral) 
G617.00 Intracerebral haemorrhage, intraventricular IC (intracerebral) 
G618.00 Intracerebral haemorrhage, multiple localized IC (intracerebral) 
G61X.00 Intracerebral haemorrhage in hemisphere, unspecified IC (intracerebral) 
G61X000 Left sided intracerebral haemorrhage, unspecified IC (intracerebral) 
G61X100 Right sided intracerebral haemorrhage, unspecified IC (intracerebral) 
G61z.00 Intracerebral haemorrhage NOS IC (intracerebral) 
Gyu6200 [X]Other intracerebral haemorrhage IC (intracerebral) 
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code term Anatomical site 
Gyu6F00 [X]Intracerebral haemorrhage in hemisphere, unspecified IC (intracerebral) 
G60..00 Subarachnoid haemorrhage IC (subarachnoid) 
G601.00 Subarachnoid haemorrhage from carotid siphon and bifurcation IC (subarachnoid) 
G602.00 Subarachnoid haemorrhage from middle cerebral artery IC (subarachnoid) 
G603.00 Subarachnoid haemorrhage from anterior communicating artery IC (subarachnoid) 
G604.00 Subarachnoid haemorrhage from posterior communicating artery IC (subarachnoid) 
G605.00 Subarachnoid haemorrhage from basilar artery IC (subarachnoid) 
G606.00 Subarachnoid haemorrhage from vertebral artery IC (subarachnoid) 
G60z.00 Subarachnoid haemorrhage NOS IC (subarachnoid) 
Gyu6100 [X]Other subarachnoid haemorrhage IC (subarachnoid) 
G621.00 Subdural haemorrhage - nontraumatic IC (subdural) 
G623.00 Subdural haemorrhage NOS IC (subdural) 
G62..00 Other and unspecified intracranial haemorrhage IC (unspecified) 
G62z.00 Intracranial haemorrhage NOS IC (unspecified) 
2F65.00 O/E - haemorrhagic bullae NOS 
Ryu7300 [X]Haemorrhage, not elsewhere classified NOS 
S750100 Spleen haematoma without mention of open wound into cavity NOS 
S751100 Spleen haematoma with open wound into cavity NOS 
SE...11 Haematoma with intact skin NOS 
SE33011 Subungal haematoma NOS 
SE45.11 Haematoma of leg NOS 
SE4z.11 Haematoma NOS NOS 
SE4z.12 Intramuscular haematoma NOS NOS 
SK02.00 Secondary and recurrent haemorrhage NOS 
SK02.11 Secondary and recurrent haemorrhage NOS 
SK02.12 Secondary and recurrent haemorrhage NOS 
2BB5.00 O/E - retinal haemorrhages ocular 
2BB8.00 O/E - vitreous haemorrhages ocular 
F404500 Intra-ocular haemorrhage ocular 
F424300 Retinal pigment epithelium haemorrhagic detachment ocular 
F42y.11 Haemorrhage - retinal ocular 
F42y100 Superficial retinal haemorrhage ocular 
F42y300 Deep retinal haemorrhage ocular 
F42y400 Subretinal haemorrhage ocular 
F42y500 Retinal haemorrhage NOS ocular 
F436.00 Choroidal haemorrhage and rupture ocular 
F436000 Unspecified choroidal haemorrhage ocular 
F436100 Expulsive choroidal haemorrhage ocular 
F436z00 Choroidal haemorrhage or rupture NOS ocular 
F437200 Haemorrhagic choroidal detachment ocular 
F4Ey000 Haemorrhage of eyelid ocular 
F4H4100 Optic nerve sheath haemorrhage ocular 
F4K2800 Vitreous haemorrhage ocular 
F4K7.00 Retrobulbar haemorrhage ocular 
FyuH400 [X]Vitreous haemorrhage in diseases classified elsewhere ocular 
7004100 Evacuation of haematoma from temporal lobe of brain procedure 
7004200 Evacuation of haematoma from cerebellum procedure 
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code term Anatomical site 
7004300 Evacuation of intracerebral haematoma NEC procedure 
7008200 Aspiration of haematoma of brain tissue procedure 
7017000 Evacuation of subdural haematoma procedure 
7032000 Evacuation of extradural haematoma procedure 
7736000 Evacuation of perianal haematoma procedure 
7D05200 Evacuation of haematoma of vulva procedure 
7D1C000 Evacuation of haematoma from vagina procedure 
7G2H400 Liposuction removal of haematoma procedure 
7M0G000 Aspiration of haematoma of organ NOC procedure 
7M0G400 Evacuation of haematoma NEC procedure 
C154200 Adrenal haemorrhage renal 
K138100 Renal artery haemorrhage renal 
K138300 Intrarenal haematoma renal 
K13y800 Perirenal haematoma renal 
S760100 Kidney haematoma without mention of open wound into cavity renal 
S760111 Renal haematoma without mention of open wound into cavity renal 
S761100 Kidney haematoma with open wound into cavity renal 
172..00 Blood in sputum - haemoptysis respiratory (lower) 
R063.00 [D]Haemoptysis respiratory (lower) 
R063000 [D]Cough with haemorrhage respiratory (lower) 
R063100 [D]Pulmonary haemorrhage NOS respiratory (lower) 
R063z00 [D]Haemoptysis NOS respiratory (lower) 
1C62.00 Has nose bleeds - epistaxis respiratory (upper) 
2D25.00 O/E - epistaxis respiratory (upper) 
2DE7.00 O/E - throat haemorrhage respiratory (upper) 
R047.00 [D]Epistaxis respiratory (upper) 
R047.11 [D]Nosebleed respiratory (upper) 
R048.00 [D]Throat haemorrhage respiratory (upper) 
 
GI= gastrointestinal; IC=intracranial; NOS= not otherwise specified 
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11.2.3 Bleeding complications coded in MINAP 
Category Definition Notes 
0 None   
1 Intracranial bleed Of any severity. Should be 
confirmed by scanning 
2 Retroperitoneal 
haemorrhage 
Of any severity. Should be 
confirmed by scanning 
3 Any bleed with 
haemoglobin (Hb) fall >5g 
From any site except options 1 and 
2. 
4 Any bleed with Hb fall >3g 
and <5g 
  
5 Any bleed with Hb fall <3g   
9 Unknown 
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11.2.4 Transfusion OPCS codes 
code term 
X33 Other blood transfusion 
X331 Intra-arterial blood transfusion 
X332 Intravenous blood transfusion of packed cells 
X333 Intravenous blood transfusion of platelets 
X338 Other specified other blood transfusion 
X339 Unspecified other blood transfusion 
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11.2.5 Transfusion Read codes 
code term 
7L14.00 Other blood transfusion 
7L14000 Intraarterial blood transfusion 
7L14100 Intravenous blood transfusion of packed cells 
7L14300 Intravenous blood transfusion NEC 
7L14311 Blood transfusion 
7L14y00 Other specified other blood transfusion 
7L14z00 Other blood transfusion NOS 
TAy0.00 Mismatched blood transfused 
TB1y000 Blood transfusion with complication, without blame 
ZV58200 [V]Blood transfusion, without reported diagnosis 
 
343 
 
11.2.6 Haematoma removal OPCS codes 
code term 
A052 Evacuation of haematoma from temporal lobe of brain 
A053 Evacuation of haematoma from cerebellum 
A054 Evacuation of intracerebral haematoma NEC 
A103 Aspiration of haematoma of tissue of brain 
A401 Evacuation of extradural haematoma 
A411 Evacuation of subdural haematoma 
D041 Drainage of haematoma of external ear 
H531 Evacuation of perianal haematoma 
P093 Evacuation of haematoma from vulva 
P271 Evacuation of haematoma from vagina 
Y221 Aspiration of haematoma of organ NOC 
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11.2.7 Bleeding cessation procedure OPCS codes 
code term 
E05 Surgical arrest of bleeding from internal nose 
E051 Cauterisation of internal nose 
E052 Ligation of artery of internal nose 
E053 Embolisation of artery of internal nose 
E054 Laser therapy of internal nose 
E058 Other specified surgical arrest of bleeding from internal nose 
E059 Unspecified surgical arrest of bleeding from internal nose 
E203 Surgical arrest of postoperative bleeding of adenoid 
F162 Surgical arrest of postoperative bleeding from tooth socket 
F365 Surgical arrest of postoperative bleeding from tonsillar bed 
T032 
Reopening of chest and re-exploration of intrathoracic operation site and surgical arrest of 
postoperative bleeding 
T301 
Reopening of abdomen and re-exploration of intra-abdominal operation site and surgical 
arrest of postoperative bleeding 
V032 
Reopening of cranium and re-exploration of intracranial operation site and surgical arrest 
of postoperative bleeding 
Y321 Re-exploration of organ and surgical arrest of postoperative bleeding NOC 
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11.2.8 Endoscopy OPCS-4 codes 
code term 
A18 Diagnostic endoscopic examination of ventricle of brain 
A188 Other specified diagnostic endoscopic examination of ventricle of brain 
A189 Unspecified diagnostic endoscopic examination of ventricle of brain 
E25 Diagnostic endoscopic examination of pharynx 
E253 Diagnostic endoscopic examination of nasopharynx NEC 
E258 Other specified diagnostic endoscopic examination of pharynx 
E259 Unspecified diagnostic endoscopic examination of pharynx 
E36 Diagnostic endoscopic examination of larynx 
E368 Other specified diagnostic endoscopic examination of larynx 
E369 Unspecified diagnostic endoscopic examination of larynx 
E37 Diagnostic microendoscopic examination of larynx 
E378 Other specified diagnostic microendoscopic examination of larynx 
E379 Unspecified diagnostic microendoscopic examination of larynx 
E49 Diagnostic fibreoptic endoscopic examination of lower respiratory tract 
E498 
Other specified diagnostic fibreoptic endoscopic examination of lower respiratory 
tract 
E499 Unspecified diagnostic fibreoptic endoscopic examination of lower respiratory tract 
E51 
Diagnostic endoscopic examination of lower respiratory tract using rigid 
bronchoscope 
E518 
Other specified diagnostic endoscopic examination of lower respiratory tract using 
rigid bronchoscope 
E519 
Unspecified diagnostic endoscopic examination of lower respiratory tract using 
rigid bronchoscope 
E63 Diagnostic endoscopic examination of mediastinum 
E638 Other specified diagnostic endoscopic examination of mediastinum 
E639 Unspecified diagnostic endoscopic examination of mediastinum 
G16 Diagnostic fibreoptic endoscopic examination of oesophagus 
G162 Diagnostic fibreoptic endoscopic ultrasound examination of oesophagus 
G168 Other specified diagnostic fibreoptic endoscopic examination of oesophagus 
G169 Unspecified diagnostic fibreoptic endoscopic examination of oesophagus 
G19 Diagnostic endoscopic examination of oesophagus using rigid oesophagoscope 
G198 
Other specified diagnostic endoscopic examination of oesophagus using rigid 
oesophagoscope 
G199 
Unspecified diagnostic endoscopic examination of oesophagus using rigid 
oesophagoscope 
G45 Diagnostic fibreoptic endoscopic examination of upper gastrointestinal tract 
G452 Fibreoptic endoscopic ultrasound examination of upper gastrointestinal tract 
G458 
Other specified diagnostic fibreoptic endoscopic examination of upper 
gastrointestinal tract 
G459 
Unspecified diagnostic fibreoptic endoscopic examination of upper gastrointestinal 
tract 
G55 Diagnostic endoscopic examination of duodenum 
G558 Other specified diagnostic endoscopic examination of duodenum 
G559 Unspecified diagnostic endoscopic examination of duodenum 
G65 Diagnostic endoscopic examination of jejunum 
G658 Other specified diagnostic endoscopic examination of jejunum 
G659 Unspecified diagnostic endoscopic examination of jejunum 
G80 Diagnostic endoscopic examination of ileum 
G803 Diagnostic endoscopic balloon examination of ileum 
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code term 
G808 Other specified diagnostic endoscopic examination of ileum 
G809 Unspecified diagnostic endoscopic examination of ileum 
H22 Diagnostic endoscopic examination of colon 
H228 Other specified diagnostic endoscopic examination of colon 
H229 Unspecified diagnostic endoscopic examination of colon 
H25 Diagnostic endoscopic examination of lower bowel using fibreoptic sigmoidoscope 
H258 
Other specified diagnostic endoscopic examination of lower bowel using fibreoptic 
sigmoidoscope 
H259 
Unspecified diagnostic endoscopic examination of lower bowel using fibreoptic 
sigmoidoscope 
H28 Diagnostic endoscopic examination of sigmoid colon using rigid sigmoidoscope 
H288 
Other specified diagnostic endoscopic examination of sigmoid colon using rigid 
sigmoidoscope 
H289 
Unspecified diagnostic endoscopic examination of sigmoid colon using rigid 
sigmoidoscope 
H68 Diagnostic endoscopic examination of enteric pouch using colonoscope 
H682 Diagnostic endoscopic examination of colonic pouch using colonoscope NEC 
H684 Diagnostic endoscopic examination of ileoanal pouch using colonoscope NEC 
H688 
Other specified diagnostic endoscopic examination of enteric pouch using 
colonoscope 
H689 Unspecified diagnostic endoscopic examination of enteric pouch using colonoscope 
H69 Diagnostic endoscopic examination of enteric pouch using fibreoptic sigmoidoscope 
H692 
Diagnostic endoscopic examination of colonic pouch using fibreoptic 
sigmoidoscope NEC 
H694 
Diagnostic endoscopic examination of ileoanal pouch using fibreoptic 
sigmoidoscope NEC 
H698 
Other specified diagnostic endoscopic examination of enteric pouch using 
fibreoptic sigmoidoscope 
H699 
Unspecified diagnostic endoscopic examination of enteric pouch using fibreoptic 
sigmoidoscope 
H70 Diagnostic endoscopic examination of enteric pouch using rigid sigmoidoscope 
H702 Diagnostic endoscopic examination of colonic pouch using rigid sigmoidoscope NEC 
H704 
Diagnostic endoscopic examination of ileoanal pouch using rigid sigmoidoscope 
NEC 
H708 
Other specified diagnostic endoscopic examination of enteric pouch using rigid 
sigmoidoscope 
H709 
Unspecified diagnostic endoscopic examination of enteric pouch using rigid 
sigmoidoscope 
J09 Diagnostic endoscopic examination of liver using laparoscope 
J098 Other specified diagnostic endoscopic examination of liver using laparoscope 
J099 Unspecified diagnostic endoscopic examination of liver using laparoscope 
J17 Endoscopic ultrasound examination of liver 
J178 Other specified endoscopic ultrasound examination of liver 
J179 Unspecified endoscopic ultrasound examination of liver 
J43 Diagnostic endoscopic retrograde examination of bile duct and pancreatic duct 
J438 
Other specified diagnostic endoscopic retrograde examination of bile duct and 
pancreatic duct 
J439 
Unspecified diagnostic endoscopic retrograde examination of bile duct and 
pancreatic duct 
J44 Diagnostic endoscopic retrograde examination of bile duct 
J448 Other specified diagnostic endoscopic retrograde examination of bile duct 
J449 Unspecified diagnostic endoscopic retrograde examination of bile duct 
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code term 
J45 Diagnostic endoscopic retrograde examination of pancreatic duct 
J458 Other specified diagnostic endoscopic retrograde examination of pancreatic duct 
J459 Unspecified diagnostic endoscopic retrograde examination of pancreatic duct 
J53 Endoscopic ultrasound examination of bile duct 
J538 Other specified endoscopic ultrasound examination of bile duct 
J539 Unspecified endoscopic ultrasound examination of bile duct 
J74 Endoscopic ultrasound examination of pancreas 
J748 Other specified endoscopic ultrasound examination of pancreas 
J749 Unspecified endoscopic ultrasound examination of pancreas 
M11 Diagnostic endoscopic examination of kidney 
M113 Diagnostic endoscopic retrograde examination of kidney NEC 
M118 Other specified diagnostic endoscopic examination of kidney 
M119 Unspecified diagnostic endoscopic examination of kidney 
M30 Diagnostic endoscopic examination of ureter 
M308 Other specified diagnostic endoscopic examination of ureter 
M309 Unspecified diagnostic endoscopic examination of ureter 
M45 Diagnostic endoscopic examination of bladder 
M455 Diagnostic endoscopic examination of bladder using rigid cystoscope 
M458 Other specified diagnostic endoscopic examination of bladder 
M459 Unspecified diagnostic endoscopic examination of bladder 
M77 Diagnostic endoscopic examination of urethra 
M778 Other specified diagnostic endoscopic examination of urethra 
M779 Unspecified diagnostic endoscopic examination of urethra 
M85 Diagnostic endoscopic examination of urinary diversion 
M851 Endoscopic examination of intestinal conduit 
M858 Other specified diagnostic endoscopic examination of urinary diversion 
M859 Unspecified diagnostic endoscopic examination of urinary diversion 
Q18 Diagnostic endoscopic examination of uterus 
Q188 Other specified diagnostic endoscopic examination of uterus 
Q189 Unspecified diagnostic endoscopic examination of uterus 
Q39 Diagnostic endoscopic examination of fallopian tube 
Q398 Other specified diagnostic endoscopic examination of fallopian tube 
Q399 Unspecified diagnostic endoscopic examination of fallopian tube 
Q50 Diagnostic endoscopic examination of ovary 
Q508 Other specified diagnostic endoscopic examination of ovary 
Q509 Unspecified diagnostic endoscopic examination of ovary 
T11 Diagnostic endoscopic examination of pleura 
T118 Other specified diagnostic endoscopic examination of pleura 
T119 Unspecified diagnostic endoscopic examination of pleura 
T43 Diagnostic endoscopic examination of peritoneum 
T433 Diagnostic endoscopic ultrasound examination of peritoneum 
T438 Other specified diagnostic endoscopic examination of peritoneum 
T439 Unspecified diagnostic endoscopic examination of peritoneum 
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11.2.9 The number of haemoglobin records per year in 224 CPRD general practices (1997-
2010) 
Note: 2010 data includes up to March only 
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11.2.10 Haemoglobin records within +/- 7 days of HES bleeding events with fitted LOESS curves by anatomical site 
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11.3 Supplementary appendix (chapter 6) 
11.3.1 Fatal, hospitalised+ and primary care+ bleeding event rates 1998-2010 stratified by initial cardiovascular disease 
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11.3.2 Hospitalised and primary care bleeding event rate 1998-2010 stratified by initial cardiovascular disease 
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11.3.3 Antithrombotic therapy prescribing rates 1998-2010 stratified by initial cardiovascular disease 
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11.3.4 The association between non-fatal bleeding severity classes and time to all-cause mortality and cardiovascular death, stroke or myocardial infarction in 
the atrial fibrillation subgroup 
 Note: 
Adjusted estimates are adjusted for age, sex and comorbidities; CV= cardiovascular; MI= myocardial infarction   
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11.3.5 The association between non-fatal bleeding severity classes and time to all-cause mortality and cardiovascular death, stroke or myocardial infarction in 
the myocardial infarction subgroup 
 
Note: Adjusted estimates are adjusted for age, sex and comorbidities; CV= cardiovascular; MI= myocardial infarction   
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11.3.6 : The association between non-fatal bleeding severity classes and time to all-cause mortality and cardiovascular death, stroke or myocardial infarction 
in the unstable angina subgroup 
 
Note: Adjusted estimates are adjusted for age, sex and comorbidities; CV= cardiovascular; MI= myocardial infarction   
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11.3.7 The association between non-fatal bleeding severity classes and time to all-cause mortality and cardiovascular death, stroke or myocardial infarction in 
the stable angina subgroup 
 
Note: Adjusted estimates are adjusted for age, sex and comorbidities; CV= cardiovascular; MI= myocardial infarction   
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11.4 Supplementary appendix (Chapter 7) 
11.4.1 Completed TRIPOD checklist 
Section Item  Checklist Item Page 
Title and abstract 
Title 1 D;V 
Identify the study as developing and/or validating a 
multivariable prediction model, the target population, and the 
outcome to be predicted. 
210 
Abstract 2 D;V 
Provide a summary of objectives, study design, setting, 
participants, sample size, predictors, outcome, statistical 
analysis, results, and conclusions. 
210 
Introduction 
Background 
and 
objectives 
 
3a D;V 
Explain the medical context (including whether diagnostic or 
prognostic) and rationale for developing or validating the 
multivariable prediction model, including references to existing 
models. 
211 
3b D;V 
Specify the objectives, including whether the study describes the 
development or validation of the model or both. 
211 
Methods 
Source of 
data 
 
4a D;V 
Describe the study design or source of data (e.g., randomized 
trial, cohort, or registry data), separately for the development 
and validation data sets, if applicable. 
212 
4b D;V 
Specify the key study dates, including start of accrual; end of 
accrual; and, if applicable, end of follow-up. 
212 
Participants 
 
5a D;V 
Specify key elements of the study setting (e.g., primary care, 
secondary care, general population) including number and 
location of centres. 
212 
5b D;V Describe eligibility criteria for participants. 212 
5c D;V Give details of treatments received, if relevant. n/a 
Outcome 
 
6a D;V 
Clearly define the outcome that is predicted by the prediction 
model, including how and when assessed. 
213; 
Table 3.4; 
Table 3.5 
6b D;V 
Report any actions to blind assessment of the outcome to be 
predicted. 
n/a 
Predictors 
 
7a D;V 
Clearly define all predictors used in developing the multivariable 
prediction model, including how and when they were measured. 
213; Table 3.3 
7b D;V 
Report any actions to blind assessment of predictors for the 
outcome and other predictors. 
n/a 
Sample size 8 D;V Explain how the study size was arrived at. 212 
Missing data 9 D;V 
Describe how missing data were handled (e.g., complete-case 
analysis, single imputation, multiple imputation) with details of 
any imputation method. 
214 
Statistical 
analysis 
methods 
 
10a D Describe how predictors were handled in the analyses. 213 
10b D 
Specify type of model, all model-building procedures (including 
any predictor selection), and method for internal validation. 
213 
10c V For validation, describe how the predictions were calculated. 214 
10d D;V 
Specify all measures used to assess model performance and, if 
relevant, to compare multiple models. 
214 
10e V 
Describe any model updating (e.g., recalibration) arising from 
the validation, if done. 
n/a 
Risk groups 11 D;V Provide details on how risk groups were created, if done. 214 
Development 
vs. validation 
12 V 
For validation, identify any differences from the development 
data in setting, eligibility criteria, outcome, and predictors. 
212; 
Results 
Participants 
 
13a D;V 
Describe the flow of participants through the study, including 
the number of participants with and without the outcome and, if 
applicable, a summary of the follow-up time. A diagram may be 
helpful. 
Figure 7.1 
13b D;V 
Describe the characteristics of the participants (basic 
demographics, clinical features, available predictors), including 
the number of participants with missing data for predictors and 
outcome. 
Table 7.1 
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Section Item  Checklist Item Page 
13c V 
For validation, show a comparison with the development data of 
the distribution of important variables (demographics, 
predictors and outcome). 
Table 7.1; 
Figure 7.2 
Model 
development 
 
14a D 
Specify the number of participants and outcome events in each 
analysis. 
Figure 7.1 
14b D 
If done, report the unadjusted association between each 
candidate predictor and outcome. 
Suppl. 11.4.3 
Model 
specification 
 
15a D 
Present the full prediction model to allow predictions for 
individuals (i.e., all regression coefficients, and model intercept 
or baseline survival at a given time point). 
Suppl. 11.4.5 
Suppl. 11.4.6 
15b D Explain how to use the prediction model. 220 
Model 
performance 
16 D;V 
Report performance measures (with CIs) for the prediction 
model. 
219 
Model-
updating 
17 V 
If done, report the results from any model updating (i.e., model 
specification, model performance). 
n/a 
Discussion 
Limitations 18 D;V 
Discuss any limitations of the study (such as nonrepresentative 
sample, few events per predictor, missing data). 
223 
Interpretatio
n 
 
19a V 
For validation, discuss the results with reference to performance 
in the development data, and any other validation data. 
221 
19b D;V 
Give an overall interpretation of the results, considering 
objectives, limitations, results from similar studies, and other 
relevant evidence. 
222 
Implications 20 D;V 
Discuss the potential clinical use of the model and implications 
for future research. 
223-224 
Other information 
Supplementa
ry 
information 
21 D;V 
Provide information about the availability of supplementary 
resources, such as study protocol, Web calculator, and data sets. 
220; 
Figure 7.9 
Funding 22 D;V 
Give the source of funding and the role of the funders for the 
present study. 
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11.4.2 Patient characteristics at index acute MI discharge and 1 year post-index acute MI in 
the development (n=12,694) and validation (n=5,613) cohorts 
 Development (n=12,694) Validation (n=5,613) 
 
At index acute 
MI discharge 
1 year post-
MI  
At index 
acute MI  
1 year post-
MI  
Age 69.1 (12.7) 70.1 (12.7) 68.1 (12.8) 69.1 (12.8) 
Smoking status     
 Ex-smoker 40.1 49.3 40.3 50.0 
 Non-smoker 42 36.7 38.7 34.2 
 Smoker 17.9 14.0 21.1 15.8 
Alcohol abuse 9.8 10.8 14.3 15.4 
Cardiovascular diseases     
Revascularisation (PCI) 24.8 43.5 18.8 33.0 
Heart failure 18.2 23.5 21.4 28.0 
Atrial fibrillation 14.9 18.0 14.8 17.9 
Stroke 6.0 6.9 7.0 8.1 
Peripheral arterial disease 8.2 9.8 11 13.1 
Diabetes     
 Type 1  1.3 1.2 0.9 0.9 
 Type 2  15.2 16.7 15.5 17 
 Unspecified 1.2 1.5 1.4 1.7 
Renal disease 8.7 13.6 9.5 14.8 
Non-cardiovascular diseases     
COPD 7.8 9.1 10.9 12.8 
Liver disease 0.3 0.4 0.5 0.5 
Non-metastatic cancer 12.9 14.4 11.3 13.2 
Metastatic cancer 0.8 1.0 0.7 1.2 
Dementia 0.8 1.3 1.4 2.0 
Chronic anaemia 11 14.3 14 17.9 
Peptic ulcer 6.6 7.3 9.3 10.2 
Bleeding diatheses and 
coagulation disorders 
0.8 1.1 0.9 1.1 
Hospitalised bleeding 4.3 6.5 5.7 8.2 
Biomarkers     
BMI (Continuous) 28.0 (5.0) 27.8 (5.1) 27.9 (5.2) 27.7 (5.1) 
BMI (Categorical)     
 Underweight 1.1 1.5 1.6 1.8 
 Normal 27.1 28.7 27.9 28.4 
 Overweight 41.8 41.2 42.1 42.2 
 Obese 30.1 28.6 28.4 27.7 
SBP (mmHg) 145 (16.3) 133 (18.6) 144 (17.0) 132 (18.4) 
Haemoglobin (g/dL) 13.9 (1.62) 13.4 (1.6) 13.9 (1.61) 13.3 (1.6) 
White blood cell count (109/L) 7.69 (2.19) 7.60 (2.3) 7.72 (2.19) 7.68 (2.3) 
Total cholesterol (mmol/L) 5.32 (1.16) 4.17 (1.0) 5.38 (1.14) 4.17 (1.0) 
HDL cholesterol (mmol/L) 1.34 (0.40) 1.28 (0.4) 1.33 (0.37) 1.26 (0.4) 
Creatinine (mol/l) Median 
(IQR) 
95 (83, 110) 98 (84, 114) 97 (85, 113) 99 (86, 117) 
Note: Categorical prognostic factors are presented as %, continuous prognostic factors are presented as mean(SD) 
unless stated otherwise 
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11.4.3 Univariable effects of prognostic factors on 5 year all-cause mortality, cardiovascular and bleeding endpoints 
 
Note: CV= cardiovascular, MI= myocardial infarction, NSTEMI= non-ST-elevation myocardial infarction, STEMI= ST-elevation myocardial infarction, COPD= chronic obstructive pulmonary disease, BMI= 
body mass index, eGFR= estimated glomerular filtration rate, NSAID= non-steroidal anti-inflammatory drugs; (log hazards compared with reference group or per unit increase for continuous prognostic 
factors and 95% confidence intervals)  
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11.4.4 Univariable proportional hazards assumption checks for the CALIBER major bleeding outcome 
 
Note: For continuous variables, Beta(t) is a time dependent coefficient and should remain constant over time if the proportional hazards assumption have not been violated. For categorical variables, 
proportional hazards have not been violated if the log(-log(survival)) curves remain parallel over time.; MI= myocardial infarction; PAD= peripheral arterial disease  
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11.4.5 Multivariable model prognostic hazard ratios and 95% confidence intervals for all-cause mortality, cardiovascular and bleeding endpoints 
Prognostic factor (measured 
at 1 year post-MI) 
All-cause mortality 
Cardiovascular 
death, stroke or MI 
Cardiovascular 
death 
CALIBER major 
bleeding 
Fatal or 
hospitalised 
bleeding 
Fatal bleeding or 
intracranial 
bleeding 
Age (per 5 years) 1.38 (1.35, 1.42) 1.28 (1.24, 1.32) 1.39 (1.34, 1.45) 1.3 (1.19, 1.42) 1.14 (1.09, 1.19) 1.35 (1.20, 1.52) 
Women 0.89 (0.81, 0.98) 0.89 (0.79, 0.99) 0.85 (0.75, 0.97) 0.85 (0.61, 1.2) 1.15 (0.95, 1.4) 0.54 (0.34, 0.85) 
Ethnicity       
 White [ref] 1 NA 1 NA 1 NA 
 Asian 0.96 (0.68, 1.36) NA 1.07 (0.68, 1.68) NA 0.68 (0.32, 1.44) NA 
 Black 1.19 (0.7, 2.04) NA 1.28 (0.63, 2.6) NA 1.20 (0.45, 3.22) NA 
 Other 1.16 (1.05, 1.28) NA 1.26 (1.1, 1.44) NA 0.58 (0.43, 0.77) NA 
Smoking status       
 Non-smoker [ref] 1 1 1 1 1 1 
 Ex-smoker 1.02 (0.93, 1.12) 0.91 (0.82, 1.01) 0.9 (0.79, 1.02) 0.88 (0.63, 1.23) 0.96 (0.79, 1.17) 0.73 (0.47, 1.14) 
 Smoker 1.47 (1.28, 1.7) 1.25 (1.06, 1.48) 1.22 (0.99, 1.5) 1.42 (0.87, 2.32) 1.23 (0.92, 1.64) 1.44 (0.77, 2.68) 
Alcohol abuse 1.24 (1.07, 1.43) 1.25 (1.07, 1.47) 1.23 (1.01, 1.5) 1.69 (1.08, 2.65) 1.28 (0.97, 1.68) 1.80 (1.02, 3.19) 
Index acute MI type       
 NSTEMI [ref] 1 1 1 1 1 1 
 STEMI 0.81 (0.7, 0.93) 0.74 (0.63, 0.87) 0.74 (0.61, 0.91) 0.67 (0.39, 1.16) 0.67 (0.5, 0.91) 0.51 (0.24, 1.06) 
 Unspecified 0.88 (0.81, 0.97) 0.78 (0.7, 0.86) 0.82 (0.73, 0.93) 0.84 (0.61, 1.15) 0.78 (0.65, 0.95) 0.61 (0.40, 0.91) 
MI (prior to index acute MI) 1.07 (0.98, 1.16) 1.23 (1.12, 1.35) 1.2 (1.08, 1.34) 1.18 (0.88, 1.59) 1.04 (0.87, 1.23) 1.14 (0.77, 1.68) 
Previous revascularisation 0.69 (0.63, 0.76) 0.72 (0.64, 0.8) 0.61 (0.53, 0.7) NA NA 0.87 (0.56, 1.34) 
Heart failure 1.47 (1.35, 1.6) 1.57 (1.42, 1.74) 1.74 (1.55, 1.97) NA NA 1.34 (0.88, 2.04) 
Atrial fibrillation 1.23 (1.13, 1.34) 1.33 (1.2, 1.47) 1.41 (1.26, 1.59) NA NA 0.85 (0.51, 1.42) 
Stroke 1.41 (1.26, 1.58) 1.86 (1.64, 2.11) 1.73 (1.49, 2) 1.6 (1.06, 2.43) 1.13 (0.84, 1.51) 2.28 (1.38, 3.78) 
Peripheral arterial disease 1.48 (1.33, 1.64) 1.45 (1.28, 1.64) 1.6 (1.38, 1.84) 1.55 (1.06, 2.27) 1.41 (1.11, 1.79) 1.64 (1.01, 2.69) 
Diabetes       
 No diabetes 1 1 1 1 1 1 
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Prognostic factor (measured 
at 1 year post-MI) 
All-cause mortality 
Cardiovascular 
death, stroke or MI 
Cardiovascular 
death 
CALIBER major 
bleeding 
Fatal or 
hospitalised 
bleeding 
Fatal bleeding or 
intracranial 
bleeding 
 Type 1 diabetes 2.33 (1.75, 3.09) 2.33 (1.7, 3.2) 2.44 (1.68, 3.52) 0.55 (0.08, 4) 1.48 (0.73, 3) 0.87 (0.12, 6.40) 
 Type 2 diabetes 1.22 (1.11, 1.35) 1.18 (1.05, 1.32) 1.15 (1, 1.33) 1.49 (1.06, 2.09) 1.29 (1.05, 1.59) 1.48 (0.95, 2.30) 
 Unspecified diabetes 2.44 (1.93, 3.1) 2.34 (1.79, 3.07) 2.89 (2.13, 3.92) 1.07 (0.33, 3.41) 1.62 (0.9, 2.89) 1.31 (0.31, 5.45) 
Renal disease 1.23 (1.1, 1.37) NA NA NA NA NA 
COPD 1.62 (1.45, 1.8) NA 1.23 (1.04, 1.44) NA NA NA 
Liver disease NA NA NA 3.94 (1.4, 11.11) NA NA 
Non-metastatic cancer 1.31 (1.19, 1.44) NA NA 1.48 (1.04, 2.12) 1.26 (1.01, 1.56) 1.49 (0.95, 2.34) 
Metastatic cancer 2.32 (1.81, 2.98) NA NA 2.19 (0.86, 5.58) NA NA 
Dementia 2.03 (1.64, 2.53) 2.03 (1.56, 2.64) 2.16 (1.62, 2.87) NA NA NA 
Chronic anaemia 1.13 (1.02, 1.25) NA NA 1.42 (0.99, 2.03) 1.40 (1.13, 1.73) 1.42 (0.89, 2.25) 
Peptic ulcer NA NA 1.02 (0.85, 1.24) NA 1.75 (1.37, 2.24) NA 
Bleeding diatheses or 
coagulation disorders 
NA 1.3 (0.95, 1.79) NA 2.02 (0.94, 4.32) NA 2.49 (0.95, 6.48) 
Hospitalised bleeding NA 0.84 (0.71, 1) 0.85 (0.69, 1.03) 1.82 (1.2, 2.78) 2.01 (1.56, 2.58) NA 
BMI       
 Underweight 1.91 (1.43, 2.53) 1.6 (1.11, 2.3) 1.65 (1.09, 2.5) NA NA NA 
 Normal [ref] 1 1 1 NA NA NA 
 Overweight 0.93 (0.82, 1.05) 0.95 (0.84, 1.08) 0.92 (0.78, 1.08) NA NA NA 
 Obese 1 (0.88, 1.15) 1.05 (0.91, 1.22) 1.02 (0.85, 1.24) NA NA NA 
White blood cell count (109/L) 1.06 (1.03, 1.08) 1.05 (1.02, 1.07) 1.05 (1.02, 1.08) NA NA NA 
Haemoglobin (g/dL) 0.88 (0.85, 0.92) 0.91 (0.88, 0.95) 0.89 (0.85, 0.93) NA NA NA 
log Creatinine (μmol/l) 1.35 (1.15, 1.59) 1.49 (1.25, 1.77) 1.72 (1.41, 2.1) 2.15 (1.29, 3.57) 1.44 (1.05, 1.97) NA 
Cholesterol ratio (HDL:total) 1.58 (0.92, 2.71) 1.46 (0.82, 2.59) 1.56 (0.77, 3.15) NA NA NA 
Antiplatelet NA NA NA NA 1.23 (1.03, 1.47) NA 
Oral anticoagulant NA NA NA 1.74 (1.19, 2.52) 1.49 (1.17, 1.9) 1.89 (1.08, 3.33) 
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Note: All models are adjusted for systolic blood pressure using restricted cubic splines. Functions are shown in Supplementary appendix 11.4.6; MI=myocardial infarction, 
NSTEMI= non-ST-elevation myocardial infarction, STEMI= ST-elevation myocardial infarction, COPD= chronic obstructive pulmonary disease, HDL= high-density lipoprotein  
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11.4.6 Linear predictor functions for systolic blood pressure in the multivariable models 
Endpoint Function 
All-cause mortality 0.011 x  SBP - 3.566 x 10-6 x max(SBP - 110,0)3 + 6.562 x 10-6 x max(SBP - 131,0)3 - 2.996 x 10-6 x max(SBP - 156,0)3 
Cardiovascular death, 
stroke or MI 
0.012 x  SBP - 5.619 x 10-6 x max(SBP - 110,0)3 + 1.034 x 10-5 x max(SBP - 131,0)3 - 4.720 x 10-6 x max(SBP - 156,0)3 
Cardiovascular death 
 
0.015 x  SBP - 6.383 x 10-6 x max(SBP - 110,0)3 + 1.174 x 10-5 x max(SBP - 131,0)3 - 5.362 x 10-6 x max(SBP - 156,0)3 
CALIBER major 
bleeding 
0.006 x SBP - 5.722 x 10-6 x max(SBP - 110,0)3 + 1.0529 x 10-5  x max(SBP - 131,0)3 - 4.807 x 10-6 x max(SBP - 156,0)3 
Fatal or hospitalised 
bleeding 
0.010 x SBP - 6.231 x 10-6 x max(SBP - 110,0)3 + 1.146 x 10-5 x max(SBP - 131,0)3 - 5.234 x 10-6 x max(SBP - 156,0)3 
Fatal bleeding or 
intracranial bleeding 
0.002 x SBP - 5.176 x 10-6 x max(SBP - 110,0)3 + 9.524 x 10-6 x max(SBP - 131,0)3 - 4.348 x 10-6 x max(SBP - 156,0)3 
 
Note: Systolic blood pressure was modelled using restricted cubic splines with 3 knots in the multivariable models. The functions in this table described the 
estimated relationship between systolic blood pressure and the studied endpoints 
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11.5 Supplementary appendix (Chapter 9) 
11.5.1 Distributions and matrix plot of measures of INR control  
 
INR= International normalised ratio; SD= standard deviation; TTR=time in therapeutic range; TAR= time above 
therapeutic range; TBR= time below therapeutic range   
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11.5.2 Base prognostic models for one year all-cause mortality, cardiovascular death, stroke 
or myocardial infarction, any bleeding and major bleeding 
 
INR= international normalised ratio; HDL= high density lipoproteins; the models were also adjusted for 
systolic blood pressure and body mass index using restricted cubic splines 
368 
 
11.5.3 All-cause mortality; integrated discrimination improvement and net reclassification improvement estimates 
Measure of INR control IDI – events a  
IDI – non- 
events b  IDI (95% CI) 
NRI - events (95% 
CI) c 
NRI – non-events 
(95% CI) d NRI (95% CI) 
TTR group 0.0107 0.0016 0.0123 (0.0105, 0.0142) 0.60 (0.57, 0.63) -0.28 (-0.30, -0.27) 0.32 (0.29, 0.36) 
Time in therapeutic range 0.0139 0.002 0.0159 (0.0137, 0.0181) 0.35 (0.31, 0.39) -0.05 (-0.06, -0.03) 0.30 (0.27, 0.34) 
Time above therapeutic range 0.0201 0.0032 0.0233 (0.0204, 0.0262) 0.12 (0.08, 0.15) 0.27 (0.25, 0.28) 0.38 (0.34, 0.42) 
Time below therapeutic range 0.0006 0.0001 0.0006 (0.0002, 0.0011) -0.08 (-0.12, -0.04) 0.18 (0.16, 0.19) 0.10 (0.06, 0.14) 
Mean INR 0.0153 0.0025 0.0178 (0.0152, 0.0204) 0.05 (0.01, 0.08) 0.27 (0.26, 0.29) 0.32 (0.28, 0.36) 
INR standard deviation 0.0305 0.0047 0.0353 (0.0317, 0.0388) 0.15 (0.11, 0.18) 0.31 (0.30, 0.33) 0.46 (0.42, 0.50) 
Minimum INR value 0.0022 0.0003 0.0025 (0.0016, 0.0034) 0.27 (0.24, 0.31) -0.15 (-0.17, -0.14) 0.12 (0.08, 0.16) 
Maximum INR value 0.0324 0.0051 0.0375 (0.0337, 0.0413) 0.12 (0.08, 0.15) 0.36 (0.35, 0.38) 0.48 (0.44, 0.52) 
First INR value 0.0012 0.0002 0.0014 (0.0007, 0.0021) -0.18 (-0.22, -0.14) 0.27 (0.26, 0.29) 0.09 (0.05, 0.13) 
Last INR value 0.02 0.0032 0.0232 (0.0202, 0.0262) -0.18 (-0.22, -0.15) 0.50 (0.48, 0.51) 0.31 (0.27, 0.35) 
INR trajectory 0.0044 0.0007 0.0051 (0.0038, 0.0064) -0.57 (-0.60, -0.54) 0.67 (0.66, 0.68) 0.10 (0.07, 0.14) 
 
INR= international normalised ratio; IDI = Integrated discrimination improvement; NRI= net reclassification improvement; CI= confidence interval; a Mean probability increase for 
events patients; b Mean probability decrease for non-events patients; c proportion of events patients with increased prediction probability- proportion of events patients with 
decreased prediction probability; d proportion of non-events patients with decrease prediction probability- proportion of non-events patients with increased prediction probability   
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11.5.4 Cardiovascular death, stroke or MI; integrated discrimination improvement and net reclassification improvement estimates 
Measure of INR control IDI – events a  
IDI – non- 
events b  IDI (95% CI) 
NRI - events (95% 
CI) c 
NRI – non-events 
(95% CI) d NRI (95% CI) 
TTR group 0.0038 0.0003 0.0040 (0.0028, 0.0053) 0.52 (0.47, 0.56) -0.30 (-0.31, -0.29) 0.22 (0.17, 0.27) 
Time in therapeutic range 0.0046 0.0003 0.0050 (0.0036, 0.0063) 0.31 (0.26, 0.36) -0.15 (-0.16, -0.13) 0.16 (0.11, 0.22) 
Time above therapeutic range 0.0046 0.0003 0.0049 (0.0033, 0.0065) -0.01 (-0.06, 0.05) 0.23 (0.22, 0.25) 0.22 (0.17, 0.28) 
Time below therapeutic range 0.0004 0 0.0004 (0.0000, 0.0008) 0.32 (0.27, 0.37) -0.25 (-0.26, -0.24) 0.07 (0.02, 0.12) 
Mean INR 0.0031 0.0002 0.0034 (0.0020, 0.0047) -0.19 (-0.25, -0.14) 0.39 (0.37, 0.40) 0.19 (0.14, 0.25) 
INR standard deviation 0.0087 0.0006 0.0093 (0.0071, 0.0116) -0.18 (-0.24, -0.13) 0.41 (0.40, 0.42) 0.23 (0.17, 0.28) 
Minimum INR value 0.001 0.0001 0.0011 (0.0003, 0.0019) 0.10 (0.05, 0.16) 0.00 (-0.01, 0.02) 0.11 (0.05, 0.16) 
Maximum INR value 0.0095 0.0007 0.0102 (0.0078, 0.0125) -0.07 (-0.12, -0.01) 0.38 (0.37, 0.39) 0.31 (0.26, 0.37) 
First INR value 0.0006 0 0.0006 (0.0001, 0.0011) 0.11 (0.06, 0.16) -0.08 (-0.09, -0.06) 0.03 (-0.02, 0.09) 
Last INR value 0.0062 0.0005 0.0067 (0.0047, 0.0086) -0.12 (-0.17, -0.06) 0.33 (0.32, 0.35) 0.22 (0.16, 0.27) 
INR trajectory 0.001 0.0001 0.0011 (0.0004, 0.0018) -0.60 (-0.64, -0.56) 0.64 (0.63, 0.65) 0.04 (0.00, 0.08) 
 
INR= international normalised ratio; IDI = Integrated discrimination improvement; NRI= net reclassification improvement; CI= confidence interval; a Mean probability increase for 
events patients; b Mean probability decrease for non-events patients; c proportion of events patients with increased prediction probability- proportion of events patients with 
decreased prediction probability; d proportion of non-events patients with decrease prediction probability- proportion of non-events patients with increased prediction probability   
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11.5.5 Any bleeding; integrated discrimination improvement and net reclassification improvement estimates 
Measure of INR control IDI – events a  
IDI – non- 
events b  IDI (95% CI) 
NRI - events (95% 
CI) c 
NRI – non-events 
(95% CI) d NRI (95% CI) 
TTR group 0.0005 0 0.0005 (0.0001, 0.0009) 0.39 (0.34, 0.43) -0.29 (-0.31, -0.28) 0.09 (0.04, 0.14) 
Time in therapeutic range 0.0008 0.0001 0.0009 (0.0003, 0.0014) -0.17 (-0.22, -0.12) 0.25 (0.23, 0.26) 0.07 (0.02, 0.13) 
Time above therapeutic range 0.0006 0 0.0006 (0.0002, 0.0011) -0.10 (-0.15, -0.05) 0.18 (0.17, 0.20) 0.08 (0.02, 0.13) 
Time below therapeutic range 0 0 0.0000 (-0.0001, 0.0001) -0.11 (-0.17, -0.06) 0.13 (0.11, 0.14) 0.01 (-0.04, 0.07) 
Mean INR 0.0002 0 0.0003 (-0.0000, 0.0006) -0.27 (-0.32, -0.22) 0.31 (0.30, 0.33) 0.05 (-0.01, 0.10) 
INR standard deviation 0.0008 0.0001 0.0008 (0.0003, 0.0014) -0.07 (-0.12, -0.02) 0.20 (0.19, 0.22) 0.13 (0.08, 0.18) 
Minimum INR value 0.0001 0 0.0001 (-0.0001, 0.0003) 0.01 (-0.04, 0.06) 0.02 (0.00, 0.03) 0.03 (-0.03, 0.08) 
Maximum INR value 0.0007 0 0.0007 (0.0002, 0.0013) -0.08 (-0.14, -0.03) 0.16 (0.15, 0.17) 0.08 (0.02, 0.13) 
First INR value 0.0003 0 0.0003 (0.0001, 0.0006) -0.08 (-0.13, -0.03) 0.09 (0.08, 0.11) 0.01 (-0.04, 0.07) 
Last INR value 0.002 0.0002 0.0021 (0.0013, 0.0030) -0.33 (-0.38, -0.28) 0.45 (0.44, 0.46) 0.12 (0.07, 0.17) 
INR trajectory 0.0005 0 0.0006 (0.0002, 0.0010) -0.54 (-0.59, -0.50) 0.57 (0.56, 0.59) 0.03 (-0.01, 0.08) 
 
INR= international normalised ratio; IDI = Integrated discrimination improvement; NRI= net reclassification improvement; CI= confidence interval; a Mean probability increase for 
events patients; b Mean probability decrease for non-events patients; c proportion of events patients with increased prediction probability- proportion of events patients with 
decreased prediction probability; d proportion of non-events patients with decrease prediction probability- proportion of non-events patients with increased prediction probability   
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11.5.6 Major bleeding; integrated discrimination improvement and net reclassification improvement estimates 
Measure of INR control IDI – events a  
IDI – non- 
events b  IDI (95% CI) 
NRI - events (95% 
CI) c 
NRI – non-events 
(95% CI) d NRI (95% CI) 
TTR group 0.0009 0 0.0010 (0.0003, 0.0017) 0.40 (0.32, 0.48) -0.24 (-0.26, -0.23) 0.16 (0.07, 0.24) 
Time in therapeutic range 0.0005 0 0.0005 (-0.0000, 0.0009) -0.05 (-0.14, 0.04) 0.13 (0.11, 0.14) 0.08 (-0.01, 0.17) 
Time above therapeutic range 0.0012 0 0.0012 (0.0004, 0.0020) -0.03 (-0.12, 0.06) 0.19 (0.18, 0.21) 0.16 (0.07, 0.25) 
Time below therapeutic range 0.0001 0 0.0001 (-0.0002, 0.0004) 0.00 (-0.09, 0.09) 0.08 (0.06, 0.09) 0.07 (-0.02, 0.16) 
Mean INR 0.0003 0 0.0003 (-0.0001, 0.0008) -0.14 (-0.23, -0.05) 0.23 (0.22, 0.24) 0.09 (0.00, 0.18) 
INR standard deviation 0.0008 0 0.0008 (0.0001, 0.0016) -0.03 (-0.12, 0.06) 0.22 (0.21, 0.24) 0.19 (0.10, 0.28) 
Minimum INR value 0.0003 0 0.0003 (-0.0000, 0.0006) 0.04 (-0.05, 0.13) 0.04 (0.02, 0.05) 0.08 (-0.01, 0.17) 
Maximum INR value 0.0014 0 0.0014 (0.0005, 0.0023) 0.06 (-0.03, 0.15) 0.06 (0.05, 0.08) 0.12 (0.03, 0.21) 
First INR value 0.0005 0 0.0005 (0.0001, 0.0009) -0.11 (-0.20, -0.02) 0.21 (0.19, 0.22) 0.10 (0.01, 0.19) 
Last INR value 0.0031 0.0001 0.0032 (0.0019, 0.0044) -0.03 (-0.12, 0.06) 0.28 (0.27, 0.29) 0.25 (0.16, 0.34) 
INR trajectory 0.0006 0 0.0006 (0.0001, 0.0011) -0.62 (-0.69, -0.54) 0.70 (0.69, 0.71) 0.08 (0.01, 0.16) 
 
INR= international normalised ratio; IDI = Integrated discrimination improvement; NRI= net reclassification improvement; CI= confidence interval; a Mean probability increase for 
events patients; b Mean probability decrease for non-events patients; c proportion of events patients with increased prediction probability- proportion of events patients with 
decreased prediction probability; d proportion of non-events patients with decrease prediction probability- proportion of non-events patients with increased prediction probability 
  
372 
 
11.5.7 Predicted any bleeding and major bleeding; comparing base models with models including measures of INR control 
  
TBR= time below therapeutic range; NRI= net reclassification improvement; IDI= integrated discrimination improvement; TTR= time in therapeutic range; SD= standard deviation   
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11.5.8 Calibration of base models and models including measures of INR control for all-cause mortality and cardiovascular death, stroke or MI 
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11.5.9 Calibration of base models and models including measures of INR control for any bleeding and major bleeding 
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